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ABSTRACT 
Adolescent tall girls have been treated with high-dose estrogens to reduce their final height 
for psychosocial reasons since the 1950s. Although the practice is uncommon now, a recent. 
survey of US paediatric endocrinologists reported that 96 (23%) of 411 respondents had 
treated girls in the 'preceding 5 years 3 . Exposure to high-dose estrogen during the pubertal 
mammary development stage could have long-term effects on breast histology, function and 
disease. This study investigated the breast related side effects of treatment in a retrospective 
cohort study of Australian girls who, between 1953 and 1993, were assessed for tall stature in 
adolescence and either treated with high-dose estrogens (diethylstilbestrol or ethinyl 
estradiol) or untreated. Breast related side effects experienced during treatment; subsequent 
effects on lactation (breastfeeding initiation and duration), breast disease or investigations 
(e.g. breast biopsies); and mammographic density, a well established risk factor for breast 
cancer, were examined over two follow-up periods. 
At the first follow-up (2002-2003) demographic information, details of assessment and 
treatment, and short-term side effects of treatment were collected from 371 treated and 409 
untreated women via postal questionnaire. History of breast disease and investigations, 
pregnancy and breastfeeding history were collected by computer assisted telephone interview 
(CATI). Treatment and anthropometric variables in adolescence were obtained from medical 
records where available. At the second follow-up (2006-2007), 167 treated and 142 untreated 
women aged 40 years or older provided access to a recent mammogram from which dense 
area, percent density, non-dense area and total breast area were measured using a computer 
assisted thresholding method. Additional risk factor data were collected and/or updated in a 
second CATI. 
Short-term effects of treatment reported by the women included breast lumps, galactorrhea, 
breast pain, dry cracked or bleeding nipples and increased pigmentation of the nipple and 
areolae. These effects were more frequently reported in women treated with diethylstilbestrol. 
Compared to untreated women, treated women were no more likely to have ever had a breast 
biopsy, breast surgery, or a diagnosis of breast cancer. There was no significant difference in 
the average duration of breastfeeding between treated and untreated women, and treated 
women were no more likely to not commence breastfeeding. Mammographic findings 
showed that treated women had a significantly lower mean dense area than untreated women 
but did not differ significantly in mean percent density, non-dense area or total breast area. 
The short-term side effects of treatment reported by women in this study would have caused 
discomfort and possibly embarrassment in adolescence. However, this investigation provides 
some reassurance for women treated with high-dose estrogens for tall stature that treatment 
'does not appear to affect their ability to lactate or increase their risk of having breast disease 
requiring a breast biopsy or surgery, and is unlikely to increase their risk of breast cancer 
through mechanisms related to mammographic density. The study also has broad 
implications for our understanding of the biology of breast development and for breast cancer 
research. It has shown us that exposure to sex hormones during adolescence can have a 
sustained effect on breast tissue as demonstrated by a reduction in mammographic dense 
tissue in adulthood. 
iv 
CONTRIBUTION OF AUTHOR 
My contribution to this PhD study included cleaning and analysing the data on breast health 
collected at follow-up 1 of the Tall Girls Study. I developed the follow-up 2 research 
question 'whether treatment with high-dose estrogens in adolescence is associated with 
mammographic density as an adult' and developed collaborations with Prof. John Hopper, 
Prof. Anne Kavanagh and Prof. Dorota Gertig to assist with equipment and training to 
undertake the study. I also contributed substantially to the development of the successful 
NHMRC project grant (403002; 2006) proposal to fund the second follow-up. 
For the second follow-up of the study, I applied for ethics approval and developed the study 
recruitment materials including the information brochure, consent forms and invitation letters 
with guidance from my primary PhD supervisor. I recruited and worked closely with the 
study administrator Emma Stubbs and the interviewer Shirley Catchpole, whose positions 
were funded by the NHMRC project grant funds. Study administration involved setting up 
and maintaining a database, sending out the recruitment materials, following-up non-
responders, organising telephone interviews with study participants and sending letters to 
BreastScreen services to request for the mammograms of women who provided their consent 
for them to be used in the study. I trained Shirley to perform the interviews and I undertook a 
number of the interviews that were scheduled after hours. 
I modified the questionnaire that was derived from the Australian Twins and Sisters Breast 
Density Study (UniMelb) and worked with Tim Albion (IT specialistat Menzies Research 
Institute, UTAS) to translate the hard copy questionnaire into a computer assisted telephone 
interview tool. I modified the protocol for mammogram retrieval that was previously used by 
Anne Kavanagh and managed the retrieval, scanning and return of mammograms. I masked 
and read all films for density measurements and undertook all statistical analysis with 
guidance from Russell Thomson, a statistician at Menzies Research Institute. 
I presented the findings of the short-term side effects on the breast at the Australasian 
Epidemiological Association Conference (Oct., 2005), the findings on the effects of treatment 
with high-dose estrogens on subsequent lactation at the Australasian Epidemiological 
Association Conference (Oct., 2006), and the mammographic density findings at The 
University of Melbourne (Dec., 2007, Work in Progress), the Menzies Research Institute, 
University of Tasmania (Sept., 2008), the International Endocrinology Association (Nov., 
2008) and the American Association of Cancer Research (Nov., 2008), 
I also contributed substantially to the conception, design and drafting of two research articles 
drawn from this PhD research 1) Jordan H. L., Bruinsma F. J., Thomson R. J., Amir L. H., 
Werther G.A. & Venn A. J. Adolescent exposure to high-dose estrogen and subsequent 
effects on lactation, Reprod Toxicol 2007; 24: 397-402. 2) Jordan H.L., Hopper J.L., 
Thomson R.J., Kavanagh A.M., Gertig D.M., Stone J. & Venn A.J. Influence of high-dose 
estrogen exposure during adolescence on mammographic density for age in adulthood. 
Cancer Epidemol Biomarkers and Prey 20 1 0; 1 9:1 21-9. 
ACKNOWLEDGEMENTS 
I would like to thank my PhD supervisor Professor Alison Venn who guided me throughout 
this study. Her enthusiasm and expertise were always on offer and contributed greatly to my 
positive PhD experience. Her common-sense and unflinching approach to the challenges that 
invariably arose gave me confidence to tackle them head-on and keep to plan. She has been a 
teacher, mentor and friend. 
I also owe my deepest gratitude to Professor David Dunt, my co-supervisor, work colleague 
and mentor, for his insistent prodding of me to undertake a PhD in the first place, his 
continued encouragement and support throughout the process, and his guidance in the 
development of this thesis. His persistence and expertise has been valuable. 
I would especially like to thank Russell Thomson for his guidance and support in all things 
statistical. He answered my questions promptly and with patience. His responses were always 
clear even when my questions were not. I have learnt much from him. 
I would also like to thank John Hopper and Jennifer Stone for their training, infrastructure 
support and guidance in the mammographic density component of this PhD study, and Anne 
Kavanagh and Dorota Gertig for their advice with the mammographic study, and help with 
writing the grant proposal. 
This thesis would not have been possible without the financial assistance provided by the 
Ruby Menzies and the Australian Postgraduate Scholarships. I would also like to thank the 
NHMRC and the Cancer Council Tasmania for their grants to implement the mammographic 
density study, BreastScreen services for their assistance in the retrieval of mammograms, and 
the Menzies Research Institute, UTAS, for its support and training. 
I would also like to acknowledge and thank Fiona Bruinsma, Jo Rayner, Penny Jones, 
Michelle Kealy, Emma Stubbs, Shirley Catchpole and Tim Albion for their contribution to 
the data collection (follow-up 1 and 2), questionnaire development, and the administration of 
the study database. • 
Thanks also to my friend Julie Cantrill who proof read this thesis. She now knows what I 
have been doing these past few years. 
This study could not have occurred without the study participants. I thank them for their time 
and effort and hope they find the findings informative. 
I would also like to express my thanks to all my friends and family who supported me with 
encouragement and advice. This includes my colleagues at the Centre for Health Policy, 
Programs and Economics. And a special thank-you to my Bendigo friends, Jennifer and 
Chris, who assisted with child pick-ups, drop-offs and school holiday supervision. 
Finally and most importantly, I would like to thank my wonderful family, Richard, Cassie 
and Penny, for their continued encouragement, patience and support. And of course Oliver, 
for his company. 
TABLE OF CONTENTS 
LIST OF TABLES 	 viii 
LIST OF FIGURES xi 
PART A 	 1 
1: INTRODUCTION 	 2 
1.1 Research aim and questions 	 4 
1.2 Overview of thesis 	 5 
2: EXPOSURE TO HIGH-DOSE ESTROGENS FOR THE TREATMENT OF 
TALL STATURE IN ADOLESCENT GIRLS 	  
2.0 Introduction 	 8 
2.1 The use of estrogen in the treatment of tall stature 	 8 
2.2 Mechanism of action 	 13 
2.3 Effectiveness of treatment 	 16 
2.4 Other effects of treatment 22 
2.5 Overview 	 36 
PART B 	 39 
3: CURRENT EVIDENCE ON THE SHORT- AND LONGER TERM EFFECTS 
OF ESTROGEN TREATMENT IN ADOLESCENCE ON BREAST 
SYMPTOMS, DISEASE AND FUNCTION 	 40 
3.0 Introduction 	 40 
• 3.1 Short-term side effects on the breast 	 41 
3.2 Benign breast disease 	 47 
3.3 Breast cancer risk 55 
3.4 Lactation 	 70 
3.5 Overview 80 
4: TREATMENT WITH HIGH-DOSE ESTROGENS IN ADOLESCENCE: 
SHORT-TERM EFFECTS ON THE BREAST AND LONGER TERM BREAST 
DISEASE 	 82 
4.0 Introduction 	 82 
• 4.1 Study Aim •83 
4.2 Methods 	 84 
4.3 Results 89 
4.4 Discussion 	 97 
4.5 Conclusion 103 
5: TREATMENT WITH HIGH-DOSE ESTROGENS IN ADOLESCENCE AND 
SUBSEQUENT EFFECTS ON LACTATION 	 105 
5.0 Introduction 	 105 
5.1 Study Aim 106• 
5.2 Methods 	 107 
5.3 Results 112 
5.4 Discussion 	 120 
5.5 Conclusion 125 
vi 
vii 
PART C 	 127 
6: CURRENT EVIDENCE OF ASSOCIATIONS BETWEEN ESTROGEN 
EXPOSURES AND MAMMOGRAPHIC DENSITY, A RISK FACTOR OF 
BREAST CANCER 	 128 
6.0 Introduction 128 
6.1 Mammographic density — what is it? 	 129 
6.2 How is mammographic density measured? 	 129 
6.3 Mammographic density and breast cancer risk 134 
6.4 Hormone exposures and mammographic density 	 137 
6.5 Adolescent exposures and mammographic density 167 
6.6 Overview 	• 	 170 
7: THE LONG-TERM EFFECT OF HIGH-DOSE ESTROGEN EXPOSURE IN . 
ADOLESCENT GIRLS ON MAMMOGRAPHIC DENSITY 	 175 
7.0 Introduction 	 175 
7.1 Study Aim 176 
7.2 Methods 	 177 
7.3 Results 197 
7.4 Discussion 	 245 
7.5 Conclusion 255 
8: CHILDHOOD AND ADOLESCENT GROWTH PARAMETERS, AND 
MAMMOGRAPHIC DENSITY IN TREATED AND UNTREATED 
WOMEN 	 257 
8.0 Introduction 	 257 
8.1 Study Aim 260 
8.2 Method 	 261 
8.3 Results 265 
8.4 Discussion 	 278 
8.5 Conclusion 283 
PART .D 	 285 
9: CONCLUSION 	 286 
REFERENCES 293 
LIST OF TABLES 
Table 2.1: Tanner stages of breast maturation. 	 24 
Table 2.2: Summary of mean total plasma IGF-I (ng/ml) before, during and after 
ethinyl estradiol treatment for tall stature reported in five studies. 	 27 
Table 2.3: Changes in prolactin concentration (mean ± SD) during ethinyl estradiol 
treatment for tall stature compared with values before treatment (fig/m1) 	31 
Table 2.4: Summary of studies reporting non-breast related short-term side effects of 
treatment with high-dose estrogens for in adolescent girls 	 33 
Table 3.1: Breast related side effects of high-dose estrogen treatment for tall stature in 
adolescent girls. 	 43 
Table 3.2: Pooled analyses of epidemiological studies examining the association 
between HRT use and breast cancer risk 	 60 	• 
Table 3.3: Summary of studies that have investigated the association between 
environmental estrogen exposures as measured by serum or breast milk 
concentrations and breastfeeding duration or initiation. 	 72 
Table 3.4: Summary of animal studies on the effect of in-utero and prepubertal 
estrogen exposures on the mammary gland. 	 77 
Table 4.1: Characteristics of treated and untreated participants. 	 89 
Table 4.2: Growth characteristics of treated and untreated participants. 	91 
Table 4.3: Use of hormones for reproductive conditions in treated and untreated 
women. 	 92 
Table 4.4: Short-term side effects on the breast by drug type 	 93 
Table 4.5: Age adjusted relative-risks of ever having had a breast biopsy, surgery, and 
breast cancer. 94 
Table 4.6: Ever had a mammogram for treated and untreated and Australian 
population (ABS 2001) by age group 	 95 
Table 4.7: Reasons for last mammogram in treated and untreated women. 	96 
Table 5.1: Characteristics of study participants. 	 113 
Table 5.2: Breastfeeding commencement. 	 114 
Table 5.3: Breastfeeding duration for those who initiated breastfeeding 	116 
Table 5.4: Reasons for stopping breastfeeding 	 118 
Table 6.1: Cross-sectional studies of the association between HRT and percent 
mammographic density and dense area measured quantitatively. 	  141 
Table 6.2 Cross-sectional studies of association between HRT and mamrhographic 
density measured qualitatively. 	 142 
Table 6.3: Longitudinal studies of the association between HRT and percent 
mammographic density (PMD) measured quantitatively 	 144 
Table 6.4 Longitudinal studies of the association between HRT and percent 
mammographic density measured qualitatively. 	 149 
viii 
ix 
Table 6.5: Cross-sectional studies of the association between oral contraceptive pill 
use and mammographic density. 	 162 
Table 7.1: Age and reproductive characteristics of study participants 	 197 
Table 7.2: Anthropometric characteristics of participants. 	 199 
Table 7.3: Use of hormone or related medications by treatment status 	200 
Table 7.4: Smoking, alcohol and socio-demographic characteristics of participants by 
treatment status 	 202 
Table 7.5: History of reproductive disease in treated and untreated women. 	203 
Table 7.6: Treatment characteristics (treated women only). 	 205 
Table 7.7: Mean and median values of mammographic density parameters: dense area 
(cm2), percent density (%), total breast area (cm 2) and non-dense area (cm 2 ). 	206 
Table 7.8: Univariable analysis of the association between treatment status and the 
outcome variables: dense area cm 2 (sqrt), percent density (%), total breast area cm 2 
(log) and non-dense area cm2 (log). 	 209 ' 
Table 7.9: Univariable analysis of the association between potential influencing 
factors and the outcome variables dense area (cm 2) (sqrt), percent density (%), total 
breast area (cm 2) (log) and non-dense area (cm2) (log) 	• 	 211 
Table 7.10: Univariable analysis of the association between potential influential 
variables and the outcome variables dense area (cm 2) (sqrt), percent density (%) 
(sqrt), total breast area (cm2) (log) and non-dense area (cm 2) (log) . 	 214 
Table 7.11: Regression coefficients of univariable and multivariable analysis of the 
association between treatment status (treated, untreated) and dense area (cm 2) (square 
root transformed) 	 223 
Table 7.12: Regression coefficient (multivariable) for treatment effect on dense area 
(sqrt) with and without digital images and breast cancer cases. 	 224 
Table 7.13: Unadjusted and adjusted regression coefficients of dense area (cm 2) (sqrt) 
by treatment type: diethylstilbestrol (DES) and ethinyl estradiol (EE) 	225 
Table 7.14: Number and percentage of women aged before and after 50 years by 
treatment type. 	 226 
Table 7.15: Regression coefficients for duration of treatment on dense area (cm 2) 
(sqrt) in treated women after adjustment for age and BMI. 	 227 
Table 7.16: Regression coefficients of unadjusted and adjusted analysis of the 
association between treatment status (treated, untreated) and percent mammographic 
density (%) (square root transformed) 	 230 
Table 7.17: Unadjusted and adjusted regression coefficients of percent 
mammographic density percent (sqrt) by treatment type: diethylstilbestrol (DES) and 
ethinyl estradiol (EE) 	 231 
Table 7.18: Adjusted regression coefficients of associations between percent density 
(%) (sqrt) and a) duration of treatment and b) estimated mature height (EMH) minus 
final height (cm). 	 232 
Table 7.19: Unadjusted and adjusted regression coefficients of the outcome variable 
percent density (%) (sqrt) and the independent variable: age at start of treatment 
(years) 	 233 
Table 7.20: Univariable and multivariable regression coefficients of the association 
between treatment and log non-dense area (cm 2) 	 235 
Table 7.21: Unadjusted and adjusted regression coefficients of non-dense area (cm 2 ) 
(log) by treatment type: diethylstilbestrol (DES) and ethinyl estradiol (EE) 	236 
Table 7.22: Adjusted regression coefficients of associations between non-dense area 
(cm2 ) (log) and a) duration of treatment and b) estimated mature height (EMH) minus 
final height (cm). 	 237 
Table 7.23: Unadjusted and adjusted regression coefficients for treatment effect on 
total breast area (cm2) (log transformed) 	 239 
Table 7.24: Unadjusted and adjusted regression coefficients of total breast area (cm 2 ) 
(log) by treatment type: diethylstilbestrol (DES) and ethinyl estradiol (EE) 	240 
Table 7.25: Adjusted regression coefficients of associations between total breast area 
(cm2) (log) and a) duration of treatment and b) estimated mature height (EMH) minus 
final height (cm). 	 241 
Table 7.26: Multiple linear regression of the association between treatment, and each 
of the mammographic measures adjusted for different sets of covariates. 	243 
Table 7.27: Adjusted least square means of total breast area (cm 2), non-dense area 
(cnn 2), percent density (%) and dense area (cm 2) for treated and untreated women. 244 
Table 8.1: Anthropometric characteristics of treated and untreated participants 	266 
Table 8.2: Childhood anthropometric characteristics of treated women. 	267 
Table 8.3: Univariable analysis of the association between pre-treatment 
anthropometric measures and the outcome variables dense area (cm 2) (sqrt), percent 
density (%), total breast area (cm 2) (log), and non-dense area (cm 2) (log). 	269 ' 
LIST' OF FIGURES 
Figure 1.1: Study design, outcomes and thesis structure. 	 7 
Figure 2.1: Growth plates at both ends of a long bone 14 
Figure 2.2: Tanner stages of human breast maturation. 	 23 
Figure 3.1: Aberration of Normal Development and Involution (ANDO classification 
of benign breast diseases. 48 
Figure 3.2: Estrogen and breast cancer risk: studies of association presented in the 
following review 	 56 
Figure 3.3: Pathways for estrogen carcinogenesis. 	 66 
Figure 4.1: Number of treated and untreated women in the Tall Girls Study who were 
identified, traced and who participated in the computer assisted telephone interview 
(CATI). 	 85 
Figure 4.2: Proportion of treated and untreated women who had ever had a 
mammogram 	96 
Figure 5.1: The breastfeeding questions asked in the computer assisted telephone 
interview 	 108 
Figure 5.2: Mean breastfeeding duration (weeks) for treated and untreated women 115 
Figure 6.1: Mammograms showing dense (white) and non-dense (dark) areas of the 
breast across varying degrees of density. 	 129 
Figure 6.2: Representative mammograms of each of the Wolfe Grades of 
mammographic density measurement. 	 130 
Figure 6.3: Image with the breast area (red) and dense area (green) outlined. 	 132 
Figure 6.4 Study specific and combined relative risks of breast cancer (incidence and 
prevalence) with increasing percent mammographic density 	 136 
Figure 7.1: Flow chart of recruitment of study participants  	180 
Figure 7.2: Sample size and difference in population means for study powers of 0 	 8 
and 0.9. 	 181 
Figure 7.3: Cranio-caudal and medio-lateral mammogram views. 	 183 
Figure 7.4: Masked (A) and verified (B) images of mammograms. 185 
Figure 7.5: Distribution of dense area, percent density, total breast area, non-dense 
area. 	 207 
Figure 7.6: Distribution of square root transformed dense area and percent density, 
and log transformed total break area and non-dense area 	 208 
Figure 7.7: Box-plots of dense area and percent density by menopausal status and age 
category (<50 years, >50years) for treated and untreated combined: 	 216 
Figure 7.8: Total breast area (cm2) and non-dense area (cm2) by menopausal status. 
and age category (<50 years, >50years) for treated and untreated combined. 	217 
Figure 7.9: Box-plot of dense area (cm 2) and BMI kg/m 2 for treated and untreated 
combined. 	 218 
Figure 7.10: Box-plot of percent density (%) and BMI kg/m 2 for treated and untreated 
combined. 	 219 
xi. 
xii 
Figure 7.11: Box-plot of total breast area (log) and BMI kg/m 2 for treated and 
untreated combined. 	 220 
Figure 7.12: Box-plot of non-dense area (log) and BMI kg/m2 for treated and 
untreated women combined. 	 221 
Figure 7.13: Smoothed lowess plot of dense area (cm 2) (sqrt) and age at start of 
treatment (years) 	 V 	 228 
Figure 7.14: Smoothed regression and lowess curves for percent density (%) (sqrt) (y- 
axis) and the age at beginning of treatment (years) in treated women 	 233 
Figure 7.15: Smoothed regression and lowess curves for non-dense area (log) (y-axis) 
and the age at beginning of treatment (years) in treated women. 	 238 
Figure 7.16: Smoothed regression and lowess curves for total breast area (log) (y- 
axis) and the age at beginning of treatment (years) (x-axis) in treated women. 	242 
Figure 8.1: Directed acyclic graph illustrating confounding of the association between 
treatment and mammographic density by pre-exposure variables. 	 258 
Figure 8.2: Directed acyclic graph.illustrating a non-confounding scenario of the 
.association between treatment and mammographic density. 	 258 
Figure 8.3: Scatter plot of age at start of treatment and height change after age 15 
years. 	 268 
PART A 
Chapter 1: Introduction 
Chapter 2: Exposure to high-dose estrogens for the treatment of tall 
stature in adolescent girls 
Chapter I:introduction 	 2 
1: INTRODUCTION 
Since the 1950s, large doses of estrogen have been used as a treatment to reduce the adult 
height of tall adolescent girls for psychosocial reasons 5 . Estrogen is believed to contribute to 
the cessation of bone growth by promoting the ossification of the epiphyseal growth plate of 
long bones6 in late puberty'. This effect of estrogen is believed to be the basis for its clinical 
use to treat tall girls 8 . Although the practice is uncommon now, a recent survey of US 
paediatric endocrinologists reported that 96 (23%) of 411 respondents had treated girls in the 
preceding five years 3 . In Australia, the treatment regimen typically involved a daily dose of 
estrogen, either diethylstilbestrol (DES) or ethinyl estradiol (EE), and a progestagen over 
several days a month to promote cyclical bleeding. 
The timing of this treatment in girls has presented a unique opportunity to study the 
effects on the breast of adolescent exposure to high-dose estrogens. Puberty in girls is an 
important stage of mammary development and involves the balanced and integrated action of 
a range of hormones that include the direct and indirect actions of estrogen on primary ductal 
growth followed by progesterone, alone or together with estrogen, on lobulo-alveolar 
development9 . 
Treatment with high-dose estrogen for tall stature is known to alter the milieu of a 
range of important hormones. Changes in the levels of IGF-1 19-13 , DHEA-S 13 ' 14 , 
testosterone", basal and GnRH stimulated gonadotropins I5 ' 16 , prolactin p • 17-19 and cortisol p 
have been reported in treated girls. It is possible the hormonal changes observed during 
treatment for tall stature may affect breast development and subsequently breast histology, 
function and disease outcomes, particularly since a number of these hormones (e.g. IGF-I) 
have been implicated in breast development and differentiation29 ' 21 . 
While short-term effects on the breast have been reported in girls receiving estrogen 
treatment3, 22-24,  no study has quantified these effects by treatment type (DES or EE). 
Furthermore, no studies have investigated the long-term effects of treatment on the breast. A 
recent study has shown long-term impaired fertility in treated girls 25 , pointing to the 
possibility of lasting effects on developing reproductive tissues. Animal studies suggest long- 
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term changes to nipple structure (in primates 26, heifersn and goats 28) and lactation levels (in 
heifersn) when exposed to estrogen during the allometric growth period of the mammary 
gland that corresponds to the pubertal growth period in girls. It is possible that girls treated 
for tall stature similarly experience long-term effects on mammary structure and hence 
function (i.e. lactation). 
Increased breast disease risk may be an adverse outcome of treatment. Benign breast 
lumps have been reported to be a side effect of treatment with high-dose estrogens in 
adolescent girls 23 ' 29 . It is possible that these exposures have long-term consequences on 
breast morphology and subsequent disease. 
The effects of hormone exposures during adolescence on breast cancer risk are of 
particular interest to the scientific community 30 . The adolescent period is considered a 
potentially important period for breast cancer risk. Evidence supporting a heightened 
sensitivity during the adolescent period comes from findings in a rat model of carcinogenesis 
where cancer initiation required the integration of chemical carcinogens with undifferentiated 
and highly proliferating mammary epithelium 31 . The cells of the pubertal mammary gland are 
highly proliferative and undifferentiated. Differentiation of the mammary gland, such as that 
induced by full-term pregnancy, was found to inhibit carcinogenic initiation. 
Mammary cellular proliferation is stimulated by exposure to estrogen and 
progesterone 32 ' 33 • It has been suggested that lower levels of these sex hormones during 
adolescence could potentially protect against breast cancer by altering breast morphology 
through a reduction in the rate of cell turnover and proliferation 34 . Early age of menarche is a 
well established breast cancer risk factor 35 and this may be attributable to longer or earlier 
lifetime exposure to estrogen and progesterone, especially during the critical period of breast 
development, 
While adult exposures to exogenous sex hormones and their influence on breast 
cancer risk have been studied extensively, no studies have examined the effect of adolescent 
exposure to supraphysiological doses of estrogen on the risk of breast cancer in women. A 
cohort study of Australian tall girls presented an opportunity to investigate whether 
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adolescent exposure to high-dose estrogens influences breast cancer risk. by comparing the 
number of breast cancer cases and mammographic density in treated and untreated women. 
The sample size of this cohort was a limitation but it was worth examining cases of breast 
cancer to rule out a large increase in risk in these women. Mammographic density is a well 
established determinant of breast cancer4 and can be considered a proxy measure of breast 
cancer risk36 . The sample size of the cohort was large enough to explore the difference in 
mammographic density between treated and untreated women. 
Treatment with sex hormones in adult women (hormone replacement therapy, 
Tamoxifen, and Gonadotropin Releasing Hormone Agonist (GnRHA), has been 
demonstrated to influence mammographic density 37-39 . However, the effect of these - 
treatments may be only temporary39' 40 . The effect of sex hormone treatments during 
adolescence is not known but it is plausible that exposures during pubertal mammary gland 
development have a more sustained influence on breast tissue composition and 
mammographic density. 
The Tall Girls Study cohort provided a unique opportunity internationally to examine 
the effects of adolescent exposure to high-dose estrogens on the breast. This cohort 
comprised Australian women who were assessed for tall stature as adolescents, had a wrist x-
ray to predict estimated mature height, and were either treated or untreated. 
1.1 Research aim and questions 
The aim of this research was to examine the short and long-term effects of adolescent 
exposure to high-dose estrogens on the breast, in particular: the short-term side effects of 
treatment on the breast, and longer term effects on breast disease, mammary function 
(lactation), and mammographic density. To achieve this aim, the following research questions 
were developed: 
1) What proportion of the women in the .Australian Tall Girls cohort experienced 
breast related short-term side effects? What were they and did they differ by treatment type? 
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2) Were women treated for tall stature more likely to develop breast cancer than 
women assessed for tall stature but not treated? 
3) Were women treated for tall stature more likely to have had a breast biopsy or 
undergone breast surgery than women assessed for tall stature but not treated? 
4) Were women treated for tall stature more likely to not commence breastfeeding; to 
breastfeed over a shorter duration, both in total and exclusively; or to differ in their reasons 
fir stopping breastfeeding when compared with women assessed for tall stature but not 
treated? 
5) Were women treated for tall stature more likely to have a higher breast density for 
their age, than women assessed for tall stature but not treated? 
To answer the first four or these questions, data that was previously collected in the 
Tall Girls Study (follow-up 1) were analysed. To answer Question 5, eligible women from 
follow-up 1 were retraced and recruited to a second follow-up (follow-up 2) and new data 
were collected from these women. 
As well as helping to address the concerns of treated women, the research provided a 
rare opportunity, internationally, to examine the long-term biological effects of this treatment. 
While exposure to supraphysiological doses of estrogen in adolescence is not common now, 
it is important to establish whether exposure to high-doses of sex hormones during 
• adolescence is likely to have a sustained effect on the breast. 
1.2 Overview of thesis 
This thesis is composed of five parts. Part A includes Chapters 1 (this chapter) and '2. The 
second chapter provides the background to the treatment of tall girls with high-dose 
estrogens. Specifically, it examines the literature on the treatment of tall girls, its indication 
of use, current use, treatment regimen, mechanism of action and effectiveness. The effect of 
treatment on pubertal characteristics is described, as is the effect of treatment on hormone 
levels (e.g. estradiol, growth factors, DHEAs and gonadotropins and prolactin). 
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Part B describes the research that involved an analysis of the data collected in follow-
up 1 and addresses the research Questions 1-4 above. This part includes Chapters 3, 4 and 5 
(See Figure 1.1). 
Chapter 3 reviews Australian and international published case-series and follow-up 
reports of adverse effects on the breast during and shortly following cessation of estrogen 
treatment in tall girls. It explores available evidence, drawn from animal and epidemiological 
studies, of the effect of hormones during all stages of mammary development, particularly the 
adolescent period, on breast morphology, function and disease outcomes. The review 
highlights the gaps in our understanding of the short- and long-term effects of high-dose 
estrogen treatment in adolescence on breast symptoms, disease and function. 
Chapter 4 describes the prevalence of short-term breast related side effects in treated 
women, and the long-term risk of ever having had a breast biopsy, breast surgery, and breast 
cancer in treated women compared with untreated women' at first follow-up. 
Chapter 5, the final chapter in Part 2, describes the long-term effects of high-dose 
estrogen for the treatment of tall stature in adolescent girls on subsequent lactation, in 
particular, breast feeding commencement and duration at first follow-up. 
Part C describes the research involving follow-up 2, and includes Chapters 6, 7 and 
8. Chapter 6 presents a review of the literature on mammographic density, an important 
breast cancer risk factor, and evidence of hormone exposures and their effects on • 
mammographic density. 
Chapter 7 follows with the research findings of the study on the effects of high-dose 
estrogen treatment in adolescent girls on mammographic density at second follow-up. 
Chapter 8 continues with the examination of the influence of pre-treatment and post-
treatment anthropometric parameters on the association between treatment and 
mammographic density. 
The overall findings are evaluated and discussed and conclusions drawn in Chapter 9 
(Part D), followed by the Appendices. 
PART C 
Chapter 6: Current Evidence 
Chapter 7: Research 
Chapter 8: Research 
PART D 
Conclusion 
Appendices 
Figure 1.1: Study design, outcomes and thesis structure. 
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2: EXPOSURE TO HIGH-DOSE ESTROGENS FOR THE TREATMENT
• OF TALL STATURE IN ADOLESCENT GIRLS 
2.0 Introduction 
This chapter provides the background and context to the research presented in this PhD 
thesis. Specifically, this chapter reviews the use of estrogens in the treatment of tall 
stature in adolescent girls: its indications for use, current use, treatment regimen, 
mechanism of action, and effectiveness. 
This chapter then follows with an exploration of the effect of estrogen treatment 
for tall stature on pubertal characteristics and endogenous hormone levels using evidence 
sourced from the literature. Reports of short- and long-term side effects of treatment are 
also described. 
The reported effects of treatment on pubertal characteristics, hormonal levels and 
reproductive organs, together support the suggestion that treatment with high-dose 
estrogens in adolescence could have long-term effects on the breast. 
2.1 The use of estrogen in the treatment of tall stature 
Estrogens have been used to reduce the adult height of tall girls since the 1950s. The 
first clinical use of estrogen treatment in tall but otherwise healthy girls appeared to be 
explored in 1946 at the Massachusetts General Hospital, as an extension of the treatment 
of acromegaly41 . Interest in the treatment increased one decade later (1956), when US 
based Goldheizher published the first clinical observations of a cohort of treated female 
patients 5 . At this time, Australian endocrinologist Norman Wettenhall, whilst visiting the 
US, became interested in the use of high-dose estrogens in the treatment of tall girls, and 
became a highly published proponent of the treatment in Australia and internationally. 
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The use of estrogen in the treatment of tall stature has been the subject of many 
published articles on its clinical use in limiting the height in girls4246 and, more recently, 
its safety in relation to possible long-term side effects42, 47, 48 and the ethical issues 
concern. ing treatment". A lack of knowledge about the long-term effects has led to 
recommendations in the clinical, scientific and wider communities (e.g. Tall Girls Inc.*) 
for the implementation of long-term follow-up studies 23, 44, 47, 50. In response to this need, 
a group of Australian researchers, based in Melbourne, recruited an Australian cohort of 
treated and untreated women who were assessed for tall stature in adolescence to 
examine the long-term effects of treatment, the results of which will be described in a 
later section of this chapter. 
2.1.1 Indication for use of high -dose estrogens in adolescent girls 
The indications for use of treatment have varied over time. Girls with an expected mature 
height exceeding between 177-188 cm 3 ' 51 , depending on the decade of assessment, or 
>2813 for age 44 ' 52 , and presenting with concerns about adverse psychosocial effects of 
tall stature, have been offered estrogen treatment for psychosocial benefits 3 ' 51 ' 52 if at an 
age when treatment might still be effective. In 1965, Wettenhall and Roche ; described 
some of the psychosocial problems faced by tall girls and said to justify treatment 52 : 
"A kyphotic posture may be adopted defensively to reduce their tall appearance,. 
depression, withdrawal from social contacts, lack of interest in school work and play, 
[and] tensions and irritability at home, are common emotional reactions." 
"Some girls feel so embarrassed with boys shorter than themselves that they 
believe their choice of male companions, both in the immediate future and as adults, will 
be seriously jeopardised." 
"They may have difficulty in buying clothes appropriate to their .age, and if 
clothes have to be tailor-made, extra expenses can be a problem." 
"Some careers, for example classical ballet, are closed to an unusually 
tall girl." p 2 10. 
• Tall Girls Incorporated is an Australian advocacy group for women who were treated with 
estrogens to reduce their final height in adolescence. 
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While the psychological benefits of treatment to the child are one of the criteria 
for treatment, the parents' own anxieties have been reported to influence the decision for 
treatment as described by Zackman 46. 
"The parents who usually are also excessively tall may be alarmed because they 
remember their own psychological sufferings as adolescents and young adults 
and fear that their child may have difficulties in finding a partner. In such 
situations, the possibility of an effective treatment is enthusiastically accepted, 
even if the effect is small and even if there is a theoretical risk." pp 13-14. 
Or as Wettenhall stated 53 : 
"The concern may originate with the parents and the child may not be bothered 
at all." p 135. 
• Of 844 Australian women who were treated with high-dose estrogens for tall 
stature, only 17.5% reported "their own unhappiness or difficulties" as the reason for 
seeking a Medical assessment of their height 54 . For most of the girls, according to 
Bruinsma et al. (2006) 54 , it was a parent and/or doctor who found the predicted final 
height to be an issue. 
2.1.2 Prevalence of use 
Although currently available, estrogen as a treatment for tall stature in girls is not as 
popular as it once was. This is likely to be due to the growing acceptability of tall stature 
in females 3 ' 41. 42 , and the waning acceptability of hormone interventions to reduce tall 
stature fuelled by the concern about potential side effects 3 . The extent of its use in the 
treatment of tall stature in Australia is not clear, as there are no studies reporting the 
prevalence of treatment, however, a recent study of US paediatric endocrinologists found 
that 33% of respondents still offered hormone treatment for tall stature in girls while 
22% had treated' girls for tall stature during the preceding five years 3 . Subsequent 
Chapter 2: Exposure to high-dose estrogens for the treatment or tall stature in adolescent girls 
	
1 1 
findings from the Australian Tall Girls Study suggesting• long-term adverse effects on 
fertility, may have led to this treatment becoming even less popular25 . 
The treatment is currently offered in Europe. An article published in The Age 
newspaper in 20O7  the increasing trend in population height • in the* 
Netherlands and included an interview with a paediatric endocrinologist from Groningen, 
• northern Holland. In the interview, the endocrinologist stated that he treated about one 
child per week with hormones for tall stature (boys t and girls) despite the warnings about 
the greater risk of long-term fertility problems in treated girls: 
" There are no medical reasons for intervening in [the growth of] these 
kids ...The reasons are practical and cosmetic... If a girl is estimated to grow 
over 185 cm..., then we offer them the choice [of treatment] ... We don't know the 
long-term side effects... All we have is an Australian study which found treated 
women were more likely to have fertility problems. I always make sure I mention 
that." 
While use of estrogen for tall stature may have waned over the years, a study 
published in 200856 that had examined the haemostatic effects and clinical effectiveness 
of treatment, promoted the continued use of high-dose estrogens in the treatment of tall 
stature in girls. 
In addition to its use in constitutionally tall girls, the use of high-dose estrogens 
to reduce the height of children with profound developmental disabilities as a way of 
facilitating their management; has recently been suggested 57 and debated°. 
2.1.3 Treatment regimen 
The type of estrogen used has varied over time and place. In the US, conjugated equine 
estrogens are the current estrogens of choice, while in Europe and Australia it is ethinyl 
* While rare, boys are generally treated with testosterone (T) ester depot preparations (250-1000 
mg/month for tall stature (Drop et al 2001)". 
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estradiol. Diethylstilbestrol was previously used until it was reported in 1971 58 to be 
associated with rare clear cell adenocarcinoma of the vagina in the daughters of women 
treated with diethylstilbestrol in pregnancy to prevent miscarriage. As part of the 
regimen, a proge.stagen is typically prescribed to induce cyclic bleeding and avoid over 
stimulation of the endometrium and has included norethisterone, medroxyprogesterone 
and dydrogesterone44 . 
Doses have varied over time. According to Drop et al. (1998) 44 ethinyl estradiol 
was used in doses of 500 lag in the 1960s reducing to 200-300 pg in the 1970s, with 
some using a dose of 100 [tg in the 1990s. Some studies have examined the use of lower 
doses59 but these have not yet come into practice. 
In Australia, from 1959 to 1971, girls were typically treated with 
diethylstilbestrol (DES) (typically 3 mg/day), combined with a progestagen (typically 
norethisterone, 5 mg twice a day for 4 days per month). After this time, DES was 
replaced with ethinyl estradiol (EE) (typically 150 pg/day). Wettenhall recommended the 
use.of ethinyl estradiol after the discontinuation of DES in 1971, because the alternative, 
Premarin (conjugated equine estrogens), used in the US, had varying amounts of 
estrogen in different production batches 60 . He recommended the dose 150 mg/day 
because it equated with the DES dose in terms of potency. According to Wettenhall, 
ethinyl estradiol has a potency approximately 25 times greater than DES. This equated to 
a dose of 120 ig/day EE, but was increased to 150 pig because the tablets were in doses 
of 50 
Ethinyl estradiol is the major component of the cohtraceptive pill, and still the 
estrogen of choice in the treatment of tall stature in girls. As an indication of the size of 
the dose, the treatment dose of ethinyl estradiol for tall stature in adolescent girls is 
approximately five times the dose used in the oral contraceptive pill (contains between 
20-30 m/day61 ' 62). Clearly supraphysiological doses of estrogen were used in the 
treatment of tall stature. 
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2.2 Mechanism of action 
The mechanism of action of high-dose estrogen on growth in adolescent girls is unclear 
though evidence suggests it has a direct or IGF-I mediated effect on the growth plate of 
long-bones as described below. • 
2.2.1 Biphasic-effect 
Estrogen has a number of roles during puberty, one of which is to stimulate the 
maturation of the long-bones in late puberty, which leads to a cessation in growth'. This 
is in contrast to the effects of estrogen during the early pubertal growth spurt, where it is 
known to stimulate growth"' 63 . The dual role is believed to depend on the level of 
endogenous estrogen, with lower levels stimulating growth and higher levels preventing 
further growth'. This is supported by in vitro studies showing a biphasic action of 
estrogen on the proliferation of human chondrocytes. At low concentrations, estrogen 
appeared to stimulate proliferation of chondrocytes while at supraphysiological doses, 
proliferation was inhibited 64 . 
2.2.2 Growth plate as the target tissue of estrogen 
Estrogen is believed to contribute to the cessation of bone growth by promoting the 
ossification of the epiphyseal growth plate of long bones 6 in late puberty'. This effect of 
estrogen is.believed to be the basis for its clinical use to treat tall girls 8 (See Figure 2.1 
for a diagram of the growth plate and proliferating chondrocytes). 
—Metaphyseal bone 
—Epiphyseal bone 
— Stem cells 
—Proliferating chondrocytes 
—Hypertrophic chondrocytes 
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Figure 2.1: Growth plates at both ends of a long bone. 
Source: Van Der Eerden B.C.J, & Wit, J.M (2003) 65 Permission to reproduce granted. 
The use of estrogen to promote epiphyseal fusion in tall girls is also founded on 
the observation that short-stature is common in children with precocious puberty. Girls 
with precocious puberty have an early onset of puberty (before 8 years of age) 66 . These 
children are tall at an early age due to the earlier pubertal growth spurt, but become short 
adults due to premature epiphyseal fusion 66 . 
Further support of a direct action of estrogen on the growth plate is the presence 
of estrogen receptor-alpha (ER-a) and estrogen receptor-beta (ER-13) within the growth 
plate and adjacent bony tissue of children in the prepubertal and pubertal age period 67 . 
Weise and colleagues proposed that estrogen acts by reducing the proliferative potential 
of the growth plate through a process of chondrocyte exhaustion68 . It has been suggested 
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elsewhere that estrogen might accelerate chondrocyte senescence by a proliferation-
independent mechanism 69 . 
2.2.3 IGF -I as a mediator 
While the mechanism of action of high-dose estrogen on growth in adolescent girls is yet 
to be made clear, growth hormone or growth factors may have a role to play 12, 44 . A 
review of the literature suggests insulin-like growth factor (IGF-I) (previously known as 
somatamedin-C) is particularly important to pubertal growth" and is mediated by 
estrogen71 . In children and adolescents, low doses of estrogen (up to 0.030 mg) have been 
found to stimulate serum insulin-like growth factor-I (IGF-I), while higher doses (greater 
than 0.100 mg) have been found to suppress IGF-I". This parallels the pattern of growth 
seen with low- and high-dose estrogens as described earlier. 
One group of investigators" disagreed with the IGF-I mediating role on the 
growth plate, and suggested that other factors were at play. This conclusion was .drawn 
after studying the effect of three doses of estrogen on both height reduction and IGF-I 
levels. While height reductions were observed for all doses (0.25, 0.5 and 1.0 mg), a 
significant reduction in IGF-I was only observed for doses 1.0 mg and 0.50 mg. A 
reduction was observed for a dose of 0.25 mg but this was not statistically significant. No 
confidence limits were provided to gauge the precision of this result. This finding 
contradicts other studies"' 12 ' 13 , however, and may in part be due to a lack of power in the 
sub-sample analysis, or the cyclic rather than continuous nature of the estrogen used. 
Three week cycles, rather than continuous daily doses, were used in the former study. It 
is also not clear whether the timing of the IGF-I measurements was consistent across the 
different doses of estrogen used in the study. 
Zackman et al. (1975)46  argued against the IGF-I mediating view on the basis 
that patients with IGF-I deficiency have been shown to have retarded bone maturation. 
Zackman presented an alternative mechanism, suggesting that epiphyseal plate 
maturation is a result of androgenic action stimulated by the high-dose estrogen. No 
subsequent articles on this topic have re-visited this potential mechanism. 
Chapter 2: Exposure to high-dose estrogens for the treatment of tall stature in adolescent girls 
	
16 
Cortisol levels may have a role to play. As described later in this chapter, 
treatment with high-dose estrogens has been observed to increase the level of circulating 
cortisol in girls, and that, according to Minuto et al. (1989)7°, cortisol exerts a direct 
inhibitory effect on cartilage replication as seen in subjects with Cushing syndrome or 
receiving corticosteroidal treatment. Despite this observation, no known reports on 
treatment of tall girls have mentioned this as a potential mechanism of action. 
The growth inhibiting effect of estrogen appears to be mediated through its 
action on the growth plate, however, it is unclear whether this is a direct effect or 
mediated through its inhibitory action on IGF-I levels. The actual mechanism of action 
on the growth plate is still to be determined. 
2.3 Effectiveness of treatment 
The following section explores the effectiveness of treatment in achieving both a 
reduction in final height and improved psychosocial outcomes. 
2.3.1 Effectiveness on final height reduction 
The primary intended clinical outcome of high-dose estrogen treatment in adolescent 
girls is a reduction in the girl's final height. Effectiveness of treatment in reducing final 
height is 'measured by calculating the difference between the estimated mature height 
(EMH) and final height. This section describes the measurement of treatment 
effectiveness, using EMII, and summarises the findings of studies that have examined 
the effectiveness of treatment using this measure. 
2.3.1.1 Measuring final height reduction 
Estimated mature height is a prediction of the final height calculated prior.to  treatment, 
and is used to determine the remaining growth potential of the girl, and therefore the 
potential for treatment. EMH can be measured by calculating bone age, and extrapolating 
EMH from this measure, using standardised tables of predicted heights, based on growth 
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data of children (e.g. Bayley-Pinneau tables 72 or Tanner-Whitehouse tables 73). Drop et al. 
(1998)44 summarised the techniques of height prediction using bone age in their review 
of the management of tall stature. The following discussion on the bone age estimation is 
drawn from this review with additional sources from the research literature. 
The tables for extrapolating final height use different methods of bone age 
estimation. Bone age is calculated by evaluating radiographic images of the wrist using 
one of a number of methods 73-75 of varying accuracy' s . One method uses the Greulich and 
Pyle atlas to estimate bone age. This atlas provides standard radiographs of the left hand 
and wrist for different ages. The bone age of the child is determined by comparing their 
radiograph with the standard. The Bayley-Pinneau tables for predicting final height 
(EMH) uses this method of bone age assessment. Another form of bone age assessment 
is the Tanner-Whitehouse technique. This technique also uses a number of maturity 
indicators, weighted and scored, for each bone of the hand and wrist. These individual. 
scores are added to form an overall bone age score. The children selected for these 
standards were from average socio-economic strata and the UK, whereas those selected 
for the Greulich Pyle were from high socioeconomic strata in the US and white. The 
Tanner-Whitehouse height (EMH) prediction tables referred to above use this method of 
bone age assessment. Bone age estimated using the Greulich and Pyle method has been 
reported to be approximately one year lower than the bone age estimated by the Tanner-
Whitehouse method". • 
According to Drop et al.(1998)" both techniques of bone age assessment are 
subjective, and this subjectivity is reflected in the inter- and intra-rater variability. The 
Bayley and Pinneau tables were used to estimate mature height in the Australian patients 
of Wettenhall. This method utilises the Greulich-Pyle atlas for bone age assessment. 
Between 1959 and 1975, for all patients, the bone age of the hand-wrist was assessed by 
one observer. The mean intra-observer difference in assessments was calculated to be 1.1 
months°. 
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If EMH and final height data are known, treatment effectiveness can be 
calculated. Treatment effectiveness is determined by calculating the difference between 
EMH and final height. In treated girls, a final height that is lower than the EMH, 
exemplifies effective treatment. A final height that is equal in magnitude, or higher than 
the EMH, suggests the treatment was ineffective. 
2.3.1.2 Reports of effectiveness of treatment in reducing final height 
Published estimates of the effectiveness of high-dose estrogen treatment in reducing 
adult height vary widely °. According to Drop et al. (1998)44 , this high variability is due 
to differences in the height prediction methods used, treatment regimens, and timing of 
treatment between studies° . 
In a review of 17 studies, Drop and colleagues reported corrected estimates of 
height reduction ranging from 2.1 to 10 cm 44 . Corrections were based on systematic 
prediction errors, as reported in the literature. Since this time at least five studies on the 
effectiveness of treatment have been reported 22, 48, 56, 76, 77 with mean height reductions of 
between 2.4-5.5 cm, though only one of these studies, Venn et al. (2008) 77, adjusted for 
error in EMH predictions. Venn and colleagues examined treatment effect (final height 
minus EMH) in the Australian cohort of treated girls, by adjusting for error in EMH 
predictions and the different distributions, using pairs of treated and untreated girls 
matched on their EMH within 1 cm 77. In the treated group, the mean difference between 
final height and EMH was found to be —1.4 cm (SE 0.29) while the difference was +1.1 
cm (SE 0.23) in the untreated group, equating to an unadjusted treatment effect of —2.5 
cm (95% CI: —3.2 to 1.8) (n=279) 77 . 
2.3.1.3 Effectiveness in relation to timing of treatment 
The significance of timing of treatment has been raised with observations by some, that 
treatment is more effective if started before menarche' s , at an earlier bone age 44 ' 50. 56' 77 
or chronological age 22, 50,56  In relation to menarche, Kuhn et al. (1977)43 did not find any 
difference in results when therapy was started before or. after menarche. This is supported 
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by Drop et al. (1998)44 . While premanarcheal girls seemed to benefit more from therapy 
than postmenarcheal girls, on further adjustment, they found this difference to be due to 
chronological age rather than timing of treatment in relation to menarche. 
While reports of treatment being more effective the younger the child at start of 
treatment, Wettenhall argued that treatment before 10 years should be avoided because 
treatment induced menstruation is undesirable in girls under this ogee° . 
Some studies"' 41 have reported delaying 'treatment until girls were at least as far 
advanced in puberty as Tanner Stage 3 (see below for a description of Tanner stages of 
the breast). No studies appear to have reported effectiveness in relation to Tanner stage at 
. start of treatment. 
2.3.2 Post -treatment growth 
Wettenhall, in the textbook Clinical Paediatric Endocrinology (1981) 53 described the 
criteria for stopping treatment as follows: 
"A girl's progress is reviewed monthly for the first three months [following 
treatment] and thereafter three or four times a year... When her height has 
remained unchanged for six months, radiology is done to determine the state of 
epiphyseal maturation, treatment being continued until epiphyseal fusion is 
complete." 
Growth is not necessarily complete following treatment. Additional growth of a 
Mean 2.7 cm on cessation of treatment has been observed ° . There are two possible 
reasons for this additional growth44 . Firstly, cessation of therapy may have been 
premature before complete closure of the epiphyses. Secondly, the additional growth 
may be due to vertebral growth as this growth is not affected to the same degree by 
estrogen's action on long bone growth e' 80 . 
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2.3.3 Psychosocial outcomes 
While psychosocial factors are often cited as the main reason for treating tall stature, 
there is no clear evidence supporting lifelong psychological damage from being tall"' 50, 
81, 82
, though short-term problems may be experienced in adolescence. Lecointre and 
Toublanc (1997) 82 examined the benefits and disadvantages of being tall by surveying 
113 French women whose height was between 175-188 cm (>2 SD of the population). 
As an adult mot of the tall women studied were satisfied with their height 85% (175— 
179 cm), though fewer were satisfied with their current height if they were 180-188 cm 
(69%)82 . The women stated the advantages and disadvantages of being a tall woman. 
According to the investigators: 
"In the great majority of cases, tall women describe difficulties mainly with 
relationships during adolescence and emphasize the crucial contribution of 
family members in providing psychological support. These difficulties may 
disappear in adulthood when the woman has overcome the disadvantages felt in 
adolescence and has succeeded in taking advantage of her tall stature in her 
professional life. Tall stature is striking and if a woman can respond 
appropriately, she may gain autonomy and sometimes advantage by her 
height. "8 2 p 531. 
While the above study identified relationship difficulties, particularly in 
adolescence, one study did not find this to be the case. Sandberg et al. (2004) 83 found no 
relationship between tall height (>1.6 SD; n=58 of which 25 were girls) and measures of 
friendship, popularity and reputation with peers in a cross-sectional study of 956 US 
students. The investigators found that height influenced the peer relationships of boys 
and girls in similar ways. 
A large study" surveyed visitors to a news website and Elle magazine (30,347 
women, mean age 34 years) using an on-line "Sex and Body Image Survey". They found 
80% of women between heights 5'7" and 5'11; 77% of women at 6'; and 60% of women 
between 6'1" to 6'3" expressed contentment with their heights. Results were similar 
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across age groups. According to the authors, the low prevalence of dissatisfaction 
observed among the tall women in their study does not support the use of estrogens to 
reduce height for psychosocial reasons. 
These observations raise the question about the effect of treatment on the longer 
term psychosocial wellbeing of tall girls. Wettenhall observed psychological 
improvement in almost all girls treated, because: 
"they were receiving help in coping with their problems. No doubt the regular 
discussions with a friendly and interested doctor were appreciated by many of 
these girls and their parents but, without estrogen therapy as well, these 
discussions would not have been enough to account for the improvement of their 
morale." p 607, paragraph 9. 
Only two studies appeared to formally investigate the psychosocial outcomes of 
treatment. A retrospective study of 56 treated and 79 untreated (control) tall girls by 
Binder et al. (1997) 84 at a mean age of 21.8 years at follow-up, revealed no major 
psychosocial or social maladjustment differences between the two groups despite treated 
women reporting teasing because of tallness more frequently than controls". 
The Australian Tall Girls Study 54, a retrospective cohort study of 396 treated and 
448 untreated Australian women who were assessed for tall stature in adolescence, also 
examined the long-term psychosocial outcomes of both groups of women (mean age at 
follow-up 39.1 years). The study found no significant difference between treated and 
untreated women for a number of psychological outcomes that included 12-month or 
lifetime major depression, eating disorders, scores on the SF-36 mental health summary 
scale, or an index of social support. However, compared with population based data, the 
prevalence of major depression in both groups was high. Self-reported difficulties during 
adolescence that led to the seeking of a medical height assessment (OR 2.25, 95% CI: 1.4 
to 3.6), and a negative experience of the assessment or treatment procedures (OR 2.04, 
95% CI: 1.4 to 3.6) were found to be significantly associated with lifetime major 
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depression. The study investigators concluded that the intended psychosocial benefit of 
treatment may not have been realised. 
Research on women's satisfaction with their treatment can also inform the debate 
about the benefits of estrogen therapy for tall stature. Weiman and colleagues (1998) 22 
retrospectively surveyed 50 treated girls, by questionnaire, for their views of treatment. 
While 84.6% of the patients were satisfied with treatment, 15.4% regretted having had it. 
This is despite the unpleasantness of the side effects of treatment: 38.4% recalled the side 
effects of treatment as unpleasant while 61.5% did not22 . Binder et al. (1997) 85 also asked 
56 treated women about their satisfaction with treatment and found the decision to opt 
for treatment was retrospectively approved by 95.8%. These two studies, however, had 
small and selected samples of women who were followed up by the treating physicians 
as opposed to independent researchers. 
The larger Australian Tall Girls Study revealed a higher rate of dissatisfaction 
with treatment86 . The study found that 42.1% of treated women expressed dissatisfaction 
with the decision that was made to treat them while untreated women were almost 
unanimously glad they were not treated (99.1%), no matter how tall they became. There 
was no clear association between satisfaction with treatment and women's final height. 
These findings do not support the rationale for treating tall stature with high-dose 
estrogens for psychosocial reasons, and highlight the continuing debate about its use. 
2.4 Other effects of treatment 
As well as height and psychosocial outcomes described above, treatment with high-dose 
estrogens for tall stature in adolescent girls has been reported to have a number of 
additional physiological effects. The onset of pubertal characteristics is accelerated, and 
• levels of circulating hormones are altered. Unwanted side effects associated with these 
changes have also been reported and are described more fully below. 
.1 
••■•• 
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2.4.1 Effect of treatment on pubertal characteristics 
Treatment accelerates the onset of secondary sexual characteristics, and onset of 
menses41 , and it is known to suppress gonadotropin secretion due to a reversible negative 
feedback mechanism". These and other effects on pubertal characteristics, including the 
Tanner stages of breast development are described below. 
2.4.1.1 Effect on breast development 
Pubertal breast development is divided into five stages according to Tanner 88 (see Figure 
2.2 and Table 2.1). 
Figure 2.2: Tanner stages of human breast maturation. 
Source: Marshall and 
Tanner (1969) 1 . 
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Table 2.1: Tanner stages of breast maturation 88 . 
Tanner Stage 	 Breast Characteristics 
1 
	
Pre-pubertal 
2 Elevation of breast bud 
Areola diameter enlarged 
3 
	
Enlargement of the breast and areola 
No separation of the breast/areola contours 
Further enlargement of the breast and areola. 
Areola forms a secondary mound above the level of the breast 
5 
	
Projection of the breast only to final adult size 
Areola within contour of the breast. 
No studies appear to report the effects , of high-dose estrogen treatment on the 
breast in relation to Tanner stages, however, it has been suggested that breast 
development, along with other pubertal characteristics, is accelerated with treatment". In 
contrast, two reports suggest the opposite; that treatment impedes breast development 23 ' 
41 . However, these potential effects were self-reported by the treated girls and not based 
on a clinical assessment (e.g. Tanner stage). 
As stated above (Section 2.3.1.3), a series of studies (in Boston, US) described . 
. by Crawford" started treatment when the tall girls were at least as far advanced in 
puberty as Tanner's Stage 3. It is unclear whether commencement of treatment in relation 
to Tanner stage is a determining factor in its effect on breast development. 
2.4.1.2 Effect on menses and ovulation 
According to Wettenhall (1981): 
"A girl who has not reached her menarche can expect to do so within three 
months of the onset of therapy, and those already menstruating develop frequent 
and often prolonged menses. These disabilities are corrected by adding 
norethisterone for four days at monthly intervals ..." 53 p 137. 
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The age at menarche in treated girls who had not yet started menstruation, is 
artificially induced by treatment53 . Whether this menstruation is ovulatory or not is 
unclear. Menstruation without ovulation is described as anovulatory. Normally, there is a 
period of anovulation months and sometimes years following natural menarche 89 . When 
ovulatory cycles occur the corpus luteum matures and progesterone is then secreted 89 . 
While menses is initiated with treatment, ovulation is unlikely during these periods given 
the suppression of the hypothalamo-pituitary-gonadal axis 87 (described in more detail 
below). No reported studies have examined the direct effect of high-dose estrogen 
treatment on ovulation in girls. Animal studies using heifers, suggest that early and 
continuous treatment with estradiol implants can retard reproductive function as 
observed by the lack of a palpable corpus luteum or a threshold serum progesterone 
In their review of case-series reports, Drop et al. (1998) 44 reported spontaneous 
bleeding to occur one to six months following the discontinuation of treatment in patients 
within these studies44 . A follow-up study (mean 10 years) by De Waal et al. (1995) 29 of 
180 women who were treated in adolescence with high-dose estrogens found 5% had not 
started menses six months following treatment cessation and 2% had not started menses 
after 12 months. 
2.4.2 Effects of treatment on circulating hormone levels 
As well as the expected increase in plasma estrogen levels, a review of the literature has 
revealed a range of treatment modulating effects on a large number of endogenous 
hormones. Treatment has been reported to suppress insulin-like growth factor-I (IGF-
0 , 10-13, 91, dehydroepiandrosterone sulphate (DHEA-S)' 3 , testosterone" and basal and 
GnRH stimulated gon'adotropins 16 ; and increase prolactin 13, 18, 19, IGF-II I2 and cortisoll3' 14 
levels. Treatment has also been shown to reduce insulin-like growth factor binding 
protein-2 (IGFBP-2)' ° ' 12 and increase insulin-like growth factor binding protein-4 
(IGFBP-4) 1° ' 12. 
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It is necessary to understand the extent to which treatment has affected 
endogenous hormone concentrations, as these changes may have implications for both 
short- and long-term effects on the breast, particularly if the hormones have a role in 
mammary gland development or function. A review of the literatures in relation to these 
hormonal changes is presented below. 
2.4.2.1 Estradiol 
Ethinyl estradiol (EE2) was the estrogen used in the treatment of girls for tall stature after 
1971. It is stronger in estrogenic potency than estradiol (E2) 16 ' 92 , which •is the 
endogenous form of estrogen. One study measured circulating exogenous ethinyl 
estradiol (EE2) and endogenous estradiol (E2) concentrations in the blood of seven girls 
treated with 500 pt.& of ethinyl estraclio1 16 . Ethinyl estradiol levels were increased to 
470-1100 pg/m1, as expected, but E2 levels were reduced to 17±1.6 pg/ml from a 
baseline of 36±2.0 pg/ml. 
2.4.2.2 Insulin-like growth factor (IGF-I) 
Insulin-like growth factor-I (IGF-I) is a polypeptide, similar in structure to insulin. Its 
release is stimulated by growth hormone (GH). Five longitudinal studies demonstrated a 
reduction in IGF-I levels with ethinyl estradiol treatment in tall girls (Table 2.2). 
Reductions of between 20% 13 and 34% 12 from baseline were observed within the first six 
months of therapy with 0.1 mg/day of ethinyl estradiol. A greater reduction was observed 
with higher doses (e.g. 56% with 1.0 mg/day 11 ). Another study 93 (not in table) reported 
average serum IGF-1 (somatamedin) levels falling 56.9% of baseline after six months of 
treatment with conjugated estrogens. This same study found a threefold increase in 
growth hormone (GH) which is the stimulator of IGF-I secretion. Von Puttkamer 93 and 
Studies were identified by a .PubMed search of the English language literature using the terms tall AND girl 
OR female AND treatment OR hormone OR diethylstilbestrol OR o/estradiol OR 0/estrogen for any field 
covering all dates up to the time of writing. The reference lists of all the publications identified by this search 
were inspected for additional studies. The findings and characteristics of all studies that explored the 
associafion between hormone treatment with high-dose estrogens and endogenous hormone levels were 
reported. 
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colleagues suggested a negative feedback mechanism between GH and IGF-I 
(somatamedin) as the reason for this response. 
Table 2.2: Summary of mean total plasma IGF-I (ng/ml) before, during and after 
ethinyl estradiol treatment for tall stature reported in five studies. 
Study Dose of 	IGF-I 	IGF-I during 	IGF-I after 
Estrogen 	before treatment treatment 
mg/day 	treatment 	ng/ml 	 ng/ml 
ng/ml 
0-6 	6-12 	0-6 	6-12 
months months months months 
'•Svan et al: 	21 	1.0 - . 	455 	200 
(1991)" 201 	0.50 411 178 
15 	0.25 	400 	311 
Rooman et al. 	16 	0.1 528 376 
(2002) 19 	8 243 	354 
Rooman et aC ' 19 	0.1 	530 	350 	
--- ---1 	 , _ 
(2005) 12 	_ 	18 258 	450 _ _ _ _ 
Gourmelen et 	13 	0.25-0.3 	1.64* 	 1.34* t 1.02* 
al. (1984)9 ' 1.39* 
0.99* _ -- --- 
.Wajs-kuto et 	22 - - 0.1 	413 	327 	302 
al. (1999) 13 	36 	0.2 478 348 	253  
222 
211 
277 
* Micromole per ml (U/ml) 
t Results at 6, 12 and 18 months, respectively. 
Most of the studies in Table 2.2 reveal lower post-treatment levels of IGF-I 
compared to baseline. It has been suggested that this reduction may be due to the age-
dependent decrease in IGF-I typically seen at the end of puberty' ) .  
As discussed earlier, the observed reduction in IGF-I levels is believed to be the 
mechanism by which estrogen promotes bone maturation and subsequently, reduces final 
height. 
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IGF-I binding proteins 
Three studies have examined the effect of estrogen treatment for tall stature on IGF 
binding proteins. IGF binding proteins (IGFBP 1-6) determine the pharmacokinetics of 
IGF-I, which in turn determines its overall bio-availability in the tissues. For example, 
IGF-I binds to IGFBP-3 that together with an acid-labile subunit, forms a ternary 
complex that cannot cross the vascular endothelium thus affecting its bioavailability to 
tissues 12 and prolonging its presence in the circulatory system. 
Rooman and colleagues observed a reduction in circulating IGFBP-2 and an 
increase in IGFBP-1 & 4 with treatment°. The change in IGFBP-2 & 4 was repeated in a 
later study with a larger group of treated girls. The significance of IGFBP-2 in relation to 
IGF-I is unknown, though a study that examined the animal model of the role of IGFBP-
2 in long bone growth, suggests it to have an inhibitory effect on IGF-1 94 . IGFBP-4 is 
known to inhibit IGF-1, and it has been suggested that the increase in this binding protein 
mediates the growth inhibiting effect of high-dose estrogens 12 . 
Rooman and colleagues 12 also observed a reduction in the levels of IGFBP-3, but 
only at the end of therapy, suggesting a reduction only with long-term use. Estrogen dil 
not appear to have an effect on IGFBP-5 in either study. IGFBP-6 decreased during 
estrogen administration and increased after therapy. The significance of these changes is 
not yet clearly understood. 
Despite these modulations of the IGF binding proteins, the changes are not 
substantial' °, particularly in relation to IGFBP-3, the main binding protein present in 
serum °. Rooman and colleagues ° suggested that the estrogen induced changes in IGF-I, 
observed with treatment in girls, is more likely to be due to a direct inhibitory action of 
estrogen on IGF-I synthesis rather than through any modulating effect on IGF binding 
proteins. 
IGF-II competes for the same binding sites on the IGF-I binding proteins 
resulting in a rise when IGF-1 drops and vice versa 12 . High-dose estrogen treatment in 
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girls has been shown to produce a slight increase in IGF-II, from a mean 407(186-612) 
ng/ml to 471(363-693) ng/ml in the first three months of treatment 12 . 
2.4.2.3 DHEA-S & gonadotropins 
Dehydroepiandroeterone sulphate (DHEA-S) is the sulphated form of a precursor to 
androstenedione which can undergo further conversion to produce testosterone, estrone 
and estradiol. DHEA-S has been shown to reduce by 40% in girls treated with ethinyl 
estradiol (0.1 mg and 0.2 mg/d) 13 . According to Wajs-Kuto et al.. (1999)' 3 , this is 
consistent with the effect observed with lower doses of ethinyl estradiol contained in the 
oral contraceptive pill. 
The gonadotropins (LH and FSH) have also been shown to be reduced in girls 
treated with high-dose estrogens 16 . These changes could have implications for pubertal 
development. Messinis (2006) 89 summarised the involvement of these gonadotropins 
during the pubertal period in normal girls. In pre-pubertal girls, LH and FSH levels are 
generally very low due to the suppression of gonadotropin-releasing hormone (GnRH) 
from the hypothalamus 89 . During puberty, the hypothalamus-pituitary system is activated 
and LH and FSH levels are increased, in a pulsatile manner89 . Circulating levels of these 
gonadotropins increase gradually as puberty progresses, with early lower levels 
stimulating follicle maturation and estrogen synthesis in the ovaries. The higher levels of 
circulating estrogen subsequently stimulate proliferation of the endometrium that leads to 
the first menstruation. This effect of estrogen on the endometrium is observed during 
treatment with high-dose estrogens for tall stature. Menses occurs within three months of 
treatment in girls who are pre-menarchial at start of treatment. 
In normal pubertal girls, even as late as Tanner Stage 5, the estrogen levels (-60 
pg/ml) are generally not high enough to exert a positive feedback mechanism on GnRH 
to increase the LH and FSH concentrations to a level sufficient enough to stimulate 
ovulation". Consequently, there is a lengthy period of anovulation after menarche as 
discussed previously. Menstrual periods are generally irregular during this anovulatory 
period, and it is not until progesterone is produced from the mature corpus luteum during 
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the ovulatory period, that menses become regular. This explains the need for a 
progestagen a few days a month in girls treated with high-dose estrogens to promote 
regular cyclic bleeding. 
Complete suppression of gonadotropin secretion (e.g LH, FSH) with high-dpse 
estrogen therapy in tall girls has been observed and, according to Commentz and 
Willie, expected, as it is an indicator of good treatment compliance. This suggests that 
girls undergoing therapy with high-dose estrogens are anovulatory despite the occurrence 
of menses. 
It may be the addition of a progestagen to the regimen, in order to induce cyclical 
bleeding, that contributes to the reduction in gonadotropins. In the oral contraceptive pill, 
adding a progestagen to the estrogen regimen appears to produce greater suppression of 
plasma gonadotropins than estrogen by itself 95 . 
An increase in cortisol has also been observed 16 . This increase is also expected 
because of estrogen's well established augmentation of cortisol-binding-globulin (CBG) 
production 16 . 
2.4.2.4 Prolactin 
Estrogen treatment for tall stature has also been shown to increase prolactin levels 13 ' 19 ' 87 . 
One study measured prolactin concentrations before and one, three, six and 12 months 
after commencement of treatment for two doses of estrogen (0.1 and 0.2 mg/day). Table 
2.3 presents the changes in prolactin levels compared with baseline levels. While the 
greatest change in prolactin levels occurred after three months of treatment, prolactin 
levels remained greater than baseline levels at least 12 months into treatment. However, 
caution is required when interpreting these findings because of the large variability in 
prolactin concentrations (as demonstrated by the size of the standard deviations). 
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Table 2.3: Changes in prolactin concentration (mean ± SD) during ethinyl estradiol 
treatment for tall stature compared with values before treatment (pg/ml). 
Study N 	Dose of 	Prolactin 
Estrogen 	before 
mg/day 	treatment 
41/m1 
Prolactin during treatment 
A (41/m1) 
3 	 .6 	12 
months 	months 	months 
Wajs -Kuto et 15 0.1 183±50 A+229±213 A+136±112 A+81±84 
al. (1999) 13 20 0.2 198±86 A+375±252 A+226±132 A+182±176 
Hanker et al.(1979) 87 (not in table) measured prolactin levels soon after estrogen 
therapy in girls. Prolactin levels >20 ng/ml (exceeding normal range) were found in eight 
of 14 girls, although these levels were only temporary, all reducing to normal levels 
within eight weeks 87 . In contrast, Houdijk et al. (2000) 19, observed sustained mean 
increases 12 months into treatment in 37 girls, treated with 0.2 mg/day of ethinyl•
estradiol. Mean prolactin levels were 180 [111/m1 before treatment, and 450, 400 and 350 
p.U/m1 at 3, 6 and 12 months into treatment, respectively. Prolactin levels dropped 
back to pre-treatment levels 0-6 months following cessation of treatment (170 [tU/m1). 
A case-study of a girl treated with 0.3 mg/d of ethinyl estradiol reported a serum 
prolactin concentration of 58.2 ng/ml, four days after cessation of treatment. This is 
compared with 1.7 ng/ml measured at start of treatment (normal <20 ng/ml). A CT scan 
of the brain identified a pituitary tumour, which one year later was reduced by 20-30% 
with bromocriptine therapy' s . The authors stated that estrogen stimulation of a pre-
existing tumour could not be excluded. 
Consistent with these findings is the observation in a cross-sectional study of an 
increase in serum prolactin concentrations in women using the contraceptive pill 
(containing ethinyl estradiol), with higher doses (i.e. 50 1.1U/day) eliciting a larger 
increase96 . This is in contrast to a study that examined the effects of the oral 
Chapter 2: Exposure to high-dose estrogens for the treatment of tall stature in adolescent girls 
	
32 
contraceptive pill on hormonal metastasis in adolescents (12-17 years) 97 . No change in 
prolactin levels were observed six or 12 months into therapy, compared with baseline 
levels. However, only 23 and 13 of the 46 recruited girls provided blood measures at six 
months and 12 months respectively. 
The effect of treatment with high-dose estrogens on the levels of these 
endogenous hormones may be important to breast physiological and disease outcomes. 
Many of these hormones have been associated with breast histology, function and disease 
(e.g. estrogen, progesterone, IGF-I and prolactin). These associations are reviewed in 
Chapters 3 and 6 in relation to breast disease and function, and mammographic density, 
respectively. 
2.4.3 Adverse effects of treatment 
Side effects of treatment with high-dose estrogens have been reported in the research 
literature. This section describes the short- and long-term side effects separately. 
2.4.3.1 Short-term side effects of treatment 
A number of short-terni side effects of treatment have been reported in the literature, 
many of these breast related. The breast related side effects reported in the literature 
include breast pain 22 , pigmentation of the areolae and nipple 22, 23, 29, 43 , gallactorrhoea23 ' 43 
and more rarely, benign breast disease 23 ' 29 . A detailed review of the short-term effects on 
the breast is presented in Chapter 3. 
The common non-breast related side effects include headache, nausea, weight 
gain and leg cramps. Less common effects of treatment include thrombosis, endometrial 
polyps or hyperplasia, ovarian cysts, and menstrual bleeding disturbances. A summary of 
case-series and follow-up studies reporting these side effects is provided in Table 2.4 
below. 
See footnote p26 for method of identification of studies. All studies identified this way that 
explored and reported on the side effects of treatment were reported. 
Table 2.4: Summary of studies reporting non-breast related short-term side effects of treatment with high-dose estrogens in 
adolescent girls. 
Study Estrogen type Dose mg/day Type of study Side effect during treatment 
Kuhn et al. (1977)43 36 EE 0.5 Case-series (reports at time of treatment) Weight gain: "almost all girls", mean 
11.1 kg 
Nausea "most girls" and vomiting 
Migraine (n=1) 
Trygstad (1986) 23 680 DES & P 5.0 Case-series (reports at time of treatment) Weight gain (90%) 
EE & P 0.5 Nausea (60%) 
EE & P 0.25 Migraine (2%) 
Other formurations or 
doses 
0.100 Vaginal fluid (2%) 
Increased myopy (2%) 
Interval bleedings (2%) 
Endometrial hyperplasia (n=1) (no 
progestagen) 
de Waal et al. (1995) 29  180 EE 0.100-0.200 Follow-up of patients (mean 10 years 
post-treatment). 
Weight gain (41%) 
Nausea (14%) 
Migraine (13%) 
Vaginal discharge (13%) 
Leg cramps at night (20%) 
Interval bleeding (6%) 
Cysts/tumours of uterus/ovaries (1%) 
Weimann et al. (1998) 22 50 Conjugated 	• 7.5-11.25 Follow-up of patients up to 6 years post-
treatment) 
Weight gain (>10 kg) (70%) 
Nausea (10%) 
Headache (14%) 
Calf cramps (6%) 
Abdominal pain (6%) 
Oedema (6%) 
Allergic skin reaction (6%) 
Hypertension (2%) 
Dysuria (6%)Hyperihernia (6%) 
Study Estrogen type Dose mg/day Type of study Side effect during treatment 
Crawford (1978) 41 130 DES & P (104) 5.0 Case-series (reports at time of treatment Weight gain 
EE & P (26) 0.25 Nausea (morning) 
Migraine (n=3) 
Night cramps ('generally familiar') 
Vaginal discharge 
Intermenstrual bleeding (10%) 
Hypertension (37%) 
Urticaria (n=2) 
Radivojevic et al. 26 1713-estradiol 4.0-8.0* Case-series (reports at time of treatment) Fatigue 
(2006)48 Nausea 
Abdominal discomfort 
Triglyceride discomfort 
Binder et al. (1997)85 56 Conjugated estrogens 7.5 mg Follow-up HO years Weight gain (13.1%) 
Calf cramps (17.2%) 
Orthostatic problems ('7.1%) 
Conte et al. (1978)51 904 Conjugated estrogens Mixed Follow-up via treating endocrinologists Weight gain (69%) 
Eth iny I estradiol (retrospective, time not reported) Nausea (48%) 
DES Leg cramps (3%) 
Estradiol Irregular menses (14%) 
• Hypertension (3%) 
Polyps or endometrial hyperplasia 
(0.3%) 
Ovarian cysts (0.3%) 
Thromboembolism (0.1%) 
Glucose intolerance (0.2%) 
EE=ethinyl estradiol 
DES=diethylstilbestrol 
P=progestagen 
*8.0 mg of 1713-estradiol is bioequivalent to 0.100 mg of ethinyl estradiol (EE) 
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In addition to the above studies, a survey of US paediatric endocrinologists by 
Barnard et al. (2002) revealed86% had patients who had experienced weight gain, 77% 
nausea or vomiting, 74% headache/migraine, 49% irregular menses, 37% polyphagia, 37% 
leg cramps, 17% dizziness/orthostatic problems, 16% polyps or endometrial hyperplasia, 
23% hypertension, 16% ovarian cysts, 16% thrombosis and 15% glucose intolerance (either 
commonly, occasionally or rarely). 
2.4.3.2 Long-term effects on reproductive tissue 
No studies have examined the long-term effects of treatment on breast tissue though the long-
term effects on a range of reproductive outcomes have been reported. De Waal et al. (1995)29 
described menstrual characteristics and reproductive outcomes for treated and untreated 
women in the Netherlands. No effect on reproductive outcomes was observed but the sample 
size was small and the average follow-up was only 10 years after treatment (mean age 25 
years). 
However, the longer follow-up study of Australian tall girls described earlier, found 
treatment with high-dose estrogens in adolescent to have long-term effects on fertility25 , 
suggesting longer term effects on reproductive tissue. In this study 1432 eligible individuals 
(mean age 39 years) were identified from medical records of Australian paediatricians who 
assessed or treated tall girls from 1959 to 1993, and from self-referrals. Wonien whose parent 
had sought a medical opinion about their tall stature and who had had a rSdiological 
assessment of their skeletal age were eligible to participate. They included girls who had 
received estrogen treatment (3 mg DES daily or 150 pig EE daily) in adolescence to reduce 
their adult height (treated group) and those who had not (untreated). Treated (n=371) and 
untreated (n=409) women completed interviews about reproductive history, fertility problems 
and sexual history25 . After adjustment for age, treated women were more likely to have ever 
tried for 12 months or more to become pregnant without success (RR 1.80, 95% CI: 1.40 to 
2.30); more likely to have seen a doctor because they were having difficulty becoming 
pregnant (RR 1.80, 95% CI: 1.39 to 2.32);. and more likely to have ever taken fertility drugs 
(RR 2.05, 95% CI: 1.39 to 3.04) 25 . Time to first pregnancy analysis showed that the treated 
group was 40% less likely to conceive in any given menstrual cycle of unprotected 
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intercourse (fecundability ratio 0.59, 95% Cl: 0.46 to 0.76) 25 . An obvious cause of the 
fertility problems could not be readily identified (sexual history was not found to be a 
confounder) but an overall excess of endometriosis and ectopic pregnancies in the treated tall 
girls compared with untreated tall girls suggested that treatment may have affected the 
developing reproductive tract. 
2.5 Overview 
This chapter outlined the use of treatment to reduce final height in tall girls and the 
effectiveness of treatment in relation to final height reduction and improved psychosocial 
outcomes. 
While available evidence strongly suggests that treatment is effective at reducing 
final height in tall girls, the degree of height reduction between studies ranges between 2.1 to 
10.0 cms. High variability in the the level of effectiveness between the studies is due to 
differences in the height prediction methods used, treatment regimens, and timing of 
treatment between studies". The study of Australian tall girls which matched treated and 
untreated women on their estimated mature height (EMH) and adjusted for error in EMH 
predictions observed an unadjusted treatment effect of minus 2.5 cm". 
While psychosocial factors are often cited as the main reason for treating tall stature, 
there is no clear evidence that treatment improves psychosocial outcomes. Apart from 
anecdotal observation from treating physicians, only two studies had formally investigated 
the psychosocial outcomes of treatment. These retrospective studies revealed no differences 
between the two groups in a range of psychosocial outcomes" 54 . 
This chapter identified studies that had Shown treatment to modify levels of some 
endogenous hormones. These modifications include the suppression of insulin-like growth 
factor-I (IGF-I) 10-13, 91 , dehydroepiandrosterone sulphate (DHEA-S) 13 , testosterone p and basal 
and GnRH stimulated gonadotropins 16 ; and increased prolactin n ' 18 ' 19 , IGF-II 12 and cortiso1 13 ' 
14  levels. While there is consistency in the findings between these longitudinal studies, some 
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degree of caution is required when interpreting these findings. The sample sizes were small 
(ranging from 8-36), and none used control groups. 
The above review examined Australian and international published case-series and 
follow-up reports of short-term side effects of treatment in tall girls. Four case-series reports 
by treating specialists, and eight follow-up studies (ranging from 6-10 years post treatment) 
desribed short-term side effects of treatment that include headache, nausea, weight gain and 
leg cramps. Less common effects of treatment include thrombosis, endometrial polyps or 
hyperplasia, ovarian cysts, and menstrual bleeding disturbances. There are a number of 
limitations to these studies. The prevalence of effects by treatment type has not been reported, 
nor have all side effects been examined consistently across studies. Most of the case-series 
reports were based on small sample sizes, and the outcomes were selected by the treating 
physicians rather than independent researchers. For uncommon outcomes, it is unclear the 
degree to which physicians systematically examined gifls for these conditions in the studies, 
and subsequently reported them. 
• While, no studies have examined the long-term effects of treatment on breast tissue, the 
long-term effects on a range of reproductive outcomes have been reported. One study 
observed no effect on reproductive outcomes but the sample size was small and the average 
follow-up was only 10 years after treatment (mean age 25 years). A longer follow-up study 
of Australian tall girls found treatment with high-dose estrogens in adolescence-to have long-
term effects on fertility 25 , suggesting longer term effects on reproductive tissue. 
These findings, together with the hormone changes and short-term side effects on the 
breast described in this chapter, suggest that high-dose estrogen treatment for tall stature in 
girls may have longer term effects on breast histology and function. 
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Box 2.1: Key points from the literature in Chapter 2. 
KEY POINTS FROM THE LITERATURE: CHAPTER 2 
• Tali girls have been treated with high-dose estrogens for psychosocial reasons 
since the 1950s. The practice of using high-dose estrogens to reduce height in 
adolescent girls is uncommon now. 
• In Australia girls were typically treated with diethylstilbestrol up to 1971 and 
ethinyl estradiol after this time. A progestagen was typically added to the 
regimen 4-5 days a month to induce cyclical bleeding. 
• Estrogen works by fusing the growth plate in long bones. The mechanism of 
action is still not clear. 
• Studies have reported estimates of height reduction ranging from 2.1 to 10 cm 
in treated girls. 
• 'There is no clear evidence that treatment improved psychosocial outcomes. 
• Treatment with high-dose estrogens appears to modify the levels of some 
endogenous hormones. 
• Short-term side effects of treatment include headache, nausea, weight gain and 
leg cramps. Less common effects of treatment include thrombosis, endometrial 
polyps or hyperplasia, ovarian cysts, and menstrual bleeding disturbances. 
• Long-term effects on fertility have been observed in the Australian study of tall 
girls. 
PART B 
Chapter 3: Current evidence on the short- and longer term effects of estrogen 
treatment in adolescence on breast symptoms, disease and function 
Chapter 4: Treatment with high-dose estrogens in adolescence: short-term 
effects on the breast and longer term breast disease 
Chapter 5: Treatment with high-dose estrogens in adolescence and 
subsequent effects on lactation 
39 
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symptoms, disease and function. 
3: CURRENT EVIDENCE ON THE SHORT- AND LONGER TERM • 
EFFECTS OF ESTROGEN TREATMENT IN ADOLESCENCE ON BREAST 
SYMPTOMS, DISEASE AND FUNCTION 
3.0 Introduction 
This chapter reviews Australian and international published case-series and follow-up reports 
of adverse effects on the breast during and shortly following cessation of estrogen treatment 
in tall girls. The review highlights the gaps in our understanding of the short- and long-term 
effects on the breast and the importance of this PhD research in narrowing this gap. This 
chapter then follows with a review of published epidemiological, molecular, in vitro and in 
vivo studies that have examined associations between estrogen exposures and breast disease. 
The evidence presented supports the suggestion that high-dose estrogen treatment for tall 
stature in adolescent girls may increase the risk of developing breast disease later in life. As 
further support, key stages in the development of the mammary gland are briefly summarised 
to highlight the importance of adolescent mammary development to adult breast health and 
function. 
This chapter then finishes with an exploration of the evidence around the postulate 
that high-dose estrogen exposure during adolescence may affect subsequent breast function, 
or more specifically, lactation. It presents the few available epidemiological and animal 
studies that have investigated the effect of exogenous estrogen exposures on lactation. When 
findings from these studies are considered .together with the reported changes in the hormonal 
milieu of girls treated with estrogens described in Chapter 2, and previous findings from the 
Australian Tall Girls Study on the long-tefm effects of treatment on fertility, it seems possible 
that treatment could have long-term effects on breast function. It is also evident that no other 
study has examined the long-term effect of high-dose estrogen treatment in adolescent girls 
on mammary function later in life. 
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3.1 Short-term side effects on the breast 
A number of breast related short-term side effects of treatment with high-dose estrogens in 
adolescent girls have been reported and include galactorrhea, increased pigmentation of the 
areolae and nipples, breast pain and, more rarely, benign breast disease (e.g fibroadenoma)". 
Case-series reports and follow-up studies that describe short-term side effects of treatment for 
tall stature on the breast are reported below. 
• 3.1.1 Galactorrhea 
Galactorrhea is a condition characterised by the milky discharge from one or both nipples not 
related to breastfeeding and has been reported to be a side effect of treatment with high-dose 
estrogens in adolescent girls. The frequency and potential mechanism for this adverse effect 
is described below. 
3.1.1.1 Frequency of side effect 
Of four case-series and two follow-up studies (see Table 3.1) the prevalence of galactorrhea 
as a side effect of treatment for tall stature ranges from 0 to 14% 43 . Two additional studies 
surveyed endocrinologists asking them how frequently particular side effects occurred in 
female patients that they treated. In the first of these studies, none of the 77 US or European 
endocrinologists surveyed (904 patients combined) revealed galactorrhea to be a side effect 
of treatment51 . The patients of the surveyed specialists were treated predominantly with 
ethinyl estradiol or conjugated estrogens. Of 82 US endocrinologists surveyed in the second 
study, none said galactorrhea was common among their patients, one said they came across it
•occasionally, 13(16%) rarely, while 68 (83%) reported that they had never come across the 
side effect among their treated patients 3 . It is unclear why the frequency of galactorrhea as a 
** See footnote p26 for method of identification of studies. All studies identified this way that explored and 
reported on the side effects of treatment on the breast were reported. 
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side effect of treatment varies widely between studies. Treatment type or dose may explain 
these differences. These studies do not differentiate between treatment types. In addition, 
some degree of random variation in prevalence is expected given the small sample sizes and 
uncommon outcomes. 
3.1.1.2 Mechanism of treatment induced galactorrhea 
Treatment induced galactorrhea is likely to be due to the increased prolactin levels that 
occurs in treated tall girls 13 . It is not clear whether the reports above refer to galactorrhea 
during treatment or galactorrhea following cessation of treatment. According to a review by 
Chatterton 98, withdrawal of estrogen, particularly if prolactin levels remain elevated, may 
precipitate galactorrhea. 
3.1.2 Increased pigmentation of the areolae and nipples 
According to published reports, increased pigmentation of the areolae and nipples is the most 
reported breast related side effect of estrogen treatment for tall stature in adolescent girls. The 
reported frequency and potential mechanism of these observed effects is described below. 
3.1.2.1 Frequency of side effect 
Of the studies described in Table 3.1 that examined breast related side effects of treatment, 
the prevalence of increased pigmentation of the areolae and nipples ranged between 3% 22 to 
38%99 ". The survey by Barnard et al. (2002)3 of US endocrinologists (not in table) who had 
treated adolescent girls with high-dose estrogens found that 72% had observed this side effect 
in one or more of their patients 3 . Of 86 respondents, 12 (14%) stated that increased 
pigmentation was common among their patients, 26 (30%) said they came across it 
occasionally, 24 (28%) rarely, and 24 (28%) never 3 . The separate survey of US and European 
endocrinologists referred to above (Section 3.1.1.1) did not report increased pigmentation of 
the nipples and areolae as a side effect of treatment51. 
" German language article cited by Drop 1998 
Study 
	
Estrogen Type* 
Kuhn et al. 
(1977)43 
Trygstad (1986)23 	680 	DES & P 
EE & P 
EE & P . 
Other formulations/doses 
, de Waal et al: 	180 	EE 
(1995)29 
Weimann et al. 	50 	Conjugated 
(1988)22 
Crawford (1978)41 	130 	DES & P (104) 
EE & P (26) 
Radiv-o.jevic et al. 	26 	1713-estradiol 
(2006)48 
Dose mg/day Type of study 
36 	EE 
	
0.5 	 Case-series 
4.0-8.00 1. 
	
Case-series during treatment 
5.0 
0.5 
0.25 
0.100 
0.100-0.200 
7.5-11.25 
5.0 
0.25 
Case-series 
Follow-up of patients 
(mean 10 years post-
treatment) 
Follow-up of patients 
(up to 6 years post-treatment) 
Case-series during treatment 
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Table 3.1: Breast related side effects of high-dose estrogen treatment for tall stature in adolescent girls. 
Side Effect (breast related)  
Increased pigmentation of areolae and nipples ("in 
many") 
Galactorrhea during therapy (14%). 
Pigmentation of areolae and nipples (23%) 
Galactorrhea (2%) 
Benign breast fibroadenoma (n=2, 0.3%) 
Flat-chestedness (n=7) 
Pigmentation of areolae and nipples (27%) 
Galactorrhea (4%) 
Breast cysts/tumours (1%) 
Breast discomfort (6%) 
Increased pigmentation (2%) 
Flat-chestedness (% not reported) 
Increased pigmentation of the areolae and nipples 
(% not reported) 
Benign intraductal papilloma (EE) (n=1) 
Breast discomfort (n=1) 
Increased pigmentation (part of body not 
specified) 
* EE=ethinyl estradiol, DES=diethylstilboestrol, P= progestagen 
f 8.0 mg is bioequivalent to 0.100 mg of ethinyl estradiol (EE) 
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3.1.2.2 Mechanism of treatment induced pigmentation of areolae and nipples 
Darkened pigmentation, a common occurrence in pregnancy, is believed to be due to high 
levels of circulating estrogen m . Darkened areolae in newborn girls is an indicator of 
estrogen excess m . This effect on the breast has also been reported to occur following the 
accidental exposure to estrogen in pre-adolescent girls. In 1953, Cook, McArthur & 
Berenberg 1°I , reported a darkening of the pigmentation of the nipples and areolae and growth 
of the breast in girls aged four and seven following the accidental ingestion of estrogen 
tablets. 
3.1.2.3 Side effects by treatment type 
Reports suggest that the severity of the increased pigmentation in girls treated with estrogens 
for tall stature depends on the form of estrogen used. According to Drop, the majority of 40 
treated girls in Zackman and colleagues' case-series report 46 had experienced darkening of 
the areolae, which was more marked in the DES treated girls than the EE treated girls. 
Wettenhall and Roche (1965) 52 described the common occurrence of darkening of the areolae 
with treatment using diethylstilbestrol which did not fade completely . on cessation of 
treatment. In contrast, a decade later, Wettenhall stated that pigmentation always faded and 
skin returned to its normal colour some months after treatment cessation 60 . 
The more pronounced effect of DES on pigmentation of the nipple and areolae was 
also observed by Crawford' s ' (p 1,193): 
" When diethylstilbestrol is given, pigmentation of the nipples, areolae, linea alba, 
and skin creases of the neck are predictable side effects in girls who are inherently 
good tanners... When ethinyl estradiol is used, the enhancement of pigmentation is so 
minor that it scarcely merits discussion with the child before therapy is begun". 
None of the reports described above provide prevalence of the side effect by treatment type. 
Chapter 3: Current evidence on the short- and longer term effects or estrogen treatment in adolescence on breast 	 45 
symptoms, disease and function. 
3.1.3 Breast hypoplasia 
Breast hypoplasia or micromastia is the incomplete or under-development of the breast and 
has been reported to be a side effect of treatment with high-dose estrogens for the treatment 
of tall stature in adolescent girls as described below. 
3.1.3.1 Frequency of side effect 
According to Crawford, one of three principal reproductive organ complaints to arise in 
follow-up studies (references not provided) of treated patients at Massachusetts General 
Hospital was 'flat-chestedness' 4 '. The number within the Massachusetts cohort (104 DES, 26 
EE treated) who reported this problem was not presented. The only other published report of 
under-developed breasts as a side effect of estrogen treatment was made by Trygstad 23 . In 
this report, complaints of under-development were made by seven of a total 680 treated tall 
girls (see Table 3.1). These reports of flat-chestedness were made by the girls themselves. It 
is unclear whether girls noticed a reduction in breast size with treatment or perceived 
treatment to have reduced the growth velocity of their breasts. There was no clinical 
assessment to verify these reports. 
An interview of a Danish endocrinologist who recently treated girls for tall stature 
was published in a prominent Australian newspaper (2007)55 . The endocrinologist was asked 
by a journalist whether treatment was likely to 'flatten the figure' as suggested by a tall girl 
(also interviewed by the journalist) who had friends who had been treated. The 
endocrinologist said that it was possibly a side effect of treatment but that the long-term 
adverse effects on the breast were not known. 
3.1.3.2 Mechanisms of treatment induced breast hypoplasia 
Under-development of the breast (hypoplasia or micromastia) can have a congenital• 
aetiology (e.g. ulnar-mammary syndrome, Poland's syndrome, Turner's syndrome, and 
congenital adrenal hyperplasia); or it can be acquired (e.g. due to trauma l°2 or radiotherapy of 
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the prepubertal breast-bud 103 ) 104. Another explanation is provided in a study by Pertzelan 
(1982) 1135 who examined breast development (according to Tanner stages—see Chapter 2, 
Section 2.4.1.1) in girls treated with estrogen for estrogen deficiency and under-developed 
breasts. In this study, 45 girls were placed into four groups: those with gonadal dysgenesis, 
isolated gonadotropin deficiency, multiple pituitary hormone deficiencies, and congenital 
adrenal hyperplasia. The patients with gonadal dysgenesis, and a normal functioning 
hypothalamic-pituitary, achieved full breast development after estrogen treatment. In 
contrast, those with isolated gonadotropin deficiency and multiple pituitary hormone 
deficiency displayed incomplete breast development even after three or more years of 
estrogen treatment. The authors of the study highlighted the major difference in hormonal 
status between those achieving full breast development and those who did not. The latter 
groups that did not achieve complete breast development lacked gonadotropins. This led the 
researchers to suggest that gonadotropins had an important role in mammary gland 
development l05 . These findings are interesting because, as reported in Chapter 2, 
gonadotropins (LH and FSH).were suppressed with treatment for tall stature 16 . It is possible 
that insufficient gonadotropin levels during treatment contributed to incomplete breast 
development. 
Another possible explanation for Under-developed breasts in treated girls may be 
related to IGF-I, a growth factor believed to play an important role in mammary gland 
development20' 21 . It is possible that the reduction in IGF-I levels,observed with treatment (see 
Chapter 2, Section 2.4.2.2), adversely affects mammary gland development. 
Treatment has been reported to accelerate the development of the breasts". In one 
report, accelerated pubertal development has been observed in up to 90% of treated girls 23 . 
Whether this acceleration results in less overall growth of the breast is unknown. 
3.1.4 Breast pain 
Breast pain, or mastalgia, not related to lactation, can have a number of causes. Preece and 
colleagues (1976) 1 " identified six specific aetiologies for breast pain, excluding causes of 
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pain arising outside of the breast and those of unknown aetiology. The aetiologies include 
cyclical pronounced .mastalgia (hormone related), duct ectasia (blocked milk duct), Tietze 
syndrome (inflammation of one or more of the costal cartilages), trauma, sclerosing adenosis 
(benign cellular proliferation of the lobule),, and cancer l06 . Other causes not included by 
Preece, particularly for moderate/severe pain for >6 months include: fibroadenoma, cysts, 
and duct papilloma l°7 . Severe cyclical mastalgia has been associated with breast cancer 
susceptibility 108-110. 
3.1.4.1 Frequency of side effect 
According to Weimann et al. (1998)22, 6% of 50 girls treated with high-dose estrogens 
reported breast discomfort during treatment with conjugated estrogens 22 (Table 3.1). In a 
separate cohort", one of 26 girls treated with 17P estradiol was reported to have experienced 
breast discomfort. No other study described in Table 3.1 reported breast pain as a side 
effect of treatment. Most of the case-series reports were based on small sample sizes, and 
the outcomes were selected by the treating physicians rather than independent researchers. 
For uncommon outcomes, it is unclear the degree to which physicians systematically 
examined girls for these conditions in the studies, and subsequently reported them. 
3.2 Benign breast disease 
Benign breast disease has been reported in the' literature to be a rare side effect of treatment. 
A description of the different types of benign breast diseases and the reported preyalence of 
this diseak in treated girls is described below. 
3.2.1 Definitions and types of benign breast disease 
Benign breast disease encompasses a large number of benign breast abnormalities and has 
many classifications. According to the AND! classification (Aberration of Normal 
Development and Involution), benign breast diseases include: giant or multiple 
fibroadenomas as an extension of aberrant lobular development (age of occurrence 15-25 
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years); incapacitating mastalgia as an extension of aberrant responses to cyclical changes 
during menstruation; periductal mastitis as an extension of aberrant lobular involution; and 
epithelial hyperplasia with atypia as an extension of aberrant epithelial turnover" (See 
Figure 3.1). 
Figure 3.1: Aberration of Normal Development and Involution (AND!)" classification 
of benign breast diseases. 
AND! Classification 
Benign Breast Disease 	 Cause 
Epithelial hyperplasia with atypia 	-0• Aberrant epithelial turnover 
Giant/Multiple fibroadenoma 	 Aberrant lobular development 
• Severe mastalgia 	 Aberrant response to cyclical 
changes during menstruation 
Periductal mastitis 
Aberrant lobular involution 
Benign breast diseases have also been classified by Dupont and Page (1985) 112 as 
three main histological types: proliferative benign breast disease, with or without atypical 
ductal or lobular hyperplasia; or non-proliferative benign breast disease. Non-proliferative 
benign lesions of the breast include cysts, papillary changes, epithelial calcifications, mild 
hyperplasias and fibroadenomas 113 . Benign breast diseases have also been classified within 
two broad categories: fibroadenomas (benign tumours), and fibrocystic disease n3 . 
Histologically, abnormalities of fibrocystic breast disease are of epithelial origin, while those 
of fibroadenomas originate in the lobules I13 . Fibrocystic disease is also commonly referred to 
as: cystic hyperplasia, cystic disease, or epithelial dysplasia 113 . The latter classification 
system seems to be used in studies reporting breast related side effects of girls treated with 
high-dose estrogens. 
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3.2.2 Frequency of benign breast disease in treated girls 
Benign breast disease has been reported as a siae effect in treated girls 29 although reports are 
less common than for the other breast related side effects (Table 3.1). Two cases of 
fibroadenoma were diagnosed in a case-series of 680 treated girls (Trygstad, 1986) 23 after 
one year of DES treatment. Benign breast cysts/tumours were also reported to occur in 1% of 
180 treated girls 29 . 
Conte et al. (1978) 51 surveyed members of two endocrine societies for their views 
and practices with respect to the use of estrogens in children and adolescents and asked about 
the side effects experienced by the patients of treating endocrinologists (n=77). Of 904 
patients treated with estrogen, cystic hyperplasia of the breast was reported as a side effect of 
treatment in eight (0.1%). 
The survey of US paediatric endocrinologists 3 by Barnard et al. (2002) 3 revealed 
17% of treating endocrinologists had observed cystic hyperplasia of the breast in one or more 
of their patients as a side effect of treatment. Of 81 responders, three had occasionally 
observed the side effect in 'their patients, 11 rarely and 67 never. It is unclear, whether or not; 
treating endocrinologists were asked to report on the occurrence of fibroadenomas as a side 
effect in their patients. 
3.2.3 Estrogen and benign breast disease 
It has been suggested that high levels of circulating estrogen. is the cause of proliferative 
benign breast disease' 14 and fibroadenoma l is . A review of the literatures identified studies 
reporting the association between estrogen therapy (estrogen replacement therapy, oral 
contraceptive pill) or abnormal estrogen/progesterone ratios and benign breast disease. While 
some of these exposures occurred in older women (e.g. menopausal women in relation to 
It Studies were identified by PubMed search of the English language literature using the terms breast 
AND benign (OR disease OR disorder OR proliferative OR fibroadenoma OR hyperplasia) AND 
hormone (OR estrogen OR progestagen OR progesterone) for any field covering all dates up to the 
time of writing. The reference lists of all the publications identified by this search were inspected for 
additional. 
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estrogen replacement therapy), this review is interested in the effects on all ages. The effects 
of hormone exposures on benign breast disease might not be age dependent. 
Prolactin and IGF-I levels, which have been shown to be modulated in some treated girls (see 
Chapter 2, Section 2.4.2) have also been linked to benign breast disease. A review of these 
studies is presented below. 
3.2.3.1 Estrogen replacement therapy 
A review of epidemiological studies by Silvera and Rohan (2008) 116 examined the 
association between HRT use and benign proliferative epithelial disorders (with and without 
atypia). It included findings from one cohort"' and three case-controls studies" 6 ' 1t8 . The 
cohort study by Rohan and Miller 117 observed a statistically significant association between 
benign proliferative epithelial disorders of the breast (BPED) and greater than eight years of 
HRT use in postmenopausal women (incidence rate ratio IRR 1.70, 95% Cl: 1.06 to 2.72), 
while one nested case-control study" 8 and two case-control studies" 9 ' 120 observed no 
association between "ever using HRT" and benign proliferative disease. One of these non-
significant studies (Berkowitz et al. 1984 120) observed a non-statistically significant 
association between HRT use >5 years versus never used: OR 3.0 (95% CI: 0.5 to 17.5). 
With such wide confidence intervals it is possible that the sample sizes for the HRT duration 
sub-categories examined were insufficient to demonstrate statistical significance. The sample 
size of the cohort studied by Rohan and Miller (1999)" 7 was much larger [total cn=6,134 
compared to 1,608 for Berkowitz et al. (1984) 1 . 
An examination of the research literature identified three case-control studies not included in 
the review above and a randomised controlled trial published after the review. One case-
control study by Pastides and colleagues' 71 reported a twofold risk of having had fibrocystic 
breast disease in postmenopausal women using estrogen replacement therapy compared with 
non-users (age-adjusted OR 2.0; 95% CI: 1.0 to 3.9), though this association was only 
observed in women who experienced natural menopause. The second case-control study 122 
found significant associations between estrogen replacement therapy (conjugated estrogens) 
and fibrocystic disease if used 10 or more years (age-adjusted OR 5.2, 95% CI: 2.2 to 12.3) 
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and if the woman was currently using and had used for 5 or more years (age-adjusted OR 2.8, 
95% CI: 1.2 to 6.5). The odds of having fibrocystic disease were greater in women who used 
0.625 mg of conjugated estrogen compared with women who used 0.3 mg. The third case-
control study 123 observed an age-adjusted OR of 1.4 (95% Cl: 1.1 to 1.8) in ever users of 
HRT compared with non-users and an OR of 1.9 .(95%CI: 1.2 to 2.9) for 15 or more years of 
use. 
These results are supported by the randomised controlled trial undertaken by the 
Women's Health Initiative (WHI). This study (n=10,739) tested the effect of conjugated 
equine estrogen (0.625 mg/d) on risk of proliferative breast disease in postmenopausal 
women and found that women who used conjugated equine estrogen (CEE) (n=155) were 
more likely to have developed proliferative benign breast disease (HR 2.11, 95% CI: 1.58 to 
2.81) 124 than untreated women (n=77) after a mean follow-up of seven years. Risk was 
greater for proliferative benign breast disease without atypia (HR 2.34, 95% CI: 1.71 to 3.20) 
compared. to proliferative disease with atypia (HR 1.12, 95% CI: 0.53 to 2.40) 124 . 
It is important to separate those studies that explored estrogen only and estrogen and 
progesterone combined HRT formulations. Of the observational studies above, only the 
cohort study by Friedenreich et al. 118 had separately reported the effects of the combined 
estrogen and progestagen (E + P) combined formulation. They found no association between 
combined hormone therapy and proliferative breast disease (OR, 1.02, 95% CI: 0.75 to 1.39). 
A second placebo-controlled randomised controlled trial undertaken by the WHI 125 , 
(n=16,608) tested the effect of combined E + P formulations (0.625 mg/day of conjugated 
equine estrogen and 2.5 mg/day of medroxyprogesterone acetate). The hazard ratio for 
benign proliferative breast disease without atypia was 2.00 (95% CI: 1.50 to.2.66), while for 
atypical hyperplasia it was 0.76(95% CI: 0.38-1.52) after a mean follow-up of 5.5 years. The 
risk ratios are greater for estrogen alone hormone therapy compared to. the combined 
formulations. However, caution is required when comparing both studies because of the 
differences in baseline characteristics, event rates, and length of interv. ention and follow-up 
time125. 
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Few studies examined the association between exogenous hormone replacement 
therapy and breast fibroadenomas. One published case-control study found an increased risk 
of fibroadenoma with ever use of estrogen replacement therapy in women 45 years and older 
(OR 2.83, 95% Cl: 1.21 to 6.60) 126 while another observed an OR of 1.6 ( 95% CI: 0.8 to 
3.5) 123 in postmenopausal women. 
Overall evidence based on randomised double blind, placebo controlled trials 
suggests that risk of benign breast disease may be greater in women who have used estrogen 
replacement therapy, or combined estrogen and progestagen combined therapy for more than 
five years. This does not parallel the findings of studies examining the association between 
oral contraceptive use and benign breast disease as described below. 
3.2.3.2 Oral contraceptive use 
Silvera and Rohan, in their recent review above (2008) 116 , also included epidemiological 
studies that had examined the association between oral contraceptive (OC) use and benign 
proliferative epithelial disease (BPED). Two cohort and six case-control studies were 
included in the review. Two of these studies, a case-control TM9 and a nested case-control 
study 127 , observed an inverse association between BPED and OC use (RR 0.35, 95% Cl: 0.16 
to 0.76) (IRR§§0.95, 95% CI: 0.85 to 1.07) respectively, while six other case-control 
studies 120, 128-132 observed no association. One of these case-control studies observed a 
stronger association between long-term use of oral contraceptives and fibrocystic disease in 
which epithelial atypia was minimal or absent compared with fibrocystic disease with 
epithelial atypia 131 . However another study did not find a difference in association between 
histologic type of fibrocystic breast disease' 33 . 
An inverse association has similarly been observed between oral contraceptive use 
and fibroadenomas (only fibrocystic or BPED were explored in the review by Silvera and 
Rohan above). A follow-up of the Oxford Family Planning Association Study cohort, found a 
negative association between hospitalisation for fibroadenoma and total duration of oral 
The incidence rate ratio (IRR) is the ratio of incidence rates in those exposed to that of those 
unexposed. 
Chapter 3: Current evidence on the short- and longer term effects olestroaen treatment in adolescence on breast 	 53 
symptoms, disease and function. 
contraceptive use for regimens containing lower dose <50 1.tg, 50 pg and >501.1g estrogen' 34 . 
Similarly, a randomised controlled study 135 observed a significant reduction in the width of 
existing fibroadenomas in women who took ethinyl estradiol (0.03 mg) and levonorgestrel 
for four consecutive cycles, suggesting a protective effect of oral contraceptives on 
fibroadenomas. 
Of the associations reported above, all showed inverse relationships. However, a 
hospital based case-control study by Berkowitz et al. (1984) 136 that was not included in the 
review by Silvera and Rohan (2008) 116, found previous exposure to the oral contraceptive pill 
to be associated with an increased occurrence of fibrocystic disease [age adjusted OR 2.52 
(95% CI: 1.33 to 4.77)] in postmenopausal women only' 36 . The' suggestion that this 
observation may be due to different doses or regimens between pre- and postmenopausal 
women was raised . by the authors. The issue concerning different doses of the oral 
contraceptive pill across studies is discussed more fully below. 
Of interest to this PhD study is the association between the use of the oral 
contraceptive pill 'at a young age and the risk of benign breast disease. Only one study was 
reported in the research literature. This Australian case-control study (Yu et al. 1992) 137 
observed an increased risk of fibroadenoma in women (117 cases) who used oral 
contraceptives before the age of 20 when compared to population controls' 37 . 
Different doses of estrogen contained within the oral contraceptive pill (0Cs) could 
be a reason for the differences in association reported in women before the age of 20. The 
contraceptive pill in the 1960s contained high-doses of estrogen (100-150 pig) in the form of 
mestranol, the 3-methyl ester of ethinyl estradiol..When information about thrombotic side 
effects was observed in the late 1960s low-dose regimens containing ethinyl estradiol became 
available. The British government phased out high-dose estrogen contraceptive pills in 1969, 
but in the US 1 38 and Australia l39 , women had the option of using high-dose or low-dose OCs 
through to the 1980s, though low-dose OCs were more popular. In 1984 low-dose estrogen 
content OCs accounted for approximately 85% of the US OC market 95 . It is possible that the 
contrasting effects observed in many OC studies are due to different doses and types of 
estrogen. As well as dose, estrogen type needs to be considered. Mestranol, while in higher 
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doses, may be less potent on a gram by gram basis compared to ethinyl estradiol in relation to 
its effects on the breast. Ethinyl estradiol is 1.7 times more potent than mestranol on a weight 
by weight basis, according to endometrial response and liver corticosteroid binding globulin 
production as endpoints 95 . They may have different potencies on breast tissue 149 . As stated by 
Goldzieher, 50 pig of mestranol is pharmokinetically bioequivalent to 35 pig of ethinyl 
estradiol, while physiologically, it ranges from 50 to 100% of the activity of ethinyl estradiol 
depending on the endpoint chosen 141 . Therefore, 150 pig of mestranol, used in the earlier oral 
contraceptive pill does is not equivalent to the same dose of ethinyl estradiol. 
While overall evidence suggests that the risk of benign breast disease may be greater 
in women who have used estrogen replacement therapy, or combined estrogen and 
progestagen combined therapy for more than five years, this does not parallel the findings of 
studies that had examined the association between oral contraceptive use and benign breast 
disease as described above. Women who are exposed to estrogen, or estrogen and 
progestagen combined hormone therapies are postmenopausal while, for the oral 
contraceptive pill, it is pre-menopausal women. Any associations between these two 
therapies with benign breast disease need to consider these differences. Premenopausal 
women have significantly higher serum levels of estrogen and progesterone compared with 
postmenopausal women and these differences in hormone levels might explain the different 
findings reported above. 
3.2.3.3 Abnormal estrogen progesterone ratio 
Higher estrogen over progesterone ratios have also been associated with benign breast 
disease. This is of interest to this study because girls treated with high-dose estrogens 
typically took a progestagen 4-5 days a month to induce cyclical bleeding. One study 142 
observed significantly lower plasma progesterone over estradiol ratios during the luteal phase 
in women with benign breast disease. Subnormal levels of progesterone have also been 
observed in women with benign breast lesions' 42 . However, no such association was 
observed in a study that measured serum progesterone levels of women with cyclical breast 
pain and biopsied benign breast disease143. 
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3.2.3.4 Exogenous estrogen in the animal model 
Animal studies also suggest a link between exogenous estrogen and proliferative tissue 
growth. In their review of estrogen and progesterone action on breast cells Mauvis-Jarvis and 
colleagues, referred to the formation of cysts and epithelial overgrowth comparable to human 
fibrocystic disease, that occurred with the administration of high-doses of estrogen to 
ovarectomised female rats I44 . Likewise, in a different study, the administration of 17 beta-
estradiol (E2) (human equivalent 1 mg/d) to postmenopausal macaques appeared to result in 
a significantly higher prevalence of hyperplasia (total and atypical) compared with 
controls 145 . 
3.2.3.5 Prolactin 
Prolactin has also been linked to benign breast disease. Girls treated with high-dose estrogen 
have been observed to have higher than normal prolactin levels (see Chapter 2).. It is possible 
then, that the increased circulating prolactin observed in girls treated with high-dose 
estrogens for tall stature contributed to the benign breast disease observed in some published 
case-series reports. Local over-expression of prolactin has been associated with benign breast 
lesions in the mouse model that include abnormally differentiated epithelium, atrophy of the 
myoepithelial layer, dilated ducts, and cysts 14 . A cross-sectional study of 153 women, found 
that 7% (n=4) of women with operable -benign breast lesions had higher than normal 
prolactin levels i47 . 
3.3 Breast cancer risk 
It is plausible that high-dose estrogen treatment (ethinyl estradiol or DES) during 
adolescence increases the risk of breast cancer in later life. De Waal et al. (1995) 29 followed 
up women an average 10 years following treatment (mean age 25 years) and described 
menstrual characteristics and reproductive outcomes for treated and untreated women in the 
Netherlands. However, women in this follow-up were too young to examine breast -cancer 
risk because breast cancer in this age group is uncommon. 
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A number of studies have demonstrated an association between estrogen exposures 
and breast cancer risk. These include studies that have examined the association between 
endogenous levels of estrogen (estradiol and/or estrone), or exogenous exposures (e.g. HRT, 
DES to prevent miscarriage in pregnant women, and the oral contraceptive pill) and breast 
cancer risk (Figure 3.2), reviewed *** in the 'following section. While some of these exposures 
occurred in older women (e.g. menopausal women in relation to estrogen replacement 
therapy), this review is interested in the effects on all ages. The effects of hormone exposures 
on breast cancer risk might be relevant to all ages. 
Figure 3.2: Estrogen and breast cancer risk: studies of associations presented in the 
following review. 
Estrogen 
Estradiol/Estrone 	Oral Contraceptive • 	HRT 	Diethylstilbestrol in 
pregnancy/ in utero 
Breast Cancer 
*." Studies were identified by PubMed search of the English language literature using the terms breast AND 
cancer AND hormone (OR 0/estrogen OR estradiol OR diethylstilbestrol (DES) or contraceptive OR 
progestagen OR progesterone) for any field covering all dates up to the time of writing. The reference lists 
of all the publications identified by this search were inspected for additional studies. The findings and 
eharacteristics of all studies and/or reviews of studies that explored and reported the association between 
estrogen therapy or combined estrogen and progesterone therapy are described. 
Endogenous Exogenous 
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3.3.1 Endogenous estrogen 
Associations between elevated serum and urinary levels of estrogen and risk of breast cancer 
have been observed. The association seems stronger in postmenopausal women as described 
below. 
The findings of a 1997 published pooled analysis 148 of six prospective 
epidemiological studies suggested an association between high concentrations of endogenous 
estradiol and breast cancer risk in postmenopausal women. In the pooled analysis, women 
who subsequently developed breast cancer (n=329) had 15% (p=0.0003) higher mean 
concentration of blood estradiol prior to diagnosis compared with women who remained free 
of cancer (n=1 ,105)148. 
One of the researchers involved with the above published pooled analysis, later in 
1999, argued that case-control studies examining the association between endogenous 
estrogen levels and breast cancer risk are limited by the possibility that any differences in 
endogenous estrogen levels observed between cases and controls, could be due to the tumour 
or treatment149. It was suggested that prospective cohort studies should only be examined. 
In 2002, the same researchers re-analysed nine prospective studies. Together these include 
663 postmenopausal women who developed breast cancer two to twelve years post estradiol 
measurement and 1,765 who did not develop breast cancer. The RRs for women with 
increasing quintiles of free estradiol relative to the lowest quintile were 1.38(95% CI: 0.94 to 
2.03), 1.84 (95% CI: 1.24 to 2.74), 2.24 (95% CI: 1.53 to 3.27), and 2.58(95% CI: 1.76 to 
3.78; P for trend<0.001). These findings suggest that levels of endogenous sex hormones are 
strongly associated with breast cancer risk in postmenopausal women 150 
A separate and later review of epidemiological studies published in 2007 by 
Hankinson and Eliassen I51 concluded that a strong positive association between breast cancer 
risk and circulating levels of estrogens is now well confirmed among postmenopausal 
women. Postmenopausal women with hormone levels in the top quintile compared to the 
lowest were reported to have a two- to threefold higher risk of breast cancer. Evidence for 
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premenopausal women was reported to be inconsistent 151 . A search of the literature identified 
additional studies published since these reviews. The findings in these studies were also 
inconsistent' 52-155 
While the above studies focused on serum levels of estrogen, one case-control study 
(n=364 breast cancer cases, 382 controls) demonstrated a positive association between 
elevated urinary levels of estrogen and risk of postmenopausal breast cancer 156 . The 
incidence 'rate ratio for estrone levels (highest versus lowest quartile) was 2.5 (95% CI: 1.6 to 
3.8), while that for estradiol Was 1.5 (95% CI: 1.0 to 2.3) 156 . 
According to Rinaldi et al. (2006) 157, the well established relationship of body mass 
index (BMI) with breast cancer in postmenopausal women could be partially explained by 
increased levels of endogenous estrogens. In their study, using the European Prospective 
Investigation in Cancer and Nutrition (EPIC) cohort, the association between BMI and breast 
cancer risk in postmenopausal women was substantially reduced after adjustment for serum 
levels of estrogen (from RR 1.1'1 95% CI: 0.99 to 1.25; to RR 0.99; 95% CI: 0.87 to 1.12) 15'7 . 
3.3.2 HRT 
Overall evidence suggests that women who currently use, and have used HRT for at least five 
years are at increased risk of breast cancer 158 ' 159 . Estrogen (E) and progestagen (P) 
formulations appear to be associated with an elevated BC risk 160 . The histological type of 
breast cancer may also differ with HRT type, with risk of lobular carcinoma being greater 
than the risk of ductal carcinoma l61 ' 162 , particularly for E + P formulations. Studies also 
support a reversible effect on risk if HRT has been discontinued for five or more years 158 . 
The Women's Health Initiative (200•) 159 was a randomised controlled trial, and one 
of three large studies to have observed an increased risk of invasive breast cancer and use of 
HRT. In this study (8,506 treated, 8,102 placebo) an increased risk of invasive breast cancer 
was observed with combined E + P HRT use after a five year follow-up: hazard ratio 1.26 
(95% CI: 1.00 to 1.59), and an absolute risk of eight extra invasive breast cancers per 10,000 
person-years 159 . This increased risk was not observed with the estrogen only HRT arm of the 
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trial, in women who had had a hysterectomy 163 . The UK Million Women cohort study 
(2003) 164 observed an increased risk of invasive breast cancer in women currently using 
estrogen only formulations and combined formulations, RR 1.30 (95% Cl: 1.21 to 1.40), 
p<0.0001; and RR 2.00(95% CI: 1.88 to 2.12), p<0.0001 . respectively. A similar but stronger 
association for estrogen only HRT was observed in the Danish Nurses cohort study (2004) 165 
(10,874 women), RR 1.96 (95% CI: 1.16 to 3.35) and for E + P combined formulations: RR 
2.70(95% CI: 1.96 to 3.73). 
A number of pooled analyses of epidemiological studies on HRT use and breast 
cancer risk have been conducted and include those by Lee et al. (2005) 166, Shah et al. 
(2005) 167, the Collaborative Group on Hormonal Factors in Breast Cancer (1997) 158 , 
Steinberg et al. (1994)168,  Silero-Arenas et al. (1992) 169, and Steinberg et al. (1991) 179, of 
which there is some overlap in studies. A summary of these studies is described in Table 3.2. 
The pooled analyses all suggest that HRT, estrogen alone or combined E + P formulations, 
increase breast cancer risk. 
Two meta-analyses, by Bush et al. (2001) 171 and Greiser et al. (2005) 172 , have also 
been published. The former analyses found little consistency among the observational studies 
that examined the association between risk of breast cancer and use of HRT (ever versus 
never) and duration of use. On the other hand, the latter study, which included the larger 
more recent randomised controlled trials, found a linear increase in overall risk of invasive 
breast cancer with HRT use. Annual increases in BC risk ranged between 0-9% foi estrogen 
and, progestagen combined formulations and 0-3% for estrogen only. 
S'ilero-.A-renas 	 27 
. 	_ 
(199v69 
12 
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Table 3.2: Pooled analyses of epidemiological studies examining the association 
between HRT use and breast cancer risk. 
Study 	 Studies Women Hormone Pooled estimates 
(N) 	(N) 
Lee et al. (2005) 166 	61* E & P 	OR 1.08(95% CI:1.07 to 1.08) per year of use 
- Shah et al. (2005) 167 	13 
	
700,000 	E 	OR 1.16 (95°/0 C-1: 1.06 to 1.28) current use 
8 
	
650,000 	E & P 	OR 1.39(95% Cl: 1.12 to 1.72) current use 
.Collaborative Group 	51 . 	209,594 	HRT 	RR 1.35 (95% CI: 1.21 to 1.49) HRT ?5 years 
on Hormonal Factors 
(1997) 158 
in Breast Cancer . 	 use 
RR 1.02 (95% Cl: 1.01 to 1.04) per year of 
Steinberg et al. 	 20 	—45,000 
	
A RR 0.00013 (95% Cl: 0.0008 to 0.0018) per 
(1994) 168 	 month of estrogen use 
RR 1.15-1.49t for 10 years of use 
HRT 	RR 1:06: (95% Cl: 1.00 to 1.12) ever use 
RR 1.17(95% Cl: 1.06 to 1.29) 4-8 years of 
use 
Steinberg et al. 	 16 
(1991) 17o 
RR 1.3 (95% CI: 1.2 to 1.6) for >15 years of 
use 
* Includes 51 studies by Collaborative Group 
t Different RRs because used different models of study inclusion 
To further support the link between HRT use and breast cancer risk a recent 
Australian study examined the association between a fall in HRT use (since the reporting of 
the Women's Health Initiative findings on HRT and breast cancer risk) and breast cancer 
incidence and found a reduction in breast cancer incidence with reduced HRT use 173 . This 
was also observed in another recently published study174. 
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3.3.3 Oral contraceptive pill 
As described above, the contraceptive pill contains ethinyl estradiol, but in much lower doses 
(30-50 jig/d) than that used in the treatment of tall girls (150 p.g/d), though higher doses, in 
the form of mestranol, were used in earlier years. A large number of studies have examined 
the association between general OC use and breast cancer, with more than 60 case-control 
studies and 10 cohort studies, several meta-analyses and a large pooled analysis among 
them 175 . A pooled-analysis of 34 case-control studies (Kahlenbom et al. 2006) 176 that 
examined the association between OC use and premenopausal cancer reported an increased 
risk of breast cancer with women who had ever used OCs (RR 1.19, 95% CI: 1.09 to 1.29) 
and an increased risk with OC use in parous women before first full-term pregnancy (FFTP) 
compared with women who used OC after FFTP (RR 1.44, 95% CI: 1.28 to 1.62). This data 
displayed a larger but similarly positive association between OC use (ever used) and breast 
cancer risk that was observed in an earlier meta-analysis m of 34 studies, and a separate 
pooled analysis of 54 studies 178 . This earlier pooled analysis observed an increased risk of 
having had a breast cancer diagnosis: current users RR 1.24 (95% CI: 1.15 to 1.33), 
2P<0.00001; 1-4 years after stopping RR 1.16 (95% Cl: 1.08 to 1.23), 2p=0.00001; five to 
nine years after stopping RR 1.07 (95% CI: 1.02 to 1.13). No significant excess risk of 
having breast cancer diagnosed 10 or more years after stopping use was observed [relative 
risk 1.01 (95% CI: 0.96 to 1.05)]. Interestingly, this pooled analysis found that women who 
began use before age 20 had higher relative risks of having had breast cancer diagnosed 
while they were using combined oral contraceptives or within the five year period after 
stopping use, when compared with women who began use at older ages. The estimated 
excess number of cancers diagnosed for women who used OC within the 10 years prior, was 
found to be 0.5 (95% CI: 0.3 to 0.7) among 10,000 women who used OCs from age 16-19 
years. 
A subsequent case-control study not included in the meta-analyses above, elucidated 
the combined effects of OC use and genetic factors in a population-based series of BRCA1/2 
mutation-tested early-onset breast cancers and found a significantly increased risk for early-
onset breast cancer for each year of OC use prior to age 20 years' 79 . This association between 
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longer durations of use before age 20 and increasing risk of early-onset breast cancer risk 
was also observed in an age-matched case control study that found for those women 
diagnosed before 36 years, risk increased for longer OC use before age 20 (RR 1.44 per year, 
p=0.04) I80 . Confidence intervals were not provided. 
In light of the overall evidence available on oral contraceptive use and breast cancer 
risk, in 2005, The World Health Organization classified combined estrogen and progestagen 
contraceptives as group 1 carcinogens I81 . In relation to the treatment of tall stature with high-
dose estrogens, Drop et al. 2001) 5° (p981) stated: 
"In view of a relationship with oral contraceptive (0C) use at an early age and 
duration of OC use with increaSed risks of breast cancer... there is a need for long-
term follow up of individuals treated with pharmacological doses of estrogens." 
3.3.4 Diethylstilbestrol (DES) 
The evidence above suggests that high endogenous levels of estrogen and exogenous 
estrogen exposures, in the form of hormonal replacement therapy are associated with 
increased risk of breast cancer risk. Diethylstilbestrol is another form of exogenous estrogen 
that has also been studied extensively in relation to breast cancer risk. Diethylstilbestrol was 
used by pregnant women to prevent miscarriage. Typically, the dose of DES was 5 mg a day 
beginning in the sixth week of pregnancy, increasing to 125-150 mg/d in the 35" week ' 82 . 
This form of estrogen was also used in the treatment of tall stature in adolescent girls 
(typically 3 mg twice a day 4-5 days a month) but ceased to be used because of reports in 
1971 58 that it was associated with rare clear cell adenocarcinoma of the vagina in the 
daughters of women treated with DES in pregnancy to prevent miscarriage. These findings 
have led to a number of follow-up studies examining the long-term effects of DES treatment 
on reproductive tissue later in life, in particular breast cancer risk in the daughters who were 
exposed in utero, and the mothers who were exposed while pregnant. A review of these 
findings is presented below. 
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3.3.4.1 In utero exposure to DES 
A cohort study involving 3,674 DES women exposed in utero and 1,219. unexposed women 
of mean age 38 years (data collection 1994), found no increased risk of breast cancer in DES 
exposed women 183 . A second follow-up (data collection 2003) of the same cohort (with an 
additional sample of women) involved 3,812 exposed and 1,637 unexposed women. The 
investigators found that females exposed to DES in utero were 40% more likely to develop 
breast cancer than unexposed women (age-adjusted IRR 1.40, 95% CI: 0.89 to 2.2) though 
this finding was not statistically significant 184 . The risk, however, was significantly increased 
for women aged 40 years and over (IRR 1.91, 95% CI: 1.09 to 3.33) and in women 50 years 
and over (IRR 3.00, 95% CI: 1.01 to 8.98). 
A re-analysis of the above DES Combined Cohort Follow-up Study' 85 was 
undertaken to assess overall cancer risk, in addition to breast cancer, using age and calendar-
year specific standardised incidence rate ratios (SIR), and age-adjusted incidence rate ratios 
(RR). This study identified breast cancer cases in 97,831 and 34,810 person-years for DES 
exposed and unexposed women, respectively. Breast cancer risk was only elevated in women 
over 40 years who were exposed in utero (RR 1.83, 95% CI: 1.1 to 3.2). While a limitation of 
this study was the incomplete retrieval of medical records to confirm breast cancer cases, 
restricting the analysis to pathology confirmed cases did not alter the relative risks I85 . Loss to 
follow-up was also a concern for this study. However, cancer deaths were followed up 
through the National Death Index, and cancer risk factors were found not to differ between 
those who had participated and those who did not' 85 . 
3.3.4.2 Exposure to DES during pregnancy 
More studies have investigated the risk of breast cancer in women exposed to DES during 
pregnancy (i.e. as mothers), compared to the daughters who were exposed prenatally. 
Women exposed to DES during pregnancy are older than women who were exposed in utero, 
providing a more optimal opportunity for breast cancer outcomes to be observed. 
Chapter 3: Current evidence on the short- and longer term effects of estrogen treatment in adolescence on breast 
	
64 
s},mptoms, disease and function. 
Three randomised controlled trials (Bibbo et al. 1978 186, Vessey et al. 1983 187 , and 
Beral et al. 1980 188) originally designed to examine treatment effectiveness of DES during 
pregnancy were later followed-up 20-27 years post-pregnancy. No association was observed 
between treatment with DES and breast cancer, however, ' these three studies had small 
sample sizes (n=693, 319 and 79 treated women, respectively) and few cdses of breast 
cancer. 
Later studies were more robust in their design and had larger sample sizes. 
Hadjimichael et al. (1984) 189 investigated breast cancer risk with larger doses of DES 
exposure (mean 2 g) in a large cohort of 1,707 US women exposed to DES during pregnancy, 
and 1,405 unexposed women matched for age, race, sex of offspring and date of pregnancy. 
This retrospective cohort study followed up 68% of DES exposed and 70% of unexposed 
women and identified breast cancer cases via cancer registry. data. The adjusted relative risk 
for breast cancer in the treated group compared to the untreated group was 1.37 (95% CI: 
0.83 to 2.28). 
The DES Mothers Study ' 9° , published the same year as Hadjimichael above involv. ed 
a cohort of 3,033 mothers exposed to DES in pregnancy through 1940-1960 (dose not 
reported), and an age-matched comparison group of similar size. Women exposed to DES 
were found to have a 40% greater risk of developing breast cancer than •untreated women 
(Crude Relative Risk 1.4, 95% Cl: 1.1 to 1.9). A similar result was observed with two 
sequential follow-ups of this study cohort. In the second follow-up (Colton et al. 1993) 19 ! 
93% of exposed and 89% of unexposed mothers from the original DES Mothers Study 
participated. A relative risk of 1.35, (95% CI: 1.05 to 1.74) was observed. The third follow-
up (Titus-Ernstoff et al. 2001) 192  involved a combined analyses of two cohorts, one of which 
was the DES Mother's Study. This study demonstrated a modest increased risk of breast 
cancer in women treated with DES in pregnancy RR 1.27 (CI: 1.07 to 1.52), a finding that is 
consistent with the earlier studies. These similar results over different lengths of follow-up 
suggest that the risk did not increase over time as the cohort aged. 
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An increased risk of dying from breast cancer has been associated with DES use in 
pregnancy. A retrospective cohort study by Calle et al. (1996) 182 observed 1,574 cases of 
fatal breast cancer among 501,536 gravid women who reported no prior history of cancer. 
Results showed a positive association between a history of DES exposure during pregnancy 
(reported by 3.9% of all women) and fatal breast cancer (adjusted rate ratio 1.34, 95% CI: 
1.06 to 1.69). This excess risk did not increase over time; women who were exposed more 
than 35 years ago (rate ratio f.35, 95% CI: 0.97 to 1.87) were not at greater risk than women 
who were exposed within the past 35 years (rate ratio 1.39, 95% confidence interval 1.01 to 
1.93). The positive association was not observed in women who used DES before age 25 
years but was seen at all other ages [rate ratio 1.00 (95% CI: 0.59 to 1.71)]. 
The available evidence supports a modest increase in breast cancer risk in women 
exposed to DES while pregnant and at a time of intense mammary gland proliferation. Guisti 
and colleagues in their 1995 review 193 of DES in pregnancy and breast cancer risk concluded 
a less than twofold increase in breast cancer risk. 
In summary, it appears that DES during pregnancy, and possibly DES exposure in 
utero (for ages 40 years and older) are associated with an increased risk of breast cancer later. 
in life. Studies on the latter group need to wait longer for these women to be at an age when 
breast cancer incidence is at its greatest. 
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3.3.4.3 Mechanism of estrogen carcinogenicity 
Yager and Davidson recently reviewed the findings related to the risk of breast cancer with 
estrogen exposure and the mechanisms that may be involved 194 . The potential mechanisms 
fall within two broad actions, the genotoxicity of estrogen metabolites and the stimulation of 
tissue proliferation. See Figure 3.3. 
Figure 3.3: Pathways for estrogen carcinogenesis. 
E2 
Metabolism 	 Estrogen Receptor 
Oxidative metabolites 	 Altered gene expression 
Covalent bonding 	Quinone adducts and 	Increased cell 	Decreased 
to DNA and proteins 	oxidative DNA damage 	proliferation apoptosis 
Modified Figure 1 of Yager & Davidson (2006) 194 
As well as these two potential mechanisms of carcinogenesis, it is possible that 
estrogen acts through other mediators such as prolactin or IGF-I. Prolactin and IGF-I serum 
levels have been associated with increased breast cancer risk and have been observed to 
change in girls treated with high-dose estrogens for tall stature. A recent review195 of 
epidemiological, animal and molecular biology findings by Harvey and colleagues strongly 
supports the postulate that prolactin is a risk factor for human breast cancer 195 . This view is 
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further supported by additional later studies 196. 197 . Similarly, a larg& number of 
epidemiological studies have examined the association between plasma IGF-I levels and 
breast cancer risk. Hankinson and Schernhammer 198 in their 2003 review of epidemiological 
studies of association between circulating IGF-I and breast cancer risk observed an overall 
positive association between the two, depending on menopausal status. In their review, the 
prospective studies tended to demonstrate a strong positive association in premenopausal 
women, but no association among postmenopausal women. This has been supported by a 
subsequent case-control study'" nested within the Nurses Health Study cohort (n=800 cases, 
and 1,129 aged-matched controls) but is not supported by a smaller study 20° (n=317 cases, 
634 age-matched controls) nested within the Nurses Health Study II cohort. 
While evidence supports an association in menopausal women only, a case-control 
study 20,1 found an association with estrogen receptor positive breast cancers only: 
progesterone receptor positive (ER+PR+) breast cancer (OR 2.4, 95% CI: 1.1 to 5.4) and 
ER+ve PR—ye breast cancer (OR 4.3, 95% CI: 1.2 to 14.3). 
Of particular interest is the study by Lukanova et al. 2006 202 that found a stronger 
association between IGF-I levels and breast cancer risk among primiparous (OR 2.2, 95% CI: 
1.1 to 4.4) compared with the non-primiparous (OR 1.4, 95% CI: 0.7 to 2.8), suggesting a 
stronger influence of IGF-I on the breast before the remodeling of the gland induced by 'a 
first pregnancy. Upper-tertile risks decreased with age: from OR 2.5 (95% CI: 0.9 to 7.6) to 
OR 2.1 (95% CI: 0.9 to 5.0) and OR 1.2 (95% Cl: 0.5 to 2.5) for the age groups <28, 28 to 
33, and >33 years of age, respectively. 
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3.3.5 Adolescent hormonal exposures 
The adolescent deyeloping breast is undergoing one of three periods of increased mammary 
tissue proliferation (in utero, pubertal development, and pregnancy). The rudimentary 
mammary structures that follow the neonatal period are quiescent throughout childhood9 , 
awaiting stimulation by the hormonally regulated pubertal stage of breast development. 
According to De Silva and Brandt203 , the pubertal stage of breast development, that occurs 
over a period of two to four years, involves the growth of adipose tissue and lactiferous 'ducts 
in response to estrogen. This is followed later (when the corpus luteum matures) by 
progesterone stimulated tertiary branching and alveolar-lobular budding at the ends of these 
ducts89, 203, 204. Consequently, this period of mammary gland development may be sensitive to 
hormonal exposures and therefore susceptible to breast disease initiation or development. 
It has been proposed that the three stages of increased mammary gland proliferation: 
in utero, puberty and pregnancy, have an increased susceptibility to mammary gland 
carcinogenesis205, 206, with recent interest expressed towards hormonal exposures during 
adolescence and breast cancer risk"' 207 . It has been postulated that breast tissue during the 
adolescent growth period is more susceptible to carcinogenesis . than later periods in life2" 
and that research efforts should place greater attention on this life-stage in particular. As 
mammary cellular proliferation is stimulated by exposure to estrogen and progesterone 32 ' 33 , it 
is possible that the degree of exposure to thee hormones during pubertal mammary 
development when glandular tissue may be particularly sensitive to carcinogenic insultsm , 
may influence the risk of breast cancer in later life. 
In concordance with this, it has been suggested that lower levels of these sex 
hormones during adolescence could potentially protect against breast cancer by altering 
breast morphology through a reduction in the rate of cell turnover and proliferation 34 . Early 
age of menarche is a well established breast cancer risklactor 35 , and it is suggested that this 
may be attributable to longer or earlier lifetime exposure to estrogen and progesterone, 
especially during the critical period of breast development. 
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Further evidence that the mammary gland may have a heightened sensitivity during 
the adolescent period comes from findings in a rat model of carcinogenesis where canter 
initiation required the integration of chemical carcinogens with undifferentiated and highly 
proliferating mammary epithelium 31 . The cells of the pubertal mammary gland are highly 
proliferative and undifferentiated. Differentiation of the mammary gland, such as that 
induced by full-term pregnancy, was found to inhibit carcinogenic initiation. This is 
supported by studies linking breast cancer later in life to exposures to carcinogens or 
estrogenic pollutants (e.g. DDT) during adolescence 209 210 . 
Girls who are treated with high-dose estrogens for tall stature also took a progestagen 
four to five days a month to promote cyclic bleeding. These girls were prematurely exposed 
to a progestagen. Normal ovulatory cycles do not start until late puberty. Girls experience 
one to two years of anovulatory menstrual periods involving estrogen stimulation of the 
breast epithelium. When ovulatory cycles begin the corpus luteum matures and secretes 
progesterone. It is uncertain to what degree this premature exposure to a progestagen has on • 
breast development. 
According to Vorherr° estrogens are responsible for the first major increase in 
mammary tissue in preadolescent females which is followed later, at onset of ovulation, by 
the combined influence of estrogen and progesterone on the breast. Progesterone is involved 
in lateral branching 204 and alveolar lobular development at the terminal end buds 203 . the 
effedt of premature exposure to progesterone on the degree of ductal development and/or 
lobular growth, and the structure or density of the terminal ductal lobular units is unknown. 
In the adult human breast, the highest proliferative activity is observed to occur during the 
luteal phase of the menstrual cycle, a time when levels of both estradiol (E2) and P are 
high211 . In addition, estrogen and progesterone hormone replacement therapies (HRT) used in 
menopausal/postmenopausal women have been associated with an increased breast cancer 
risk compared with HRT formulas containing only estrogen 167 . This may be due to the added 
proliferative activity of the combined therapy. It is possible that the combined estrogen and 
progestagen treatment for tall stature increases the proliferative activity of the breast and 
hence the risk of breast cancer later in life. 
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3.4 Lactation 
When the evidence above is considered together with the reported changes in the hormonal 
milieu of girls treated with estrogens as described in Chapter 2 and previous findings from 
the Australian Tall Girls Study on the long-term effects of treatment on fertility, it seems 
possible that treatment could have long-term effects on breast histology and therefore, 
function. This section explores the few available epidemiological and animal studies that 
have investigated the effect of exogenous estrogen exposures on lactation tn . These studies 
suggest long-term effects of pubertal estrogen exposures on nipple structure and lactation 
ability. It is also evident, from the review of studies, that no other study has examined the 
long-term effect of high-dose estrogen treatment in adolescent girls on mammary function 
later in life. 
, 3.4.1 Effect of exogenous estrogen exposures on lactation 
Very few epidemiological studies have examined pubertal or adolescent hormonal exposures 
on lactation. A number of epidemiological and animal studies have examined the effect of 
population level exposures to estrogenic pesticide pollutants such as 1,1,1-trichloro-2,2- 
bis(4-chlorophenyl) ethane (DDT), or its metabolite, 1,1-dichloro-2,2-bis(p-chlorophenyl) 
ethylene (DDE) on lactation. An overview of these studies is presented below and 
summarised in Table 3.3. 
1." Studies were identified by PubMed search of the English language literature using the terms lactation 
(OR breastmilk OR breast-milk OR 'milk AND production/initiation/duration/quality) AND hormone OR 
0/estrogen OR DES/DDE/DDT OR contraceptive OR progestagen/progesterone) for any field covering all 
dates up to the time of writing. The reference lists of all the publications identified by this search were 
inspected for additional studies. The findings and characteristics of all animal and human studies and/or 
reviews that explored and reported the association between estrogen exposure and lactation were described. 
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3.4.1.1 The effect of DDT/DDE exposures on lactation initiation and duration 
Rogan et al. (1987)212 investigated the effect of exposure to the pesticide metabolite DDE on 
breast feeding duration in mothers who had not previously breastfed. They followed up 802 
babies from birth to one year of age in North Carolina USA, and observed a reduced duration 
of breastfeeding in the children of mothers with higher concentrations of DDE in their breast 
milk compared to children of mothers with lower levels: age and socio-economic adjusted 
regression coefficient —0.9 (95% CI: —1.7 to —0.1). They also observed a positive.association 
between DDE levels and rates of lactational failure. 
Similar findings were observed in another study by the same authors, published eight 
years later213 . This cross-sectional study of 229 Mexican women, observed median 
breastfeeding duration of 7.5 months in women with the lowest DDE levels in their 
breastmilk, compared to three months in those with the highest levels. The effect, however, 
was only observed in women who had lactated previously. 
Chapter 3: Current evidence on the short- and longer term effects of estrogen treatment in adolescence on breast symptoms, disease and function. 	 72 
Table 3.3: Summary of studies that have investigated the association between environmental estrogen exposures as measured 
by serum or breast milk concentrations and breastfeeding duration or initiation. 
Study N Estrogen Source Outcome 
Rogan et al. 
(1987)212 
802 DDE Breastmilk Duration of 
breastfeedirig 
Gladen & Rogan 229 DDE Breastmilk Duration of (1995)213 breastfeeding 
Karmaus et al. 
(2005)2 " 
91 DDE Serum Breastfeeding 
initiation 
Duration of 
breastfeeding 
Finding 	 Adjusted 
Regression Coefficient 	 Age and SES 
—0.9 (95% CI: 71.7 to-0.1) 
FIR 0.7 (95% CI: 0.4 to 1.5) for 2.5 -5.0 versus 0-2.5 
	
Multi-variable 
ppm 
HR 1.3 (95% CI: 0.6 to 2.6) for 5.0-7.5 ppm 
HR 1.3 (95% CI: 0.6 to 2.5) for 7.5-10.0 ppm 
HR 1.3 (95% CI: 0.6 to 3.0) for 10.0-12.5 ppm 
HR 2.6 (95% *CI: 1.1 to 5.9) for >12.5 ppm 
Only in women who previously breastfed 
IR 0.42 (95% CI: 0.10 to 1.03) for >10 mg/L versus 	Birth cohort, 
0<5 mg/I. only in women who had previously 	maternal age at 
attempted to initiate breastfeeding 	 birth, 
education of 
Inverse association between DDE concentration and 	the mother, and 
duration HR: 8.73 (95% CI: 1.84 to 41.5) in women 	smoking during 
who had not previously breastfed 	 pregnancy 
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Study 	N 	Estrogen 	Source 
	Outcome 
	 Finding 	 Adjusted 
Weldon et al. 
(2006)215 
366 DDT 	Serum 
DDE 
PCB 
Duration of 	No association with DDT or DDE 
breastfeeding 	PCB (HR 1.5, p=0.02) 
Parity, years in 
US, poverty 
status, marital 
status, 
caesarean 
delivery, 
maternal age, 
education, 
occupation, and , 
BMI 
Cupul-Uicab et 	784 	DDE 	Serum 
al. (2008)216 
Duration of 
breastfeeding 
Breastfeeding 
initiation 
HR 1.40(95% CI: 1.06 to 1.87) for 3-6 lig versus <3 
lig only in women who had previously breastfed. 
OR 1.96(95% Cl: 1.18 to 3.26) in women who had 
not breastfed previously 
DDT: 1,1,1-trichloro-2,2-bis(4-chlorophenyl) ethane . 
DDE: 1,1 -dichloro-2,2-bis(p-chlorophenyl) ethylene 
PCB: polychlorinated biphenyl 
ppm=parts per million 
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Karmaus et al. (2005) 214 (Table 3.3) examined both initiation and breastfeeding duration 
with maternal serum DDE concentrations in non-smoking women and observed an incidence ratio 
for breastfeeding initiation 0.42 (95% CI: 0.10 to 1.03) when maternal serum DDE concentrations 
were 210 mg/L, compared with the lowest DDE exposure group. However, no effect was 
observed when the analysis was restricted to women who had never previously attempted to 
initiate breastfeeding. In the offspring (of non-smoking mothers), breastfeeding duration was 
shorter when DDE concentrations were higher: 13 weeks for 210 mg/L DDE, compared with 30.3 
weeks for lower DDE in women who had not previously breastfed (adjusted HR: 8.73, 95% CI: 
1.84 to 41.5) 214 . The sample size was small in each group e.g. n=9 for 210 mg/L DDE and 19 in 
the reference group. 
Weldon et al. (2006) 215 (Table 3.3) found no association between DDE or DDT and 
breastfeeding duration in a cohort of 366 US women but did find an association with 
polychlorinated biphenyl (PCB), which has estrogenic properties (See Table 3.3). 
Cupul-Uicab et al. (2008) 21 (Table 3.3) observed similar results to Gladen and Rogan 
(1995)213 in relation to breastfeeding duration. In their cross-sectional study of 784 Mexican 
women, they found an association between DDE serum levels and breastfeeding duration in 
women who had previously breastfed, but they did not observe an association with women who 
had not previously breastfed. In women who had previously breastfed, the adjusted hazard ratios 
of weaning for DDE concentrations 3.01-6.00 1.i/g; 6.01-9.00 Wg; and >9.00 Wg, compared to 
DDE concentrations <3.00 p/g lipids, were 1.40 (95% Cl: 1.06 to 1.87); 1.91 (95% Cl: 1.24 to 
2.93); and 1.76 (95% Cl: 1.22 to 2.53) respectively. 
Women who had breastfed previously have reduced levels of DDT stored, and hence 
metabolised (to DDE) and available in serum, compared with women who had not previously 
breaStfed213 . Cupul-Uicab et al. (2008)216 argued that the effect should have been observed in both 
groups of women, those who had previously breastfed and those who had not, and suggested that 
the effect observed in women who had previously breastfed must be due to a non-causal 
association. According to Cupul-Uicab et al. (2008)216 and Gladen and Rogan (1995) 213 , a woman 
who breastfed longer in her first lactation will tend to breastfeed longer the second time as well, 
and, because DDE is excreted in milk, women with longer periods of lactation would eliminate 
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more DDE than women with shorter durations, creating a non-causal association between higher 
DDE and shorter periods of lactation in women who previously breastfed 216 . 
Like Karmaus above, Cupul-Uicab et al. (2008) 216 examined breastfeeding initiation. The 
adjusted odds ratio for having had problems with breastfeeding initiation per unit increase in 
DDE levels (natural log scale) for women who had not breastfed previously was 1.96 (95% CI: 
1.18 to 3.26) and for women who had previously breastfed: OR 0.97 (95% Cl: 0.0 to 1.57) 216 . 
The study investigators suggested that women who had not breastfed previously may be more 
susceptible to endocrine effects on lactation initiation. 
Cupul-Uicab216 and colleagues have suggested that DDE and therefore DDT, and 
possibly other estrogenic compounds, only affect the establishment of lactation, not duration. 
Milk production is only under endocrine control for the first two to three days after which, if 
lactation has been established, autocrine mechanisms mainly operate 2 ". Cupul-Uicab et al. 
(2008)216 surmised that DDE might reduce milk production during these early endocrine 
controlled days, but if lactation still managed to be established, and autocrine control of lactation 
dominated, DDE would no longer have any effect on lactation. A 1977 BMJ article (anonymous 
author)218 reported that estrogens are more effective at preventing initial milk production, than 
stopping lactation once established. If this is true, it is unclear why Karmaus et al. (2005) 214 , 
observed shorter breastfeeding durations at higher DDE concentrations in women who had not 
previously breastfed214 . 
Estrogenic pesticides such as DDT and its metabolite DDE are stored in fatty deposits 
including the fatty component of breast milk and are released into the serum. It is impossible to 
separate these effects on lactation and attribute them to any particular period of exposure — it may 
represent cumulative exposure over a lifetime or it may represent current exposure. 
Epidemiological studies that have examined estrogen exposures during adolescence and 
subsequent lactation performance have not been found in the literature. One possible area of 
investigation is the association between oral contraceptive use at a young age and subsequent 
effects on lactation. A number of studies have examined the effect of oral contraceptive use on 
lactation, but these exposures either occurred after pregnancy, during lactation 219-221 , or shortly 
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before it222 . A number of animal studies have examined the effect of prepubertal or pubertal 
exposures to estrogens on lactation. A review of these studies is presented below. 
3.4.1.2 Animal studies of early-life hormonal exposures and lactation 
Animal studies have investigated the effect of early-life hormonal exposures and lactation ability. 
The effects of prenatal and prepubertal/pubertal exposures are described separately below. 
Prenatal exposures 
Prenatal exposures to estrogens have been reported to alter mammary gland development in 
ratS223-227 that has persisted into adulthood (See Table 3.4). Whether these morphological effects 
translated to lactational effects was not explored. One study indirectly examined the effect of 
prenatal exposures to estrogenic substances on later lactation 226. Rayner et al. (2005)226 exposed 
rats prenatally to "atraiine, a herbicide with estrogenic properties. The female rats displayed 
delayed mammary gland development when examined in adulthood. Compared to control rats, 
the glands of treated animals had less epithelial branching, and contained many more terminal 
end buds suggesting lack of maturity of the gland. The offspring of these exposed rats had a lower 
mean body weight than the offspring of control rats 226 . The researchers speculated that this was 
due to poor lactational support of the offspring suggesting that in utero exposure to estrogens can 
have long-term effects on mammary• gland development and lactation as an adult. 
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Table 3.4: Summary of animal studies on the effect of in-utero and prepubertal estrogen exposures on the mammary gland. 
Study Animal Estrogen Dose 	• Stage at 
Model Exposure 
Markey et al. 
(200 1)2_" 
Rat Bisphol-A 25 and 250 
t1g/kg/thy 	_ 
in-utero 
Fenton et al. Rat Dioxin 1 jig in-utero 
(2002)2" TCDD/kg/day 
Foster et al. Rat Genestein 10 p.g/g/day in-utero 
(2004)224 
Rayner et al. Rat Atrazine 100 mg/kg/day in-utero 
(2005)226 
Fielden et al. 
, (2002)223 
Mice DES 0, 0.1, 1, 10 
jig/kg/day 
in-utero and 
lactation 
Golub et al. Rhesus Methoxychlor 25 and 50 peripubertal 
(2003)26 Monkeys (MXC) mg/kg/day 
DES 0.5 mg/kg/day. 
Lammers et 
al. (1999)27 
Heifers Estradio1-17b NS prepubertal 
Folley Goats Hexbestrol 0.5 mg/day prepubertal 
(1956)28  
Outcome 
Increased percentage of ducts, terminal ducts, terminal 
end buds, and alveolar buds 
Reduced primary branches, decreased epithelial 
elongation, and significantly fewer alveolar buds and 
lateral branches 
Ductal hyperplasia and fibrosis 
Delayed mammary gland development and poor 
lactational nutritional support of their subsequent 
offspring " 
Increase in mammary gland growth 
Decrease in terminal end buds 
Retarded growth of the nipple for both estrogens 
Reduced teat length by 30% 
First lactation milk production decreased by 5.2% 
Lobular alveolar growth but abnormalities e.g. large or 
cystic alveoli, immature lobules, papillomatous 
outgrowths and an overall deficiency of secretory 
epithelial surface area28 
NS: Not stated 
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Postnatal exposures 
Whether pubertal exposures exert long-term effects on later lactation is unknown. Animal 
studies have suggested that mammary development in the pubertal period is critical for future 
lactation228 . Studies involving rhesus monkeys229, prepubertal heifers 27 and goats28 have 
reported effects of estrogen on ductal and lobular/alveolar proliferation, nipple structure and 
lactation (see Table 3.4) 
Folley (1956) 28 exposed young ovariectomised virgin goatlings with the estrogen , 
hexoestrol. They compared the mammary tissue of the subsequent lactating animal when 
compared with the mammary tissue of unexposed lactating goats. They observed excessively 
large or cystic alveoli, immature lobules, papillomatous outgrowths and an overall deficiency 
of secretory epithelial surface area28 . Lactation performance was not measured, but it is 
possible that these abnormalities lead to • deficiencies in lactation. The addition of a 
progestagen reduced the incidence of abnormalities. 
Golub et al. (2003)26  examined the consequences of treating female rhesus monkeys 
with high-dose estrogen (n=8 per treatmen(type) during the peripubertal period (six months 
before and following the expected age at menarche). The estrogens used included the 
estrogenic pesticide methoxychlor, (MXC), 25 and 50 mg/kg/day; and diethylstilbestrol 
(DES), 0.5 mg/kg/day. DES completely suppressed adolescent growth (weight and height) 
while both estrogens led to swelling of skin, and retarded growth of the nipple compared to 
control animals (n=8) 26 . While effect on lactation was not examined, a consequence of 
retarded nipple growth might be reduced ability to initiate lactation. 
Lammers et al: (1999)27 observed a similar effect of high-dose prepubertal estrogen 
exposure on teat growth in heifers and also explored the effect of exposure on lactation. 
Fourteen prepubertal heifers were exposed to estrogen implants over a 20 week period. 
Estrogen implants initially stimulated a large increase in teat length growth during the 
treatment period, but the advantage was lost post-treatment. Over the treatment and post-
treatment periods the estrogen implants reduced teat length by 30%. The effect of the 
implants on lactation milk volume was also examined. First lactation milk production 
decreased by 5.2%27. 
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3.4.2 Estrogen exposure in adolescence: possible effects on lactation 
For the first three to four weeks of pregnancy the mammary gland, in preparation for future 
lactation, undergoes ductular sprouting and branching, and lobular formation 9. At about five 
to eight weeks into pregnancy, women should notice a definite enlargement and feeling of 
heaviness of the breasts9 . The extent of this mammary. change during pregnancy depends on 
the woman's pre-pregnancy size, the number of mammary lobuli, and the age and parity of 
the woman9 . Since pre-pregnancy size and number of mammary lobuli may be altered by 
high-dose estrogen exposure during adolescence, then mammary change during pregnancy 
and subsequent lactation may also be affected. 
Breast hypoplasia or insufficient glandular development could result in lactation 
failure. An associated characteristic of women with breast hypoplasia is absence of typical 
breast changes with pregnancy and failure of postpartum breast engorgement leading to a 
failure or reduced ability to lactate230. These changes that are expected to occur during 
pregnancy may depend on events in adolescence. Anecdotal- reports of incomplete breast 
development or 'flat chestedness' as a side effect of treatment for tall stature has been 
published elsewhere 23.41 . 
According to Tucker (2000) 231 , in his historical perspective of mammary growth and 
lactation; hormones are involved and absolutely necessary for the initiation of lactation, but 
not without a well developed mammary lobule-alveolar system. It is possible that the 
hormonal and physiological effects observed during treatment for tall stature have longer 
term effects on the mammary lobule-alveolar system and subsequently, later lactation. 
The attenuation of IGF-I levels in girls treated with high-dose estrogens for tall 
stature (See Chapter 2, Section 2.4.2.2) could lead to changes to mammary development and 
functional deficiencies. Two studies, one by Lammers et al. (1999) 27 and the other by 
McCann et al. (1989) 232 found rapid weight gain at puberty to impair mamrnaiy gland 
development and later milk production in the heifer27 and ewe232 . One possible reason for the 
effect on mammary development and later milk production in the animal model, is a reduced 
sensitivity of the tissues to IGF-1 27 . Weight gain and reduced IGF-I levels have been reported 
to occur in adolescent girls treated with high-dose estrogens (Chapter 2, Sections 2.4.3.1 and 
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2.4.2.2 respectively), further supporting the suggestion that treatment could affect mammary 
gland development and subsequent lactation 
3.5 Overview 
The above review examined Australian and international published case-series reports of 
adverse effects on the breast during and shortly following cessation of estrogen treatment in 
tall girls. The review highlighted the limitation of existing reports on the short-term side 
effects of treatment on the breast. The prevalence of effects by treatment type has not been 
reported, nor have all side effects been examined consistently across studies. Most of the 
case-series reports were based on small sample sizes, and the outcomes were selected by the 
treating physicians rather than independent researchers. For uncommon outcomes, it is 
unclear the degree to which physicians systematically examined girls for these conditions in 
the studies, and subsequently reported them. There is a need for a more systematic 
'examination of side effects of treatment on the breast in relation to treatment type. 
The review also highlighted the gaps in our understanding of the long-term effects on 
the breast, brought about by the scarcity of long-term follow-up studies, and the importance 
of this PhD research in narrowing this gap. Published epidemiological, molecular, in vitro 
and in vivo studies examining the association between estrogen and benign breast disease and 
breast cancer risk were presented. The evidence suggests that estrogen (and progestagen) 
exposure in adolescence could influence the risk of these breast diseases later in life. 
The review above also described findings from epidemiological and animal studies 
on the effect of estrogen exposures on nipple structure and lactation. While caution is 
•required when extrapolating effects on animal tissues and physiological functions to humans; 
when combined with evidence of breast related side effects described above, it is plausible 
that high-dose estrogen exposure during puberty, at a time of intense mammary development, 
could have long-term effects on lactation. No other study has examined the long-term effect 
of this treatment on mammary function. 
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Box 3.1: Key points from the literature in Chapter 3. 
KEY POINTS FROM THE LITERATURE: CHAPTER 3 
• Reported breast related short-term side effects of treatment with high-dose 
estrogens in adolescent girls include breast pain, pigmentation of the areolae and 
nipples, galactorrhea and, more rarely, benign breast disease. 
• Overall, evidence suggests that women who currently use and have used HRT for at 
least five years are at increased risk of benign breast disease and breast cancer. 
• DES exposure in pregnancy appears to be associated with an increased risk of 
breast cancer later in life. 
• Few studies have examined the effect of hormone exposures in adolescence on later 
lactation in humans. However, studies that have examined the association between 
environmental estrogen exposures (DDT, DDE) on lactation in humans suggest that 
exposure to high-doses of these estrogenic chemicals can affect the initiation of 
lactation. 
• High-dose estrogen exposure at a time of intense mammary development has been 
shown to affect nipple/teat length and structure, epithelial growth, and lactation 
volume in the animal model. 
• Breast hypoplasia, or insufficient glandular development, could result in lactation 
failure. An associated characteristic of women with breast hypoplasia is absence of 
typical breast changes with pregnancy and failure of postpartum.breast 
engorgement leading to a failure or reduced ability to lactate. 
• Studies have found rapid weight gain at puberty to impair mammary gland 
development and later milk production in the animal model. Weight gain and 
reduced IGF-I levels have been reported to occur in adolescent girls treated with 
high-dose estrogens. 
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4: TREATMENT WITH HIGH-DOSE ESTROGENS IN ADOLESCENCE: 
SHORT-TERM EFFECTS ON THE BREAST AND LONGER TERM BREAST 
DISEASE 
4.0 Introduction 
Chapter 3 highlighted the gaps in our understanding of the short- and long-term effects on the 
breast of high-dose estrogen treatment in adolescent girls and the importance of this PhD 
research in narrowing this gap. The Australian Tall Girls Study provided a unique 
opportunity to examine the prevalence and risk of breast symptoms and disease in women 
exposed to high-dose estrogen during adolescence. 
The Tall Girls Study is a retrospective cohort study. It followed up women who were 
assessed for tall stature in adolescence and either treated (mean age 39.8 years) or untreated 
(37.7 years) with high-dose estrogens to reduce their final height. At follow-up I of this 
study, data on the side effects of treatment and breast disease history were collected from 
both treated and untreated women. This data were available for analysis. This chapter 
presents the methods and findings of this analysis; in particular, the prevalence of short-term 
breast related side effects in treated women, and the long-term risk of ever having had a 
breast biopsy, breast surgery, and breast cancer in treated women compared with untreated 
women. The cohort size was too small, and participants relatively too young, to expect to 
pick up many cases of breast cancer. As such, it was not suitable for a reliable assessment of 
the level of breast cancer risk associated with high-dose estrogen treatment in tall girls (see 
footnotern), but it could provide some indication of the incidence in the two groups of•
women, and whether the rates for treated women appeared out of the ordinary. 
A sample size of approximately 27,000 would be required for each of the treated and untreated 
groups to detect a 20% relative increase (RR 1.2) in risk for breast cancer in the treated group 
. compared with the untreated group, with 80% power; or 1550 each for a RR of 2.0 (See Appendix 1 
for further details of this analysis). 
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4.1 Study Aim 
• This study aimed to use data collected in first follow-up of the Australian Tall Girls cohort 
study to: 1) examine the prevalence of breast related side effects on treated women according 
to treatment type (e.g DES and EE), 2) test the hypothesis that treated women are at greater 
risk of developing benign breast disease than untreated women, and 3) to describe the 
occurrence of cancers in treated and untreated women. 
The next section of this chapter presents the methodology used to collect and analyse 
the data; the findings of this analysis; and finally, the discussion and conclusion. 
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4.2 Methods 
4.2.1 Eligibility 
Women were eligible to participate in the Australian Tall Girls Study if they obtained a 
medical opinion about their tall stature and had a radiological assessment of their skeletal age 
during adolescence. They included women who received daily estrogen treatment during 
adolescence, 3 mg diethylstilbestrol (DES) or 150 lig ethinyl estradiol (EE), to reduce their • 
adult height (treated group) and women who had not (untreated). The most common reasons 
for not being treated with estrogen included: the woman's predicted height as a girl did not 
warrant treatment, the family preferred not to have treatment or there was little remaining 
growth suppression potential at the time of the assessment25 . 
4.2.2 Recruitment 
As described elsewhere 25 , individuals were identified from medical records of Australian 
paediatricians who assessed or treated tall girls from 1959 to 1993, and from self-referrals. 
Women who self-referred to the study included women who had heard about the study 
through publicity, and members of Tall Girls Inc., an advocacy group for women treated with 
high-dose estrogens in adolescence. The Australian Paediatic Endocrinology Group (APEG) 
and specific doctors identified through professional networks were contacted to seek 
assistance from endocrinologists who had treated tall girls or knew of people who had. 
The Tall Girls Study identified a cohort of 1,432 eligible participants: 1,248 from 
medical records of whom 1,222 were from one paediatric endocrinologist, and 184 from self-
referrals. Of this cohort, 572 women were treated and 860 untreated. Women were traced . 
with the use of electoral rolls and telephone listings then a letter of invitation, information 
brochure, and consent form to participate in the study were sent to the women by mail. The 
number of eligible women traced and invited to participate in the study was 1,243. Non-
respondents were followed up by mail and telephone. 
1000 _ 
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600 - 
400 - 
200 - 
No. of 
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women 
Treated 
	
Untreated 
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Written informed consent was obtained from all study participants.  The study had the 
approval of the La Trobe University Human Ethics Committee (00/03). See Appendix 2 for a 
copy of the invitation letter and study information sent to eligible participants. 
Of the women invited, 398 treated (77%) of treated and 448 (62%) of untreated 
women agreed to participate and completed the postal questionnaire. Of these, 371 treated 
women (72% of traced), and 409 (56%) untreated women completed the computer assisted 
telephone interview (See Figure 4.1). 
Figure 4.1: Number of treated and untreated women in the Tall Girls Study who were 
identified, traced and who participated in the computer assisted telephone interview 
(CAT!). 
• Identified 
• Traced 
• Did CATI 
4.2.3 Exposure data 
Treatment information was extracted from the medical records of women who provided 
consent and for whom records were available, or was self-reported by women in the postal 
questionnaire used in the first follow-up. Written consent to extract data from medical records 
was provided by 726 (91% treated, 95% untreated) of the women who completed the 
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interview, however, medical records were available for only 618 (75% treated, 95% 
untreated). More records were available for untreated women because a greater proportion of 
them (97%) compared with treated women (68%) were sourced from one endocrinologist 
who retained and allowed access to the medical records. More treated women self-referred to 
the study and had been treated by other endocrinologists whose records could not be 
accessed. 
Type of treatment, and start and end date of treatment (from which duration of 
treatment was calculated) was collected from the records. If records were not available, 
women were asked in the postal questionnaire to give the name of the drug that they took 
(1=DES, 2=EE, 3=other, 4=not sure/can't remember name) and how old they were when they 
started and completed treatment (years and months) (Questions C22-24 in the postal 
questionnaire, Appendix 3). They were also asked whether or not they took the tablets 
regularly (Q C25). 
4.2.4 Breast disease 
In the postal questionnaire, treated women were asked if they experienced particular breast 
related side effects while on treatment. These included: increased pigmentation of the nipples, 
galactorrhea, breast pain, breast lumps, and "other- please specify". They were also asked, 
"After treatment had finished, did you ever notice a spontaneous leakage of the milk or 
discharge from your breasts?" (Questions C26-C27 of postal questionnaire in Appendix 3). 
During the computer assisted telephone interview women were asked whether they 
had cancer of the reproductive organs or any other cancer and if yes, what kind of cancer. 
Breast cancer reports were validated by medical records where possible. In the CATI, women 
were asked: 'Have you ever had a breast biopsy [sample of breast tissue], a mastectomy 
[surgery to remove breast], and other breast surgery followed by 'please specify' if yes to the 
latter (Question A2 in the CAT! questionnaire, Appendix 4). 
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4.2.5 Other covariates 
Demographic data including marital status, educational level, and smoking history were 
collected in the postal questionnaire. The smoking history questions were derived from the 
Australian Longitudinal Study on Women's Health (Women's Health Australia 233 ). 
Data on oral contraceptive and fertility drug use, and the use of hormones for a range of 
reproductive conditions were collected in the telephone interview. Reproductive conditions 
specified included: cramps or backache associated with menstruation, irregular menstrual 
cycles, premenstrual syndrome, heavy or prolonged menstrual bleeding; absence of a period 
for at least six weeks, not due to pregnancy, breastfeeding or taking the pill; menopause, or 
other menstrual problems. 
Data on estimated mature height was collected from the medical records and final 
height was collected by postal questionnaire at follow-up. Participants were asked to measure 
their height before noon and in bare feet, standing on a hard floor without carpet. They were 
asked to stand straight, stretch with their backs against a wall, place a picture frame or similar 
firm square or rectangular object on their head, and draw a mark on the wall immediately 
below the frame edge. They were requested to measure the height from the floor to the mark 
with a tape measure and repeat the process as a check. 
Information about mammographic screening history was gathered from the postal 
questionnaire. The questions were derived from the National Health Survey (NHS). Women 
were asked if they 'ever' had a mammogram, and if yes, the reason for having their last one. 
Australian Bureau of Statistics 2001 NHS data on mammographic screening rates were 
compared with rates for treated and untreated women across age categories. This data 
provided insight into the potential differences in health screening behaviours and the 
potential for a disease outcome to be identified or surgical procedure to be performed in both 
groups. 
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4.2.6 Data analysis 
Statistical analysis was performed with Stata Version 8. Log binomial regression was used to 
calculate the age-adjusted relative risk of treated women having ever had a breast biopsy, 
non-elective and elective breast surgery, and breast cancer. Chi-square tests were performed 
for tests of significance for categorical data, and t-tests for continuous data. All tests of 
significance were two-sided. 
The precise p-values were reported for descriptive data comparisons. Following 
convention, nominal statistical significance was based on a p-value less than 0.05. Ninety-
five percent confidence intervals were described for all log binomial regression generated 
relative risks (RR). While it is recognised that the 0.05 threshold for p-values and the 95% 
confidence level is arbitrarily derived (a z value of 1.96 corresponds to a p-value of 0.05), the 
range of the confidence interval as well as the position of the null value in relation to the 
interval will be considered when interpreting confidence interval data234. 
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4.3 Results 
4.3.1 Characteristics of study participants 
The characteristics of study participants are shown in Tables 4.1. The mean age of 
participants was 39.8 years (range 20-55) in the treated group and 37.7 years (23-54) in the 
untreated group. This difference was statistically significant (p<0.001). Treated and untreated 
study participants were similar in their marital status, though slightly more untreated women 
were single than treated women. Women were similar in the highest educational level 
achieved in most categories, though more treated than untreated women did not complete 
secondary school and fewer had a degree. Treated and untreated women were also similar in 
family income, smoking history, oral contraceptive use and mean age at first livebirth. 
Table 4.1: Characteristics of treated and untreated participants. 
Characteristic Treated 
(N=371) 
Untreated 
(N=409) 
P-value 
Age 
Mean (years) (range) 39.8 (20-55) 37.7 (23-54) <0.001 
Age first livebirth 
Mean (years) (range) 29.0 (18-40) 28.9 (18-42) 0.93-7 
_ 
Marital Status; n (%) 
Married or cohabitating 281 (75.7) 308 (75.3) 0.682 
Divorced, separated, or widowed 43 (11.6) 33(8.1) 0.088 
Single 43 (11.6) 68 (16.6) 0.051 
Data missing 4(1.1) 0 
Highest Education level achieved; n (%) 
Did not complete secondary school 36 (9.7) 21(5.1) 0.014 
Completed secondary school 61 (16.4) 73 (17.9) 0.616 
Apprenticeship/certificate 84 (22.7) 88 (21.5) 0.689 
Degree 106 (28.6) 144 (35.2) 0.050 
Postgraduate •82 (22.1) 82 (20.1) 0.469 
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Characteristic Treated 
(N=371) 
Untreated 
(N=409) 
P-value 
Data missing 
; Family income ($) 
2 (0.5) 1 (0.2) 
0-25,999 35 (9.4) 40 (9.8) 0.996 
26,000-51,999 78 (21.0) 85 (20.8) 0.736 
52,000-77,999 71 (19.1) 88 (21.5) 0.560 
78,000-103,999 67 (18.1) 83 (20.3) 0.576 
104,000 + 88 (23.8) 91 (22.2) 0.446 
Data missing 32 (8.6) 22 (5.4) 	. 
Smoking 
Ever smoked 195 (52.6) 213 (52.1) 0.769 
Data missing 4 (1.1) 0 
. 	 , 
, Oral contraceptive use 
Ever used -352 (94.9) 390 (95.4) 0.896 
Data missing 2 (0.5) 1 (0.2) 
Treated and untreated women differed in their predicted final height and their actual 
final height (Table 4.2). Specifically, more untreated women than treated women had an 
estimated mature height <177.0 cm while more treated than untreated women had an 
estimated mature height >183.0 cm. Treated women were taller than untreated women despite 
being treated in adolescence with high-dose estrogens to reduce their final height. 
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Table 4.2: Growth characteristics of treated and untreated participants. 
Characteristic Treated n (/0) 
(N=371) 
Untreated n (%) 
(N=409) 
P-value 
Estimated mature height (cm) 
<177.0 70 (18.9) 292 (71.4) <0.001 
. 	177.1-182.9 175 (47.2) 97 (23.7) <0.001 
>183.0 118 (31.8) . 12(2.9) <0.001 
Data missing 8 (2.2) 8 (2.0) 
Adult height (cm) . 
<177.0 109 (29.4) 200 (48.9) 'c0.001 
177.1-182.9 211 (56.9) 174 (42.5) <0.001 
>183.0 50 (13.5) 35 (8.6) 0.027 
Data missing 1 (0.3) 0 
The groups also differed in 'ever use' of exogenous sex hormones for reproductive 
conditions: treated 146 (39.4%), untreated 124 (30.3%) (p=0.008). This observation is due to 
the greater use of fertility drugs in treated women, as reported previously 25 . In addition, 
treated women n=248 (66.9%) were significantly less likely to have ever had a livebirth than 
untreated women n=267 (65.3%): age-adjusted RR 0.87 (95% CI: 0.79 to 0.95), though this 
difference was small 25 . The reasons for 'ever using' sex hormones for reproductive conditions 
are summarised in Table 4.3 below. Treated women were, on average, older than untreated 
women. This is likely to explain the greater *portion of treated women using hormone 
treatment for menopause and heavy bleeding (during the perimenopausal period). However 
these differences were not statistically significantly. 
. 
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Table 4.3: Use of hormones for reproductive conditions in treated and untreated 
women. 
Reasons for other hormone use 	 Treated 	Untreated 	P-value 
(ever used) 	 n (%) 	n (%) 
	
(N=371)* 	(N=409)* 
, Cramps/backache associated with periods 37 (10.0) 52 (12.7) 0.240 _ 
Irregular menstrual cycles 47 (12.7) 41 (10.0) 0.232 
Premenstrual tension 11(3.0) 20(4.9) 0.174 
Heavy or prolonged menstrual bleeding 45 (12.1) 36 (8.8) 0.121 
_ 
Absence of period apart from pregnancy, 
breastfeeding or the pill 
17(4.6) 10(2.4) 0.100 
Menopause 23(6.2) 15 (3.7) 0.097 
rOther menstrual problems 8 (2.2) 10 (2.4) 0.798 
-  Infertility 68 (18.3) 34(8.3) 0.0001 
* 3 missing treated, 1 missing untreated. 
4.3.2 Side effects of treatment 
Side effects reported at or around the same time as treatment included increased pigmentation 
of the nipple, breast pain, breast lumps, dry cracked/bleeding nipples, and galactorrhea either 
during treatment or immediately following treatment. Dry cracked/bleeding nipples arose 
from the 'other' side effect question in the postal questionnaire. 
Overall, the reports of side effects were more common for women treated with DES 
compared to EE. Breast related side effects were reported by 40% of treated women: 
91(59.9%) (95% CI: 51.9 to 67.3%) DES treated women and 56 (26.3%) (95% CI: 20.8 to 
32.6%) EE treated women (p=0.0001), in the postal questionnaire. More DES treated women 
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than EE treated women experienced increased pigmentation of the nipple and galactorrhea 
(Table 4.4). As galactorrhea might be a result of sudden withdrawal of medicine, all the 
women who experienced galactorrhea during treatment had stated that they took their tablets 
regularly. . 
The exclusion from the analysis of women who self-referred to the study ,made little 
difference to the percent of women reporting breast related side effects (DES 57.5%, EE 
23.8%, and all treated women 36.6%). 
Table 4.4: Short-term side effects on the breast by drug type. 
Side Effect DES n (/0) 
(N=152)* 
EE n (/0) 
(N=213)* 
P- 
value 
Total n (%) 
(N=398)t 
Increased pigmentation of the 
areolae and nipple 
Breast pain 
- — 
1 
Breast lump 
,81 (53.3) 
16 (10.5)- 
43 (20.2) - 
14(6.6) 
0.0001 
, 
0.175 
-0.94-8 
0.19-1 	-- 
0.009 
134 (33.7) 
32 (8.0) 
8 -(2.6):- - 
_ 
4(L0) 
14(3.5) - 
3(2.0) 
3 (2.0) 
10(6.6) 
4(1.9) 
1(0.5) 
3(1.4) 
8 (3.8) 
Dry cracked/bleeding nipples 
Galactorrhea dUring tsreatment 
Galactorrhea immediately 
following treatment t 
12 (7.9) 0.087 21(5.3) 
*Does not include those treated with both DES and EE (n=5) or drug type unknown (n=28). 
tIncludes those treated with both DES and EE (n=5) and drug type unknown (n=28). 
t 9/21 who experienced galactorrhea following treatment also reported experiencing it during 
treatment. 
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4.3.3 Risk of breast biopsy, surgery and cancer 
The age-adjusted relative risks for ever having a breast biopsy, other breast surgery and 
breast cancer are described in Table 4.5. While 2% of treated women reported having had 
experienced breast lumps as a side effect of treatment, treated women were no more likely to 
have ever had a breast biopsy (n=45, 12.1%) than untreated women (n=46, 11.3%) (age 
adjusted RR 0.95, 95% CI: 0.6 to 1.4). 
Risk of elective or non-elective surgery was not significantly greater for treated 
women. The majority of surgical procedures involved a lumpectomy (n=27, 77.1%) of which, 
14 treated women (3.8%) and 13 untreated women (3.2%) had had this procedure (age 
adjusted RR 1.10 (95% Cl: 0.5 to 2.4). Other types of non-elective surgery included: 
papilloma removed (n----2), breast abscess at six months of age (n=1), removal of cancer (n=1), 
breast abscess drained (n=2), removal of ingrown hair (n=1). Two treated women, and no 
untreated women had a mastectomy. 
Cosmetic or elective surgeries (n=18) included: mole excised (n=1), birthmark 
removed (n=1), breast enlargement/implants (n= 9), reduction (n= 4), removal of extra nipple 
(n=2), and one unknown. There were four breast cancer cases in the treated group and two in 
the untreated group (age adjusted RR 1.15, 95% Cl: 0.2 to 7.2). Five of six of these cases 
were verified with medical records. 
Table 4.5: Age adjusted relative-risks of ever having had a breast biopsy, surgery, and 
breast cancer. 	• 
Treated n (')/0) 
(N=371) 
Untreated n (°/0) 
(N=409) 
Age adjusted 
RR (95°/0C1) 
Breast biopsy , 45 (12.1) 46 (11.3) 0.95 (0.6 to 1.4) 
_ 
Other breast surgery 
Elective 8(2.2) 10(2.4) 0.86 (0.3 to 2.2) 
Non-elective 20 (5.4) 15(3.7) 1.32 (0.7 to 2.6) 
' Breast cancer 4 (1.1) 2 (0.5) 1.15 (0.2 to 7.2) 
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4.3.4 History of rnammographic screening 
In each age decade grouping, treated women had slightly lower rates of ever having had a 
mammogram compared with untreated women except in the 40-49 year age group (Table 
4.6) (Figure 4.2). While treated women had a higher overall proportion of ever having had a 
mammogram (39.9%) compared with untreated women (32.0%) (p=0.014), after adjusting 
for age the difference did not remain (p=0.98). More untreated women had had a 
mammogram in the 18-29 and 50-59 year age groups compared with ABS 2001 population 
rates, though numbers are too small to be confident in this finding. 
Table 4.6: Ever had a mammogram for treated and 
population (ABS 2001) by age group. 
untreated and Australian 
Ever had a mammogram Treated 
n (%) 
N=371* 
Untreated 
n (%) 	• 
N=409* 
ABSt 
% 
18-29 years 
•
• 	
30-39 years 
1(3.6) 
26 (18.4) 
3 (8.6) 
45 (20.5) 
3.8 
18 
40-49 years 96 (56.1) 73 (50.7) 49.4 
50-59 years 25 (83.3) 10 (100) 78.1 
Total n (%) 148 (39.9) 131 (32.0) 
* Missing n=9 treated, n=4 untreated. 
j Source: Australian Bureau of Statistics 2001 National Health Survey Summary of Results 
(p 92). 
Figure 4.2: Proportion of women who had ever  had a mammogram. 
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The reasons for having the most recent mammogram are summarised in Table 4.7. Reasons 
were similar between treated and untreated groups except that more untreated women had 
their most recent mammogram because they experienced symptoms, while more treated than 
untreated women had their most recent mammogram because of a family history of breast 
cancer, however these differences were not statistically significant. 
Table 4.7: Reasons for last mammogram in treated and untreated women. 
Reason for last mammogram Treated 	n ("Yo) 
N=148 
Untreated n CYO 
N=131 
P-value 
Symptoms present 50 (33.8) 51 (39.9) 0.300 
Family history of breast cancer 25 (16.9) 14 (10.7) 0.153 
Had breast cancer in the past 4(2.7) 1 (0.8) 0.231 
General check up 44 (29.7) 38 (29.0) 0.983 
Don't know 1 (0.7) 1 (0.8) 0.919 
Other 19 (12.9) 19 (14.5) 0.635 
Missing 5(3.7) 7 (5.3) 
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4.4 Discussion 
Short-term side effects reported by treated women included breast lumps, galactorrhea, breast 
pain, dry cracked or bleeding nipples and increased pigmentation of the nipple. These effects, 
apart from dry cracked and bleeding nipples, have been reported elsewhere 3. 22-24 . It is 
possible that the reports of cracked nipples were associated with nipple hyperkeratosis which 
is known to be associated with estrogen treatment in humans 235 and animals236 . The only 
mention of hyperkeratosis in relation to estrogen treatment for tall stature was by Zackman et 
al. (1975)46 and Drop et al.( 1998)44 , where they mentioned that diethylstilbestrol (DES) more 
than other estrogen preparations has the clear disadvantage of causing marked pigmentation 
and hyperkeratosis of the• nipples: This is odd because, unlike the former side effect of 
marked pigmentation, hyperkeratosis is not reported as an observed side effect for any of the 
subjects in the case-series report by Zackman et al. (1975)46. 
Increased pigmentation of the nipple was the most frequently reported breast related 
side effect. The greater proportion of DES treated women than ethinyl estradiol (EE) treated 
women experiencing this side effect was not unexpected and has been reported elsewhere 41 . 
The second most frequently reported breast related side effect was breast pain, with, 
8% of all women experiencing breast pain during treatment. Weimann reported breast 
discomfort in 6% of women treated with conjugated equine estrogens 22 . Of interest is the 
positive association observed elsewhere between breast pain or tenderness and breast cancer 
risk. Cyclical mastalgia is reported to be sensitive to estrogen and a marker of breast 
susceptibility to estrogen and breast cancer risk. In their case-control study, Plu-Bureau et al. 
(1992) M0  observed an increasing risk of developing breast cancer with increased duration of 
cyclical mastalgia (RR 1.12 for 6-48 months, 2.24 for 49-96 months, and 5.54 for 97 
months; P for trend=0.001). A later study by Crandall et al. (2009) 237 analysed data from the 
WH I Estrogen and Progestin randomised controlled trial involving 8,506 women treated with 
conjugated estrogens and a progestin and 8;102 with placebo. They found significantly more 
women treated with E & P experienced new-onset breast tenderness (NOBT) compared with 
the placebo group, and that breast cancer risk was greatest in those treated with E & P who 
experienced NOBT compared to those who did not (HR 1.48; 95% Cl: 1.08 to 2.03). 
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Tamoxifen, an anti-estrogen, has been used for treatment of breast pain (mastalgia) 238 and 
conclusions following a meta-analysis suggest it to be the drug of choice239 . Another anti-
estrogen (centchroman) has since been recommended . as another option for the treatment of 
breast pain240 . These findings support the association between breast pain, estrogen exposures 
and breast cancer risk. Of interest is the positive association observed between new-onset 
breast pain or discomfort and mammographic density after hormone therapy 241-243. 
Mammographic density is a well established risk factor of breast cancer4 . It is possible that 
women who experienced breast pain following treatment with high-dose estrogens in 
adolescence also experienced an increase in mammographic density. Mammographic density 
is examined in later chapters of this thesis. 
In this study, breast lumps, observed in 2.0% of DES treated women and 1.9% of EE 
treated women, did not differ by treatment type. These figures are slightly greater than that 
observed by Trygstad 23 who had observed benign fibroadenoma in 0.3% of DES treated girls. 
It is possible that breast lumps retrospectively reported by women in this study included 
benign forms other than fibroadenoma. 
It appears that galactorrhea, both during treatment and following treatment, occurred 
in more DES treated girls than EE treated girls. No other studies differentiate between 
treatment type and galactorrhea prevalence. Rates varied between 0% 22 to 14%43 across all 
studies. In the study by Kuhn et al. (1977)43 , 14% of treated girls had experienced 
galactorrhea as a side effect of treatment. The estrogen used by the girls in this study was 
ethinyl estradiol and the dose was 500 ug/day; much greater than that used by treated girls in 
this study. 
Galactorrhea occurred during treatment or immediately following treatment. None of 
the case-series reports reviewed differentiated between the two distinct occurrences. It is 
possible the side effect is due to increased prolactin levels which have been observed in 
studies of treated girls I3 . According to Chatterton 98 , the positive feedback of estrogen on 
prolactin secretion provides a stimulus for breast development. Withdrawal of the steroid, 
particularly if prolactin levels remain elevated for any reason, may precipitate galactorrhea. 
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Galactorrhea has been associated with the cessation of oral contraceptive use in a case-
control study 244. 
It is uncertain why galactorrhea was observed in girls during treatment. This 
observation may be associated with poor compliance to treatment resulting in a sudden drop 
in estrogen levels and therefore prolactin levels, though this is unlikely because all women 
who had reported that they had experienced galactorrhea during treatment had also reported 
that they had taken their medication regularly. Alternatively, it is possible that the increased 
prolactin levels that occur in some treated girls may be transient and drop back to normal 
levels or below normal levels while still undergoing treatment. This has been observed 
elsewhere". 
While reports suggest that some girls have experienced incomplete breast 
development as a result of treatment23 ' 41 , no women in this study reported this to be a side 
effect of treatment. It is a subjective measure, and it is unlikely that women noticed cessation 
of growth unless there was a reduction or regression in breast volume with treatment. Total 
breast area is examined in a later chapter as a necessary measure for the calculation of percent 
mammographic density and could provide additional information about breast .size 
differences between treated and untreated women. 
It appears from the papers reviewed that this is the first study to quantify the rates of 
breast related side effects for different treatments from the same cohort of women. Overall, 
DES treated women reported more breast related side effects (59.9%) than EE treated women 
(26.3%), with the increase largely due to the different rates for galactorrhea and pigmentation 
•of the nipple. 
Treatment with high-dose estrogens to reduce the adult height of tall girls was 
associated with short-term side effects on the breast but did not appear to be associated with 
breast disease in the long-term. There was no significant difference between treated women 
and untreated women in having ever had a breast biopsy, breast surgery (including 
lumpectomy), or a diagnosis of breast cancer. 
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Mammographic screening history was collected to determine the degree and direction 
of ascertainment bias that might have existed due to non-random sampling of the treatment 
and untreated groups. Women who have a mammogram are more likely to have a lump or 
abnormal tissue identified in the screening process, leading to a breast biopsy, diagnosis of 
benign breast disease or breast cancer. It is possible that fewer treated than untreated women 
had ever had a .mammogram, picking up fewer cases of breast lumps or tissue abnormalities 
requiring a breast biopsy, and diagnoses of breast cancer, or vice versa. Age adjusted rates of 
mammographic screening did not differ between treated and untreated women. 
Treated women were no more likely than untreated women to have had their most 
recent mammogram because of the presence of symptoms. This is consistent with the finding 
that treated women were no more likely to have had a breast biopsy, or breast cancer than 
untreated women. 
It is also likely that women who had their most recent mammogram because of a 
family history of breast cancer, themselves had a higher risk of breast cancer and as a 
consequence of the screening, had breast cancer detected, albeit earlier, before symptoms 
presented. However, treated women were no more likely to have had their most recent 
mammogram because of a family history of breast cancer than untreated women. 
One limitation of this study is the reliance on self-reporting by women. In relation to 
the short-term side effects of treatment, women were asked to recall events that occurred 
between 10 and 40 years earlier. The self-reporting of side effects of treatment could result in 
under-reporting of minor breast ailments. For instance, the prevalence of breast lumps 
occurring during treatment may be under-represented. Breast lumps can be painful; however, - 
if not painful, the presence of a lump may not have been known. Even for those symptoms 
that were known at the time, they may not be recalled if they were not too unpleasant. On the 
other- hand, recall bias might result in the over-reporting of breast ailments. Treated girls 
might have been more watchful of breast changes and symptoms during treatment and readily 
attributed these changes to treatment. However, a difference was observed in only some 
breast related side effects between the two groups. This suggests that recall bias is unlikely. 
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History of breast biopsies and breast surgery were more likely to be remembered by 
participants compared with reporting a diagnosis of benign breast disease or a breast lump, 
and evidence of a clinical investigation was considered important for a diagnosis. However, 
the number of breast biopsies should not be seen to accurately represent the prevalence of 
benign breast disease in this study. A breast biopsy is performed to partially or fully extract a 
suspicious breast lump and perform a diagnostic test on the tissue. The abnormal tissue is 
then diagnosed as either benign, or cancerous. Not all women with benigh breast disease are 
symptomatic. Asking women if they ever had a breast biopsy will only identify those women 
whose lumps were brought to notice through self examination, a doctor's clinical 
examination or mammogram. 
In addition, not all identified lumps are biopsied. The doctor may request an 
ultrasound or MRI to first rule out a breast cyst (fluid filled sac). If it is a solid mass, a breast 
biopsy or breast surgery to remove the lump may be performed. Therefore, asking if a woman 
has had a breast biol* is unlikely to pick up breast cysts. Findings to the question 'have you 
ever had a breast biopsy' will only be representative of biopsy-demonstrated benign breast 
disease (excluding those who were diagnosed with cancer or found to have no abnormality at 
all). However, if treated women had more cases of breast disease than untreated women, it 
would be expected that they would have.had more breast biopsies for a given age. 
At the start of this study, it was recognized that the cohort size was too small, and 
participants relatively too young, to expect to pick up many cases of breast cancer, and that it 
was not suitable for a reliable assessment of the level of breast cancer risk associated with 
high-dose estrogen treatment in tall girls. However, it was also recognised that the cohort 
could provide some indication of the incidence in the two groups of women, and whether the 
rates for treated women appeared out of the ordinary. As anticipated, the numbers of breast 
cancer cases were small for both groups, and the rates did not appear out of the ordinary. In 
Australia, the 20 year prevalence rate for women 35-39 years of age in 2006 was 
1.6%. This prevalence rate is based on the number of surviving persons who received 
a breast cancer diagnosis in the last 20 years 245 . The mean ages of women in the Tall 
Girls Study were 39.7 years (treated) and 37.7 years (untreated) at the time that they 
were asked about their breast cancer history. Assuming there was no increased or 
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decreased risk of breast cancer in these women and based on the population 
prevalence rates, it would be expected that at least 1.6% of women would have had.a 
diagnosis of breast cancer previously. In this cohort, the rate was 1.1% for treated and 
0.5% for untreated.. 
A larger sample size and a longer follow-up period would be needed to better 
investigate breast cancer risk. For instance, with the existing sample size, at least 6% of 
treated or untreated women would need to have had breast cancer for the study to have 80% 
power to detect a significant difference between the two groups (assuming the proportion for 
the other group was similar to the Australian population prevalence of 1.6%). 
A larger sample size and more systematic collection of breast cancer risk factors 
would also provide the opportunity to perform multivariable 'analyses to address any 
systematic differences between treated and untreated women that might explain any 
association between breast disease and treatment with high-dose estrogens in adolescence. A 
prospective or randomised controlled trial, while stronger in design, would not be possible. 
The practice of treating tall girls with high-dose estrogens is no longer common, and 
unethical given the adverse effects on fertility that have been reported previously25. 
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4.5 Conclusion 
This study identified a number of breast related side effects of treatment and found some 
were more prevalent among women who were treated with diethylstilbestrol compared with 
ethinyl estradiol. These effects are likely to have caused significant discomfo .rt and, in some 
cases, embarrassment in treated girls. Treated women might be concerned about these 
findings and the potential for longer term effects on the breast. Reassuringly for treated 
women, this investigation found no significant difference between treated women and 
untreated women in having ever had a breast biopsy, breast surgery (including lumpectomy), 
or a diagnosis of breast cancer. 
An alternative measure of breast cancer risk is mammographic density. This was 
examined in follow-up 2 as part of this PhD research study, and the findings are presented in 
Chapters 7 and 8. Prior to this, the findings in relation to the effect of treatment with high-
dose estrogen in adolescent girls for tall stature on breast function are presented in Chapter 5. 
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Box 4.1: Summary of key chapter 4 findings. 
KEY FINDINGS: CHAPTER 4. 
• Short-term breast related side effects of treatment included breast lumps, 
galactorrhea, breast pain, dry cracked or bleeding nipples and increased 
pigmentation of the nipple. 
• Short-term side effects of treatment were more frequently reported in women 
treated with diethylstilbestrol compared with those treated with ethinyl 
estradiol. 
• There was no significant difference between treated women and untreated 
women in having ever had a breast biopsy, breast surgery (including 
lumpectomy), or a diagnosis of breast cancer. 
• The cohort size was too small and follow-up period too short to pick up 
sufficient cases for a reliable assessment of the level of breast cancer risk 
associated with high-dose estrogen treatment in adolescence. However it has 
provided some indication of the difference in the rates between the two 
groups of women. 
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5: TREATMENT WITH HIGH-DOSE ESTROGENS IN ADOLESCENCE AND 
SUBSEQUENT EFFECTS ON LACTATION 
5.0 Introduction 
An important finding in Chapter 4 is that study participants treated with estrogens for 
tall stature reported a range of short-term side effects on the breast, confirming similar 
findings in the literature. When this information is considered together with the reported 
changes in the hormonal milieu of girls treated with estrogens described in Chapter 2, and 
previous findings from the Australian Tall Girls Study on the long-term effects of treatment 
on fertility, it seems possible that treatment could have long-term effects on breast histology 
and therefore, function. 
This char:4er describes the part of this PhD study that investigated the long-term effects of 
treatment with high-dose estrogen on lactation, in particular breast feeding commencement 
and duration, in the Australian Tall Girls Study cohort. 
Chapter 5: Treatment with high-dose estrogens in adolescence and subsequent effects on lactation • 
	
106 
5.1 Study Aim 
The aim of this chapter is to use data collected in follow-up 1 of the Australian Tall Girls 
Study to 1) study the effect of treatment on breastfeeding commencement by comparing 
breastfeeding initiation rates between treated and untreated women, 2) compare breastfeeding 
duration in treated and untreated women, 3) compare the reasons for stopping breastfeeding 
between treated and untreated women, 4) and compare the rates of pregnancy induced breast 
enlargement in treated and untreated women. 
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5.2 Methods 
This section presents the methodology used to collect and analyse the data, the findings; and 
finally, the discussion and conclusion. 
5.2.1 Participants 
As described in Chapter 4, participants included women who obtained a medical opinion 
about their tall stature and had radiological assessment of their skeletal age during 
adolescence. They included women who received estrogen treatment (3mg DES or 150 pg 
EE daily) in adolescence to reduce their adult height (treated group) and women who had not 
(untreated). Data on reproductive and breastfeeding history (those who consented to the 
CAT!) were available for 371 treated (72% of those traced) and 409 (56%) untreated women. 
Recruitment strategies and responses are described more fully in Section 4.2.2. The collection 
of exposure data from medical records is described more fully in Section 4.2.3. 
5.2.2 Measures of breastfeeding 
The breastfeeding questions asked in the computer assisted telephone interview are presented 
in Figure 5.1 below. 
For every livebirth, women were asked if they commenced (initiated) breastfeeding 
their baby, and if they did, how long their baby was breastfed with breast-milk only, how 
long they breastfed their baby altogether (including when this baby had formula &/or solids), 
and the reason why they stopped breastfeeding the baby. If they did not commence 
breastfeeding, they were asked the reason for not commencing breastfeeding. Duration of 
breastfeeding was expressed in days, weeks or months in the questionnaire, and converted to 
weeks. 
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Figure 5.1: The breastfeeding questions asked in the computer assisted telephone interview (set up for 8.babies). 
Now I would like to ask you some Questions about BREASTFEEDING starting with your first child. 
C8. DID YOU 
COMMENCE 
BFtEASTFEEDING 
THIS BABY? 
C9. How long did your 
baby have breast milk 
only? 
C10. How long, did you 
breastfeed this baby all 
together (including when 
this baby had formula 
&/or solids) 
Cl la. Why did you stop 
breastfeeding this baby? (Ask 
as an open ended question 
and enter numbers that apply) 
See Table Cllb 
C12a. If you didn't commence 
breastfeed this baby —what 
was the reason? (Ask as an 
open ended question and 
enter numbers that apply) See 
Table C12b 
C13. Did you 
notice that 
your breast 
increased in 
size while 
pregnant? 
YES 
NO 	LI 
BABY 
1 
YES 	—> C9 
NO 	—› C12 
• 
DLI Days 
DLI Weeks 
Months 
LI currently b'feeding 
LILIDays 
DO Weeks 
O0Months 
LI currently b'feeding 
ENTER NUMBER(s) 
, 	, 	— go to C13 0,0,00 
ENTER NUMBER(s) 
----). o to C 
BABY 
2 
YES 	—> C9 
NO LI—›  C12 
Days 
Weeks 
DLI Days 
Weeks 
ENTER NUMBER(s) ENTER NUMBER(s) 
• 
• , • , III III 
—>go to C 
YES 
NO 	LI 
• LI Months • LI Months 
III currently b'feeding III currently b'feeding • ,111,• NI —>go to C13 
BABY 
3 
YES 	--> C9 
NO 	—> C12 
LILI Days 
DLI Weeks 
LID Months 
LI currently b'feeding 
DLI Days 
DLI Weeks 
DLI Months 
LI currently b'feeding 
ENTER NUMBER(s) . 
0 , 0,00 —go to C13 
ENTER NUMBER(s) 
0,0,00. 
to C 
YES LI 
NO 
BABY 
. 4 
YES • —> C9 • LI Days • LI Days ENTER NUMBER(s) . 
, 	, 	—)go to CI3 
ENTER NUMBER(s) 
DLI,LILI  
-go to C 
YES LI 
NO 	LI 
. 
NO LI—>  C12 LILI Weeks DLI Months 
LI currently b'feeding 
DLI Weeks 
DLI Months 
LI currently b'feeding 
BABY 
5 
YES 	—) C9 
NO LI—>  C12 
DLI Days 
DLI Weeks 
DLI Months 
LI currently b'feeding 
DLI Days 
00 Weeks 
ENTER NUMBER(s) 
,D DLILI —ego to C13 
ENTER NUMBER(s) 
DD DLI, 
to C 
YES LI 
NO 	LI 
• •LI Months 
LI currently b'feeding 
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Figure 5.1 continued. 
Cllb Reason why stopped breastfeeding 
I. 	Didn't want to breastfeed or didn't want to breastfeed any longer 
2. Nipple trauma 
3. Nipple pain 
4. Felt there was not enough milk 
5. Unable to get baby to attach/suck/difficulties attaching the baby to the breast 
6. Baby very premature 
7. Lack of help/support/supervision with breastfeeding 
8. Mastitis 
9. Recurrent mastitis 
10. Baby had poor weight gain 
11. Advice from professional — who (please state e.g. GP, psychiatrist) 
12. Employment reasons 
13. Baby lost interest/always looking around/stopping & starting feeding 
14. Breasts didn't fill or became engorged in first few days 
15. Other (please specify) 	  
C12b Reason Why never attempted to breastfeed baby 
1. Did not want to breastfeed 
2. Wanted to bottle feed 
3. Employment/work reasons 
4. Partner preferred me to bottle feed• 
5. Family preferred me to bottle feed 
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These questions had been used previously in a study of attachment to the breast and 
family attitudes to breastfeeding 246 where the interview questions were piloted extensively 
and modified before use247 . Reasons for stopping breastfeeding were asked of women to 
separate physiological (e:g. nipple trauma, nipple pain, mastitis) and convenience (e.g. 
employment248) reasons for stopping breastfeeding. An 'Other — please specify' option was 
listed for those responses that did not fit any of the reasons listed. If treatment did influence 
lactation the reasons for stopping breastfeeding would be expected to be physiological or due 
to inadequate nutritional support of the baby. These explanatory questions therefore validate 
any associations observed between treatment and breastfeeding duration. 
Women were asked whether they noticed their breasts increase in size while 
pregnant. The question on breast changes during pregnancy was asked to ascertain whether 
there was mammary development during pregnancy in preparation for lactation and in 
response to anecdotal evidence that this may have been a problem in treated women. 
5.2.3 Other covariates 
Parity has been positively 249, and negatively 250  associated with breastfeeding duration in 
Australian studies, while breastfeeding initiation has been found to be negatively 249 
associated with parity. In the CATI, women were asked how many pregnancies they had, the 
outcome of each pregnancy and the date when each pregnancy ended. Number of livebirths 
was derived from this data. Maternal age at birth, which has been shown to be positively 
associated with breastfeeding duration in Australian WOMer1249-252 , was derived from the date 
of each livebirth collected in the CATI. 
Data on other potential confounders such as maternal education25I-255 and other 
socio-economic indicators256 Were collected in the postal questionnaire as described in 
Chapter 4 (Section 4.2.5). 
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5.2.4 Statistical methods 
Stata software (version 8) was used for all statistical analysis. Chi-square tests were 
performed for tests of significance for categorical descriptive data, and t-tests for 
continuous descriptive data. All tests of significance were two-sided. The precise p-
values were reported for descriptive data comparisons. Following convention, 
nominal statistical significance was based on a p-value less than 0.05. Relative risks 
and 95% confidence intervals were calculated using log binomial regression. A 
discussion of the choice of threshold for statistical significance is described in section 
4.2.6. 
For the regression analysis of breastfeeding duration data, the assumption that the errors 
were distributed normally was checked using normal quantile plots of the residuals. If 
transformation of the breastfeeding duration variable was required, the Box-Cox niethod 257 
was used to identify the most appropriate transformation. Treated and untreated transformed 
data were compared using linear regression and medians and 5% and 95% percentiles 
reported. 
Potential confounding variables (e.g. number of livebirths, age, year of birth and 
maternal age at first live birth) were entered into the model one at a time and retained if their 
presence was significant. This study examined breastfeeding initiation and duration in treated 
and untreated primiparous women so did not include number of livebirths in the risk 
estimation model. However, when breastfeeding duration was explored for all livebirths, the 
number of livebirths a woman ever had was included in the model. 
Since fertility problems have been associated with treatment25 statistical interaction 
between treatment status and maternal age at birth and number of livebirths was examined 
when comparing treated and untreated results for breastfeeding commencement or duration. 
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5.3 Results 
5.3.1 Characteristics of study participants 
The characteristics of study participants are shown in Table 5.1. The mean age of 
participants was 39.8 years (range 20-55) in the treated group and 37.7 years (23-54) in the 
untreated group (p=<0.001). As reported in Chapter 4, treated and untreated study 
participants were similar in their marital status, though slightly more treated women were 
single than untreated women (p=0.051). Women were similar in the highest educational level 
achieved in most categories, though more treated than untreated women did not complete 
secondary school (p=0.014) and fewer had a degree (p=0.050). Treated and untreated women 
were also similar in family income, smoking history, oral contraceptive use and mean age at 
first livebirth. As reported elsewhere 25 , treated women n=248 (66.9%) were significantly less 
likely to have ever had a livebirth than untreated women n=267 (65.3%): age-adjusted RR 
0.87 (95% CI: 0.79 to 0.95), though this difference was small. 
5.3.2 Treatment characteristics 
Of the treated women completing the CATI, 146 (39.4%) used DES, 195 (52.6%) used EE, 
five (1.3%) used both and the estrogen type was missing for 25(6.7%). Women were treated 
for a mean duration of 24.7 months and commenced treatment at a mean age of 12.8 years. 
Treatment commenced before menarche in 52.9% of treated girls. First assessment and hence 
treatment occurred at or after Tanner stage 3 (breast development) for 51% (54.8% DES, 
49.0% EE) of treated girls. In addition to estrogen, a progestagen was routinely administered 
as 5 mg twice daily for 4 days every month to induce cyclical bleeding. 
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Table 5.1: Characteristics of study participants. 
Characteristic Treated 
(n=371) 
Untreated 
(n=409) 
Age 
Mean (years) 	, _39.8 37.7 
Age first livebirth 
Mean (years) 29.0 28.9 
Marital Status n (%) 
Married or cohabitating 281 (75.7) 308 (75.3) 
Divorced, separated or widowed 43 (11.6) 33(8.1) 
Single 43 (11.6) 68 (16.6) 
Data missing 	, 	. 4_(1.1) , 0 . 
Highest Education Level n (%) 
Did not complete secondary school 36 (9.7) 21(5.1) 
Completed secondary school 61 (16.4) 73 (17.9) 
Apprenticeship/certificate/diploma 84 (22.7) 88 (21.5) 
Degree 106 (28.6) 144 (35.2) 
Postgraduate 82 (22.1) 82 (20.1) 
Data missing 	 _ 2(0.5) 1(0.2) 
Family Income (Aust$) n (%) , 
$0-25,999 • 35 (9.4) 40 (9.8)' , 
$26,000-51,999 78 (21.0) 85 (20.8)! 
$52,000-77,999 71 (19.1) 88 (21.5) 
$78,000-103,000 67 (18.1) 83(20.3) •  
$104,000+ 88 (23.8) 91 (22.2) 
Data missing 32(8.6) 22(5.4) 
Smoking n (%) 
Ever smoked 195 (52.6) 213 (52.1) 
Data missing 	_ 4(1.1) 0 
Oral contraceptives n (%) 
• Ever used 352 (94.9) 390 (95.4) 
Missing data 2 (0.5) 1 (0.2) 
_ 
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5.3.3 Breaitfeeding commencement 
Women who had been treated with estrogens to reduce their adult height were no more likely 
than untreated women to not commence breastfeeding following their first live birth (age 
adjusted RR 1.13, 95% 'CI: 0.50 to 2.52) or any livebirth (age adjusted RR 1.12, 95% CI: 
0.43 to 2.90) (Table 5.2). No significant statistical interaction was observed between 
treatment status and maternal age at first pregnancy or number of livebirths. 
Table 5.2: Breastfeeding commencement. 
Treated 
n (%) 
Untreated 
n (%) 
Adjusted RR* 
(95%CI) 
Did not 
commence 
breastfeeding 
first livebirth 
11(4.4) 11(4.1) 1.13 (0.50 to 2.52) 
Did not 
commence 
breastfeeding 
any livebirth 
8(3.2) 8(3.0) 1.12 (0.43 to 2.90) 
N=248 treated, 267 untreated (those having had a livebirth) 
* Adjusted for maternal age at first livebirth. 
Reasons for not commencing breastfeeding the first baby included having had no 
milk (treated n=2, untreated n=1), non 'breast-related Medical reasons for mother or baby 
(treated n=4, untreated n=2), did not want to breastfeed, preferred bottle feeding or for 
employment reasons (treated n=4, untreated n=4), baby was not interested (untreated n=1), or 
reason missing (treated n=1, untreated n=3). 
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5.3.4 Breasffeeding duration 
In women who commenced breastfeeding, there was no meaningful difference between 
treated and untreated women in duration of breastfeeding in total or exclusively for the first 
or all livebirths (Figure 5.2) (Table 5.3). 
Figure 5.2: Mean breastfeeding duration (weeks) for treated and untreated 
women. 
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Table 5.3: Breastfeeding duration for those who initiated breastfeeding 
Treated 	Untreated 
Median 	 Median 	value 
95 th percentile h,t —th percentile 
range) range) 
Breastfeeding duration 
for first birth (weeks)* 
39.0 (6.0-77.9) 43.3 (6.0-77.9) 0.77 
Breastfeeding duration 
for all livebirths 
(weeks) (mean)** 
41.1 (6.0-95.3) 43.3 (5.0-82.3) 0.77 
Feeding . duration for 
breastmilk only, all 
livebirths • 
(weeks) (mean) 
17.3(2.3-30.3) 17.3 (1.5-28.9) 0.81 
N=240 treated, 259 untreated. Missing 11 treated and eight untreated for breastfeeding 
duration for first and all livebirths, six treated and one untreated of breastmilk only duration. 
Number of women who ever breastfed is greater than number who breastfed their first 
livebirth. 
Adjusted for maternal age at first livebirth 
** 	Adjusted for age at interview 
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The distribution of the breastfeeding duration data was not normal. The square root 
transformation emerged as the most suitable method for total breastfeeding duration. No 
transformation was required for feeding duration for exclusive breastfeeding. Maternal age at 
first livebirth and age was significant for duration for first livebirth and all livebirths 
respectively and were included in the regression model. Adding year of first livebirth to the 
regression did not change the result. No significant interaction effect was observed between 
treatment status and age of first pregnancy or number of livebirths. 
Treated women who commenced breastfeeding their first baby were no less likely to 
be breastfeeding at four, 24 or 52 weeks than untreated women. Of those who breastfed their 
first baby 2.7% treated and 4.0% untreated women had stopped breastfeeding by four weeks. 
At 24 weeks, 75.4% untreated and 77.4% treated were continuing to breastfeed their first 
baby, and at 52 weeks, 24.6% untreated and 20.4% treated were continuing to breastfeed 
their first baby. 
Women whose treatment started before menarche were not significantly more likely 
to stop breastfeeding earlier than women whose treatment started after menarche. Of those 
who commenced treatment before menarche, 1.8% stopped breastfeeding before four weeks 
while 3.5% of those who commenced treatment after menarche stopped before four weeks 
(p=0.42). 
There was no difference in the duration of breastfeeding the first baby, in total 
(p=0.18) or exclusively (p=0.93), between women treated with DES and EE. 
5.3.5 Reasons for stopping breasffeeding 
Treated women were no more likely than untreated women to have stopped breastfeeding 
their first baby for physiological reasons affecting the breast (Table 5.4). Reasons included: 
feeling that there was insufficient milk or it had dried up (13.1% treated, 12.9% untreated), 
they had nipple pain (1.3% treated, 3.1% untreated), nipple trauma (0.9% treated, 2.3% 
untreated), or because of mastitis (1.7% treated, 1.6% untreated). It appeared that treated 
women were more likely to have stopped breastfeeding because their breasts did not fill or 
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become engorged (adjusted RR 4.48, 95% CI: 0.98 to 20.60) but very few women were in 
this category for both groups. 
Table 5.4: Reasons for stopping breastfeeding for physiological reasons. 
Reason for stopping 
breastfeeding 
	
. Treated 
	
Untreated 
n (%) n (Y0) 	RR (95% CI) 
(N=236)* (N=256) 
31 (13.1) 33 (12.9) 1.02 (0.65 to 1.61) 
2(0.9) 6(2.3) 0.36 (0.07 to 1.77) 
3 (1.3) 8(3.1) 0.41 (0.11 to 1.52) 
4(1.7) 4(1.6) 1.08 (0.27 to 4.23) 
8(3.4) 2(0.8) 	, 4.48 (0.98 to 20.60) 
Felt there . was not enough 
milk/milk dried up 
Nipple trauma 
Nipple pain 
Mastitis 
Breasts did not fill or become 
' engorged 
A woman may have provided more than one reason for stopping breastfeeding. 
Four untreated and two treated women were still breastfeeding. 
* Missing n=1 treated 
f Adjusted for maternal age at first birth and number of livebirths 
Treated women were no more likely than untreated women to have stopped 
breastfeeding for a range of non-physiological reasons• that included not wanting to 
breastfeed any more or the baby was old enough to be weaned (adjusted RR 0.94, 95% Cl: 
0.74 to 1.18), poor baby weight gain (RR 0.81, 95% Cl: 0.29 to 2.31), baby lost 
interest/weaned itself (RR 0.99, 95% CI: 0.68 to 1.44); employment reasons (RR 0.92, 95% 
Cl: 0.50 to 1.72), next pregnancy planned or started (RR 0.91, 95% Cl: 0.48 to 1.73), unable 
to get baby to suck/attach (RR 1.19, 95% CI: 0.52 to 2.76), and lacking confidence/support 
(adjusted RR 0.75, 95% Cl: 0.29 to 1.93). 
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5.3.6 Change in breast size during pregnancy 
Treated women n=12 (4.9%) were no more likely than untreated women n=15 (5.7%) to have 
reported that their breasts did not increase in size during their first livebirth pregnancy (RR 
0.87, 95% CI: 0.41 to 1.82) or for any livebirth pregnancy (7.0% treated, 7.6% untreated). 
Of the women who reported that they stopped breastfeeding because their breasts did 
not fill or become engorged after their first livebirth, (eight treated, two untreated), six of the 
treated and all of the untreated had reported that their breasts had increased in size during that 
pregnancy.. 
Of the women who did not commence breastfeeding their first baby because they did 
not produce milk (two treated, one untreated), all had reported that their breasts increased in 
size during pregnancy. 
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5.4 Discussion 
This is first study to examine the long-term effects of estrogen treatment for tall stature on 
lactation. This study found no meaningful differences in breastfeeding commencement rates 
or breastfeeding duration, between women treated with high-dose estrogens during 
adolescence and untreated women. This is despite women reporting short-term side effects 
on the breast as described in Chapter 2. 
As previously reported, women with insufficient glandular tissue of the breast are 
known to suffer from lactation failure and a lack of breast enlargement during pregnancy 230 ' 
258. Complaints of flat-chestedness by girls treated with estrogens for tall stature have been 
reported23 ' 41 . It is possible that the reduced IGF-I levels observed with treatment" could 
increase the risk of breast hypoplasia, and consequently a lack of breast enlargement during 
pregnancy and lactation insufficiency. However, in this study, women treated with estrogen 
during adolescence for tall stature were no more likely to report a lack of breast enlargement 
during pregnancy, or lactation insufficiency, than untreated women. 
In addition, a lack of breast engorgement or filling of the breasts did not seem to be 
associated with breast hypoplasia because most of the women reporting a lack of breast 
engorgement or filling of the breasts reported an increase in breast size during pregnancy. 
There was no difference in the number of treated and untreated women who reported that 
their breasts did not increase in size during any pregnancy. 
A strength of this study was the collection of data on the reasons for stopping 
breastfeeding. If treatment affected breastfeeding duration it would be expected that more 
treated women would have stopped breastfeeding because of difficulties with it. The reasons 
for stopping breastfeeding were similar between treated and untreated women. Treated 
women were no more likely to have stopped breastfeeding because of a lack of milk, nipple 
trauma or pain, or mastitis. More treated than untreated women reported stopping because 
their breasts did not engorge or fill with milk but the numbers were small for both groups. 
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One limitation of the study is that women were asked to recall their breastfeeding 
history on average 10.7 years (range 0.4-33 yrs) after breastfeeding their first livebirth. A 
review of 11 studies that examined the reliability and validity of breastfeeding recall data 
suggests that maternal recall is a valid and reliable estimate of breastfeeding initiation and 
duration, but is less satisfactory for exclusive breastfeeding 259 . Tomeo et al. (1999)260 , for 
instance, observed a high reliability of long-term recall of breastfeeding duration (-0.86). 
Two Australian studies support the use of maternal recall data 10- 15 years after the event26I 
262 . Tienboon et al. (1994) 26 ' reported that one third of women in their study recalled 
breastfeeding duration with a one month accuracy, while 59% recalled it accurately within 
two months, 14-15 years post the breastfeeding event. On average, mothers overestimated 
duration by 1.3 months 26. 
A later study examined the recall accuracy of reasons for. weaning by comparing 
data collected by interview soon after breastfeeding with data collected years later from the 
same women, and found varied results depending on the reason (54% sensitivity for nipple 
cracks/sores, 84% for mastitis) 1.3-5 years following birth 263 . 
In 1991, The World Health Organization 264 developed a definition of exclusive 
breastfeeding that only allows breastmilk to be received from the mother, a wet nurse, or 
expressed, and no other liquids or solids with the exception of drops or syrups consisting of 
vitamins, mineral supplements or medicines to be taken during the period of exclusive 
breastfeeding. When women reported on the length of time their baby was breastfed with 
breast-milk only, it is possible that the babies had taken water during this period. This study 
is interested in the difference in breastfeeding duration (exclusively, and in total) between 
treated and untreated women and there is no reason why treated and untreated women would 
differ in their interpretation of this question. According to Chapman et al. (2009)265 slight 
variations in wording of the breastfeeding duration questions can result in different estimates 
of bteastfeeding duration, especially among infants receiving predominantly expressed breast 
milk. Women who expressed their breast milk for instance, might respond to the 
breastfeeding duration question in this study differently to those who received their 
breastmilk by the breast. However, it is unlikely that treated and untreated women would 
interpret the question differently. 
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As suggested in a study reporting DDE and PCB exposures on lactation duration and 
initiation214 , some mothers may have stated that they did not commence breastfeeding when 
in fact they had but stopped feeding in the first few days following birth. These women 
would have otherwise been included in the group of women who had commenced 
breastfeeding, and for whom breastfeeding duration was calculated. If this occurred, the 
number of women who did not initiate breastfeeding would be lower than reported, and the 
number of women with a shorter duration of breaitfeeding would have been larger than 
reportea214 . If misclassification occurred as described, but equally between the treated and 
untreated women, then there would be no effect on the regression results, though the median 
number of women who commenced breastfeeding would be higher, and the median duration 
would be lower for both groups of women. It is very unlikely that this form of 
misclassification was greater in one group compared with the other. 
As well as maternal age and parity, which were included in the risk estimation 
models in this chapter, maternal education 251-255 and other socio-economic indicators 256 , 
a 255, 267, 268 smoking252, 255, 266 nd BMI , 	 at time of birth of offspring have also been shown to be 
associated (inversely) with breastfeeding duration. Mothers with greater levels of self-
confidencem during pregnancy have been shown to breastfeed for longer. In their 
prospective cohort study of 556 Western Australian women and 503 women from 
Queensland, Scott et al. (2001)250 found that mothers born in Australia 250 were more likely to 
breastfeed for longer, while Baghurst etal. (2007)252 in their prospective study of 317 South 
Australian primiparous women, found the opposite. Similarly, breastfeeding initiation in 
Australian women has been positively associated with higher occupational status249 and 
overall socioeconomic index for areas (SEIFA) 254 , and inversely associated with BMI 267 , 
! being Australian-born, umnarried, and current smoking 270 . 
Treated and untreated women were similar overall in educational and marital status 
and level of family income, and the majority of treated and untreated women were born in 
Australia. These factors were not included in the multivariable model for breastfeeding 
duration or initiation. Data on BMI and smoking during pregnancy or at time of birth was not 
collected in this study. There is no clear evidence to suggest that smoking rates differed 
between treated and untreated women during pregnancy, as current rates of smoking were 
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similar between the groups. As well as self-confidence reported above, longer breastfeeding 
duration has been associated with lower levels of anxiety and depression; increased self-
esteem and coping capacity, and stronger social health in Australian women 255 ' 271 . An 
examination of the long-term psychosocial outcomes of the Australian Tall Girls Study 
cohort using the depression, mania and eating disorders modules of the Composite 
International Diagnostic Interview (CIDI), the SF-36, and an index of social support; 
observed higher levels of depression in both treated and untreated women compared to the 
findings of population based studies54 . There was no difference in psychosocial outCome 
between treated and untreated women. 
Animal studies suggest that estrogen exposure during the period that corresponds to 
allometric growth of the mammary gland in humans can exert histological and functional 
effects on the mammary gland. Long-term effects on lactation were not demonstrated in this 
study of women exposed to high-dose estrogens during adolescence. We need to be cautious 
when comparing species in relation to such exposures. The typical time period between 
puberty and gestation in many laboratory and domestic animals is short, making comparisons 
with humans difficult. Estrogen induced changes to the mammary gland in animals during 
the prepubertal or pubertal period may not have had time to recover before the occurrence of 
gestation and lactation. For example, in the study on heifers reported earlier, calving occurred 
12.5 months following the end of pre-pubertal treatment with estrogen implants 27 . In our 
study, the mean time between the end of treatment and first birth was 15.7 years. 
While recognising the need for caution when comparing species in relation to 
exposures, the author contacted Herbert Allen Tucker (1936-2009), a renowned dairy 
scientist who had decades of research behind him in the area of mammary development and 
dairy lactational research, for his view on the likelihood of long-term effects of pubertal 
exposure to high-dose estrogen on later lactation. 
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His email response (a few years before his death) was as follows: 
"I don't know of any effects of estrogen given during adolescence on subsequent 
long-term effects on . mammary function. During the actual administration of 
'estrogens you can be sure that mammary duct gi-owth will be markedly increased. I 
would expect that following withdrawal of estrogen the gland would regress. In fact,• 
we stimulated mammary growth in young growing heifers with melengesterol (MGA, 
which blocks the estrous cycle because of its estrogenic and progestin activity), then 
stopped the MGA to allow resumption of estrous activity, bred the animals, and 
measured subsequent lactational performance. Mammary growth was temporarily 
increased, but there was no long-term effect on milk production". (2005) 
This study supports the prediction by H. Allen Tucker. 
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5.5 Conclusion 
While treatment with high-doses of estrogens in adolescence is associated with short-term 
adverse effects on the breast, in the longer term, treated women appeared to be no different to 
untreated women in their ability to breastfeed their babies. There was no difference between 
treated and untreated women in breastfeeding initiation, and duration. These findings are 
reassuring in light of evidence of adverse effects on other reproductive outcomes 25 . 
Whether treatment for tall stature has effects on mammary tissue growth in the short-
and long-term is unknown. The next part of this chapter (Part C) examines the effect of high-
dose estrogen treatment in adolescence on mammographic density, a well established risk 
factor for breast cancer, and a measure of the area of epithelial and stromal tissue in the 
breast. 
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Box 5.1: Summary of key findings: Chapter 5. 
KEY FINDINGS: CHAPTER 5 
• This study found no meaningful differences in breastfeeding 
commencement or breastfeeding duration between women treated with 
high-dose estrogens during adolescence and untreated women. 
• Treated women were no more likely to report a lack of breast 
enlargement during pregnancy or lactation insufficiency than untreated 
women. 
• The reasons for stopping breastfeeding were similar between treated and 
untreated women. Treated women were no more likely to have stopped 
breastfeeding because of a lack of milk,'nipple trauma or pain, or 
mastitis. More treated than untreated women reported stopping because 
their breasts did not engorge or fill with milk but the numbers were small 
for both groups. 
• A lack of breast engorgement or filling of the breasts did not seem to be 
associated with breast hypoplasia because most of the women reporting a 
lack of breast engorgement or filling of the breasts reported an increase in 
breast size during pregnancy. 
PART C 
Chapter 6: Current evidence of associations between estrogen 
exposures and marnmographic density, a risk factor of breast cancer 
Chapter 7: The long-term effect of high-dose estrogen exposure in 
adolescent girls on mammographic density 
Chapter 8: Childhood and adolescent growth parameters and 
mammographic density in treated and untreated women 
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6: CURRENT EVIDENCE OF ASSOCIATIONS BETWEEN ESTROGEN 
EXPOSURES AND MAMMOGRAPHIC DENSITY, A RISK FACTOR OF 
BREAST CANCER 
6.0 Introduction 
Chapter 3 presented strong evidence of an association between hormonal exposures and 
breast cancer risk. Studies of hormonal exposures during periods of intense mammary 
development demonstrate evidence of an association with breast cancer risk. It is plausible 
then, that girls treated with high-dose estrogens during adolescence have an increased risk of 
breast cancer later in life. Breast cancer cases in the Tall Girls Study cohort were examined 
in Chapter 4. However, the size of the cohort was too small to pick up sufficient cases for a 
reliable assessment of the level of breast cancer risk associated with high-dose estrogen 
treatment in tall girls. An alternative measure is mammographic density, a marker of breast 
cancer risk. 
This chapter begins by describing mammographic density and the different methods 
of density measurement, and then follows with a review of studies that have examined 
associations between mammographic density and breast cancer risk. It explores the evidence 
of hormonal influences of mammographic density (both exogenous and endogenous) to 
support the suggestion that hormone use in adolescence could possibly affect mammographic 
density. Evidence of associations between adolescent exposures and mammographic density 
later in life is examined. Evidence presented in this chapter, when viewed together with the 
findings reported previously, highlights the plausibility that adolescent exposure to high-dose 
estrogens may lead to changes in mammographic density in adulthood. 
Treated girls might differ from untreated girls in some growth parameters associated 
with mammographic density (e.g. birthweight, birth-length, or childhood height). From 
previous reports it is known that untreated girls generally have less growth potential than 
treated girls, reflected by a greater level of pubertal maturity and more advanced bone age 
when compared to their chronological agen . Finally, a comparison of studies of association 
Example for each of 
the categories for 
classifying 
mammographic 
density using the six 
category system. 
Fibroglandular tissue is 
categorised as follows: 
(a) 0, (b) <10%, (c) 
10-25%, (d) 26-50%, 
(e) 5 1-7 5%, (f) >75%. 
Source2 which was a 
clearer reproduction 
from4 11 (d) (e) 
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between a number of childhood/ adolescent growth parameters and mammographic density is 
undertaken. 
6.1 Mammographic density — what is it? 
Fat is radiolucent and appears dark on a mammogram, while stromal and epithelial tissue 
appears light4 . The area of tissue that appears light on a mammogram is referred to as breast 
or mammographic dense tissue. Figure 6.1 shows representative images of mammograms of 
varying degrees of density from (a) no density to 0 very dense. 
Figure 6.1: Mammograms showing dense (white) and non-dense (dark) areas of the 
breast across varying degrees of density: a) no density to f) very dense. 
6.2 How is mammographic density measured? 
Mammographic density can be measured using qualitative descriptors or quantitatively by 
visual estimation or with computer assistance. Since the studies reviewed later in this chapter 
use different methods of mammographic density measurements, each of these measurement 
methods are described below. 
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6.2.1 Qualitative measurement of mammographic density 
Qualitative methods of mammographic measurement include the Wolfe grading system, and 
the BI-RADS scaling system. These two qualitative systems use four categories of density 
classification, and consequently, are only able to detect large changes or differences in 
density272 . They are measured by visual estimation and are more subjective than the 
quantitative measures of density. The Wolfe and BI-RADS systems of measurement are each 
described below. 
6.2.1.1 Wolfe grade 
John Wolfe first defined four categories of breast parenchyma breast patterns that could be 
used as an index of risk for developing breast cancer in 1976273 . It is a subjective scale that 
takes into account the quantity of density and nature of the density in the breast. The 
categories and their representation are as follows: N pattern represents a fatty radiolucent 
breast, P1 and P2 patterns refer to greater levels of prominence of fibroglandular tissue 
(hence density) while the DY pattern refers to dense sheets of fibroglandular tissue. See 
Figure. 6.2 for examples of mammograms that represent these four categories. 
Figure 6.2: Representative mammograms of each of the Wolfe Grades of 
mammographic density measurement. Source Ruth Warren. 
NI 
 
PI 
 
P2 
 
DY 
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6.2.1.2 (BI-RADSTM) 
BIRADSTM refers to the Breast Imaging Reporting and Data Systems of categorising breast 
density developed by the American College of Radiology 274 . The four categories are as 
follows: 1: entirely fat, 2: scattered fibroglandular densities, 3: heterogeneously dense and 4: 
extremely dense. 
The BI-RADS mammographic density categories have been matched to quantitative 
quartile measures of percent density: <25% dense for almost entirely fatty, 25-50% dense for 
scattered fibroglandular densities, 51-75% for heterogeneously dense, and >75% dense for 
the extremely dense category. The accuracy of the new definitions was evaluated by 
Nicholson and colleagues275 . They found that fatty and extremely dense BI-RADS categories 
compared relatively well to the percent density definitions but the scattered fibroglandular 
densities and heterogeneously dense categories (the middle categories) did not perform as 
well275 . This discrepancy has also been observed elswhere276 and is consistent with the 
explanation for the poor inter-observer reliability estimates reported below 277 . 
6.2.2 Quantitative methods 
Mammographic density can also be measured quantitatively as percent or dense area, and 
estimated visually with or without computer assistance. Examples are described below. 
6.2.2.1 Visual estimation 
Percent density has been visually estimated on a continuous scale278 or using a six category 
classification scheme developed by Boyd and co-workers 4 . Figure 6.1 above contains 
representative images of each of the six classifications of percent density: (a) 0, (b) <10%, (c) 
10-25%, (d) 26-50%, (e) 51-75%, (f) >75%. 
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6.2.2.2 Computer assisted method of measurement 
Computer assisted methods of measurement are believed to be less subjective than the visual 
estimation methods described above. This method requires the mammogram to be scanned 
and digitised for viewing on the computer screen. Using an interactive computer method 279 
with software such as Cumulus 280, the reader chooses a brightness level defining dense tissue, 
and defines the boundary of the breast outline, and separately, the boundary of breast dense 
tissue. The computer program calculates the number of pixels in the digitised image of the 
breast within the margins determined by the operator  for total breast area and dense area (the 
area that shows up white on the mammogram). (See Figure. 6.3 for an illustration of these 
boundaries). The computer program then calculates non-dense area in pixels by subtracting 
dense area from total breast area, and percent density which is the proportion of the breast 
area that is dense. 
Figure 6.3: Image as it appears on the screen with the breast area (red) and 
dense area (green) outlined. 
40, 
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These images are two-dimensional (2D). Volumetric three-dimensional (3D) 
methods such as MRI and ultrasound tomography 281 , are available but are still being 
validated. MRI has been recently used on young women by Lisa Martin and Norman Boyd in 
Canada282 . Wei et al. (2004)283 examined the correlation between percent density 
measurements using the 3D MRI method and a 2D method (segmented approach). The two 
measures were highly correlated (0.91), while Boyd et al. (2009) 282 found percent water, as 
measured by MR1, to be strongly correlated with percent mammographic density (r=0.85). 
Some degree of subjectivity is still involved in the 2D computer assisted method. 
The computer assisted methods also require specific software and density measurement 
training. For this reason, according to Duffy et al. (2008) 278 , some large studies still prefer 
visually assessing percent breast density. 
. 6.2.2.3 Planimetry 
The 2D measurement of percent or absolute density can also be preformed directly using a 
planiometer. Planimetry involves tracing the edges of dense tissue on the mammogram and 
the total area (2D) of the breast. From these measurements percent density can be calculated. 
The reader is able to draw boundaries at different levels of brightness across different areas 
of the film, thereby allowing for different compressions across the breast. The computer 
assisted thresholding technique does not provide the option to alter the brightness across 
different parts of the breast. While less subjective than the visual estimation methods, the 
planimetry method has been reported to be labour intensive and not practical for large 
numbers of mammograms 2 . 
6.2.2.4 Reliability assessments of the different methods of measurement 
A recently published paper by Gao et al. (2008) 284 described the comparative inter-rater and • 
intra-rater reliability assessment of qualitative and quantitative visual subjective 
• mammographic density methods of measurements. The inter- and intra-rater reliability scores 
for the Wolfe grade system of measurement were: weighted kappa 0.89 (p<0.0001) and 0.87 
(p<0.0001), respective! y284. These reliability estimates were similar to those for the six 
category quantitative method of measurement of percent density described below at 0.84 
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(p<0.0001) and 0.86 (p<0.0001) respectively 284 . The inter- and intra-rater agreement for the 
visual estimation of percent density on a continuous scale has been reported to be higher 
again: iritraclass correlation coefficient (ICC) 0.94; and 0.96 respectively 284 . 
• Three studies calculated the kappa values for intra-observer agreement for the BI-
RADs method of measurement. The values were 0.77 (95% CI: 0.69 to 0.85) 285 , 0.72 (range 
. 0.66 to 0.78)286, and 0.71 (range 0.32 to 0.88) 277 . Inter-observer agreement was much lower: 
kappa 0.59 (range 0.55-0.62)286 and 0.54 (range 0.02-0.77) 277 . For one of the studies, the low 
level of inter-observer agreement was partly due to a major disagreement in the intermediate 
categories277 
McCormack et al. (2007)287 examined the reliability of a volumetric method and the 
more common 2D thresholding method described above. They 2D method was found to have 
a higher reliability score (ICC 0.92) compared to the 3D method (0.77). 
While the continuous quantitative measurement of mammographic density (as 
percent or absolute density) produces the highest reliability scores, it is also provides a more 
sensitive measure of change in density compared with the qualitative measures and 
categorical quantitative measures described above. The broader qualitative categories or the 
6-category measure of percent density can only detect changes that are large enough to 
warrant a change in density category. For this reason, longitudinal studies of change in 
mammographic density should aim to use a continuous measure of density. 
6.3 Mammographic density and breast cancer risk 
Mammographic density is an outcome of interest in this PhD investigation because of its 
association with breast cancer risk. Mammographic density has been consistently found to be 
strongly and positively associated with risk of breast cancer. Boyd and colleagues4 undertook 
a review of studies that examined the association between mammographic density and breast 
cancer. Of the 34 studies that measured density qualitatively, and nine case-control studies 
that measured percent mammographic • density quantitatively, all observed an association 
between mammographic density and breast cancer. A meta-analysis of the quantitative 
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studies showed that women with dense tissue in more than 60-75% of the breast had 4-6 
times greater risk of breast cancer than those with a lower proportion of dense tissue after 
adjustment for relevant covariates 4 . Boyd et al. (1995) 36 previously estimated that, on a 
continuous scale, a 1% increase in percent breast density (multivariable adjusted) equated to 
a 2% increase in the relative risk (RR) of mammographic cancer and a 406 mm 2 (4.06 cm 2) 
change in total dense area equated to a 3% increase in RR 36 . 
A more recent review published in 2006 by McCormack and dos Santos Si1va 288 
involved a meta-analysis of 42 published studies that had examined the association between 
breast cancer risk and mammographic density. The reviewers examined the possible reasons 
for disparity between studies and observed a difference between incident and prevalent breast 
cancer studies. They combined the relative risks of incident breast cancer across five 
categories of percent mammographic density using findings from nine nested case-control or 
cohort studies (4,508 cases, 8,342 controls). The combined relative risks for incident breast 
cancer were 1.79 (95% CI: 1.48 to 2.16), 2.11(95% CI: 1.70 to 2.63), 2.92(95% CI: 2.49 to 
3.42), and 4.64 (95% CI: 3.64 to 5.91) for percent mammographic density categories 5 to 
24%,.25 to 49%, 50 to 74%, and >75% relative to <5%. They also combined the relative 
risks of prevalent breast cancer derived from five case-control or cross-sectional studies. • 
While slightly lower than the relative risks observed for incident breast cancer, a positive 
trend was evident; RR 1.39(95% CI: 1.10 to 1.76), 2.22 (95% CI: 1.75 to 2.81), 2.93 (95% 
CI: 2.27 to 3.79) and 3.67 (95% CI: 2.72 to 3.79) for percent mammographic density 
categories 5 to 24%, 25 to 49%, 50 to 74%, and >75% 288 respectively (See Figure 6.4). 
Breast cancer risk was 4-5 fold larger in women with >75% dense breasts compared with 
women with less than 5% dense breasts288 ; consistent with Boyd's earlier estimates 4 . 
The majority of research studies on mammographic density have used the relative 
measure of density (% density). The studies that also used the absolute measure of dense area 
have also observed a positive association with breast cancer riSk289-293 . In a comparative 
assessment, Torres-Maija and co-investigators found absolute density to be a stronger 
predictor of breast cancer risk than percent mammographic density 290 . This has been 
supported by others289, 294  but not all292, 295, 296. Mostly, it appears that the two measures are 
similar in their association with breast cancer risk 292,295,296 . 
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Figure 6.4 Study specific and combined relative risks of breast cancer (incidence and 
prevalence) with increasing percent mammographic density. Sourced from 
McCormack and dos Santos Si1va 288 . 
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The strength of the evidence supporting mammographic density as an important breast cancer 
risk' factor presented above has led to suggestions that it be included in breast cancer risk 
prediction mode1s 297-30I . 
6.4 Hormone exposures and mammographic density 
It is unknown whether that treatment with high-dose estrogens in adolescence affects 
mammographic density later in life. No studies have examined this possible association, 
however, a number of studies have examined the effect of exogenous and endogenous 
hormone levels on mammographic density at other life stages. These are summarised 
below. 
6.4.1 Exogenous hormones and mammographic density 
It has been shown that exogenous hormones influence mammographic density. HRT (both E 
and E&P combined formulations), tamoxifen, and gonadotropin releasing hormone agonist 
(GnRHa) are some examples. HRT increases mammographic density, while tamoxifen, 
regarded as an estrogen antagonist, and GnRHa which blocks ovarian function, reduce 
mammographic density. A review of the studies that have investigated these associations is 
presented below. 
§§§ Studies were identified by a PubMed search of the English language literature using the terms 
mammographic (OR breast AND density OR parenchymal patterns) AND hormone OR 0/estrogen 
OR estradiol OR contraceptive OR progestagen/progesterone OR IGF-I or insulin) for any field 
covering all dates up to time of writing. The reference lists of all the publications identified by this 
search were inspected for additional studies. The findings and characteristics of all studies and/or 
reviews of studies that had explored and reported the association between hormones and 
mammographic density are described. When an attempt to describe all studies for an association 
excluded a study, the study and the reason for exclusion is described in the footnote of the relevant 
table. 
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6.4.1.1 Hormone replacement therapy and mammo graphic density.  
- A large number of cross-sectional 302306  and longitudinal40, 243, 307-322 studies have reported 
increased levels of mammographic density with hormone replacement therapy (HRT) use. 
The studies measured mammographic density qualitativel y37, 243, 302, 303, 307, 309, 310, 312-315, 317-323  
or quantitatively, as percent density 304, 305, 309, 312, 316, 317 or dense area394' 324 • The quantitative 
studies classified mammographic density in categories 309' 311 ' 312 (e.g. <25%, 25-75%, and 
>75%)319 or used the continuous measure (e.g. % density,. or cm 2)305 . The different study 
types are reviewed separately beginning with cross-sectional studies. 
Cross-sectional studies: continuous measures of mammoqraphic density 
It is not possible to measure change in mammographic density using the cross-sectional 
study. Change can be measured in longitudinal studies. See Figure 6.5 for an illustration of 
changes in mammographic density in two women using HRT from baseline. While the cross-
sectional design cannot measure change in density directly, it can be used to measure 
differences in mammographic density between groups (e.g. between users and non-users of 
HRT), or to measure associations (e.g. between mammographic density and duration of HRT 
use). 
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Four of six cross-sectional studies that used continuous measures of mammographic 
density are summarised in Table 6.1. Of these studies, current users of HRT had between 3.3 
to 7.0% greater percent density compared with never or former users 304-306, 325• The cross-
sectional study by Bremnes et al. (2007)3°4 also examined dense area. They found current 
users of HRT had —9 cm 2 higher density compared with never or former users. 
Two studies were not provided in Table 6.1 because of a lack of relevant data. In 
their comparative cross-sectional analysis of two twin studies to determine the proportion of 
the residual variation in percent mammographic density explained by genetic factors, Boyd 
and colleagues326 found no evidence of an independent association between percent density 
and current or past use of HRT (data not presented). While Martin et al. (2000) 327 undertook 
a study of 425 participants in the Women's Health Initiative study to identify predictors of 
percent mammographic density in postmenopausal women controlling for confounders. They 
found that previous use of HRT predicted a lower percent mammographic density (data not 
shown), but only among women who had had a hysterectomy. 
Cross-sectional studies: qualitative or cateqorical measures of mammoqraphic density 
Seven cross-sectional studies that used qualitative measures of density are summarised in 
Table 6.2. Of these, five observed a greater proportion of HRT users with a higher density 
category compared to never or former users. El-Bastwissa et al. (2000) 328 observed an age 
effect on the association between HRT use and higher grades of mammographic density. The 
odds ratio for women who currently used HRT compared to never used was 1.4 (95% CI: 1.2 
to 1.7), 1.8 (95% CI: 1.5 to 2.0) and 2.2 (95% CI: 2.0 to 2.5), for women aged 45-55, 56-65, 
and >65 years, respectively. This difference between non-users and users appears to widen 
with age. Kaufman et al. (1991)3°3 ' observed a higher proportion of low density Wolfe 
patterns with ageing in non-HRT users compared to users. This further supports the 
suggestion made by Maskarinec et al. (2006) 3. 29, and Sterns and Zee3I1 that HRT inhibits 
involutional processes within the breast resulting in an higher dense patterns with age. 
Table 6.2 Cross-sectional studies of association between HRT and mammographic density measured qualitatively. - 
Study Country N Age* Density Results Adjusted 
Measure 
El-Bastawissi et 
al. (2000)328 
USA 17,978 20-79 BI-RADS OR 1.2 (95% CI: 1.1 to 1.3) former vs never used 
OR 1.8(95% CI: 1.7 to 1.9) current vs never used 
of having highest two grades of density 
Age, parity, age at first birth, and 
BMI 
Kaufman et al. 
(1991)3°3 
UK 595 54 Wolfe 
grade 
No significant difference between low and high 
risk patterns and duration of HRT use (p=0.74) 
Higher proportion of low risk patterns with ageing 
was observed in non-HRT users compared with 
women who used HRT for 5 or more years 
Roubidoux et USA 528 BI-RADS Current users are more likely to have a higher BI- Age, parity, ethnicity 
' al. (2003)306 RADS category than non-users of HRT (p=0.05) 
Roubidoux et 
al. (2003) 323 
USA 455 53 BI-RADS Current estrogen HRT users were more likely to 
have a higher BI-RADS category than non-users 
Age, weight, parity 
(p=0.03) 
Sala et al. 400 NS Wolfe OR 2.48 (95% CI: 1.32 to 1.61) current vs non- Menopause, parity, BMI, history of 
(2000)3°2 grade users of having ,a higher BI-RADS category benign breast disease 
Bland (1980)33° USA 129 60 Wolfe 
grade 
No increase in the incidence of the highest Wolfe 
Grade in users vs non-users (p=0.168) 
NS 
Bergkvist et al. 
(1989)331 
Sweden 35,560 >35 Wolfe 
grade 
OR 1.36 (95% CI: 1.24 to 1.49) for user during 3 
year period vs non-user during 3 year period, of 
having higher Wolfe grade 
Age, parity, age at first parity, 
history of breast cancer and biopsy, 
family history of breast cancer 
NS: Not specified * If no range specified, age is stated as the mean. 
Excluded study by Leung et al. (1997) 332 . Scoring system for density grade not clearly defined. Also excluded study by Panpanit et al. (2004) 333 who had 
examined the effect of HRT on mamrriographic density change in 66 hysterectomised women, and observed an increase in density in 2 women after 12 months of 
HRT use using BI-RADs. Baseline for some women (number unknown) began 3 months into use of HRT. 
Table 6.1: Cross-sectional studies of the association between HRT and percent mammographic density and dense area measured 
quantitatively. 
Study.  Country N HRT type Effect Size 
Percent Mammographic . Density 
Vachon et al. (2000)3°5 US 1554 HRT + 5% in current vs never/former users 
(p=0.001) 
Gapstur et al. (2003) 325 USA 296 HRT + 3.3% in current vs never/former users 
(p=0.03) 
Bremnes et al. (2007)3°4 Norway 1007 All 
E + P* 
+ 3.6% in current vs never users (P for 
trend<0.001) 
+ 6.1% in current vs never 
+ 4.8% in <5 years use vs never 
+ 7.0% in >5 years use vs never 
Roubidoux et al. US 528 HRT + 4.6% in current vs never users (p=0.001) 
(2003)3°6 
Dense Area cm 2 
Bremnes et al. (2007) 3°4 Norway 1007 E + P* +8.7 cm2 <5 years use vs never (P for 
trend<0.00 
+10.9 cm2 25 .years use vs never 
Adjusted 
Age, BMI, WHR, family history 
of breast cancer, physical activity, 
education, alcohol, age at 
menarche, age at first birth and 
number of births, smoking history 
Age, BMI, and parity 
Age, BMI, parity 
Age, parity, 'history of biopsy 
Age, BMI, parity 
*Progestagen is continuously administered. Study by Boyd et al. (2002) 326 is not included in the table because relevant data is not provided. Findings are 
described in text. 
Chapter 6: Current evidence orassociations between estrogen exposures and marnmographic density, a risk 'Factor of breast 
	143 
cancer 
Longitudinal studies: continuous measures of mammograohic density 
Unlike cross-sectional studies, longitudinal studies can measure change in mammographic 
density following HRT use. Longitudinal studies using continuous quantitative measures and 
qualitative measures are reviewed separately in this section. 
Longitudinal studies using continuous measures of mammographic density are 
summarised in Table 6.3. Three of the five RCTs described in the table had a 12 month 
follow-up. Of these, Descensi et al. (2004) 334 found no significant difference between the 
treatment (E + P) and placebo groups after 12 months, while the larger RCTs by Greendale et 
al. (2003)316 and McTiernan et al. (2005) 335 observed mean percent mammographic density 
increases of 5.0% 334 and 8.8%335 , respectively. If these increases in percent mammographic 
density were sustained, they would equate to a 10-17% increase in the relative risk(RR) of 
breast cancer according to Boyd's 36 risk estimation model reported above (Section 6.3). 
The RCTs by Lundstrom et al. (2007) 336 and Freedman et al. (2001)337 followed up 
women for six months and 24 months, respectively. Freedman observed a significant 
difference in the 24 month change in percent mammographic density between placebo and 
the group of women who had received postmenopausal estrogen therapy. This is in contrast 
to the 12-month follow-up in the PEPI study by Greendale et al. (2003) 316 reported above, 
which found no effect with estrogen only therapy. It is possible that a longer follow-up of 24 
months might be needed to observe an effect with estrogen only formulations. 
Lundstrom observed no significant 6-month change in percent mammographic 
density between placebo and the group who received estrogen and progestagen combined 
HRT. Six months follow-up, might have been too short• to observe a significant effect. 
Though Decensi et al. (2004) 334 also found no effect with E and P combined HRT and their 
study involved a longer follow-up of 12 months. Also, the two studies that did observe a 
significant increase in mammographic density following estrogen and progestagen combined 
formulation HRT compared to placebo (Greendale et al., 2003 and McTiernan et al., 2005) 
had larger sample sizes than the studies that did not find a significant change following 
treatment. 
Table 6.3: Longitudinal studies of the association between HRT and percent mammographic density (PMD) measured 
quantitatively*. 
Study Country Follow-up Treatment type Effect Size (Change in PMD) 
Greendale et al. US 12 months (RCT) 571 Placebo -0.05% (95% CI: -1.50 to 1.38) 
(2003) 316 +1.3% (95% CI: -0.05 to 2.63)$ 
E + cyclic P +5.1% (95% CI: 3.5 to 6.7) 
E + continuous P +4.5N (95% CI: 2.7 to 6.3) 
Decensi et al. (2004) 334 Italy 12 months (RCT) 227 Placebo +4.1% (95% CI: 2.5 to 5.6) 
E + cyclic P . (oral) +3.0% (95% CI: 1.5 to 4.4) $ 
E+ cyclic P (transdermal) +4.0% (95% CI: 2.5 to 5.5) 
McTiernan et al. US 12 months § 413 Placebo -1.1% (95% CI: 0.3 to 1.9) 
(2005)3" 	. (RCT) E + continuous P _ 	_ +7.7% (95% CI: 5.9 to 9.5) 
Lundstrom et al. Sweden 6 months (RCT) 255 Placebo +0.7% 
(2007)"6 E + continuous 13- low-dose 1 
E + continuous P low-dose 2 
Freedman et al: (2001) 337 Multiple 24 months (RCT) 18 Placebo -1.3% (95% CI: -2.2 to -0.4) 
+1.2% (95% CI: -0.6 to 3•0)T 
Laya et al. (1995) 317 US • 12 months 41 _ E + continuous P _ 	 _ +6.7% (95% CI: 2.5 to 11.0) 
Eiletsen et al. (2008)338 ' Norway 12 months 202 E + P (low-dose) +2.6% ¶ (p<0.0001) 
E +P (standard dose) +2.3% II (p<0.0001) 
Van Duijnhoven et al. Netherlands/UK 3 years (mean) 1240 Placebo -7.4% 
(2007)324 E + P -3.4% (p<0.01 cf. placebo) 
* All results above unadjusted. Age and BM1 similar between comparison groups. Characteristics not reported by Laya. et al. (1995) 317. Age was not associated with change 
in mammographic density. Greendale et al. (2003) 3 ' 6 also adjusted for baseline percent density, age, BMI, alcohol use, smoking, level of physical activity, 12-month change 
in BMI, clinic site, and hysterectomy status; but results similar to unadjusted. All treatment arms significantly different from placebo. 
t Not significantly different to baseline, but statistically significantly different to placebo. 
I Not statistically significantly different to placebo. 
§ 24 months also reported, but not in table. (results above only provided for those women who were adherent to treatment (or non-treatment). 
Volumetric method of measurement, compared to baseline. 
Excluded cross-sectional paper by Martin,C. et al. (2000) 327 conference abstract only. Insufficient information. Excluded Ursin et al. (2004)339, sub-group analysis of same 
PEPI cohort (n=452) described by Greendale et al. (2003) 316, results the same. 
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Of the remaining three studies, Laya et al. (1995) 3 ' 7 and Eiletsen et al. (2008)338 did not use a 
placebo group. They compared baseline and 12-month percent mammographic densities 
following estrogen and progestagen combined HRT use. Twelve-month changes in percent 
mammographic densities were 6.7% and 2.3% respectively. These differences were 
statistically significant. It is possible that these changes might have occurred without 
treatment. However, since percent mammographic density reduced in three of the five 
placebo controlled studies, it is likely that HRT contributed to the positive changes observed 
in the studies by Laya et al. (1995) 3 ' 7 and Eiletsen et al. (2008) 338 . The study by Eiletsen et al. 
(2008)338 was the only to use the 'volumetric method of mammographic measurement and 
observed a similar increase in percent volume density for both low dose and standard dose 
combined HRT compared to baseline. 
Unlike the other studies . in Table 6.3 , the retrospective longitudinal study by Van 
Duijnhoven et al. (2007) 324 observed a reduction in mammographic density with HRT use 
with age. These investigators observed an age related decrease in mammographic density in 
(E & P) HRT users (-3.4%) over the study period (multivariable adjusted), but this reduction 
was less than the reduction observed in women who had never used HRT (-7.4%, p<0.01). 
Similarly, for dense area, the mean reduction was —9.4 cm 2 in the placebo group and —5.6 
cm2 in the HRT user group (p<0.01 for difference). The investigators explained this result by 
suggesting that HRT reduced the age related reduction in mammographic density 324 . It is 
unclear why this study observed a decrease in mammographic density with HRT use, while 
other longitudinal studies observed an increase in mammographic density. This difference 
could be explainedby the length of follow-up. The longitudinal studies described in Table 
6.3 had a follow-up of between 6-24 months while the median follow-up in Van 
Duijnhoven's study was three years. Another possible explanation is the ages of the cohort 
since the age-related reduction in mammographic density has been observed to be modified 
by age as described above and elsewhere 329 ' 335 . However, age does not appear to be an issue 
here. The mean age of the cohort in the study by Van Duijnhoven et al. (2007) 324 was 55 
years and is similar to most of the longitudinal studies described in Table 6.3. Both studies 
by Laya et al. (1995) 3 ' 7 and Greendale et al. (2003) 316 had a mean cohort age of 56 years. The 
mean age of the cohorts in the studies by Freedman et al. (2001) 337 and McTieman et al. 
(2005)335 were 52 years and 62 years, respectively. 
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Longitudinal studies: qualitative or categorical measures of density 
The longitudinal studies reported above measured percent density or dense area as a 
continuous variable. A larger number of longitudinal studies used categorical or qualitative 
measures of mammographic density. These are summarised in Table 6.4. Each of these 
studies reported the proportion of women who had experienced a change in mammographic 
density with HRT use. Of the studies that examined the effect of estrogen only HRT on 
mammographic density change, between 0% (Berkowitz et al.,1990 340) and 22% (Erel et al., 
2001 320) of HRT users had experienced an increase in mammographic density. The study by 
Berkowitz et al., was the only study where none of the women exposed to estrogen HRT 
experienced an increase in mammographic density, however, this study had a number of 
limitations that include a small sample size (n=14), and a . varied exposure duration (1-72 
months) and follow-up period (3-14 months). 'However, in this same study, 17% of women 
who had used estrogen and progestagen combined HRT had experienced an increase in 
density. 
Only 14 of the 25 studies described in Table 6.4 included a control or placebo group. 
Those without cannot exclude the possibility that the change in mammographic density 
observed after estrogen HRT might have occurred anyway. Of the studies that did include a 
control group and examined the effect of estrogen only HRT on mammographic density, five 
presented a test of significance or confidence intervals. Each of the studies by Colarcurci et 
al. (2001) 319, Christodoulakos et al. (2003)341 and Orguc et al. (2006) 342 observed a 
statistically significant increase in the number of women whose mammographic density 
increased after estrogen HRT, compared to a control or placebo group; p<0.05, 0.02 and 
<0.05 respectively. Greendale et al. (1999) observed an increase in mammographic density in 
3.5% (95% CI: Ito 12) of women who had used estrogen only HRT for 12 months. 
Stems and Zee 311 followed up women over menopause and not only reported the 
proportion of HRT users and non-users whose breast density increased, but also the 
proportion whose density reduced and remained the same over the duration of the study 
period (from approximately 46 to 55 years of age) (See summary in Table 6.4). Of 117 
nonusers of HRT followed over menopause, 38% had a density decrease to a lower category 
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before age 55, 62% had no change, while none showed an increase in density. In comparison, 
the density decreased in 18%, remained stable in 80% and increased in 2% of HRT users3I I 
(p-values or confidence intervals were not provided). The investigators suggested that HRT 
preserved the existing dense tissue in the majority of women by negating the age-related 
decline observed in non-HRT users 3l I , similar to that observed by Maskarinec et al. (2006) 329 
who measured percent mammographic densities from mammograms collected consecutively 
over a 20 year period. In a shorter follow-up of women using HRT (mean 27 months), Sterns 
. and Zee observed an increase in percent mammographic density (from one category to the 
next) in 8% of women following HRT use3I I . 
It becomes clear from the studies summarised in Table 6.4 that mammographic 
density does not increase in all women exposed to HRT. The most reported was 68% by 
Connor et al. 312 for continuous estrogen and progestin combined HRT. Continuous measures 
of density change would provide a more accurate measure of the proportion of women on 
HRT who experience changes in mammographic density. 
Longitudinal studies: continuous measures of density (% women whose density changed) 
A number of the longitudinal studies using continuous measures of mammographic 
density described in Table 6.3 above also presented the proportion of women whose 
mammographic density increased with HRT use. In the study by Freedman et al. (2001) 332 , 
only 30% of women who undertook estrogen replacement therapy experienced an increase in 
percent density greater than 1 SD above the mean placebo change. McTiernan et al. 
(2005)335 , on the other hand, reported 74% 335 • Laya et al. (1995) 312 observed a similar result 
(73% after a 12 month period). Laya and co-investigators also measured density change 
according to Wolfe grade. Using this grading system, a record of change in density was only 
made if an increase occurred from one Wolfe grade category to the next. Only 24% of the 
women experienced an increase from one Wolfe grade to another. This lower figure is 
similar to the proportions in the studies using categorical or qualitative measures of 
mammographic density described in Table 6.4 37, 307, 309, 320, 321. The qualitative or categorical 
measures of density might not be sensitive enough to identify increases within the density 
categories. Counter to this argument, Sendag et al. (2001) 309 reasoned that the 73% figure 
148 Chapter 6: Current evidence of associations between estrogen exposures and mammographic density, it risk factor of breast 
cancer 
provided by Laya et al. (1995) 3 ", was flawed because for 41% of women in the study, the 
magnitude of the density change was <10%, apparently too small be visually measured. 
While Laya et al. measured percent density using a planimetry computer program, which is 
less subjective than the visual estimation of percent density, there is some merit in the 
statement by Sendag and colleagues. Many of the studies using categorical or qualitative 
measures of mammographic density could not detect changes less than 10%. Laya's finding 
of 73% would reduce to 32% if changes less than 10% (41% of reported changes) were not 
included. The result would be similar to the proportions observed for combined formulation 
HRT in the studies that used qualitative measures of change (Table 6.4). 
Table 6.4 Longitudinal studies of the association between HRT and percent mammographic density measured qualitatively. 
Study Country Study Design 
(follow-up time) 
Density 
measure 
Age HRT Type (n) Change in density 
(% women) 
' Lundstrom et al. (2001) Sweden Longitudinal Wolfe Grade* 52 E (51) (Estriol ) 6% 
318 (Not specified) 49 E (55) (Estradiol patch) 2% 
53 E + P continuous (52) (CEE MPA) 40% 
Persson et al. (1997). 3 Sweden Longitudinal Wolfe Grade and 48-58 Control (554) 3% 
(18 months) visual estimation . 5% 
of change. E+ cyclical P 10% 
E + continuous P _28%, 
Stomper et al. (1990) 3°7 US • Longitudinal Anatomically 52 E(12) 17% 
_ (18 months) definedf, E&P(38) 26% 
Ozdemir et al. (1999) 344 Turkey Longitudinal Change recorded 50 Control (30) 0% 
(17-21 months) if >15% change E (22) 18% 
E & cyclic P (24) 46% 
Lundstrom et al. Sweden Longitudinal Wolfe Grade* 48-51 E(50) 18% 
' (1999)3 ' 5 (12 months) E & P continuous (50) (E2 plus NETA) 52% 
E &P_cyclic (75) 13% 
Christodoulakos et al. Greece (12 months) Wolfe Grade —52 Control (27) 0% 
poop , E (25) (CEE) 8% 
E + P (34) (CEE plus MPA) - 11.8% 
E + P (35) (E2 plus NETA) 31.4% 
Marugg et al. (1997) 32 ' 	. Netherland Longitudinal Wolfe Grade 50-70 Control (575) 0% 
(1-2 years) E(23) 8.7% 
E&P(58) 31% 
Change in density 
(% women) 
A 
0% + 
• 3.5% + 
23.5% + 
16.4% + 
• 
19.4% + 
7.0% + 
21.7% _ 
3.9% 
24.9% 
+ 
_ 
0% + 
17% + 
22% 
35% + 
Study 	 Country 	Study Design 	Density 	Age 	 HRT Type (n) 
(follow-up time) 	measure 
Greendale et al. (1999) 37 	US 	Longitudinal 	BI-RADS 	59 	Placebo 
(12 months) E (CEE) 
RCTI 	 E & cyclic P 
(CEE plus MPA) 
(CEE plus micronised P) 
E & continuous P 
(CEE plus MPA) 
Bergvist et al. (1989)331 - Sweden 	Longitudinal 	Wolfe Grade 	>35 	Control (653) (age-matched) 
HRT (653) 
Berkowitz et al. (1990) 34° US 	Longitudinal 	Change recorded 	NS 	E(l4) 
(3-14months) 	if >10% change E&P(15 §) 
Erel et al. (2001)37° 	Turkey 	Longitudinal 	Wolfe Grade 	49-51 E (23) 
(4 yrs) 	 (CEE) 
E & continuous P (26) 
(CEE and MPA) 
E & cyclic P (21) 	 19% 	+ 
(CEE and MPA ) 
Sendag et al. (2001)3°9 	Turkey 	Longitudinal 	Wolfe Grade and 50-53 E (76) 	 3.9% 
(mean 17.4 change recorded 	 (patch or oral) 
months) 	if >10% change. E + continuous P (61) 	 31.1% 	+ 
(E2/NETA) (CEE/MPA) 
E * cyclic P (44) 	 2.2% 
Junkermann et al. 	Germany & 	Longitudinal 	Visual 	 55 	E & continuous P (159) 	 32.4% 
(2005)310 	 Austria 	(RCT) 	estimation of 	 (E2/NETA) 	 3.4% 
(9 months) 	change 
E & cyclic P (132) 
	
31.2% 
(CEE/ medrogestone) 	 4.0% 
Study Country Study Design 
(follow-up time) 
Density 
measure 
Age HRT Type (n) Change in density 
( 4)/0 women) 
Sterns & Zee (2000) 311 Canada Longitudinal Minimal density —46 HRT (87) 8% 
(27 months) =0; >minimal to (Mixed) 
<25% =I, >25— 
<75%=II, >75% 
=III _ 	. _ . 	. 	. 
Sterns & Zee (2000) 3 " Canada Longitudinal Minimal density - 46. Control (117) 0% 
(-9 years) =0; >minimal to 38% 
<25% =I, >25— (45) • HRT 2% 
<75%=II, >75% (Mixed) 18% 
=III. 
Conner -et al. (2004)312 Sweden Longitudinal Wolfe Grade & 55 E & continuous P (23) 48% Wolfe_ 
(RCT) PMD visual (Estradiol valerate/dienogest) 52% quintiles 
(6 months) 0-20% 56 
21-40% E & continuous P (22) 45% Wolfe 
41-60% (E2NETA) 68% quintiles 
61-80% 
81-100% 
Marchesoni et al. 	• Italy Longitudinal Wolfe Grade 52 Placebo (16) 0% 
(2006) 313 (RCT) E + continuous P (35) 45.1% 
(12 months) (CEE/MPA) 
Chen et al. (2005)314 Taiwan Longitudinal BI-RADS 50 E (200) 10% (1-2yrs) 
Follow-up at 1— 12% (2-3 yrs) 
2,2-3,3-4,4-5 
and >5 years 
14% (3-4 yrs) 
10% (4-5yrs) 
12% (>5 yrs) 
E + P (267) 8% (1-2yrs) 
14% (2-3 yrs) 
17% (3-4 yrs) 
21% (4-5 yrs) 
22% (>5 yrs) 
A 
Study Country Study Design 
(follow-up time) 
Density 
measure 
Age HRT Type (n) Change in density 
(°/0 women) 
Rutter et al. (2001)49 *US Longitudinal BI-RAOS 67 Control (2942) 11.6% + 
(— 2years) 6.5% — 
63 - HRT (335) 28.4% + 
3.3% _ 
McNiColas et al. Ireland Longitudinal a)10% change 55 Control (31) 0% 
(1994)243 (-13 months) b) visual 
assessment 
52 HRT (33) a) 18% b) 27% + 
• Colacurci et al. (2001)319 • Italy Longitudinal I=<25% dense 	- 51 Control (23) 10% + 
(12 months) 11=25-75%. E( 23) 21% + 
II1=>75% E + cyclic P (26) 
transdermal E2/acetate nomegestrolo 
. 35% + 
E + continuous P (25) 
transdermal E2/acetate nomegestrolo 
43% + 
Topai et al. (2006) 345 Turkey Longitudinal Wolfe Grade 50 E (37) 2.7% + 
(14 months) E + cyclic P (16) 12.5% + 
E + continuous P (60). 38.3%_ 
Kilicdag (2004) 346 Turkey Longitudinal >10% change . ' 50 Control (47) 0% 
(12 months) E(27) 11.1% + 
. 	. 	. E & P (75) 33.3% +_ 
Orguc (2006)342 	• Turkey Longitudinal Wolfe Grade/ 49 Control (79) 0%/0% + 
(16 months) Segmented E (62) 0%/21% + 
approach if E+P (98) 8.1%142% + 
Bulbul (2003)347 Turkey . Longitudinal Visual 49 E (80) 18.8% 
(12 months) estimation of E + cyclic P (40) 12.5% + 
change E + continuous P (44) 25.0% + 
Study Country 	Study Design 	Density 	Age 	 HRT Type (n) 	 Change in density 
(follow-up time) 	measure ( )`/0 women) 
Nahas-Neto (2006) 348 	Brazil 	Longitudinal 	BI-RADS 	59 	Control 	 16% 
(RCT) 	 E + continuous P (E2/NETA) 	 48% 
_(6 months) . 	 54 _ 
Laya et al. (1995)3 ' 7 	US 	Longitudinal 	Wolfe Grade 	41 	E + continuous P 	 24% 
(retrospective) 
(12 months)  
* Within each Wolfe category, differences of 10-25% between films were also recorded. 
f No change; or change: diffuse increase in density (at least 10% change); increased multifocal asymmetric densities that did not exhibit mass 
effect or architectural distortion (at least 10% change); cyst development 
MPA medroxyprogesterone acetate, NETA norethisterone acetate, E2 1713-estradiol 
• Study also examined 24 and 36 months but most of the changes occurred within the first 12 months. 
§ 16 patients originally but one did not have a mammogram before treatment with HRT. 
Novel approach called 'comparison wheel'. 
Studies not included in the table: Bland et al. (1980) 33°  insufficient information provided about the effect of estrogen HRT on change in 
mammographic density; Geroiiev 2002 349 — insufficient numbers.; Berkowitz et al. (1990) 340 unable to assess when mammograms were taken in 
relation to start of HRT. 
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Estrogen vs combined estrogen and pro qestin HRT.  
One consistency that does exist across studies is the larger effect on mammographic densitY 
observed with combined estrogen and progestagen compared with estrogen only HRT 
formulations. The longitudinal studies using quantitative continuous measures (Table 6.3) 
have observed mean increases in mammographic density between 2.8% and 7.7% after 
estrogen and progesterone combined HRT exposure, compared with 1.2-1.3% after estrogen 
only HRT exposure. 
In the majority of the longitudinal studies using qualitative or categorical measures of 
mammographic density described in Table 6.4, the proportion of women who experienced an 
increase in mammographic density following exposure to combined HRT ranged from 2 to 
68%, with the majority of studies reporting between 20% and 40%. This is much larger than 
the proportion who experienced an increase in mammographic density following estrogen 
only HRT (3.9 to 22%). Statistically significant differences in these proportions, between 
combined and estrogen only HRT exposures were observed in the following studies: Ozdemir 
et al. (p=0.04)344 , Marugg et al. ( 0=0.046) 321 , Greendale et al. (p=0.024) 37, Berkowitz et al. 
(p=0.045)340, Sendag et al. (p=0.001) 3. 09 and Kilicdag et al. (p=0.04) 346 . Statistical significance 
was not observed in the studies by Stomper et al. (p>0.70) 307, Christodoulakos et al 
(p>0.18) 341 , and Erel et al. (p not stated) 320, though in the latter studies, the size of the 
samples were small (see Table 6.4). 
Martin et al. (2000) 327 observed a lower percent mammographic density among HRT 
users who had had an hysterectomy and suggested that the higher frequency of 
oophorectomies in this group may be the cause of the lower percent density and consequently 
increase the likelihood of HRT use. This is an interesting point because in most studies using 
E only HRT, the women have had a hysterectomy. The combined formulation HRT is 
typically used in women who have not had a hysterectomy, and it is the E and P formulations 
that more frequently lead to an increase in density in treated women as observed above. It is 
possible that the women using estrogen only HRT are experiencing dual responses — a 
reduction due to oophorectomy and an increase due to the exogenous estrogen. However 
Greendale et al. (2003) 316, randomly assigned women to estrogen only or estrogen and 
progestin combined HRT and adjusted for hysterectomy status. Estrogen only HRT was 
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found not to have any effect on mammographic density. This does not explain, though, the 
increases observed in mammographic density with E only HRT in some studies. 
Cyclic vs continuous combined HRT 
Potentially, the type or frequency of progesterone in the HRT regimen might also determine 
the size of effect on mammographic density. The progestagen can be taken cyclically (a few 
days a month) or continuously (daily). This is of particular relevance to this PhD study 
because girls treated with high-dose estrogens for the treatment of tall stature were typically 
given a progestagen for a few days each month (cyclically). A number of studies have 
examined the association between mammographic density and the two forms of combined 
HRT (See Tables 6.3 and 6.4) In the Turkish longitudinal study by Sendag et al. (2001) 3°9 , 
(Table 6.4) a greater proportion of women who were treated with continuous combined HRT 
(31.1%) experienced an increase in Wolfe grade from baseline (mean follow-up 28 months) 
compared with women who were treated with cyclic combined HRT (2%) (p=.0002). 
Lundstrum et al. (1999)315 also reported a difference in the Wolfe grade increase between 
women treated with continuous combined formulations (52%) compared to those treated with 
cyclic combined HRT six months following treatment (13%, p-value or confidence intervals 
not provided). A difference was similarly observed by Topal et al. (2006)345 ; 38% and 12%, 
respectively (p<0.001). However a number of studies did not observe any statistical 
significant difference between the two E & P regimens, these include: the PEPI trial reported 
by Greendale et al. (2003) 316 , and Ursin et al. (2004) 339 (Table 6.3) , the RCT study by 
Junkermann et al. (2005)310 that used a visual estimation of change in mammographic 
density, and the non-randomised controlled trial by Colarcurci et al. (2001) 319 that measured 
increases in density according to Wolfe Grade (Table 6.4). The study by Erel et al. (2001) 32° 
observed a greater proportion of continuous combined users (35%) than cyclical combined 
users (19%) showing an increase in Wolfe grade after HRT use but the difference was not 
statistically significant (p-value not provided). It is unclear why the more insensitive 
measures of change used by Lundstrom et al. (1999) 315 , Sendag et al. (2000 3" and Topal et 
al. (2006)345 detected a difference in effect between cyclic and continuous forms of combined 
HRT while the more sensitive quantitative measure used in the PEPI trial did not. 
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Twe of progestagen 
It should be noted that progestins, like estrogens, have different potencies and physiologic 
actions. For instance, some have androngenic, nonadrogenic and antiandrogenic actions350 . 
The type of progestagen used in the combined HRT formulations might also influence the 
effect observed on mammographic density. The two common forms of progestagen used in 
combined HRT formulations include norethisterone acetate (NETA) and 
medroxyprogesterone acetate (MPA). In the study by Sendag et al. (2001) 3" (Table 6.4) a 
greater proportion of women exPerienced an increase in percent density category following 
continuous combined HRT with norethisterone acetate (34.1%) compared to women using 
medroxyprogesterone acetate (23.5%), though this difference was not statistically significant 
(p=0.42). Christodoulakos et al. (2003)341 also examined the difference between NETA and 
MPA on percent mammographic density, and like Sendag et al. (2001)309 observed a more 
frequent increase in percent density in women using NETA (31.4%) compared with women 
using MPA (11.8%), but the difference was not statistically significant (p=0.3). Nor was the 
difference in the proportion of women who had a BI-RADs category increase following HRT 
containing micronised progestagen (16.4%) and MPA (23.5%) in the PEPI trial by Greendale • 
et al. (1999)37 statistically different (Table 6.4). No difference in the frequencies of increases 
in percent density were observed between the two progestageris MPA with cyproterone 
acetate3" or NETA and dienogestm . 
Tall girls were typically treated with estrogen plus a cyclic progestagen. The 
evidence presented above suggests that E only formulations increase mammographic density, 
but for most studies, the effect was stronger with the combined E + P formulations. Similarly 
for combined formulations with cyclic compared to continuous progestagen. While effects of 
E and cyclic progestagen have been shown to affect mammographic density, the continuous 
progestagen formulations have been shown to have a larger effect again. 
HRT induced breast pain and mammoqrabhic density 
Of particular interest to the tall girls follow-up is the observation made by two studies that 
breast pain in relation to HRT use is associated with an increase in mammographic density. 
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In a prospective study of HRT users, McNicolas et al. (1994) 243 observed that seven of nine 
women (78%) who had experienced an increase in mammographic density after commencing 
HRT, had also experienced moderate or severe breast pain. In contrast, only five of 24 (21%) 
of those who did not experience an increase in mammographic density experienced moderate 
or mild breast pain. No women belonging to a control group of non-HRT users (n=31) 
reported breast pain during the same follow-up period. 
Crandall et al. (2006) 241 , observed a similar association in a subset of the PEPI RCT 
cohort. Women who experienced the onset of breast discomfort within a 12 month period 
following HRT commencement, had a3.9% increase (age and multivariable adjusted) in 
mean percent mammographic density following HRT use, compared with an 0.6% increase in 
. women who did not experience breast discomfort (p<0.001). 
As described in Chapter 3 of this thesis, a number of women in the Australian Tall 
Girls cohort reported breast pain as a'side effect of treatment as an adolescent. It is possible 
that an increase in breast pain during treatment coincided with an increase in mammographic 
density. Whether an increase in density during adolescence remains in adulthood is unknown. 
Evidence suggests that the effect of HRT on mammographic density is only transient. The 
following section presents a review of the evidence that concerns the permanence of the 
effect of HRT on mammographic density. 
Duration of the HRT effect on mammoqraphic density 
As it appears from the evidence above, HRT increases or reduies the age-related decline in 
mammographic density in postmenopausal women. From the few studies that have followed-
up mammographic density changes after the cessation of treatment, it appears that this effect 
is not permanent. The first apparent study to examine the effects of HRT cessation on 
mammographic density was undertaken in the US by Harvey, Pinkerton and Herman 
(1997) 35 '. They followed up 47 women who had either experienced an increase in 
mammographic density or a new mass of dense tissue while using HRT. Of these, 75% 
experienced a reduction in visually assessed dense tissue approximately two weeks after 
stopping HRT. The investigators proposed that short-term cessation of HRT might avoid 
unnecessary biopsy of unusual masses, and improve mammography specificity. 
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Colarcurci et al. (2001) 352 undertook a controlled clinical trial (not randomised), 
involving 97 menopausal women in one of three treatment arms: estrogen alone (n=37) and 
combined formulation HRT (n=39), and no medication (n=21). A mammogram was 
performed at study entry and after 12 months. Mammographic density was visually assessed 
by planimetry and classified into three categories (<25%, 25 to 75%, >75% density). Of those 
treated with estrogen and combined HRT, a subset (18, 20 respectively) had suspended 
treatment for a mean period of 22 days prior to the second mammogram. At second 
mammogram, mammographic density increased from one dense category to a higher category 
in 21% of estrogen HRT users, 37% of combined HRT users, and 0% of non HRT users. Of 
the subsets of the treated group that discontinued HRT shortly before the follow-up 
mammogram, only six and 5% of the estrogen and combined HRT users had experienced an 
increase in mammographic density, respectively. The increase was significantly different for 
those who had continued with combined HRT (p<0.05), but not estrogen HRT (p>0.05). 
A larger study by Rutter et al. (2001)4° compared the change in mammographic 
density in non-HRT users (n=2,942) with HRT users who had stopped using it prior to a 
follow-up mammogram (n=111). The investigators found that women who stopped using 
HRT, (up to 25 months prior to follow-up) were more likely to demonstrate a reduction in Bl-
RADS category of mammographic density compared with non-users of HRT over the follow-
up period, (age and BMI change adjusted RR, 1.81; 95% CI: 1.06 to 2.98): These findings 
suggest that mammographic density changes reverse with the discontinuation of HRT. 
The findings of a more recent study by Weaver et al. (2008) 353 conflict with the three 
studies above. In this later study, density change in 48 women was assessed four weeks 
following the cessation of HRT using four different methods of mammographic density 
measurement: Wolfe grade, six-categorical visual scale of percent density, and two computer 
assisted methods. No significant change in mammographic density was observed, despite the 
method used (p>0.08). Possible reasons for the inconsistency between the studies include 
different study populations and duration and types of HRT used. The study population used 
in the study by Harvey, Pinkerton and Herman only included women who had already 
experienced an increase in mammographic density or a new dense mass while using HRT. 
This subset of women may be more responsive to the cessation of HRT compared to other 
women. 
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Different HRT durations may explain the discrepancies. Mean durations of HRT use 
were 57 months (range six months-14 years), 12 months, and 12 months or greater. (upper 
limit not specified) in the studies by Weaver et al. (2008) 353 , Colacurci et al. (2001) 352 , and 
Harvey, Pinkerton and Herman (1997)351 , respectively. Duration was not reported in the study 
by Rutter and colleagues. Different forms of HRT were used in each of the studies by Weaver 
et al. (2008) 353 , Rutter et al. (2001) 4° and Colacurci et al. (2001) 352 , but only the latter study 
stratified by type of HRT. HRT type was not specified by Harvey, Pinkerton and Herman. 
Former versus current HRT use 
It appears from the evidence presented above, that the duration of effect on mammographic 
density is limited to the duration of HRT treatment. Mammographic density returns to 
baseline levels soon after the cessation of treatment. It would be expected then, that 
mammographic densitS , would be lower in former users of HRT compared with current users 
if all other risk factors remained the same. Three cross-sectional studies compared 
mammographic density levels between former and current users of HRT. Vachon et al. 
(2000)" 5 and Gapstur et al. (2003) 325 (Table 6.1), reported a 3-5% multivariable adjusted 
increased mean percent density in current users of HRT compared with former users, while 
El Bastawissi et al .(2000) 328 found current users to have an increased odds of having a higher 
BI-RAD,S category of mammographic density compared with former users:, OR 1.2(95% Cl: 
1.1 to 1.3) (Table 6.2): 
6.4.1.2 Estrogen' antagonists and mammographic density 
It is clear from the evidence presented above, that exogenous estrogen, particularly when 
combined with a progestin, increases mammographic density in some women. It would be 
expected then, that the inhibition of these hormones would result in a reduction in 
mammographic density. 
Many studies have examined the effect of tamoxifen, a selective estrogen receptor 
• modulator, on mammographic density. The metabolites of tamoxifen have a high affinity for 
the estrogen receptor and therefore compete with estrogen for binding sites. They act as 
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estrogen agonists or antagonists, depending on the site of the receptors. In the breast, 
tamoxifen acts as an antagonist, while in the endometrium, it acts as an agonist. Its antagonist 
effect on the breast is the basis of its use in the treatment of estrogen receptor positive breast 
cancer, and as preventive therapy in women with a high risk of breast cancer 354 . 
A number of studies have also examined the effect of gonadotropin releasing 
hormone agonist (GnHRA) on mammographic density. Like tamoxifen, GnRHA has been 
called an `antiestrogen'. It •is a synthetic form of gonadotropin releasing hormone that 
stimulates the release of the pituitary gonadotropin hormones LSH and FSH. GnHRA binds 
to the gonadotropin releasing hormone receptor, thereby competing with the endogenous 
hormone equivalent. While it is an agonist, it acts by down-regulating gonadotropin releasing 
hormone receptor numbers and consequently, reducing LSH and FSH release from the 
pituitary. Since these gonadotropins stimulate estrogen synthesis in the ovary, a concomitant 
reduction in estrogen production results. 
A more detailed review of the studies that examined the effect of tamoxifen and 
GnRHA use on mammographic density is presented in Appendix 5. Overall, the findings of 
the controlled longitudinal studies suggest that mammographic density is reduced by 
tamoxifen and GnRHA. For instance, in one of these studies (Chow et al., 2000) 355 reported a 
4.3% mean density reduction with tamoxifen use per year over a period of 2.5 years. While, 
Gram et al. 2001) 39 using the computer thresholding technique of mammographic density 
measurement observed consecutive reductions in percent density from baseline in women 
using GnRHA; 9.7% (+1-3.5%; p=0.01) and 11.4% (+1-3.5%, p=0.01) after 12 months and 
24 months, respectively. No statistically significant change was observed in the control group 
—3.2% (+1-3.0%) (p=0.30), —2.5% (+1-2.5) (p=0.47), at 12 months and 24 months, 
respectively. The reduction in densities, however, was not sustained after cessation of 
treatment. Reductions in percent mammographic density at the levels observed by Gram et al. 
(2001) after 24 months of GnRHA treatment, would equate to a 23% reduction in the relative 
risk of breast cancer using Boyd's 36 risk estimation reported above (Section 6.3). However, 
this reduction in risk would not be sustained after cessation of GnRHA treatment. • 
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6.4.1.3 Oral contraceptive use and mammo graphic density 
Another exogenous hormone of interest is the oral contraceptive pill, particularly the studies 
of OC use in young women and mammographic density. Only a few . studies have examined 
the association between the oral contraceptive pill and mammographic density specifically 356- 
358
, others have examined the association among one of many other breast cancer Fisk 
factors302, .305, 326, 359-361'  are described below and summarised in Table 6.5. 
All but the two earlier cross-sectional studies by Gravelle et al. (1980) 361 and Leinster 
and Whitehouse (1986) 358 , found no association between oral contraceptive use and percent 
density or density grade. The largest of these studies, by de Stavola et al. (1990) 359, initially 
observed a univariable association between the two, but this disappeared after adjustment for 
age. Both studies had observed a higher proportion of OC users with lower risk Wolf grade 
patterns than non-OC users. These were not adjusted for age, however the latter of these 
studies stratified by menopausal status. Leinster and Whitehouse (1986) 358 examined the 
assoCiation between low-dose and high-dose estrogen OCs with mammographic density, and 
while there appeared some differences, these were not statistically significant. 
Jeffreys et al. (2004) 360 examined the association between percent density (six 
categories) and oral contraceptive use at a young age (before 20 years). Women who used the 
oral contraceptive pill prior to 20 years of age did not have greater odds of having a higher 
percent breast density category compared to older users (P for trend 0.78). A case-study 
report (not included in Table 6.5) describes the longitudinal mammographic density changes 
that occurred in two women after the discontinuation of Depo-Provera, an injectable 
progestagen based contraception, containing depot-medroxyprogesterone acetate. Dillis and 
Schreiman (2003) 357 compared baseline density readings, taken when the women were treated 
with Depo-Provera, with a later mammogram, after the women had stopped using the 
contraceptive. They observed an increase in mammographic density for both women. This 
suggests that Depo-Provera reduced mammographic density over the term of treatment, either 
through its action on ovarian suppression (including estrogen suppression), and that this 
effect was reversed after the discontinuation of treatment. Larger studies are needed to 
confirm these findings. 
Table 6.5: Cross-sectional studies of the association between oral contraceptive pill use and mammographic density. 
Study Country Density N Age* 
Measure 
Vachon et al. US % density 1,900 47 
(2000)3°5 (5% increments) 
Gram et al. (2002)356 Norway Parenchymal 
grade 
3,218 40-56 
I-Ill low risk 
IV-V high risk 
Boyd et al. (2002)326 US % density 951 50-55 
Australia twin 
pairs. 
Jeffi-eys et al. 
(2004)369 
Scotland Six category 
classification of 
628 59 
% density 
Sala et al. (2000)302 UK Wolfe grade 400 NS1- 
P2/DY- high 
NI/Pt- low 
de Stavola et al._ UK Wolfe grade 4,954 All 
(1990)359 
Leinster and UK Wolfe grade 5,319 NS 
Whitehouse 
(1986)3" 
Gravelle et al. Wolfe grade 942 >38 
(1980)361 
Results 	 Adjusted 
4% difference in percent density 	Age, BMI, WHR, family history of 
between never and current users (P for 	breast cancer, physical activity, 
trend 0.45) 	 education, alcohol, age at menarche, 
age at first birth, # births, smoking _ 
Ever users more likely to have high risk Age, BMI, menopausal status, parity, 
Wolfe grade: OR 1.27, 95% CI: 1.0-1.6 age at first birth, BMI 
vs never users 
No association between 	 Age and Possibly others — NS 
mammographic density and present or 
previous use. (data not shown) 
Use in any age group or before first 	Age, BMI, birth cohort menopausal 
birth, not associated with breast 	status, HRT 
density. Cls supplied 
OR: 0.81 (95% CI: 0.44 to 1.47) for 	Age matched, adjusted for BMI, 
ever vs never users at having a high- 	menopausal status, number of 
risk mammographic pattern (p=0.49) 	children, HRT, history.of benign 
breast disease 
No association with Wolfe grade once 	Age, parity and Quetelet's Index 
multivariable adjusted 
OC ever users had a greater incidence 	Stratified by menopausal status 
of lower risk patterns lower incidence 
of P2 pattern.. _ 
Lower proportion of high density (P2 
	
None 
and DY) grades in OC users 
* Age reported as mean/median/range 1 - NS: not specified 
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6.4.2 Exogenous hormones and breast epithelial proliferation 
A number of studies have also examined the effect of exogenous hormones on the 
proliferative activity of breast tissue. One study found mammographic density to correlate 
highly with the proliferative activity of breast tissue. Harvey et al. (2008) 362 measured Ki-67, 
a biomarker of cellular proliferation, using non-cancerous tissue from mastectomy breast 
samples, and compared this measure with the mammographic density of the contralateral 
breast. A high correlation was observed between mammographic density and Ki-67 in both 
the epithelial ducts (p=0.031) and lobules (p=0.023). 
Studies have examined the proliferative activity of breast epithelial tissue with HRT 
and tamoxifen use. Human363. 364 , organ culture 365-368 and' animal studies 145 ' 369-371 have shown 
estrogen or combined HRT formulations to increase epithelial proliferative activity. In 
contrast, tamoxifen has been associated with reduced epithelial proliferative activity 372 ' 373 ' 
and observed to directly reduce proliferation in vitro368 . Some studies observed no effect of 
HRT on proliferative activity in normal breast tissue 374 or breast cancer cells lines 375 . A US 
study observed lower proliferative activity in breast cancer cells of women who used estrogen 
or combined HRT for 10 or more years 376. This coincided with an observation of 'increased 
cancer surVival rates in HRT users in the same study. The explanation for this observation is 
unclear. 
Of the studies that examined the effect of oral contraceptives on the proliferative 
activity of mammary gland epithelial tissue; most observed a positive association 364 ' 377.381 
while others found no such association 382.384 . The studies differed in the methodology used to 
, measure proliferation (e.g. thymidine labelling379. 383, 384 Ki-67 antibody 364, 377, 378,, ) the study 
population, and the type of oral contraceptive used. Controlling for potential influencing 
factors also varied between the studies. According to Garcia et al. (2008) 377 proliferation of 
normal breast tissue is influenced by the phase of the menstrual cycle, chronological age, 
breast age, use of hormonal formulations (especially if nulliparous), and recent parity. The 
study by Potten et al. .(1998) 383 found no increased proliferative activity in the breast tissues 
of contraceptive users, when age and stage of the menstrual cycle was taken into account. 
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Garcia et al. (2008) 377 observed an increased level of proliferative activity in younger 
women (under 27 years) using oral contraceptives, and, along with Williams et al. ( 1 99 0380 
only observed an increased proliferative index during the luteal phase of the menstrual cycle. 
There was no difference in epithelial proliferation between users and non-users of oral 
contraceptives during the other stages of the menstrual cycle. While estrogen contraceptives 
have been associated with increased proliferative activity of breast epithelial tissue 364  379 , 
progesterone based oral contraceptives have been associated with a greater level of 
proliferative activity when compared with estrogen only contraceptives364 ' 379 . 
6.4.3 Endogenous hormones and mammographic density 
Many studies • have examined the association between endogenous hormone levels and 
mammographic density. The findings of these studies are particularly relevant to this PhD 
study. The treatment of tall girls with high-dose estrogens to reduce their final adult has been 
shown to modify the serum levels of endogenous estrogen, IGF-I and prolactin. (See Chapter 
2, Section 2.4.22). Only one known study that has examined the effect of adolescent 
endogenous hormone levels on mammographic density. This study by Boyd et al. (2009) 282 
measured mammographic density using magnetic resonance imaging in 400 young women 
(ages 15-30 years) and took blood samples to measure endogenous hormone concentrations. 
Percent breast water content is derived from the resonance images and is a measure of the 
fibroglandular tissue content of the breast, and therefore percent breast density 385 . Evidence 
of a positive association between serum levels of estradiol and percent water in women 15-19 
years of age was observed. IGF-1 was not associated with percent water content in women 
between 15-30 years of age, while a positive association was observed with sex hormone 
binding globulin (SHBG), a binding protein that reduces free estradiol in the circulation and 
growth hormone. While this seems to be the only study examining endogenous estrogen 
levels and mammographic density in young females, a large number of studies have 
examined the relationship in adult women. A detailed review of these findings can be found 
in Appendix 6. 
Of these studies, eight studies examined the association between circulating estrogen 
levels and mammographic density in postmenopausal women. Three studies found no 
association386-388, one an inverse association389 and four a positive association between 
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circulating estrogen (one or more forms) and mammographic density 390-393 . Three studies 
examined the association between plasma levels of estrogen and mammographic density in 
premenopausal women. None of these studies found an association between mammographic 
density and each of the estrogens measured including the study by Meyer et al. (1986) 394 
which examined urine levels of estradiol, estrone arid estriol. 
Cumulative versus current endogenous hormone exposures and mammographic density.  
The assumption underpinning these investigations is that estrogen levels at any given time are 
associated with mammographic density, yet evidence suggests that it is cumulative lifetime 
exposure to estrogen that is associated with mammographic density 395 . Tamimi et al. 
(2005) 386 reported the possibility that postmenopausal percent mammographic density might 
be more reflective of premenopausal circulating levels than postmenopausal levels. 
A question to be asked is whether circulating estrogen levels are associated with 
change in mammographic density at any given period of time. A recent longitudinal study 
attempted to answer this question. Crandall et al. (2008) 396 , examined the association between 
change in rnammographic density and circulating estrone sulfate with HRT use. This US 
study followed up 428 women who had participated in the PEPI randomised controlled trial 
and had taken HRT. After adjusting for age, BMI, parity and a number of other risk factors ; 
the investigators observed a 1.3% increase in mammographic density for every 1 ng/ml 
increase in estrone sulfate (p<0.0001) in women who had taken HRT. While Ursin et al. 
(2004) 339 , using the PEPI cohort, observed a 2.95% increase in percent mammographic 
density for every 0.1 ng/ml increase in serum estrone level (p=0.0003) in women who used E 
and P hormone therapy but not estrogen only HRT. Crandall et al. 396, in the study reported 
above, observed a greater association between change in estrone sulfate level and change in 
mammographic density in women who used combined HRT compared to women who used 
estrogen only HRT (p=0.05). 
Local tissue estrogen concentrations 
Another suggestion for the lack of a clear association between mammographic density and 
circulating estrogens is the assumption that circulating estrogens reflect local tissue specific 
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concentrations of estrogens. According to Simpson (2003) 397, the levels of circulating 
estrogens and their precursors are unlikely to reflect the concentration of estrogen or the 
availability of its precursors in the breast tissue. It is possible that the concentration of 
estrogen within the breast provides a better reflection of the exposure to breast tissue, and it is 
the tissue specific estrogen concentrations that are likely to be associated with 
mammographic density. In the mouse model, paracrine (or local produced IGF-I), rather than 
endocrine concentrations have a more important role in mammary gland morphogenesis 398 . 
Endogenous estrogen and breast cancer risk 
While there is inconsistency among the studies that examined the association between plasma 
estrogen levels and mammographic density, there appears to be greater consensus among 
studies that had examined the association between estrogen levels and breast cancer risk. A 
summary of these studies can be found in Chapter 3, Section 3.3.1. It is possible that 
circulating estrogens and mammographic density are independent risk factors of breast 
cancer. The study by Tamimi et al. (2007) 399 examined this proposal, and found circulating 
estrogens and mammographic density to be independently associated with breast cancer risk 
in postmenopausal women. 
6.4.3.2 IGF-I and mammo graphic density 
A number of epidemiological studies have examined the association between IGF-I and 
mammographic density. The findings of these studies are relevant to this PhD study because 
girls treated with high-dose estrogens for tall stature have been shown to have reduced 
circulating IGF-I levels throughout the duration of treatment. For a more detailed review of 
the nine cross-sectional and one prospective study of the association between IGF-I and 
mammographic density see Appendix 7. 
Overall the evidence for an association between mammographic density and IGF-I is 
still inconclusive, but based on the larger of the studies summarised in Table 6.6, it appears 
that a positive association is likely, particularly in premenopausal women. These findings on 
mammographic density and IGF-I, at least for premenopausal women, are consistent with the 
effect of IGF-I on the proliferative activity of mammary tissue shown in anima120, 400-402 and 
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primate403 studies. The findings are also consistent with the positive association between IGF-• 
I and breast cancer risk described earlier in Chapter 3, Section 3.3.4.3. It is possible that 
levels prior to menopause, when levels are typically higher, particularly during adolescence 
(see Figure 6.7), contribute more to mammographic density than postmenopausal levels. A 
prospective study by Verheus et al. (2007) 4°4 suggests that postmenopausal mammographic 
density is dependent on premenopausal levels of IGF-I. Based on the evidence above, it is 
plausible that treatment with high-dose estrogens for the treatment of tall stature in adolescent 
girls could reduce mammographic density. Treated girls have been shown to have reduced 
levels of IGF-I as described in Chapter 2. 
6.4.3.3 Prolactin and mammo graphic density 
Prolactin, similarly, has been shown to be positively influenced by mammographic density in 
postmenopausal women 197' 392 ' 495 and in one study, premenopausal women394 . Though, some 
studies have not observed an association 390' 393 in postmenopausal women. The possible 
association between prolactin and mammographic density is relevant to this study because 
girls treated with high-dose estrogen have been shown to have higher than normal prolactin 
levels during treatment (See Chapter 2, Section 2.4.2.4). It is plausible then, that the 
increased circulating prolactin observed in girls treated with high-dose estrogens for tall 
stature might lead to increased levels of mammographic density. 
6.5 Adolescent exposures and mammographic density 
Evidence presented above suggests that exogenous hormone treatments are associated with 
mammographic density in the adult. The hormone induced changes in mammographic 
density also appear to be associated with change in circulating estrogens. However, this 
change in mammographic density appears to be short-lived; only lasting the duration of 
treatment. Whether estrogen treatment in adolescence affects mammographic density and 
whether this effect, if any, lasts to adulthood, is unknown. The research literature was 
reviewed for any evidence of adolescent exposures affecting mammographic density through 
to adulthood. A summary of the studies that were identified is presented below. 
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6.5.1 Age at menarche and mammographic density 
Age at menarche has been associated with mammographic density in some studies 302, 406-409, 
but not other's360, 361, 410-414. In all but one of the studies that observed an association, age at 
menarche was positively associated with mammographic density or high-risk parenchymal 
patterns. Gram et al. (1985)415 , in their study involving 3,640 Norwegian women, observed a 
dual response depending on menopausal status. They observed an inverse association in 
postmenopausal women, and a positive association in premenopausal women. Either way, it 
appears that hormonal exposures in adolescence might affect mammographic density later in 
life. 
6.5.2 Adolescent lifestyle factors and mammographic density 
A number of studies examined the association between adolescent lifestyle factors and 
mammographic density including alcohol, smoking, diet and physical activity. Vachon et al. 
(2005)416 found no influence of alcohol intake during adolescence on mammographic density 
in adulthood, while studies have observed positive associations with current alcohol use 365 ' 417 ' 
418, but not lifetime use417, as an adult. 
Sellers et al. (2007) 419 found no association between physical activity levels in 
adolescence with mammographic density in adulthood. However, some studies420-423 have 
observed an association between adult levels of physical activity with percent density while 
others have not305, 424-428. Jeffreys et al. (2004) 360 'observed an inverse relationship between 
age at start of smoking and percent mammographic density in a cross-sectional study 
involving 628 women attending the University of Glasgow Health Service. They observed a' 
positive association between age when smoking started and mammographic density. The 
odds of having a high-risk density category (>25% density vs <25% density) for each year of 
age that smoking was started was 1.08 (95% CI: 0.99 to 1.16, P for trend 0.058) 'after 
adjusting for HRT use, OC ever use and adult BMI. These findings are consistent with the 
association observed between smoking exposure as a child and breast cancer risk in 
postmenopausal (but not premenopausal) women 429 . In this case-control study by Ahern et al. 
(2009)429, postmenopausal (but not premenopausal) women exposed to cigarette smoke as a 
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child had a modestly increased risk of breast cancer (adjusted OR 1.8: 95% CI: 1.0 to 3.3) 
compared to women who were never passively exposed at any age. 
Of three reported studies that have investigated the association between adolescent 
diet and mammographic density, two419' 430 found no association while Maskarinec et al. 
(2006)329 found early life soy intake (self reported as an adult) to be associated with lower 
mean percent density (-8.6%, p=0.07) in Japanese women (mean age 57 years of age), 
suggesting that adolescent exposures can have lasting effects on mammographic density. 
6.5.3 Childhood anthropometric factors and mammographic density 
A number of childhood anthropometric factors have also been shown to be associated with 
mammographic density as an adult. These include birthweight 431 , childhood height419 , 
weight419, 426 and height yelocity406 . The two studies43I ' 432 (of six) that examined the 
association between percent density and birthweight using a continuous measure of percent 
density found a positive association in postmenopausal women. No association has been 
observed in premenopausal women 431 . The two reported studies432 ' 433 that examined the 
association between birth-length and mammographic density found no association. 
Childhood height406, 419 at particular ages, and growth velocity406 have been positively 
associated with mammographic density. Interestingly, McCormack et al. (2003) 406 found 
significant but opposing associations with higher Wolfe grade density for height at ages 2 and 
11; adjusted OR 1.13 (95% Cl: 1.01 to 1.26) (p=0.03) (n=1033), and OR 0.89 (95% CI: 0.80 
to 1.00) (p=0.04) (n=1090), respectively. No significant association was observed for ages 4, 
7, or 15 years. 
McCormack et al. (2003) 406 , Sellers et al. (2007)419 and Samini et al. (2008) 426 
observed an inverse association between childhood BMI or weight and mammographic 
density. The one study that examined the association between age at maximum height and 
mammographic density found no such association, though it relied on self reported age at 
maximum height as an adult. A more detailed summary of these and other reported studies
•that have examined the association between childhood anthropometric factors and 
mammographic density is in Appendix 8. 
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In those studies observing an association with marnmographic density as an adult, it 
would be expected that an association would also be present in adolescence. Few studies have 
directly measured mammographic density in adolescent girls which is not unexpected given 
the difficulty of exposing adolescents to mammogram related radiation. Magnetic resonance 
imaging (MRI) 282 and dual-energy x-ray absorptiometry434 are two methods . that have been 
used for the measurement of mammographic density in young women and are promising 
techniques for future studies. 
Of particular interest is the study by Boyd et al. (2009) 282 . They examined the 
association between serum hormone levels and percent water content of the breast in 260 
women aged 15-30 years (median age 18 years) using MRI. The water content of the breast 
corresponds with the fibro-glandular tissue, which is mammographic4Ily dense. In this study, 
percent water content measured using MRI was highly correlated with percent 
mammographic density in the mothers of the young women (Spearman correlation coefficient 
= 0.85)282. They found growth hormone and sex hormone binding globulin; but not IGF-I, 
estradiol or progesterone, to be associated with mammographic density. Whether or not 
hormone levels measured at a young age remain associated with mammographic density later 
in life is unknown. 
6.6 Overview 
This chapter began by describing mammographic density and the different methods 
of density measurement, and then followed with a review of studies that have examined 
associations between mammographic density and breast cancer risk. Many studies have 
examined this association and have subsequently been reviewed separately by Boyd and 
colleagues (1998)4 and McCormack and dos Santos Silva (2006) 288. In their meta-analysis of 
quantitative studies, Boyd et al.(1998) 4 showed that women with dense tissue in more than 
60-75% of the breast had 4-6 times greater risk of breast cancer than those with a lower 
proportion of dense tissue after adjustment for relevant covariates 4 . While this risk gradient 
was derived from multiple-studies, there were disparities between studies. McCormack and 
dos Santos Si1va288 explored possible reasons for these disparities and observed a difference 
between incident and prevalent breast cancer studies. Between these two types of studies, 
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they found breast cancer risk to be 4-5 fold larger in women with >75% dense breasts 
compared with women with less than 5% dense breasts 288 . 
The majority of research studies on mammographic density have used the relative 
measure of density (% density). The studies that also used the absolute measure of dense area 
have also observed a positive association with breast cancer riSk289-293 . In a comparative 
assessment, Torres-Maija and co-investigators found absolute density to be a stronger 
predictor of breast cancer risk than percent mammographic density 290. This has been 
supported by others 289 ' 294 but not all292, 295, 296. Mostly, it appears that the two measures are 
similar in their association with breast cancer risk292, 295, 296. 
This chapter also described the different methods that have been used to measure 
mammographic density. Qualitative methods of mammographic measurement include the 
Wolfe grading system, and the BI-RADS scaling system. These two qualitative systems use 
four categories of density classification, and consequently, are only able to detect large 
changes or differences in density 272 . They are measured by visual estimation and are more 
subjective than the quantitative measures of density that include visual estimation, computer 
assisted thresholding and planimetry. There is no gold standard in .mammographic density 
measurement. As described in detail in Section 6.2.2.4 above, the comparative inter-rater and 
intra-rater reliability assessments of qualitative and quantitative methods suggest that 
continuous quantitative measurement of mammographic density (as percent or absolute 
density) produces the highest reliability scores. The computer assisted technique is less time 
consuming than planimetry (both in training and execution), and in the case of visual 
estimation, is less subjective. It is the method used and described in the following chapter. 
This chapter also explored the evidence of hormonal influences of mammographic 
density (both exogenous and endogenous). A review of cross-sectional and longitudinal 
studies suggest that exogenous hormone exposures in adulthood (e.g. HRT) and endogenous 
hormone levels (e.g. IGF-I) have been associated with mammographic density. While the 
cross-sectional studies cannot measure change in density directly, they can measure 
differences in mammographic density between groups (e.g. between users and non-users of 
HRT), or to measure associations (e.g. between mammographic density, and duration of HRT 
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use). The cross-sectional studies consistently reported increased levels of mammographic 
density in HRT users compared to non-users. The longitudinal studies generally observed an 
increase in HRT compared to baseline or for one study, a reduction in the rate of age-related 
decline in mammographic density. Not all studies supported these findings however. The 
randomized placebo controlled studies also differed in their findings. Direct comparisons 
between the studies are difficult due to the differences in length of follow-up, levels of 
adjustment, and type of hormones used. 
One consistency that does exist across studies is the larger effect on mammographic 
density observed with combined estrogen and progestagen compared with estrogen only HRT 
formulations .  The longitudinal studies using quantitative continuous measures have observed 
mean increases in mammographic density between 2.8% and 7.7% after estrogen and 
progesterone combined HRT exposure, compared with 1.2-1.3% after estrogen only HRT 
exposure. 
• 	HRT appears to only increase mammographic density in some women. In the 
majority of the longitudinal studies using qualitative or categorical measures of 
mammographic density, the proportion of women who experienced an increase in 
mammographic density following exposure to combined HRT ranged from 2 to 68%, with 
the majority of studies reporting between 20% and 40%. These figures are much larger than 
the proportion who experienced an increase in mammographic density following estrogen 
only HRT (3.9 to 22%). It is unclear why HRT influences mammographic in some women 
and not others. The qualitative or categorical measures of density might not be sensitive 
enough to identify increases within the density categories. Many of the studies using 
categorical or qualitative measures of mammographic density could not detect changes less 
than 10%. Laya's finding of 73% would reduce to 32% if changes less than 10% (41% of 
reported changes) were not included. 
Overall the evidence for an association between mammographic density and 1GF-1 is 
still inconclusive, but based on the larger of the studies, if appears that a positive association 
is likely, particularly in premenopausal women. These findings on mammographic density 
and IGF-I, at least for premenopausal women, are consistent with the effect of IGF-I on the 
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-4 proliferative activity of mammary tissue shown in animal2 0, 40002  and primate403 studies. 
While caution is required when translating findings in the animal model to humans, they can 
support similar findings in human studies. The findings are also consistent with the positive 
association between IGF-I and breast cancer risk described earlier in Chapter 3, Section 
3.3.4.3. It is possible that levels prior to menopause, when levels are typically higher, 
particularly during adolescence contribute more to mammographic density than 
postmenopausal levels. A prospective study by Verheus et al. (2007) 4°4 suggests that 
postmenopausal mammographic density is dependent on premenopausal levels of IGF-I. 
Based on the evidence presented in this chapter, it is plausible that treatment with 
high-dose•estrogens for the treatment of tall stature in adolescent girls could reduce 
mammographic density. Longitudinal studies have been described that appear to show 
treatment with high-dose estrogens reduce levels of IGF-I as described in Chapter 2. 
However, it is important to note that these studies are not placebo controlled. 
A number of adOlescent factors were found to be associated with mammographic density as 
an adult (e.g. age at menarche, anthropometric variables). While these studies suggest that 
hormone exposures influence mammographic density, no study has examined the effect of 
exposure to high-dose estrogens in adolescence on mammographic density as an adult. The 
following chapter outlines the research study that explores this association. 
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Box 6.1: Key points from the literature in Chapter 6. 
KEY POINTS FROM THE LITERATURE: CHAPTER 6 
• Mammographic density is a strong risk factor for breast cancer. 
• There are a number of methods for measuring mammographic density, with the 
computer assisted thresholding method the most reliable method for quantitative 
continuous measures of density. 
• Cross-sectional and longitudinal studies suggest that exogenous hormone exposures 
in adulthood (e.g. HRT) and endogenous hormone levels (e.g. IGF-I) have been 
associated with mammographic density. 
• HRT appears to only increase mammographic density in some women. 
• Increases in mammographic density with HRT use coincides with breast pain in 
some women, which is also associated with increasing breast cancer risk. 
• Studies suggest that HRT reduces the age-related reduction in mammographic 
• density and that the difference in density between HRT and non-HRT users 
increases with increasing age. 
• HRT has been shown to increase mammographic density with the combined 
• estrogen and progestagen formulations having a stronger effect than estrogen only 
formulations. Combined formulations containing a continuous progestagen have 
been shown to have a stronger effect than those that use a cyclic progestagen. 
• A number of adolescent factors have been associated with mammographic density 
as an adult (e.g. age at menarche, anthropometric variables). 
• While these studies suggest that hormone exposures influence mammographic 
density, no study has examined the effect of exposure to high-dose estrogens in 
adolescence on mammographic density as an adult. 
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7: THE LONG-TERM EFFECT OF HIGH-DOSE ESTROGEN EXPOSURE IN 
ADOLESCENT GIRLS ON MAMMOGRAPHIC DENSITY 
7.0 Introduction 
In Chapter 6, it was shown that mammographic density is a well established risk factor of 
breast cancer and is influenced by exogenous and endogenous hormone levels in adulthood 
and adolescence. The chapter also presented evidence suggesting that adolescent exposure to 
high-dose estrogens may lead to changes in mammographic density in adulthood. 
It is unclear what the direction would be for an association between high-dose 
estrogen exposure in adolescence and mammographic density. HRT use has been associated 
with an increase in mammographic density. Consequently, estrogen plus cyclic progestagen, 
the typical treatment regimen in girls treated for tall stature, might result in an increase in 
mammographic density in adulthood. An alternative scenario is a reduction in 
mammographic density. Treatment for tall stature with high-dose estrogens has been shown 
to attenuate IGF-I levels in girls. Some of the studies presented in Chapter 6 demonstrated a 
positive association between circulating IGF-I levels and mammographic density. Similarly, 
earlier age at menarche is associated with decreasing levels of mammographic .density. 
Treatment induces menarche in girls who have not yet reached menarche at the start of 
treatment. Consequently, it is possible that mammographic density is lower in women treated 
with high-dose estrogens as an adolescent compared to women who were not treated but 
assessed for tall stature. 
The Tall Girls Study cohort provided a unique opportunity to examine the influence 
of treatment with high-dose estrogens in adolescence on rnammographic density in 
adulthood. NHMRC research funding was sought for a second follow-up of the Tall Girls 
cohort and a project grant was successfully attained. The following sections describe the 
methodology and results of this research. 
Chapter 7: The long-term effectoh high-dose estrogen exposure in adolescent girls on mammouraphic density 
	
176 
7.1 Study Aim 
This study aimed to examine the association between exposure to high-dose estrogen in 
adolescence and mammographic density as an adult using a second follow-up of the 
Australian Tall Girls cohort. 
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7.2 Methods 
7.2.1 Eligibility 
This retrospective cohort study included women who had previously participated in the Tall 
Girls Study 25 , were 40 years of age or older, and had stated that they were willing to be re-
contacted for further research. As described in Chapter 3 and elsewhere 25 , women were 
eligible to participate in the Australian Tall Girls Study if, between 1953 and 1993, they had 
obtained a medical opinion about their tall stature during adolescence and had a radiological 
assessment of their skeletal age in order to predict their adult height; they included women 
who were treated with high-dose estrogens and women who were not treated. 
7.2.2 Recruitment 
7.2.2.1 Follow-up 1 
In follow-up 1, most of the women were identified through the records of one paediatric 
endocrinologist. Other treating paediatricians (n=50) were identified through professional 
networks and by treated women themselves. The paediatricians were sent letters requesting 
their permission to identify eligible participants. Of those approached, only three were able to 
assist. As previously reported25 , the remainder did not assist because they no longer held 
records or could not readily identify eligible individuals (n=25), were unwilling to assist 
(n=2), were deceased or unwell (n=11) or could not be contacted (n=9). 
A total of 1,432 eligible participants were identified: 1,248 from medical records 
(1,222 from one paediatric endocrinologist) and 184 from self-referrals. Self-referrals 
included women who were members of the advocacy group Tall Girls Inc. and women who 
contacted the study investigators directly as a result of publicity about the study. Of the 
eligible identified, 1,243 women were traced and invited to participate in the study. Of these, 
371 treated (72% of those traced) and 409 (56%) untreated women provided their consent, 
and completed a postal questionnaire and telephone interview in 2002-2003. 
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7.2.2.2 Follow-up 2 
This study of mammographic density involved a second follow-up of women in the Tall Girls 
Study cohort who were aged 40 years and over and therefore eligible to have a free 
mammogram as part of the national breast screening program. Of the 780 women (371 
treated and 409 untreated) who had participated in the first follow-up, 517 (263 treated, 254 
untreated) were eligible to participate in this second follow-up. 
The contact details of women eligible for the second follow-up study were checked 
and updated with information from the electronic electoral roll, and on-line telephone 
directory. Of the 517 eligible, 483 were successfully traced and .contacted. A consent form, 
letter of invitation, study inform,ation brochure and mammogram release form was sent to the 
women inviting them to participate in the study. The study background and aims were 
outlined and a letter of invitation asking women to be interviewed by telephore and provide 
the study with access to a mammogram they may have had in the previous two years, or to 
have a mammogram at their closest publicly funded breast cancer screening service 
(BreastScreen) and provide us with access to the film for scanning. The mammogram release 
form asked for information about the whereabouts of the last mammogram and when it was 
performed. To assist us in retrieving films and information from the BreastScreen services,. 
women were also asked to provide their permission to allow BreastScreen to provide us with 
information about their BreastScreen attendances. This was later sent to the relevant service 
holding the film. See Appendix 9 for a copy of the consent form, study invitation letter, 
information brochure and mammogram release form. 
If the women did not respond by mail or phone, a follow-up phone call was made 
within two weeks to check that they had received the study promotion material, and if they 
had, whether they were interested in participating in the study. If women declined 
participation, they were thanked and not contacted again. If women registered their interest 
and stated that they intended to return their consent forms to us, they were followed up again 
by telephone if we did not receive their consent forms within approximately a month. 
Up to three phone-calls were made to study participants to remind them to return the 
completed consent form if they wanted to participate in the study. Of the women who, had 
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returned a consent form, up to two reminder phone calls were made to remind them to book a 
mammogram if the BreastScreen service had no record of them having presented for a 
mammogram. 
Of the 483 women contacted, 339 (70%) provided their written consent to participate 
(185 treated, 154 untreated) and 336 were subsequently interviewed by telephone in 200&-
2007. The three women who consented but were not interviewed were unable to be contacted 
by phone to organise an interview. A letter was sent to these women to organise the 
interview, but they did not respond. 
The mammograms of 319 participants were obtained from BreastScreen (77% of 
treated, 73% of untreated), from private screening services directly or from participants 
themselves, if they held them. Seventeen women who were interviewed did not have a 
mammogram. Women's reasons for not having a mammogram at a BreastScreen service 
included, lack of time, inflexible access to BreastScreen services in some rural areas and in 
one case, a recommendation from her GP not to have a mammogram because of the 
exposure to radiation. Of the 319 mammograms obtained for the study, 309 were eligible for 
breast density measurements (167 treated, 142 untreated). Mammograms were ineligible for 
density measurements if the woman had breast surgery in both breasts before the 
mammogram (treated=4, untreated=3), if tamoxifen was used within two years prior to the 
mammogram (treated=1, untreated=1), or if the image was of poor quality (treated=1). 
Figure 7.1 summarises the numbers of women identified, traced, interviewed and included in 
the final mammographic density study. 
Contacted 
N=483 
Consented 
N=339 
Mammograms Retrieved 
N=319 
Interviewed 
N=336 
Eligible for BD measure 
N=309 
59.8% of eligible 
63.8% of contacted 
Figure 7.1: Flow chart of recruitment of study participants 
! X ( 
Treated 263 (50.9%) Eligible Population 
N=517 
Untreated 254 (49.1%) 
Treated 167 (54.3%) 
63.5% of eligible 
66.5% of contacted 
Untreated 142 (45.7%) 
55.9% of eligible 
61.2% of contacted 
7.2.3 Sample size determination 
As the population of eligible women was known from the outset, power calculations were 
undertaken to identify the difference in percent density that would produce statistical 
significance if 60% of the eligible population participated in the study. To do this, the 
standard deviation for percent density for the eligible population was needed. A search of the 
literature identified the variance derived standard deviation (SD) of percent mammographic 
density across the age range 40-70 (mean PMD is 40% at age 40 and 30% at age 70), and 
adjusted for the covariates age, BMI, age at menarche, parity, number of live births, age at 
1000 
800 -- power 100% 
— 0.8 
— 0.9 participation rate 
600 
60% participation 
rate o. 
co 200 
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first birth and cessation of periods, to be 17 395 . This standard deviation is consistent with 
other reported population standard deviations for a similar age range435. 436 • The age range of 
participants in the study is narrower than those above (40-59 years), so the  SD estimate will 
be conservative. 
Sample sizes from participation rates ranging from 60-100% with alpha at 0.05 and 
power of 0.8-0.9 would allow the study to detect a 3-4% difference in mean percent 
mammographic density between the treated and untreated groups (Figure 7.2). Given that all 
of the women in the sample population participated in the previous follow-up and had stated 
their interest in being involved in further research, it was accurately anticipated that at least 
60% of eligible participants would be recruited for this new investigation. 
Figure 7.2: Sample size and difference in population means for study powers of 
0.8 and 0.9. 
0 	5 	10 	15 20 	25 	30 	35 	40 
Difference in Population Means 
a = 0.05 
SD= 17 
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7.2.4 Measurement of outcomes: mammographic density 
7.2.4.1 Interactive computer thresholding method 
A number of methods are available to measure mammographic density. These were 
summarised earlier in Chapter 6 (see Section 6.2). The method used in this study was the 
interactive computer thresholding method using Cumulus software developed at the 
University of Toronto and described elswhere437 . This method provided a continuous 
quantitative measure of percent density, dense area, total area and non-dense area, which is 
preferable to the qualitative forms of measurement, and less subjective than the visual 
estimation of density. The equipment and opportunity for training was provided at the Centre 
for Molecular, Environmental, Genetic and Analytic Epidemiology (MEGA) at the 
University of Melbourne. Training was provided by radiologist, Jenny Cawson, and PhD 
student, Jennifer Stone, both of whom had extensive experience in the use of the Cumulus 
software and were trained by Professor Norman Boyd in Toronto. 
7.2.4.2 Cranio-caudal view 
The left and right cranio-caudal mammograms of each study participant were collected and 
digitised using a Lumisys 85 scanner housed at the University of Melbourne. The cranio-
caudal view of the breast is taken from above a horizontally compressed breast. The other 
common view is the medio-oblique (MLO) view which is taken from the side of a 
diagonally-compressed breast. See Figure 7.3 of an illustration of the cranio-caudal 
perspective of mammogram compared to the medio-lateral perspective. 
Two state BreastScreen services did not allow the interstate -movement of 
mammograms. To accommodate this, the scanning equipment was transported to these states 
where the films were scanned by Jennifer Stone or myself. 
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Figure 7.3: Cranio-caudal and medio-lateral mammogram views. 
Sourced from http://breastcancer.about.com/od/mammograms/a/mamm  views, him 
CC MLO 
The right breast was preferentially used for mammographic density measurements. If 
the right mammogram was unavailable or was not suitable for density measurement (see 
eligibility criteria, Section 7.2.2.2 above), the left was used. 
According to Byng et al. (1996)438,  representative information on mammographic 
density is satisfactorily provided in a single view. Pearson correlation coefficients of between 
0.86-0.96 have been observed between the right and left breast and between cranial-caudal 
and medial-lateral oblique views for quantitative measurements of mammographic density. 
Yaffe and colleagues439 also examined the consistency in mammographic density results 
between four views of the breast (left and right cranio-caudal and medio-lateral oblique) and 
concluded that studies of mammographic density can use any one of the four views. 
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7.2.4.3 Masking of image 
Each film had to be masked to hide patient identifying information and to remove any white 
parts of the film outside of the breast area that would be picked up as 'dense' material. 
Masked areas appeared red on the film. The masking process also involved outlining the 
back of the breast. Pectoral muscle appears white on the screen and was excluded from 
analysis. . 
7.2.4.4 Measuring density 
Once all the films were masked, breast density measurements were undertaken in eight 
batches of 50-100 left and right cranio-caudal films by one reader (myself). The films were 
randomly placed in batches. Masking and randomisation ensured the reader was blinded to 
the treatment status of the women. 
The breast was outlined using a sliding thresholding scale on the screen with the aide 
Of a mouse. This thresholding scale simultaneously adjusted the contrast of the breast with 
the dark background, detecting the difference between the two. Once the breast was outlined, 
a second thresholding scale was Used to clearly delineate the dense area of the breast from the 
non-dense area, and a third sliding scale used to outline the dense area pixels. After the 
thresholds were set, the verification button was pressed to observe the areas of the breast that 
would be register as dense. This was performed for each film. This allowed the 'masker' to 
see if all sections of the border and pectoralis were hidden. If they were not, the masking was 
adjusted accordingly. 
The first image in Figure 7.4 highlights the total breast area and dense area 
boundaries. The red and green lines define total breast area and dense area respectively. Red 
areas outside of the breast area are there to mask identifying information and/or white edges 
of the film that may otherwise be picked up in the analysis. The second image in Figure 7.4 
shows the verified image. In this image, the white area that would be included as dense breast 
tissue is highlighted. 
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Figure 7.4: Masked (A) and verified (B) images of mammograms. 
A. 	 B. 
Masking and the measurement of breast density of the films occurred over a two 
week period. 
Mean of two sets of reads 
The films were all re-read twice on separate occasions. It was felt that some 'settling in' 
occurred with the first read of the batches, and consequently the last two reads of the batches 
were used in the analysis. 
Spearman's Rho of 0.95 was calculated for all data in Reads 2 and 3. Intra-observer 
within subject reliability was measured by using the intra-class correlation (ICC) coefficient 
using the loneway command in Stata. The ICC was 0.93 for both percent density and dense 
area and the means of these two sets of reads were used in the analysis. 
In addition, the opportunity arose for a repeat analysis to be undertaken using the 
mean of two sets of reads performed by a second experienced reader (Jennifer Stone) 12 
months later. These data are reported separately in the results section. 
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Calibration of.the scanner 
Films were scanned over an 11 month period. While there would be no systematic bias in the 
order of the reads it was important that the optical density and pixel grey values were 
constant across the reads. These parameters were measured after each scanning batch and 
compared with the previous batch. No significant variation occurred between the batches. 
• See Appendix 10 for the plot of optical density and pixel grey values over time. 
Films used in the analysis 
The right mammogram was used for 93.0% treated and 92.8% untreated women, unless 
surgery, cancer or benign breast disease had occurred in that breast, in which case the left 
film was used. The use of the contralateral film in such circumstances has been performed 
elsewhere". See Appendix 11 for a plot of percent mammographic density of the right 
breast with benign breast disease against the corresponding left non-diseased breast of the 
same woman. A Spearman coefficient of 0.99 was calculated between the two sides. 
If the woman had a history of benign breast disease in both breasts, and no surgery, 
the right breast was used (n=10 treated, n=3 untreated). One treated participant (0.6%) and 
three untreated participants (2.1%) had a history of breast cancer in the breast not used. to 
measure density. • 
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Transformation of mammociraphic density data 
The outcome variables dense area, non-dense area, total breast area and percent density were 
treated as continuous variables. A breast area of 1 cm 2 is equal to 6.67 x 104 pixels. Pixels 
were converted to cm 2 by multiplying the number of pixels by 0.000676 for dense area, non-
dense area and total breast area. 
The distribution of each of the dependent variables was checked and if the data were 
skewed, a Box-Cox method 257 was used to identify the most appropriate transformation 
approach to ensure the data fulfilled the criterion of normality for linear regression analysis. 
7.2.5 Measurement of exposures: treatment 
Detailed information on treatment characteristics of these women who participated in the 
second follow-up are described in the results section below. 
Treatment information was extracted from the medical records of women who 
provided consent and for whom records were available (67% of treated and 92% of untreated 
women) or was self-reported by women in the postal questionnaire used in the first follow-
up. The majority of women were treated or assessed by one paediatric endocrinologist (81%). 
More records were available for untreated women because a greater proportion of them 
(97%) compared with treated women (68%) were sourced from one endocrinologist who 
retained and allowed access to the medical records. More treated women self-referred to the 
study and had been treated by other endocrinologists whose records could not be accessed. 
Type of treatment, and start and end date of treatment (from which duration of 
treatment was calculated) was collected from the records. If records were not available, 
women were asked in the postal questionnaire the name of the drug that they took (IDES, 
2=EE, 3=Other, 4=Not sure/can't remember name) and how old they were when they started 
treated and completed treatment (years and months). 
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Age at menarche and Tanner Stage of the Breast was also collected from the medical 
records. Start of treatment in relation to age at menarche and Tanner Stage were derived from 
this data. 
7.2.6 Covariates 
Potential confounders were identified from the research literature, through being either 
associated with mammographic measure(s) and/or breast cancer risk, and being measured 
using the questionnaires and other data sources (See Appendix 12 for a list of covariates 
collected and analysed in this study). 
While there are a few inconsistencies across the studies, it is apparent that age 305 ' 306 ' 
325, 328, 359, 407, 409, 413, 440-443 , Bm1305, 325, 328, 359, 360, 407, 409, 413,442, 444 and parity 305, 306, 328, 359, 360, 407, 
409, 413, 440-444 are inversely associated with percent density. Other potential confounders 
302, 328, 359, 407, 409, 444 include age at menarche 	 and age at first livebirth 328 ' 360' 409, 445, 446 and 
history of breast biopsy 306, 444-447 which have been reported to be positively associated with 
mammographic density, and menopause 325, 328, 409, 444, 448 which has been reported to be 
negatively associated. Associations have also been reported between mammographic density 
, 	45. 1-453 and smokin g305, 360, 449, alcohol417, 444, 450 diet444, 	, height446, breastfeeding444, and having 
had a first degree relative with breast cancer 454 . The association between exogenous hormone 
use and mammographic density has been described in detail in Chapter 6 (Section 6.4.1). 
At the time the questionnaire was being developed, some factors did not appear to be 
associated with mammographic density but had been shown to be associated with breast 
cancer risk (e.g. fertility drue s and aspirin use456). Since mammographic density is also 
associated with breast cancer risk, these data have been collected as they may influence any 
association between treatment and mammographic density. Similarly, while no studies 
appear to have investigated the link between hormone treatments for endometriosis or 
menstrual disorders and mammographic density, data was collected on these factors. It is 
possible that any difference in mammographic density between women treated with high-
dose estrogens in adolescence and untreated women might be due to other hormonal 
exposures. For instance, data from the Tall Girls Study (not published) suggests that treated 
Chapter 7: The long-term effect of high-dose estrogen exposure in adolescent girls on mammouraphic density 	 189 
women are at higher risk of endometriosis compared to untreated women. It is possible that 
women who have had a history of endometriosis have taken hormonal medication. 
Information on hormonal medications Other than for contraceptive, HRT, or fertility use were 
therefore collected. 
7.2.6.1 Covariate data collection tools 
Data on covariates were collected from a questionnaire used in follow-up 1 and follow-up 2. 
The follow-up 2 questionnaire was developed to update information collected in the first 
follow-up and to collect additional information. A copy of the questionnaires can be found in 
Appendices 3 (postal) and 4 (CATI) for follow-up 1 and Appendix 13 (CATI), for the second 
follow-up. 
Questionnaire development 
The follow-up 2 questionnaire was derived from the Australian Twins and Sisters Breast 
Density Study457 questionnaire with some amendments. Questions only relevant to twins 
were removed, while additional questions about hormone use for reproductive problems were 
added. Some questions that were used in the follow-up 1 study questionnaire were repeated 
in this questionnaire to update previously collected data (e.g. breastfeeding and pregnancy 
data). 
The follow-up 2 questionnaire was developed for coinputer assisted telephone 
interview (CATI). This process required extensive testing and piloting. An Access 2000 
database was used as the'platform for the CATI questionnaire. The questionnaire was piloted 
with women not associated with the study. Questions were fine-tuned, and it was again 
piloted. Two interviewers (myself and Shirley Catchpole) performed the telephone 
interviews. 
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Questionnaire questions 
Data on the following covariates were self-reported by participants at follow-up 1 only: age 
at last menstrual period (CATI) and highest education level achieved, and marital status 
(postal questionnaire). 
Data on the following covariates were self-reported by participants at follow-up 1 
(by postal questionnaire or CAT1) and updated at follow-up 2 (by CATI): reproductive 
history (including pregnancy outcomes, breastfeeding history and menstruation); history of 
breast and gynecological disorders (e.g. has a doctor ever told you that you had/ have you 
ever been diagnosed with endometriosis, uterine fibroids, ovarian cysts, benign breast disease 
and breast cancer); use of hormonal medications, hormonal contraceptives, hormone 
replacement therapy and hormones for infertility; smoking and alcohol consumption, and 
current height and weight from which BM1 was derived (kg/m 2). At follow-up 2, family 
history of breast cancer, and country of birth was also collected. Smoking and alcohol history 
questions were derived from the Australian Longitudinal Study on Women's Health 
(Women's Health Australia). 
The CATI questions on reproductive and gynecological health in follow-up 1 and 
later updated in follow-up 2 were derived from large-scale studies of reproductive health and 
health outcomes in women exposed to DES conducted in the USA by Wilcox 458 and Baird459 . 
At follow-up 1 information on reproductive history was collected by asking women for each 
pregnancy: in what month and year did your pregnancy end, how did the pregnancy end, how 
many weeks did this pregnancy last, did you commence breastfeeding this baby, how long 
did your baby have breast milk only, and how long did you breastfeed this baby all together. 
Follow-up 2 updated this information by asking, since the last interview (date of interview at 
follow-up 1 was provided to participant), have they been pregnant, and for each pregnancy 
what month and year the pregnancy ended, how many weeks pregnant were they when the 
pregnancy ended, how the pregnancy ended, and how long they breastfed if they did. 
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Women were asked if they had ever taken prescription estrogens, progesterone or 
other female hormones for menopause, that is, prescription hormone replacement therapy or 
HRT not including birth control pills or hormonal contraceptives, whether they were still 
having periods when they first took HRT and how long after their last period they took HRT. 
To obtain information on overall HRT exposure, women were 'asked when they stopped and 
started HRT use and whether they commenced again after that. The questions continued this 
way until they answered that they did not commence HRT again after stopping or they were 
currently using HRT. A similar format of questioning was used to measure cumulative oral 
contraceptive use. 
The questions on HRT use in follow-up 2 asked women for the names of the.•
hormonal replacement therapies if they could recall these and whether they knew whether 
they contained an estrogen and/or progestagen. The hormones were later categorised into 
estrogen only or estrogen and progestin combined HRT formulations. This information was 
derived from a list developed for a recent Australian study by Nickson'and Kavanagh 460 , on 
the reliability of recall of menopause therapy. This list was developed by cross-referencing 
prescription names listed on the Australian Pharmaceutical Benefits Scheme, and the internet 
for non-prescription medicines. 
At follow-up 2, menstrual history was collected by asking women what age they 
were when they had their last period and why their menstrual periods stopped (from which 
menopausal status was derived). Women were defined as postmenopausal if the time since 
their last period was >52 weeks and a) they had not started HRT before their periods ended 
or b) they started HRT before their periods ended and they were >55 years of age. 
Recognising that some women would have not had a period for >52 weeks because of 
hysterectomy (while retaining one or both ovaries), endometrial ablation, IUD, or hormone 
implants, we also-examined menopausal status using a definition that considered these 
women to be premenopausal unless they were >55 years of age. 
Additional childhood anthropometric measures were collected and analysed as 
described in Chapter 8 (see Appendix 12 for a list of these measures). The aim, methods and 
findings of these data analyses are reported in Chapter 8. 
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7.2.7 Ethics approval 
7.2.7.1 Ethics approval granting bodies 
The study was granted institutional research ethics committee approval from the Southern 
Tasmania Health and Medical Human Research Ethics Committee (H0008334), ACT Health 
HREC (ETH.5/06.313), Department of Health (SA) HREC (14/12/05), Cancer Institute NSW 
(2006/06/003), BreastScreen Victoria Research and Evaluation Committee (25/10/05), 
BreastScreen Queensland Monitoring Research and Evaluation Sub-committee (0243-0271- 
003), and the Uniting Care Health HREC Queensland (20/6/07). Copies of these approvals 
are provided in Appendix 14. Prior to obtaining formal ethics approval from each of the state 
BreastScreen services and relevant bodies, discussions were made with the primary 
BreastScreen service within each state to discuss the protocol for the retrieval and return of 
mammograms. 
7.2.7.2 Ethical issues 
A number of ethical issues needed to be taken into consideration in the study. These are 
described below. 
Mammographic screening 
The mammographic screening process had the potential to cause discomfort to women. Also, 
having a mammogram involves exposure to ionising radiation. This exposure was considered 
to be minimal. BreastScreen mammogram is routinely available to Australian women over 
the age of 40 years and radiation safety issues are managed by the BreastScreen program. 
Data handling and management 
The digitised images are stored with the personal information provided on the 
mammographic films as the scanner will not function with anything attached to the film 
which could be used to conceal the personal details. BreastScreen Service mammograms are 
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routinely identified. To ensure confidentiality of the digitised images was maintained, the 
digitised images were only viewed by the investigators performing the density calculations. 
A de-identified data file, with a coded ID number was used for the analysis. If 
necessary, it is possible to link the ID code to the original identifiers and identify the 
individual to whom the information relates. While it is possible for the data to be re-
identified, it is unlikely that this will be necessary. 
The file containing names and ID numbers was kept separately, and password 
protected. The back up and archived copies density calculations, and interview data was 
saved on a password protected database and stored at Menzies Research Institute. On 
completion of the study the digitised images were archived on a separate password protected 
database at Menzies Research Institute. 
Reporting the findings 
The identity of participants was known to the investigators but not to others outside the 
research team. Participants are not identifiable in presentations or publications. Names have 
been stored separately from data on completion of the data collection. 
Informed consent 
Consent was required to participate in the study. This required two consent forms — giving 
consent to participate in the study (being interviewed and allowing the study to access a 
mammogram they had in the previous two years, or if they did not have one, to have a 
mammogram at a local BreastScreen service). A second form, indicated consent to allow the 
investigators to access the women's mammograms. A copy of this signed form was sent to 
services holding the mammogram. Consent was also required of women for the study to 
access medical records. This consent was obtained in follow-up I. Consent forms are 
contained in Appendix 15. 
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An information brochure was provided with the consent forms to ensure women had 
a clear understanding of the aims of the study and the procedures involved. The information 
brochure is in Appendix 9. 
7.2.8 Data analysis 
A range of descriptive and inferential data analyses were performed as described below. Slata 
software (version 9) was used for all analyses. 
7.2.8.1 Descriptive analysis 
Descriptive analysis of the data included scatter plots and box and whisker plots and 
univariable analysis of the association between each of the mammographic parameters and 
the range of potential determinants. 
Characteristics of study participants were summarised for treated and untreated 
women and p-values for differences in characteristics were calculated using t-tests for means 
and chi-square for proportions. Following convention, nominal statistical significance was 
based on a p-value of less than 0.05. All tests of significance were two-sided. (See Section 
4.2.6 for a discussion on the choice of threshold for statistical significance.) 
7.2.8.2 Regression analysis 
Multiple linear regression was then used to assess effects of treatment (regression coefficient 
representing the difference between means of treated and untreated women after adjustment 
for covariates). 
Least square means 
The estimate for treatment effect was difficult to interpret because of the transformed nature 
of the dependent variables. Least squares means (LSMs) for each treatment were calculated 
from the regression coefficient estimates adjusted for mean age and BMI and number of 
livebirths. For ease of interpretation, these LSMs and their confidence intervals were back-
transformed. 
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Analysing potential confounders 
Potential confounders were entered into regression models that included treatment, starting 
with age and BMI. Thereafter, order was determined by forward selection, and variables 
were retained if the treatment coefficient changed by 10% or more. 
Interactions were examined by age (before and after 50 years) and treatment type 
because a greater proportion of women 50 years or older were treated with DES. The 
difference in each of the dependent variables between treated and untreated women was 
examined by treatment type using a variable coded as 0 for untreated, 1 for EE and 2 for 
DES. Two women were treated with both and were not included in this sub-analysis. 
Post-estimation diagnostics 
Post-estimation diagnostic tests were performed to evaluate the validity of the regression 
results and included tests of collinearity and normality including the functional form of the 
model; residual vs predictor plots, tests of outliers and leverage, and Cook's distance. 
Component plus residual plots indicated non-linearity of the BMI variable against 
non-dense area of the breast. A fractional polynomial model comparison test was performed 
and the square root inverse model was found to be the best fit. BMI was inverse square root 
transformed in the regression analysis examining treatment effect on non-dense area. 
Sub -group analysis 
The association between treatment duration and effectiveness, and age and pubertal stage at • 
start of treatment with each of the dependent variables was examined within the treated sub-
group only. 
In order to investigate whether there was evidence of selective participation at 
follow-up 2, the characteristics of participants were compared with those of participants at 
follow-up 1 with respect to age, height, BMI and history of having had a breast biopsy. 
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Sensitivity analysis 
Twenty-one of the images (13 treated, 8 untreated) were derived from digital images. A 
repeat analysis was performed with these removed. • 
Women with a history of breast cancer may have been more likely to participate in 
the study, or depending on the stage of their illness, less likely. More treated than untreated 
participants had a history of breast cancer. It is possible that these cases may have inflated 
the difference in dense area observed between treated and untreated women. Participants who 
had a history of breast cancer were removed and a repeat analysis performed.. 
As an additional measure, women who self-referred themselves to the study were 
removed from the analysis. The results of the restricted analysis were similarly presented. 
Chapter 7: The long-term effect of high-dose estrogen exposure in adolescent girls on mammographic density 
	
197 
7.3 Results 
7.3.1 Characteristics of study participants 
Age, reproductive, anthropometric, lifestyle and reproductive disease characteristics of study 
participants are presented separately in Tables 7.1 to 7.5 and described below. 
7.3.1.1 Age and reproductive characteristics of participants 
Table 7.1 describes the age and reproductive characteristics of both treated and untreated 
women. Treated women were slightly older at time of interview and at mammogram than 
untreated women and were more likely to be postmenopausal (using either definition of 
menopausal status), but were similar in age at menarche, mean age at first livebirth, and total 
duration of breastfeeding in those who had ever breastfed. As reported elsewhere 25 , treated 
women were less likely (78.4%) to have ever had a livebirth than untreated women (81.7%), 
though this difference was small (p=0.48). 
Table 7.1: Age and reproductive characteristics of study participants. 
Characteristic Treated 
(n=167) 
Untreated 
(n=142) 
P-value 
Age Mean (SD) (years) 
At interview 48.4 (4.8) 46.2 (4.1) <0.001 
At mammogram 48.0 (4.7) 45.8 (4.1) <0.001 
Postmenopausal n (%) * 57 (34.1) 25 (17.6) 0.001 
_ 
Postmenopausal n (%) t 23 (13.8) 8 -(5.6) 0.018 
Age at menarche $ Mean, (SD) (years) 12.8 (1.6) 12.8 (1.4) 0.858 
_ 
Livebirths n (%) 
0 36 (21.6) 26 (18.3) 0.478 
1 23 (13.8) 11(7.8) 
>2 108 (64.7) 105 (74) 
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Characteristic Treated 
(n=167) 
Untreated 
(n=142) 
P-value 
Age at first livebirth Mean (SD) (years) 
Ever breastfeed n (%) 
Breastfeeding total mean (range) 
30.0 (4.6) 
125 (75.8) 
98.7 (2-374) 
29.4 (4.5) 
115 (81) 
97.2 (0.7-309.6) 
0.248 
0.197 
0.848 
' (weeks) § 
* Definition of postmenopausal: last period >52 weeks, and if HRT started before last period 
and current age was >55 years. 
t Definition of postmenopausal: Same as above but women who had not had a period for >52 
weeks because of hysterectomy (while retaining one or both ovaries), endometrial ablation, 
IUD, or hormone implants, they were considered to be premenopausal unless they were >55 
years of age. 
Age at menarche: 1 missing 
§ Breastfeeding duration of women who had ever breastfed and for all livebirths. 
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7.3.1.2 Anthropometric characteristics of participants 
• 
Table 7.2 describes the anthropometric characteristics of treated and untreated women. 
Treated women were slightly taller and had a lower BMI than untreated women. Untreated 
women were slightly heavier than treated women, and had a greater weight gain between the 
ages 18 and 30, 18 to current and 30 to current, but these differences were small (p>0.30). 
Table 7.2: Anthropometric characteristics of participants. 
Characteristic 	 Treated 
	
Untreated 
	
P.. 
(n=167) (n=142) value 
Height (cm) 
Mean (SD) (range) 
Weight (kg) 
Mean (SD) (range) 
BMI (kg/m2) 
Mean (SD) (range) _ 
EM Ill-final height (cm)' 
Mean (SD) (range) . 
Weight change (kg) 
Mean (SD) (range) 
18 to 30 years 
18 years to current 
30 years to current 
j78.4(3.8) (165.0 to 191.8) 
78.4 (16.2) (52.0 to 155.0) 
2.1 (2.8) (-3.5 to 11.7) 
4.4 (7.7) (-27.8 to 41.5) 
12.3 (12.2) (-25.0 to 59.0) 
7.9 (10.7) (-13.0 to 59.0)  
175.6 0.7) (160.0 to 194.0)__ ION .; 
0.397 
- 
25.9 (4.9) (18.0 to 40.3) . 	,, 0.030 
-1.0 (3.2) (-12.3 to 9.0) 
4.6 (7.0) (-11 to 33) 0.765 
13.8 (12.5) (-10.0 to 50.0) 0.314 
9.1 (10.0) (-24.0 to 56.5) 0.304 
79.9 (15.7) (52.0 to 127.0) 
A summary of childhood anthropometric characteristics by treatment status, is 
presented and described in Chapter 8 (Table 8.1). These variables include birthweight, birth-
length, bone age minus chronological age, and height, weight and BMI at first assessment. 
As well, weight and BMI change the first year following treatment, age at maximum height, 
and height change after 15 years is described for treated women only. The analyses of these 
data are described in Chapter 8 also (Table 8.2). , 
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7.3.1.3 Use of hormone and related medicines by participants 
Table 7.3 describes the use of hormones and hormone related medicines in treated and 
untreated women. Treated women were more likely to have had fertility drug treatment 
(consistent with fertility effects reported elsewhere 25) and to currently use, and have ever 
used hormone replacement therapy, particularly the estrogen only formulation, but were 
similar in oral contraceptive use (ever used and currently use), though treated women used 
oral contraceptives for a longer duration. 
Table 7.3: Use of hormone or related medications by treatment status. 
Characteristic Treated 
(N=167) 
Untreated 
(N=142) . 
P. 
value 
; Fertility drugs taken n (%) 43 (25.8) 18 (12.7) 0.004. , 
, Fertility cycles Mean (range) 6.0 (1 to 18) 7.2 (1 to 36) 0.117 
. Fertility cycles (categories) 
. 	0 124 (74.3) 124 (87.3) 0.004 
1-<5 18 (10.8) 9 (6.3) 0.168 
5-<10 16 (9.6) 4 (2.8) 0.016 
>10 9 (2.1) 5(3.5) 0.431 
HRT 
Ever used n (%) 35 (21.0) 15 (10.6) 0.013 
Current use 22 (13.2) 7(4.9) 0.013 
Total use (years) 
Mean (range)* 3.9 (0.02 to 27.7) 2.6 (0.02 to 10.6) 0.073 
HRT type n (%) t 
, Estrogen 17 (10.2) 4(2.8) 0.010 
Estrogen & progestagen 12 (7.2) 8 (5.6) 0.581 
Progestagen 4 (2.4) 2 (1.4) 0.531 . 
Testosterone, estrogen & progestagen 0 1 (0.7) 0.277 
, Unknown 2(1.2) 0 
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Characteristic • Treated 
(N=167) 
Untreated 
(N=142) 
P- 
value 
, Hormonal contraceptive 
Ever used n (%) 161 (96.4) 138 (97.2) 0.701 
Current use n (%) 20 (12.0) 22 (15.5) 0.369 
Total use (years)t 
Mean (range) 10.1 (0.08-33) 11.9 (0.11-29.2) 0.028 
Age first used 
Mean (range) 19.4 (13-36) 19.1 (13-33) 0.495 
Ever used hormones for 
endometriosis n (%) 10 (6.0) 4 (2.8) 0.182 
Duration of hormone use to 
treat endometriosis (weeks) . 	• 
Median (95% CI) 26 (13-192) 26 (26-104) 0.452 
Ever used hormones for 
menstrual problems n (%) 9(5.4) 10(7.0) 0.547 
Ever used aspirin § n (%) 22 (13.2) • 18 (12.7) 0.897 
Ever used over the counter anti-
inflammatories § n (%) 21 (12.6) 11(7.8) 0.165 
Ever used prescription anti-
inflammatories § n (%) 37 (22.2) 28 (19.9) 0,622 
* HRT total use for treated n=1 missing 
t% is of total treated and untreated, not just those who used HRT 
Of those who used hormonal contraceptive 
§ Twice a week for a month or longer 
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7.3.1.4 Smoking, alcohol use and socio-demographic characteristics of 
participants 
Table 7.4 describes the smoking, alcohol use and socio-demographic characteristics of 
treated and untreated women. Treated women had a similar smoking and alcohol history than 
untreated women. The majority of treated (94.0%) and untreated women (98.6%) were born 
in Australia and marital status and educational levels were similar for both groups. 
Table 7.4: Smoking, alcohol and socio-demographic characteristics of 
participants by treatment status. 
Characteristic Treated n (/0) 
(N=167) 
Untreated n ( YO ) 
(N=142) 
P-value 
! Smoking 
Ever smoked 88 (52.7) 83 (58.4) 0.310 
Currently smoke 18 (10.8) 17 (12.0) 0.741 
Alcohol use 
Never or rarely drink 	• 24 (14.3) 24 (16.9) 0.541 
Occasionally (<once a week) 28 (16.8) 25 (17.6) 0.845 
Once or twice a week 33 (19.8) 34 (23.9) 0.374 
Three or moredays a week _ 82 (49.1) 59 (41.5) 0.184 
Marital status 
Married 115 (68.9) 96 (67.6) 0.813 
De facto 15 (9.0) 11(7.8) 0.697 
Separated 6 (3.6) 5 (3.5) 0.973 
Divorced 9 (5.4) 6 (4.2) 0.683 
Widowed 6 (3.6) 2 (1.4) 0.228 
Single 16(9.6) 22 (15.5) 0.115 
Educational level 
Primary School 0 	. 0 
Intermediate/Year 11 5 (3.0) 7 (4.9) 0.380 
High School/Year 11 & 12 33 (19.8) 22 (15.5) 0.328 
Certificate/Diploma 42 (25.2) 34 (23.9) 0.806 
University Degree 49 (29.3) 50 (35.2) 0.270 
Higher University Degree 38 (22.8) 29 (20.4) 0.620 
Country of Birth 
Australia 157 (94.0) 140 (98.6) 0.038 
UK 7 (4.2) 1 (0.7) 
Other 3(1.8) 1(0.7) 
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7.3.1.5 History of reproductive disease in participants 
Table 7.5 describes the reproductive disease history of treated and untreated women and 
breast and ovarian cancer in their first degree relatives. Treated women were no more likely 
to have been diagnosed with benign breast disease and endometriosis compared with 
untreated women. Ovarian cysts were a reported short-term side effect of treatment in some 
treated girls in this cohort (data not presented), and in the literature', possibly explaining the 
difference observed in the history of having had ovarian cysts between treated and untreated 
women. 
Table 7.5: History of reproductive disease in treated and untreated women. 
Characteristic Treated n ("/0) 
(N=167) 
Untreated n (/0) 
(N=1.42) 
P-value 
, Benign breast disease 37 (22.2) 23 (16.2) 0.187 
Polycystic ovary syndrome 5(3.0) 4 (2.8) 0.926 — 
Ovarian cysts 39 (23-.4) 20 (14.1) 0.04 	' 
. 	- Uter ine fibroid 28 (16.8) 24 (16.9) 0.975 
Endometriosis 30 (18.0) 16 (11.3) 0.10-0 	-1 
Breast cancer 1 (0.6) 3 (2.1) 0.241 
_ 	. 
' Vaginal/Uterine cancer 5 (3.0) 6 (4.2) 0.560 
Breast cancer: 1st  degree relative 27 (16.2) 19 (13.4) 0.493 
Ovarian cancer: 1st  degree relative 2 (1.2) 3 (2.1) 
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7.3.1.6 Characteristics of eligible participants and non-participants 
Characteristics were compared between eligible women who participated in the 
mammographic density study (n=309) and eligible women who did not (n=208). Participants 
were of similar age (mean 47.5 years), height (mean 177.4 cm) and BMI (mean 24.7 kg/m2) 
to non-participants (mean age=46.3 years; mean height=177.5 cm; mean BM1 24.7 kg/m 2). 
History of having had a breast biopsy was also similar for participants (12.9%) and non-
participants (13.9%). 
7.3.2 Exposure characteristics 
A description of treatment duration, type and timing in relation to pubertal development is 
presented in Table 7.6. Of the 167 treated women participating in the study, more women 
were treated with DES, than were treated with EE. Treatment type was unknown for 13 
(7.8%) women. The mean age at start of treatment was 12.8 (SD 1.7) years, with a mean 
treatment duration of 23.6 months (21.0 months EE, 25.8 months DES). Treatment 
commenced after menarche in 85 (51.2%) women. Data were available on Tanner Stage of 
breast development for 103 (61.7%) treated women. Of these, 82.5% commenced treatment 
at or after Tanner Stage 3. 
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Table 7.6: Treatment characteristics (treated women only). 
Characteristic Treated (all) EE DES 
Treatment type* n (%) 167 62 (37.1) 90 (53.9) 
Age, start of treatment 
Mean (range) 12.8 (8-17.5) 13.2 (8-17.5) 12.7 (9.0-16.2) 
Duration of Treatmentt 
Mean (range)(months)I 24.3 (1.896) 24.1 (1.8-96) 24.6 (4.3-49.1) 
Mean (range) (years) § 1.97 (0.2-4.1) 1.75 (0.2-3.3) 2.15 (0.4-4.1) 
Treatment commence lj 
Before menarche n (%) 81 (48.8) 29 (46.8) 44 (49.4) 
After menarche n (%) 85 (51.2) 33 (53.2) 45 (50.6) 
Breast Tanner Stage at 
beginning of treatment n (%) 
• 1 3(1.8) 0 (0) 3(3.3) 
• 2 15 (9.0) 5(8.1) 10 (11., 1) 
3 40 (24.0) 15 (24.2) 24 (26.7) 
4 23 (13.8) 8 (12.9) • 15 (16.7) 
5 22 (13.2) 14 (22.6) 8(8.9) 
Missing 64 (38.3) 20 (32.3) • 30 (33.3) 
* Number of treated who used both types at different times n=2 (1.2%); number of treated 
whose treatment type is missing n=13 (7.8%) 
t Missing n=3 
t Sourced from medical records and self report 
§ Source from Medical records only (n=111) 
I Missing n=1 
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7.3.3 Mammographic density characteristics of participants 
While dense area and percent density are the primary outcome measures of interest to this 
study, both non-dense area and total breast area will be described and similarly analysed as 
they may explain and confirm the differences, if any, observed between dense and percent 
density. 
Mean and median values of the mammographic density parameters dense area, 
percent density, total breast area and non-dense area are presented in Table 7.7 for treated 
and untreated women. Mean dense area was less in treated women than untreated women. 
There was no difference in percent density and non-dense area between treated and untreated 
women. Total breast area was greater in untreated women compared to treated women but 
this difference was not statistically significant. 
Table 7.7: Mean and median values of mammographic density parameters: 
dense area (cm2), percent density CYO, total breast area (cm 2) and non-dense 
area (cm 2). 
Characteristic Treated Untreated P-value 
Dense area (cm 2) 
Median (5 th  & 95 1h percentile) 26.4 (3.1-60.0) 27.8 (4.7-77.6) 
Mean (SD)• 27.6 (17.6) 32.8 (22.8) 0.022 
Percent density (%) 
Median (5 th & 9 5 th percentile) 26.8 (2.2-67.1) 28.2 (2.5-66.1) 
Mean (SD) 29.5 (20.4) 30.8 (19.6) 0.575 
Total breast area (cm 2) 
Median (5 th  & 95 th percentile) 102.6 (49.7-232.9) 111.8 (57.4-236.0) 
Mean (SD) 114.5 (57.2) 123.9 (55.5) 0.149 
-  Non-dense area (cm 2  ) 
Median (51h & 95th percentile) 71.7 (18.5-226.9) 69.2 (27.0-225.8) 
Mean (SD) 87.0 (60.5) 91.1 (59.8) 0.554 
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7.3.4 Transformation of outcome variables 
Dense area and percent dense area were square root transformed while total breast area and 
non-dense areas were log transformed to fulfill the assumption of normality for regression 
analyses. The distributions of the raw and transformed data for each of these mammographic 
parameters are plotted in histograms in Figures 7.5 and 7.6 respectively. 
Figure 7.5: Distribution of dense area, percent density, total breast area, non-
dense area. 
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Figure 7.6: Distribution of square root transformed dense area and percent 
density, and log transformed total breast area and non-dense area. 
Square root dense area (cm 2) 
Log non-dense area (cm 2 ) 
Log total breast area (cm 2 ) 
Square-root percent density (%) 
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7.3.5 Univariable analysis 
A univariable analysis of the association between treatment and each of the mammographic 
measures: dense area (sqrt), percent density (sqrt), non-dense area (log) and total breast area 
(log) is described below. This is followed by a univariable analysis of single covariates and 
each of the mammographic measures. 
• 7.3.5.1 Univariable analysis of association between treatment and 
mamma graphic outcome variables 
The results of a univariable analysis of the association between the binary treatment variable 
(treated=1, untreated=0) and the transformed dependent outcome variables are presented in 
Table 7.8. Dense area and total breast area were significantly associated with treatment 
status. The direction of the coefficients indicates that treated women have a lower mean 
dense area and total breast area than untreated women. 
Table 7.8: Univariable analysis of the association between treatment status and 
the outcome variables: dense area cm 2 (sqrt), percent density ("/0), total breast 
area cm 2 (log) and non-dense area cm 2 (log). 
Independent variable Dependent variable Coefficient (95% CI) P-value 
Treatment status 	Dense area 	—0.45 (-0.87 to —0.04) 	p=0.03 
Percent density 	—0.17 (-0.62 to 0.28) 	p=0.47 
Total breast area 	—0.09 (-0.19 to 0.01) 	p=0.07 
Non-dense area 	—0.08 (-0.23 to 0.08) 	p=0.32 
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7.3.5.2 Univariable analysis of the association between single covariates and 
the mammo graphic outcome variable 
A number of potential confounding or mediating variables were examined for a univariable 
association with. the outcome variables: sqrt transformed dense area (cm2), sqrt percent 
density (%), log 'transformed total breast area (cm 2) and log non-dense area (cm 2). T-tests 
were used for continuous variables and chi-squared tests for binary variables. Those variables 
for which an association was observed for any one of the four mammographic variables (p-
value > 0.10) are highlighted in bold in Table 7.9 below. 
Table 7.9: Univariable analysis of the association between potential influencing factors and the outcome variables dense area 
(cm2) (sqrt), percent density (%), total breast area (cm 2) (log) and non-dense area (cm 2) (log). 
Variable Dense Area (sqrt) 
• Coefficient 
(95% CI) 
P-
value 
% Density (sqrt) 
Coefficient 
(95% CI) 
P-
value 
Total Breast Area 
(log) 
Coefficient 
(95% CI) 
P-
value 
Non-dense Area 
(log) 
Coefficient 
(95% CI) 
P-
value 
Age -0.08 (-0.12 to -0.04) 0.001 -0.10 (-0.14 to -0.05) <0.001 0.01 (-0.003 to 0.02) 0.171 0.03 (0.01 to 0.04) 0.002 
Menopause' -0.62 (-1.09 to -0.15) 0.009 -0.77 (-1.27 to -0.26) . 0.003 0.08 (-0.03 to 0.20) 0.159 0.21 (0.64 to 0.38) - 0.018- 
Menopause -1.22 (-1.90 to -0.54) <0.001 -1138 (-2.11 to -0.65) 0.10 (-0.07 to 0.27) 0.233 6.31 (0.65 to 0.57) - 0-.618- 
<0.001 _ 
Age at 
menarche 
0.17 (0.04 to 0.31) 0.012 0.37 (0.23 to 0.52) <0.001 -0.10 (-0.13 to -0.06) <0.001 -0.15 (-0.20 to -0.10) <0.001 
BMI -0.10 (-0.14 to -0.06) <0.001 -0.21 (-0.25 to -0.17) <0.001 0.06 (-0.05 to 0.06) <0.001 0.09 (0.08 to 0.10) <0.001 
Height - 0.01 (-0.03 to -0.06) 0.579 0.03-(-0.01 to 0.09) 0.164 -0.01 (-0.02 to 0.002) 0.123 -0.02-(-0.04 to -0.001) 0.040 
Weight-- -0.03 (-0.04 to -0.02) <0.001 -0.07 (-0.08 to -0.05) • <0.001 0.02 (0.02 to 0.02) - <0.001 0.03 (0.02 to 0.03) < 0.001 
Ever used -0:63 (-1.19 to -0.07) 0.028 -0.63 (-1.24 to -0.02) 0.042 -0.04 (-0.18 to 0.10) 0.562 0.08 (-0.13 to 0.29) 0.435 
HRT 
Benign breast 0.56 (0.04 to 1.08) 	• 0.036 0.43 (-0.14 to 0.99). 0.141 0.02 (-0.10 to 0.15) •0.709 -0.05 (-0.25 to 0.14) 0.603 
• 
• 
• • • 
disease • • • 
Variable Dense Area (sqrt) 
Coefficient 
' 	(95% Cl) 
P-
value 
% Density (sqrt) 
Coefficient 
(95% Cl) 
P-
value 
Total Breast Area 
(log) 
Coefficient 
(95% CI) 
value 
Non-dense Area 
(log) 
Coefficient 
(95% CI) 
value 
Ovarian cysts 
Endometriosis 
Ever smoked 
Currently 
smoke 
Alcohol 
(never/rarely) 
-0.34 (-0.87 to 0.19) 
0.71 (0.13 to 1.29) 
0.13 (-0.28 to 0.55) 
-0.89 (1-1.54 to -0.24) 
-0.56 (-1.13 to 0.01) 
0.210 
0.017 
0.521 
0.007 
0.054 
-0.72 (-1.3 to -0.15) 
0.51 (-0.12 to 1.1-4-) 
0.02 (-0.43 to 0.47) 
-1.08 (-1.78 to -0.38) 
-0.72 (-1.34 to -1.09) 
0.013 
0.113 
- 0.931 
0.003 
0.021 
0.18 (0.05 to 0.30) 
0.001 (-0.14 to 0.14) 
0.05 (-0.05 to 0.15) 
0.14 (-0.02 to 0.30) 
0.09 ( -0.05 to 0.23) 
0.006 
0.988 
0.309 
0.086 
0.221 
0.29 (0.10 to 0.48) 
-0.04 (-0.26 to 0.17) 
0.05 (-0.11 to 0.20) 
0.31 ( 0.07 to 0.55) 
0.19 -(-0.02 to 0.40) 
0.004 
0.686 
0.555 -- 
0.012 
0.080 
* Definition of postmenopausal: last period? 52wks, and if HRT started before last period and current age was >55 years. 
f Definition of postmenopausal: Same as above but women who had not had a period for >52 weeks because of hysterectomy (while retaining one or both 
ovaries), endometrial ablation, IUD, or hormone implants, they were considered to be premenopausal unless they were >55 years of age 
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The univariable analyses demonstrated a number of associations with one or more of 
the mammographic outcome variables. The following variables were inversely and 
significantly associated with dense area: age, menopause" 2 , weight, BMI, HRT (ever used) 
and smoking (current). In contrast, age at menarche, diagnosis of benign breast disease or 
endometriosis, and alcohol use were positively associated with dense area. Since dense area 
is strongly associated with age, this variable was added to the regression. All of these 
associations remained after adjustment for current age except for menopause l and ever use of 
HRT. 
Similar associations were observed for p. ercent mammographic density as was 
observed for dense area, apart from diagnosis of benign breast disease or endometriosis 
which wee not significantly associated with percent density. Ever been diagnosed with an 
ovarian cyst was significantly and inversely associated with Percent density. All of these 
associations remained after adjustment for current age, except for menopause and ever use 
of HRT. 
Total breast area was negatively and significantly associated with age at menarche, 
and positively associated with BMI, weight and having been diagnosed with an ovarian cyst. 
These associations remained after adjustment for current age. 
Non-dense area was positively and significantly associated with age, menopause l ' 2 , 
BMI, weight, smoking (current) and ever been diagnosed with having had an ovarian cyst. It 
was negatively associated with age at menarche and height. The association with 
menopause 1.2 and height did not remain after adjustment for current age. 
Variables that were not significantly associated with any one of the four 
mammographic outcome variables included: number of livebirths, age at first livebirth, 
breastfeeding, current use of HRT, ever or currently using hormonal contraceptives, fertility 
drug use (ever), and first degree family member with breast cancer (See Table 7.10). 
Table 7.10: Univariable analysis of the association between potential influential variables and the outcome variables dense area 
(C111 2) (sqrt), percent density ("/0) (sqrt), total breast area (cm 2  ) (log) and non-dense area (cm 2) (log). 
Variable Dense Area (sqrt) 
Coefficient 
(95% CI) 
P- 
value 
% Density (sqrt) 
Coefficient 
(95% CI) 
P- 
value 
Total Breast Area 
(log) 
Coefficient 
(95% CI) 
P- 
value 
Non-dense Area 
(log) 
Coefficient 
(95% CI) 
value 
Livebirths 
-0.09 (-0.27 to 0.09) 0.324 -0.09 (-0.30 to 0.10) 0.323 -0.01 (-0.04 to 0.05) 0.828 0.03 (-0.04 to 0.09) 0.462 
Age at first 
livebirth 0.04 (-0.01 to 0.09) 0.110 0.03 (-0.02, to 0.09) 0.266 0.0003 (-0.01 to 0.01) 0.966 -0.002 (-0.02 to 0.02) 0.780 
Breastfeeding 
(total weeks) 0.001 (-0.002 to -0.004) 0.689 0.001 (-0.002 to 0.004) 0.622 -0.0001 (-0.001 to 0.001) 0.767 -0.0002 (-0.001 to 0.001) 0.722 
HRT Current 
-0.30 (-1.0 to 0.42) 0.416 -0.15 (-0.93 to 0.62) 0.694 -0.08 (-0.26 to 0.09) 0.349 -0.05 (-0.31 to 0.22) 0.736 
OC use 
current -0.02 (-0.63 to 0.59) 0.954 -0.12 (-0.78 to 0.54) 0.718 0.04(0:11 to 0.19) 0.594 0.09 (-0.14 to 0.31) 0.451 
OC use 
ever 0.47 (-0.70 to 1.65) 0.428 0.56 (-0.71 to 1.83) 0.383 -0.04 (-0.32 to 0.25) 0.789 -0.07 (-0.51 to 0.37) 0.758 
Fertility drug 
(ever used) -0.03 (-0.56 to 0.49) 0.898 -0.12 (-0.69 to 0.54) 0.664 0.02 (-0.11 to 0.14) 0.812 0.06 (-0.14 to 0.25) 0.565 
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7.3.6 Box-plots of mammographic measures 
Box-plots are illustrated in Figures 7.7 and 7.8 below. The mammographic outcome 
measures are on the y-axis and the covariate of interest on the x-axis of each plot. The Box-
plots represent the median (mid-line in coloured boxes) the top and bottom of the box 
represents the 25 th and 75 th percentiles. Since these plots represent the median, untransformed 
outcome data was used. 
Menopausal status and BMI are examined in these Box-plots for illustrative 
purposes. A range of other variables were also examined but are not included. Dense area and 
percent density appear to be lower in older and postmenopausal women (Figure 7.7), 
consistent with the findings of the univariable analyses in Table 7.9 above. The opposite can 
be seen for total breast area and non-dense area (Figure 7.8). Median total breast area and 
median non-dense area appears to be greater in older and postmenopausal women. However, 
the plots suggest that menopause has a more dramatic effect in women before 50 years of age 
compared to women older than 50. It could be that the effect of age reduced baseline dense 
area or percent density for premenopausal women after 50 compared to <50 years, and 
consequently reduced the potential for further reduction with menopause (or increase for non-
dense and total breast areas). The potential for interaction between age and menopause on 
each of the mammographic parameters is examined later. Similar box plots are presented for 
the alternative definition of menopause in Appendix 16. 
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Figure 7.7: Box-plots of dense area and percent density by menopausal status 
and age category (<50 years, >50years) for treated and untreated combined. 
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Figure 7.8: Total breast area (cm2) and non-dense area (cm 2) by menopausal status and 
age category (<50 years, ?50years) for treated and untreated combined. 
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BMI is negatively associated with dense area and percent density, and positively 
associated with total breast area and non-dense area.  This is confirmed by the direction of the 
univariable regression estimates presented above in Table 7.9 and the box-plots in Figures 
7.9 to 7.12 below. 
Figure 7.9: Box-plot of dense area (cm 2) and BMI kg/m 2 for treated and 
untreated combined. 
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Figure 7.10: Box-plot of percent density (/0) and BMI kg/m 2 for treated and 
untreated combined. 
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Figure 7.11: Box-plot of total breast area (log) and BMI kg/m 2 for treated and 
untreated combined. 
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Figure 7.12: Box-plot of non-dense area (log) and BMI kg/m2 for treated and 
untreated women combined. 
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7.3.7 Multivariable analysis 
Potential anthropometric, reproductive, hormonal and lifestyle determinants described in 
Tables 7.1 to 7.5 [e.g. menopausal status, HRT use (ever, current, years in total), number of 
livebirths, age at first livebirth, age at menarche, family history of breast cancer, smoking and 
alcohol use, hormonal contiaceptive use, and fertility hormone use], were included in the 
regression model for treatment effect on dense area, percent density, non-dense area and total 
breast area, one at a time. They were only retained if the magnitude of the coefficient for 
treatment changed by more than 10% with their addition to the model. If they did not fulfill 
this criterion, they were excluded from the analysis. The results of this analysis are presented 
for each of the mammographic measures separately below. 
7.3.7.1 Multivariable analysis: dense area 
Table 7.11 presents the regression . coefficients for the treatment effect on absolute breast 
density (cm2) (sqrt), adjusted for age and BMI. Additional covariates (listed in Tables 7.1 to 
7.5) were added to the regression model one at a time to observe their effect on the 
coefficient of the treatment variable. Only age and BMI were found to significantly influence 
the treatment effect. 
The results tabulated in Table 7.11 suggest that dense area is lower in treated women 
than untreated women. 
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Table 7.11: Regression coefficients of univariable and multivariable analysis of 
the association -between treatment status (treated, untreated) and dense area 
(cm 2) (square root transformed) (N=309). 
Regression coefficients (SE) 
Treatment -0.45 (0.21) -0.30 (0.21) -0.45 (0.21) 
Age -0.07 (0.21) -0.06 (0.02) 
BMI -0.10 (0.02) 
P-value for Tx p = 0.032 p = 0.163 p = 0.032 
95% Cl -0.87 to -0.04 -0.72 to 0.12 -0.86 to -0.04 
After the additional adjustment for endometriosis and benign breast disease, the 
association between treatment and dense area was strengthened [regression coefficient -0.54 
(95%0: -0.95 to -0.12; p=0.009)]. 
The adjusted coefficients. were used to calculate least square means to aid in their 
interpretation. Treated women had lower adjusted mean dense area than untreated women. 
Mean dense area adjusted for age and BMI was 24.5 cm 2 (95% Cl: 21.9 to 27.2) in treated 
Women and 29.1 cm2 (95% CI: 26.0 to 32.4) in untreated women. The difference, which 
equates to a mean difference of 4.6 cm 2 dense breast tissue was statistically significant 
(p=0.032). 
Postestimation diagnostics: dense area 
A number of diagnostic tests were performed on the regression model to verify that it 
fulfilled the assumptions of linearity and normality, and to identify and examine highly 
influential data points. The assumptions of linearity, and normality were found to be fulfilled. 
No influential points were found to significantly change the results if removed from the 
analysis (See Appendix 17). 
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Sensitivity analysis 
Twenty-one of the images (13 treated, 8 untreated) were derived from digital images. 
Removing these values from the regression had little effect on the regression coefficient, 
changing it from —0.45 to —0.42 (see Table 7.12). The p-value moved to borderline statistical 
significance which is expected from the smaller sample size. Additional adjustment for 
covariates livebirths and current use of HRT increased the association to —0.47 (p=0.030). 
Table 7.12: Regression coefficient (multivariable) for treatment effect on dense 
area (sqrt) with and without digital images and breast cancer cases. 
Coefficient (SE) 95% CI P-value 
i Full sample regression 
(n=309)* 
Regression w/o dig 
films (n=288)* 
Regression w/o dig 
films (n=288)t 
Regression w/o breast 
cancer cases (n=305) 
• 
—0.45 (0.21) 
—0.42 (0.22) 
—0.47 (0.22) 
—0.44 .(0.21) 
—0.86 to —0.04 
—0.84 to —0.004 
—0.90 to —0.05 
—0.84 to —0.03 
0.032 
0.052 
0.030 
0.034 
* Adjusted for age and BMI 
f Adjusted for age, BMI, number of livebirths and HRT (current use) 
Women with a history of breast cancer may have been more likely to participate in 
the study, or depending on the stage of their illness, less likely. More treated than untreated 
participants had a history of breast cancer. It is possible that these cases may have inflated the 
difference in dense area observed between treated and untreated women. Removing 
participants who had a history of breast cancer did not have any meaningful effect on the 
regression coefficients (see Table 7.12 above). 
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Self-referrals to the study: addressing a potential bias 
As an additional measure, women who self-referred themselves to the study were removed 
from the analysis. Restricting the analysis did not significantly alter the results for dense area 
(coefficient —0.49 (95% CI: —0.95 to —0.02), p=0.041 (n=253). 
Repeat measurement and analysis 
To give added confidence to the positive findings for the inverse association between 
treatment for high-dose estrogens and dense area, the films were prepared and re-masked and 
breast density measurements undertaken by a second reader. This repeat analysis using a 
second reader's measurements of breast density also produced a statistically significant 
difference in dense area in treated compared with untreated women; (age and BMI adjusted 
regression coefficient —0.51; 95% CI: —1.02 to —0.0; p=0.048). Pearson coefficient of 0.90 for 
dense area and 0.92 for percent density. 
Treatment type: dense area 
Two forms of treatment were used, diethylstilbestrol (DES), and ethinyl estradiol (EE). The 
following two tables contain the regression coefficients for treatment type (DES vs no 
treatment, EE vs no treatment) on dense area . (sqrt). Table 7.13 contains the results for the 
adjusted and unadjusted analysis. 
Table 7.13: Unadjusted and adjusted regression coefficients of dense area (cm 2) 
(sqrt) by treatment type: diethylstilbestrol (DES) and ethinyl estradiol (EE). 
Treatment Unadjusted P-value Adjusted t P-value 
type*t coefficient (95% CI) coefficient (95% CI) 
DES —0.64 (-1.13 to —0.15) p=0.010 —0.44(-1.01 to 0.08) 0.11 
.EE —0.27 (-0.82 to 0.28) p=0.33 —0.53 (-1.06 to —0.01) 0.054 
* Univariable categorical variable, 1=no treatment, 2=DES, 3=EE; 13 missing plus 2 who 
. used both treatment types were not included in the analysis. 
t Adjusted for age, BMI. 
Chapter 7: The long-term effect of high-dose estrogen exposure in adolescent girls on manunographie density 
	
226 
The results in Table 7.13 suggest that ethinyl estradiol (EE) has a slightly larger 
negative coefficient than that for DES after adjustment for age and BMI. One possibility is 
that an interaction is acting between age and treatment type, as only two participants aged 50 
years and older used EE (See Table 7.14). Women under 50 years of age (n=224) had a 
- higher mean dense area (32.3 crn 2 , SD 21.1) than women 50 years or older (n=85) (23.9 cm2 , 
SD 16.0). 
Table 7.14: Number and percentage of women aged before and after 50 years by 
treatment type. 
No treatment 	DES 	EE 	Unknown 	Total 
Age <50 years 116(51.8%) 36(16.1%) 60(26.8%) 12(5:4%) 224 
Age ?'50 years 26 (30.6%) 54 (63.5%) 2 (2.4%) 3 (3.5%) 85 
Interaction effects were examined between age (before and after 50 years) and 
treatment type, as treated women over 50 were more likely to have been treated with DES 
(n=54, 91.5%) than EE (n=2). No significant interaction was observed (p=0.32). 
• 	Examining the difference in treatment type by menopausal status is difficult because 
of low numbers (10 postmenopausal women treated with EE). Testing for interaction between 
treatment type (no treatment, DES and EE) with menopausal status, resulted in a p-value for 
interaction >0.10, when treatment type was examined within the treated group only. There 
was no difference in square root dense area between DES and EE treated women (p=0.6) 
adjusted for age and BMI. 
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Treatment duration and effectiveness: dense area 
The observed treatment effect on breast density might be modified by the duration of 
treatment or the effectiveness of treatment on final height reduction. Associations between 
dense area and duration of treatment and estimated mature height minus final height were 
eXamined within the treated group. Regression coefficients are presented in Table 7.15 and 
suggest a negative but statistically insignificant association• between dense area and 
increasing duration of treatment. No significant association was observed between dense area 
and EMH minus final height, suggesting the effectiveness of treatment on height was not 
related to any treatment effect on the breast. 
Table 7.15: Regression coefficients for duration of treatment on dense area (cm 2) 
(sqrt) in treated women after adjustment for age and BMI. 
Coefficient (SE) (95% CI) 	P-value 
• 
Duration of treatment (years) —0.14 (0.21) (-0.55 to 0.28) 0.51 111 
EMH minus final height (cm) 0.05 (0.06) (-0.06 to 0.17) 0.38 114 
* Adjusted for age and BMI 
Age at start of treatment: dense area 
It is possible the treatment* effect on breast density is related to the timing of start of 
treatment. The association between dense area and age at start of treatment was examined 
within the treated group. Square root transformed dense area was positively associated with 
age at start of treatment: regression coefficient 0.12 (95% CI: —0.04 to . 0.28) (p=0.154) 
though this association was not statistically. significant. See lowess smoothed plot of dense 
area (y-axis) and age at start of treatment (x-axis) in Figure.7.13. 
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Figure 7.13: Smoothed lowess plot of dense area (cm 2) (sqrt) and age at start of 
treatment (years). 
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• This eff'ect did not change with adjustment for age, but disappeared after further 
adjustment for current BMI: coeff —0.02 (95% CI: —0.18 to 0.15) (p=0.85). These findings 
suggest a greater net dense area in those girls who started treatment later, or who 
matured later. 
Treatment timing on dense area: pubertal staging 
The observed treatment effect on breast density might be modified by the timing of treatment 
in relation to the stage of pubertal development at start of treatment. Associations between 
dense area and Tanner Stage of breast development add menarche at start of treatment were 
examined within the treated group. Dense area was greater if girls were treated after Tanner 
Stage 2 (breast) (age and BMI adjusted regression coefficient 0.26 (95% CI: —0.63 to 1.16) 
but this difference was not statistically significant (p=0.56). 
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There was no meaningful difference in dense area between women who were treated 
before menarche (median 25.2 cm2) compared with women treated after menarche (26.4 
cm2); age and BMI adjusted regression coefficient: 0.06 (95% Cl: —0.46 to 0.58) (p=0.83). 
Dense area may be reduced as a result of a reduction in the total breast area, as this is 
observed later (though this reduction in total breast area is not significant). Adjusting for total 
breast area does not alter the treatment effect on dense area: regression coefficient —0.42 (SE 
0.20) (95% Cl: —0.82 to —0.01) (p=0.043). 
Breast related side effects during treatment and dense area 
Seventy-five women experienced breast related side effects (e.g. galactorrhoea, breast pain, 
dry and cracked nipples) (n=75) during treatment as an adolescent girl. There was no 
difference in dense area (sqrt) in treated women who experienced breast related side effects 
during treatment compared with treated women who did not (age and BMI adjusted 
regression coefficient 0.05 (SE 0.27) (95% CI: —0.48 to 0.57) (p=0.87). 
Twelve treated women experienced breast pain as a side effect during treatment as an 
adolescent girl. These girls had a higher dense area (sqrt) compared to women who did not 
experience breast pain during treatment (age and BMI adjusted regression coefficient 0.58 
(SE 0.51) (95% CI: —0.42 to 1.59) but this difference was not significant (p=0.26). 
7.3.7.2 Multivariable analysis: percent mammo graphic density 
Table 7.16 presents the adjusted regression coefficients for the treatment effect on percent 
mammographic density (%) (sqrt). Additional covariates (listed in Tables 7.1 to 7.5) were 
added to the regression model one at a time to observe their effect on the coefficient of the 
treatment variable. Only age, BMI and number of livebirths were found to influence the 
"treatment effect. The coefficients tabulated in Table 7.16 suggest that percent density is 
lower in treated women than untreated women though this difference is not statistically 
significant. 
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Table 7.16: Regression coefficients of unadjusted and adjusted analysis of the 
association between treatment status (treated, untreated) and percent 
mammographic density CYO (square root transformed) (N=309). 
Regression coefficient (SE) 
Treatment —0.17 (0.23) —0.06 (0.23) —0.25 (0.19) —0.28 (0.20) 
Age (years) — —0.10 (0.02) 408 (0.02) —0.08 (0.02) . 
BMI (kg/m2) — —0.21 (0.02) —0.21 (0.02) 
Livebirths — —0.10 (0.08) 
P-value for Tx 0.47 0.81 0.20 0.159 
95% Cl —0.62 to 0.28 —0.40 to 0.51 —0.63 to 0.13 —0.66 to 0.11 
The adjusted coefficients were used to calculate least square means to aid in their 
interpretation. Women who had been treated with high-dose estrogens to reduce their adult 
height had less percent density than untreated women. Mean percent density adjusted for age, 
BMI and number of livebirths was 24.8% (95% Cl: 22.4 to 27.4) for treated women, and 
27.7% (95% Cl: 24.8 to 30.7) for untreated women. This equates to a difference of 2.9% 
mammographic density between treated and untreated women. The difference, however, was 
not statistically significant. This study lacks the power to detect a significant difference of 
this size (see Section 7.2.2 in Methods). 
Postestimation diagnostics: percent density 
Post estimation diagnostics and sensitivity analysis was performed as for dense area and the 
assumptions of linearity, and normality were found to be fulfilled. No influential points were 
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found to significantly change the results. Removing digital images from the analysis did not 
affect the results. 
Treatment type: percent density 
Table 7.17 provides a summary of the results for the univariable and multivariable adjusted 
analysis. It appears that ethinyl estradiol has a slightly larger negative coefficient for percent 
mammographic density than that for DES, after adjustment for age, BMI and number of 
livebirths. 
Table 7.17: Unadjusted and adjusted regression coefficients of percent 
mammographic density percent (sqrt) by treatment type: diethylstilbestrol 
(DES) and ethinyl estradiol (EE). 
Unadjusted 	 Adjustedt 
Treatment type* coefficient (95% CI) P-value coefficient (95% CI) P-value 
DES 	—0.45 (-0.97 to . 0.07) 0.09 	—0.28 (-0.78 to 0.22) 	0.27 
EE 	0.07 (-0.82 to 0.28) 0.80 	—0.40 (-0.90 to 0.10) 	0.11 
* Univariable categorical variable, 1=no treatment, 2=DES, 3=EE. 
t Adjusted for age, BMI, number of livebirths 
Treatment duration and effectiveness: percent density 
The associations between percent mammographic density and duration of treatment and 
estimated mature height (EMH) minus final height were examined within the treated group. 
Regression coefficients are presented in Table 7.18 and suggest a negative but statistically 
insignificant association between percent density and increasing duration of treatment. No 
significant association was observed between percent density and EMH minus final height. 
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Table 7.18: Adjusted* regression coefficients of associations between percent 
density (°/0) (sqrt) and a) duration of treatment and b) estimated mature height 
(EMH) minus final height (cm). 
Coefficient (SE) (95% CI) 	P-value 
Duration of treatment (years) —0.10 (0.22) (-0.53 to 0.33) 0.64 111 
EMH minus final height (cm) 0.04 (0.06) (-0.08 to 0.16) 0.52 114 
* Adjusted for age, BMI and number of livebirths 
Age at start of treatment: percent density 
The association between percent density and age at start of treatment was examined within 
the treated group. Square root transformed percent density was positively and significantly 
associated with age at start of treatment (Figure 7.14 and Table 7.19). This effect did not 
change with adjustment for age or livebirths but disappeared after adjusting for current BM1. 
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Figure 7.14: Smoothed regression and lowess curves for percent density CYO 
(sqrt) (y-axis) and the age at beginning of treatment (years) in treated women. 
 
Percent 
density 
(log) 
 
Table 7.19: Unadjusted and adjusted regression coefficients of the outcome 
variable percent density (%) (sqrt) and the independent variable: age at start of 
treatment (years). 
Age at start of treatment (years) 
	
Coefficient (SE) (95% CI) 	P-value 
Unadjusted 	 0.31 (0.061) (0.13 to 0.49) 	0.001 
Adjusted * 0.07 (0.09) (-0.10 to 0.24) 0.41 
* Adjusted for age, BMI, number of livebirths (n=167) 
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Treatment timing on percent density: pubertal staging 
Associations between percent density and Tanner Stage of breast development and menarche 
at start of treatment were examined within the treated group. Square root percent density was 
less in girls treated after Tanner Stage 2 (breast) (age, BMI and number of livebirths adjusted 
regression coefficient —0.19 (95% CI: —1.14 to 0.76) compared to those who were treated 
before this stage, however, this effect was not statistically significant (p=0.69). The direction 
of the association between percent density and Tanner Stage at start of treatment opposed that 
observed with dense area. Similarly, there was no meaningful difference in mean percent 
density between women treated before and after menarche; age, BMI and number of 
livehirths adjusted regression coefficient: —0.02 (95% CI: —0.56 to 0.51) (p=0.92). 
7.3.7.3 Multivariable analysis: non -dense area 
Table 7.20 presents the adjusted regression coefficients for the treatment effect on non-dense 
area (cm2) (log). Additional covariates (listed in Tables 7.1 to 7.5) were added to the 
regression model one at a time to observe their effect on the coefficient of the treatment 
variable. Only age, BMI and number of livebirths were found to significantly influence the 
treatment effect. The coefficients tabulated in Table 7.20, suggest that non-dense area is 
slightly but insignificantly greater in treated women compared with untreated women. 
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Table 7.20: Univariable and multivariable regression coefficients of the 
association between treatment and log non-dense area (cm 2). 
Variables Regression coefficients (SE) 
Treatment -0.08 (0.08) -0.14 (0.08) 0.01 (0.06) 0.02 (0.06) 
Age 0.03 (0.01) 0.02 (0.01) 0.02 (0.01) 
BMI * -25.3 (1.64) -25.5 (1.66) 
0=0.00 
1=- 0.07 Livebirths t 2= - 0.01 
>3= 0.04 
P-value for Tx 0.32 0.07 0.90 0.78 
95% CI -0.23 to 0.08 -0.30 to 0.01 -0.14 to 0.10 -0.10 to 0.14 
BMI is square root inverse transformed 
t Categorical variable: livebirths 0=0, 1=1, 2=2 3>=3 
The adjusted coefficients were used to calculate least square means to aid in their 
interpretation. Mean non-dense area adjusted for age, BMI and number of livebirths was 71.7 
cm 2 (95% CI: 66.2 to 77.7) in treated women, and 70.5 cm 2 (95% CI: 64.7 to 76.9) in 
untreated women. On average, treated women had 1.2 cm 2 greater non-dense area, adjusted 
for age, BMI and livebirths, compared with Untreated women, though this difference was not 
statistically significant (p=0.78). 
Postestimation diagnostics: non-dense area 
Post estimation diagnostics and sensitivity analysis was performed as for dense area and 
percent density. No influential points were found to significantly change the results. 
Removing digital images from the analysis did not affect the results. While the assumptions 
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of linearity and normality were found to be fulfilled for the independent variables age and 
livebirths, this was not the case for BMI. While BMI and non-dense area are positively 
correlated, the relationship is curvilinear (the gradient is reduced at the larger end of the BMI 
scale). For BMI adjusted analyses, where the response variable is non-dense area, an inverse 
square root transformation of BMI was carried out to meet the assumptions of linearity. This 
transformation was determined using a fractional polynomial technique 461  . To illustrate this 
association, component plus residual plots for BMI are presented in Appendix 18. 
Treatment type 
Table 7.21 contains the results for the unadjusted and adjusted analysis for treatment type 
(DES vs no treatment, EE vs no treatment) on non-dense area (log). 
Table 7.21: Unadjusted and adjusted regression coefficients of non-dense area (cm 2) 
(log) by treatment type: diethylstilbestrol (DES) and ethinyl estradiol (EE). 
Treatment type* Unadjusted 
coefficient (95% CI) 
P- 
value 
Adjusted t 
coefficient (95% CI) 
P-value 
DES 
EE 
—0.002 (-0.18 to 0.18) 
—0.13 (-0.33 to 0.07) 
0.98 
0.22 
—0.03 (-0.18 to 0.13) 
0.09 (-0.07 to 0.24) 
0.74 
0.27 
* Categorical variable, 1=no treatment, 2=DES, 3=EE. 
t Adjusted for age, BMI, number of livebirths 
It appears that ethinyl estradiol has a slightly larger positive coefficient for non-dense area 
than that for DES, though this is only marginal. 
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Treatment duration and effectiveness: non-dense area 
Regression coefficients are presented in Table 7.22 for duration of treatment and treatment 
effectiveness (EMH minus final height), and suggest no association between duration of 
treatment or treatment effectiveness with non-dense area (log). 
Table 7.22: Adjusted regression coefficients of associations between non-dense 
area (cm 2) (log) and a) duration of treatment and b) estimated mature height 
(EMH) minus final height (cm). 
Coefficient (95% CI) 	P-value 	N 
Duration of treatment (years)* —0.01 (-0.14 to 0.13) 0.91 111 
EMH minus final height (cm)* —0.002 (-0.04 to 0.04) 0.93 114 
* Adjusted for age, BMI and number of livebirths 
Age at start of treatment: non-dense area 
Log transformed non-dense area was significantly and negatively associated with age at start 
of treatment (regression coefficient —0.14 (95% CI: —0.20 to —0.08) (p<0.001) (See Figure 
7.15). This association was diminished when adjusted for BMI: —0.05 (95% CI: —0.10 to 
0.01) (p=0.16). 
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Figure 7.15: Smoothed regression and lowess curves for non-dense area (log) (y-
axis) and the age at beginning of treatment (years) in treated women. 
Non-dense 
area (log) 
(cm2) 
Age at start of treatment (years) 
• 
Treatment timing on non-dense area: pubertal staging 
Women who started treatment at Tanner Stage 5 have a greater non-dense area than those 
who began treatment at Stages 1 or 2: regression coefficient 0.31 (95% CI: —0.05 to 0.66) 
(p=0.09). This effect is heightened when adjusted for age at start of treatment: 0.57 (95% CI: 
0.16 to 0.97) (p=0.01).Women who started treatment before menarche (n=81) have a slightly 
lower mean non-dense area 82.0 cm 2 (SD 51.9), compared to those who started treatment 
following menarche 92.6 cm2 (SD 67.5) (n=85) but this difference is not significant (p=0.71). 
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7.3.7.4 Multivariable analysis:• total breast area 
Table 7.23 presents the adjusted regression coefficients for the treatment effect on total 
breast area (cm 2 ) (log). Additional covariates (listed in Tables 7.1 to 7.5) were added to the 
regression model one at a time to observe their effect on the coefficient of the treatment 
variable. Only age and BMI were found to significantly influence the treatment effect. The 
coefficients tabulated in Table 7.23, suggest that total breast area is smaller in treated women 
compared with untreated women but this difference does not remain after adjustment for 
BMI. 
Table 7.23: Unadjusted and adjusted regression coefficients for treatment effect 
on total breast area (cm 2) (log transformed). 
Regression coefficients (SE) 
Treatment —0.09 (0.05) —0.12 (0.05) —0.03 (0.04) 
Age .0.01 (0.01) 0.01 (0.004) 
BMI 0.06 (0.003) 
P-value for treatment 0.07 0.03 0.41 	. 
95% Cl —0.19 to 0.01 —0.22 to —0.01 —0.11 to 0.05 
The coefficients for treatment effect on total breast area in the age and BMI adjusted 
regression equation presented above were used to calculate least square means to aid in their 
interpretation. Mean total breast area adjusted for age and BMI was 105.6 cm 2 (95% CI: 
100.1 to 111.4) in treated women, and 109.3 cm 2 (95% CI: 103.1 to 115.8) in untreated 
women. The least square means of total breast area adjusted for age and BMI suggest a 
difference of just under 4 cm2 between treated and untreated women. This is small in breast 
terms, and the confidence intervals overlap suggesting a small but insignificant difference 
between the groups. 
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Postestimation diagnostics: total breast area 
Post estimation diagnostics were performed and the assumptions of linearity, and normality 
were found to be fulfilled. The removal of influential observations as identified by Cooks D 
(n=9), digital images (n=21) or breast cancer cases did not significantly alter the coefficients. 
These diagnostics provide added confidence to the regression findings. 
Treatment type 
Table 7.24 contains the unadjusted and adjusted analysis for treatment type (DES vs no 
treatment, EE vs no treatment) on total breast area (log). 
Table 7.24: Unadjusted and adjusted regression coefficients of total breast area 
(cm2) (log) by treatment type: diethylstilbestrol (DES) and ethinyl estradiol 
(EE). 
Treatment Univariable P- Multivariable t P- 
type* coefficient (SE) (95% value coefficient (SE) (95% value 
CI) CI) 
DES — 0.07 (-0.19 to 0.05) 0.24 —0.04 (-0.15 to 0.06) 0.44 
EE 0.11 (-0.24 to 0.03) 0.12 —0.01 (-0.12 to 0.09) 0.85 
* Univariable categorical variable, 1=no treatment, 2=DES, 3=EE. 
t Adjusted for age, BMI 
' There appears to be no difference between the two types of treatment on total breast area. 
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Duration and effectiveness of treatment: total breast area 
Regression coefficients are presented in Table 7.25 for duratiqn of treatment and treatment 
effectiveness (EMH minus final height) with total breast area, and suggest no association 
between either variable with total breast area. 
Table 7.25: Adjusted regression coefficients of associations between total breast 
area (cm 2) (log) and a) duration of treatment and b) estimated mature height 
(EMH) minus final height (cm). 
Coefficient (SE) (95% CI) • 
	
P-value 
Duration of treatment (years)* —0.03 (0.04) (-0.12 to 0.05) 0.46 111 
EMH minus final height (cm)* 0.003 (0.01) (-0.02 to 0.03) 0.81 114 
*Adjusted for age and 13MI 
Aqe at start of treatment: total breast area 
Log transformed total breast area was.significantly and negatively associated with age at start. 
of treatment (regression coefficient —0.09(95% CI: —0.13 to —0.05) (p<0.001) (Figure 7.16). 
This effect was reduced when adjusted for BMI: coefficient —0.03 (95% Cl: —0.06 to 0.01) 
(p=0.16). 
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Figure 7.16: Smoothed regression and lowess curves for total breast area (log) 
(y-axis) and the age at beginning of treatment (years) (x-axis) in treated women. 
Age at start of treatment (years) 
Treatment timing on total breast area: pubertal staging 
Women who started treatment at Tanner Stage 5 had a greater total breast area than those 
who began treatment at Stages 1 or 2 when adjusted for age and BMI regression coefficient 
0.12 (95% CI: 0.004 to 0.47) (p=0.05). This effect could be due to an earlier age at start of 
treatment. When adjusting for this, the size of the effect was increased (regression 
coefficient: 0.42 (95% CI: 0.15 to 0.69) (p=0.003).. This suggests that those women who 
started treatment later in development had greater total breast area than those who started 
early in breast development. 
Total breast area is similar whether women started treatment before or after menarche 
age and BMI adjusted regression coefficient: 0.01 (95% CI:-0.10 to 0.13); age, BMI and age 
at start of treatment adjusted: —0.004 (95% CI: —0.12 to Oil) 
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7.3.7.5 Summary of multivariable analyses for all outcome measures 
For comparative purposes, a summary table of the final multivariable models for treatment 
effect on dense area, -percent density, non-dense area and total breast area is provided below 
(Table 7.26). As outlined above, age and BMI were retained for dense area and total breast 
area, and age, BMI and number of livebirths for percent mammographic density and non-
dense area. Use of the alternative definition of menopausal status (see methods Section 
7.2.6.1) resulted in 23 (13.8%) treated women and eight (5.6%) untreated being classified as 
postmenopausal. This alternative definition did not change the results for dense area, percent 
density, non-dense area or total breast area. 
Table 7.26: Multiple linear regression of the association between treatment and 
each of the mammographic measures adjusted for different sets of covariates*. 
Mammographic measure and covaiiates Regression 
coefficient 
95% CI 
value 
Dense area t 
Age, BMI —0.45 —0.86 to 70.04 0.032 _ 
PMD t 
Age, BMI, live births —0.28 —0.67 to 0.11 0.16 
Total breast area 
_ Age, BMI —0.03 —0.11 to 0.05 0.41 	, 
Non-dense area 
Age, BMI, live births 0.02 —0.10 to 0.14 0.78 
* Age (years),.BMI (kg/m2), HRT (current), menopause (postmenopausal if last 
period >52 weeks, and if HRT started before last period and >55 years) 
t Square root transformed; $Log transformed 
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A summary table of adjusted regression . coefficients for the effect of high-dose 
estrogen treatment on square root dense area, square root percent density, log total breast area 
and log non-dense area is presented below (Table 7.27). 
Table 7.27: Adjusted least square means of total breast area (cm 2), non-dense 
area (cm 2), percent density (')/0) and dense area (cm 2) for treated and untreated 
women. 
• Treated 
mean (95% CI) • 
Untreated 
mean (95% CI) 
Total breast area (cm 2)* 105.6 (100.1 to 111.4) 109.3 (103.1 to 115.8) 
Non-dense area (cm 2) t 71.7 (66.2 to 77.7) 70.5 (64.7 to 76.9) 
Percent mammographic 
density (%) t 
24.8 (22.4 to 27.4) 27.7 (24.8 to 30.7) 
Dense area (cm 2)* 24.5 (21.8 to 27.2) 29.1 (26 :0 to 32.4) 
* Adjusted for age, BMI. 
t Adjusted for age, BMI and number of livebirths. 
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7.4 Discussion 
This is the first study to examine the long-term effects of high-dose estrogen exposure in 
adolescence on mammographic density. This study found that treated women had a 
significantly lower mean dense area than women who were also assessed for tall stature but 
untreated. Treated women had less mean total breast area and percent density, and slightly 
greater mean adjusted non-dense area compared with untreated women but these differences 
were not statistically significant. 
Hormone replacement therapy is known to increase mammographic density 343 yet 
this study found women treated with high-dose estrogens (plus a cyclic progestagen) in 
adolescence had reduced mammographic density as an adult, compared with untreated 
women. However, these results are plausible. Puberty in girls treated with,high-dose estrogen 
is accelerated. Treatment induces menarche earlier, and closes the epiphyses of the long 
bones, as typically occurs at the end of puberty. Given that dense area for age tracks through 
adulthood462, the lower mean adult dense area observed for treated women suggests less net 
growth in dense area during puberty, consistent with accelerated maturation. This is also 
consistent with the many cross-sectional observations that earlier age at menarche is 
associated with reduced adult mammographic density407-409, 463. 464 . 
There are a number of biological mechanisms that might explain the observed effect 
on mammographic density in this study. High-dose estrogens may have a direct inhibitory 
effect on the developing breast, in particular the epithelial and stromal tissue that makes up 
the dense part of the breast. This effect may be mediated by reduced levels of insulin-like 
growth factor (IGF-I) observed in treated girls during treatment 1011 91 . While, IGF-I has been 
positively associated with mammographic density 465-467 , no studies have examined the 
association between IGF-I levels during adolescence and mammographic density as an adult. 
Kleinberg and co-authors have highlighted the importance of IGF-I in ductal morphogenesis 
during pubertal mammary development in IGF-I insufficient animals 468 . 
This relationship between dose of estrogen and IGF-I response is dependent on age 
and dose. Rooman and colleagues l° reviewed a number of studies on estrogen and subsequent 
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effects on IGF-I levels and observed that in children and adolescents, low doses of estrogen 
(up to 0.030 mg) increase serum IGF-I while higher doses (higher than 0.100 mg) decrease 
IGF-I levels. In adults, this biphasic effect is not as evident. Both low-dose estrogens (e.g. 
oral contraceptives or HRT) and high-dose estrogens as observed in human volunteers, in the 
treatment of acromegaly or male to female trans-sexuals, decrease IGF-I levels I° . 
Unfortunately, plasma IGF-I levels were not collected from the women in this study 
at time of treatment, therefore there is no capacity to examine the possibility that the 
reduction in dense area might be mediated by a reduction in IGF-I. 
Another potential mechanism for the effect of high-dose estrogen in adolescence on 
mammographic density as an adult is the suppression of ovarian function, suggested by the 
published reports of a reduction FSH and LH levels in treated girls (See Chapter 2, Section 
2.4.2.3). GnRH agonists have been shown to reduce mammographic density 469 (See Section 
6.4.1.2 of Chapter 6). One possibility is that the reduction in ovarian function that occurs with 
high-dose estrogen treatment in adolescence, contributes to the overall reduction in dense 
area observed in treated women in this study. 
Some case-series reports of the outcomes of treatment for tall stature have noted 
some girls' concerns about a lack of breast development 4t23 . This may explain some or all of 
the reduction in dense area observed in the treated women of this cohort. As percent density 
was reduced, it appears that at least some of the reduction in dense area was independent of 
total breast area. Adjusting for total breast area, did not reduce the treatment estimate on 
dense area. 
Dense area and percent mammographic density were negatively associated with 
duration of treatment, though these associations were not statistically significant, possibly 
due to the smaller sample size after restricting the analysis to individuals with medical record 
data for this parameter. 
In this study, a positive association was observed between age at start of treatment 
and dense area. It is possible that girls treated at an earlier age matured earlier (the majority 
• Chapter 7: The long-term effect or high-dose estrmlemexposure in adolescent girls on mammographic density 	 247 
of girls were treated on or after Tanner Stage 3 of the breast). The positive association' 
between dense area and age at start of treatment was removed once adjusted for BMI, 
supporting the early maturity effect. That is, if girls started treatment later, they are likely to 
have matured later also. They• had more time for mammographic density development 
consistent with the • established positive association between age at menarche and 
302, 328, 359, 407, 409, 444 mammographic density" 	 described above. Adjustment with BMI removed 
the effect observed between dense area and age at start of treatment possibly because adult 
BMI is associated with timing of pubertal maturity. Adult BMI is highly correlated with BMI 
during adolescence 470 ' 471 , and it is reported that high BMI in adolescence is correlated with 
early age at menarche4 70, 471. As well, adult BMI has been inversely associated with age at 
rnenarche472 , an indicator of early sexual maturity. Correspondingly, non-dense area and total 
breast area were both significantly and negatively associated with age at start of treatment. 
This association also diminished when adjusted for BMI. 
A positive association was observed between total breast area and Tanner Stage of 
breast development at start of treatment. Women who started treatment at Tanner Stage 5 had 
a greater total breast area than those who began treatment at stages 1 or 2 when adjusted for 
age and BMI. This effect could be due to an earlier age at start of treatment. When adjusting 
for this, the size of the effect was strengthened. A similar finding was observed for non-dense 
area. These findings suggest that those women who started treatment later in development 
had greater total breast area (and non-dense area) than those who started at the early stage of 
breast development. It would be expected then, that treated women would have a lower mean 
total breast area than untreated women. A lower mean total breast area was observed in 
untreated women compared to treated women (adjusted for age), but this effect was no longer 
statistically significant after further adjustment for BMI. These findings are consistent with 
those described in Chapter 5. This chapter reported no difference in the proportion of treated 
and untreated women whose breasts did not increase in size during pregnancy (a symptom of 
breast hypoplasia). Also, the findings reported here in relation to total breast area, do not 
support the anecdotal reports that treatment caused flat-chestedness in girls, at least in the 
longer term. 
Findings from the first follow-up of Tall Girls'', have shown large variability in the 
effectiveness of treatment in reducing adult height, with a mean difference between the 
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estimated mature height (EMH) and final height in the treated group of-2.5 cm (95% CI: — 
3.2 to 1.8). Clinical effectiveness of estrogen treatment on final height reduction (EMH—final 
height) did not appear to be associated with any of the mammographic parameters, 
suggesting that any treatment induced change in the mammographic parameters occurred 
independently of the effect of treatment on epiphyseal closure and hence height reduction. 
While dosage of estrogen was standard across the cohort, the girls' plasma levels 
might have varied. Brody et al. (1989 )473 , observed extreme inter and intra-variability in 
plasma levels following doses of 35 lig ethinyl estradiol (compared to the 150 1.tg typically 
given to treated tall girls in this cohort). Maximum plasma levels ranged between 55-311 
pg/ml in different individuals (n=24). Intra-individual variability when provided in three 
consecutive monthly doses at the same time of cycle, had a coefficient of variation of 41% or 
range of —79% to +134% around. the mean of the per individual 473 . According to 
Goldzieher474 , the "...range of inter and intra-individual variability [in plasma levels] have 
important clinical implications. This accounts for the well-established observation that the 
same dose may produce overdosage effects (e.g. nausea) in one person and underdosage 
effects (e.g. breakthrough bleeding) in another. It also points out that efforts at fine-tuning 
dosage to minimise adverse effects of either variety are not going to succeed except "on the 
average" Goldzieher argued that this variability is not due to differences in the absorption and 
excretion components of pharmacokinetics but rather, through differences in metabolism. 
This might explain why some girls developed side effects with treatment while others 
did not. Seventy-five treated women in this cohort experienced breast related side effects 
during treatment as an adolescent girl (e.g. galactorrhoea, dry and cracked nipples and breast 
pain). Of. interest is the obsdvation made by two studies that breast pain with HRT use is 
associated with an increase in mammographic density. In a prospective study of HRT users, 
McNicolas et al. 243 observed that seven of nine women (78%) who had experienced an 
increase in mammographic density after commencing HRT, had also experienced moderate 
or severe breast pain. In contrast, only five of 24 (21%) of those who did not experience an 
increase in mammographic density experienced moderate or mild breast pain. No women 
belonging to a control group of non-HRT users (n=31) reported breast pain during the same 
follow-up period. 
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Crandall et al. 2006 241 , observed a similar association in a subset of the PEPI RCT 
cohort. Women who experienced the onset of breast discomfort within a 12 month period 
following HRT comniencement, had a 3.9% increase (age and multivariable adjusted) in 
mean percent mammographic density following HRT use, compared with an 0.6% increase in 
women who did not experience breast discomfort (p<0.001). 
It is possible that an increase in breast pain during treatment coincided with an 
increase in mammographic density. In this study, the 12 treated women who experienced 
breast pain as a side effect had a higher dense area (sqrt) compared to women who did not 
experience breast pain during treatment but this difference was not significant (p=0.26) and 
the numbers were too small to be confident with this finding. Including women in the sample 
who experienced any breast related side effect during treatment would increase the sample 
size to 75. It is possible that this group had higher plasma levels of estrogen compared with 
treated girls who did not experience breast related side effects. There was no difference in 
dense area (sqrt) in treated women who experienced any breast related side effect during 
treatment (e.g. galactorrhoea, breast pain or dry and cracked nipples) compared with treated. 
women who did not. 
The mean levels of each of the mammographic density parameters in this study are 
similar to those reported by Boyd et al. (2002) 392 for women of a similar mean age (44.8 
years). Boyd et al. reported mean values for each of the mammographic measures using a 
similar computer assisted thresholding technique to measure density. Mean percent density in 
their study was 28.5% and dense area 30.2 cm 2, non-dense 101.43 cm 2 , and total breast area 
131.63 cm 2 . In comparison the mean age of women in this PhD study was 48.4 years. Mean 
percent density was 29.5% for treated and 30.8% for untreated, dense area was 27.6 cm 2 for 
treated and 32.8 cm 2 for untreated, while non-dense area was 87.0 cm 2 and 91.1 cm 2 total 
breast area was 114 cm2 for treated and 123 cm 2 for untreated women. 
Dense area and total breast area in this study were adjusted for age and BMI, while 
percent mammographic density and non-dense area were adjusted for age, BMI and number 
of livebirtlis as they were found to warrant inclusion in the regression equations for treatment 
effect on these parameters. Age has previously been reported to be a strong predictor of dense 
area407, 475, 476, percent density 305, 306, 325, 327, 328, 359, 407, 409, 413, 440-443, and non-dense area407 ' 476. 
Chapter 7: The long-term effect of high-dose estrogen exposure in adolescent girls on rnammographic density 
	
250 	• 
5 BMI has been strongly associated with percent densi ty305, 325, 328, 359, 360, 407, 409, 413, 442, 444 non- 
dense area407, 408, 476, 477 and total breast area477 and to a greater475 or lesser408 ' 477 extent, dense 
area. Number of livebirths has also been previously associated with percent densi ty305, 306, 328, 
359, 360, 407, 409, 413, 440-444 and non-dense area407, 408, 476. Age at menarche was not found to 
contribute to the estimates for any of the mammographic measures. Age at menarche in 
treated girls is not an accurate measure for treated girls who started treatment before natural 
menarche. In these girls, treatment induced menstruation. 
HRT use, both current and past use, was greater in treated women. It is also 
associated with mammographic density as reviewed extensively earlier in Chapter 6 (Section 
6.4.1.1) however, despite HRT use being a potential confounder, it did not have any effect 
when included in the regression for treatment on either of the mammographic measures. This 
is not all that unexpected. It has not always been found to be an important predictor of 
mammographic density. According to Ursin and Pike 478 , although mammographic density can 
be increased by hormone therapy exposure, the effects of these exposures are only —5% (See 
Table 6.3 in Chapter 6), "the contribution of hormonal exposure in determining the variation 
in the distribution of mammographic density at any point in time is therefore quite small". 
To interpret the findings it helps to consider the potential mechanism for any 
covariates included in the regression equation. A decision will need to be made .as to the 
effect of adjustment of variables that may share risk factors with the outcome of interest as 
well as be affected by the exposure variable. As stated by Wilcox (2006) 479 , investigators 
should "Never adjust for covariates just because they are handy, Epidemiologists cannot 
depend on adjustments (or stratifications of any sort) to bring results closer to the truth" p 
1,123. Before adjusting for a variable, it is important to consider its role in the causal 
pathway. 
Age and BMI were included in the final regression models for treatment effect on 
dense area, percent density, non-dense area and total breast area. Number of livebirths was 
included in the regression model for percent density and non-dense area. Age possibly acted 
as a confounder because it was negatively associated with dense area, percent density and 
non-dense area as demonstrated by the univariable analysis and reports elsewhere, and was 
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assocjated with treatment status (treated women were on average older than the untreated 
women). This difference in mean age between treated and untreated women was possibly 
because fewer tall girls accepted treatment in later years. 
BMI was associated with each of the mammographic outcome measures and differed 
between the groups. It was possibly associated with the offer of treatment for tall stature. 
Untreated girls might have reached maturity earlier than treated girls, leaving them with little 
growth potential to warrant treatment at time of assessment. As stated above, early maturity 
(puberty) is associated with higher BMI in adolescence and adolescent BMI has been shown 
be highly correlated to adult BMI. 
Number of livebirths might have acted as an effect mediator. It have been previously 
reported to be influenced by treatment 25 and has been found to have an inverse relationship 
with mammographic density. Adjusting for livebirths did not influence the association 
observed between treatment and dense area. Similarly, benign breast disease and 
endometriosis might have acted as effect mediators. However, adjusting for these variables 
strengthened the association between treatment and mammographic dense area. 
There are a number of limitations of the study that need to be considered. Firstly, 
there is the possibility that selective participation may have introduced bias. Women are 
generally not aware of the degree to which their breasts are dense, and are therefore unlikely 
to select themselves on the basis of this knowledge. However, women with breast problems 
may have been more receptive to the invitation to participate in the study. Participants were 
no more likely to have had a breast biopsy at time of the original study than non-participants. 
A history of biopsies for benign breast disease has been associated with an increase in percent 
mammographic density 390 480 . While more treated than untreated women in this study 
reported a previous diagnosis of benign breast disease, any selection bias in this regard would 
have led to an underestimation of the effect of treatment on mammographic density. 
Adjusting for a history of benign breast disease, amplified rather than attenuated the estimate 
for treatment effect on dense area. 
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The findings could be prone to selection bias due to differential non-response in the 
original follow-up of the Tall Girls Study cohort since 28% of treated and 44% of untreated 
women did not agree to participate. However, we are interested in associations not prevalence 
estimates, so non-response would only be a problem if it were systematically associated with 
both the predictor and outcome variables of interest. There is no obvious plausible reason 
why women in the treated and untreated groups in the earlier cohort, from which this study 
sample was derived, would vary in their willingness to participate in ways that were 
differentially related to mammographic density. Earlier findings on impaired fertility were 
largely unaffected by non-response and the inclusion or exclusion of self-referred women 25 . 
A sensitivity analysis was performed by removing women who self-referred to this 
mammographic study from the dataset. This made no difference to the results. 
Women are not generally aware of the degree to which their breasts are dense, and 
are therefore unlikely to select themselves on the basis of this knowledge. However, it is 
possible that women lost to the study, or not participating to the study had breast cancer, and 
therefore had higher levels of mammographic density. Removing all participants who had a 
history of breast cancer from the analysis (more treated than untreated) did not affect the 
results. 
The observed effect of adolescent exposure to high-dose estrogens on dense area 
cannot be generalised to all exogenous estrogen exposures that might occur during 
adolescence (e.g. diet or the environment). Estrogen has a biphasic effect on some tissues' 
exerting a different action at low concentrations than at high concentrations. For example, at 
low plasma concentrations endogenous estrogen is believed to stimulate the growth spurt at 
the start of puberty, while at higher concentrations, at the end of puberty, endogenous 
estrogen plays a role in the cessation of growth. It may follow therefore, that lower 
exogenous estrogen exposures during adolescence may have a different effect on 
mammographic density than that observed with the high estrogen exposures in this study. 
Receptor mediated responses do not always follow linear one-way dose-responses that are 
often assumed with hormonal exposures. Welshons and colleagues 48/ have argued that studies 
should not extrapolate lower dose effects linearly from high-doses or assume the dose-
response relationships are monotonic. Receptor-mediated responses do saturate at some 
point, and can .increase then decrease as the dose increases 481 . 
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The oral contraceptive pill contains ethinyl estradiol in much smaller doses than 
those used in the treatment of tall stature in our study. Overall evidence suggests that oral 
contraceptive use at a younger age (before 20 years) is associated with a greater risk of breast 
cancer than use at a later age 178-18° . Whether early use of oral contraceptives also equates to a 
corresponding increase in mammographic density is unknown. One study found no 
association between oral contraceptive use as a young adult and percent mammographic 
density later in life 360 . 
The exploration of the association between estrogen treatment in adolescence 
and mammographic density as an adult involved multiple comparisons. The 
association between mammographic density and different forms of treatment (e.g. 
DES, EE, and both combined) were explored as was different measures of 
mammographic density (percent density and dense area) with treatment. Since one in 
twenty comparisons is expected to be statistically significant at the 5% level by 
chance alone (Kirkwood and Sterne, 2002), it is expected that the greater the number 
of comparisons, the greater the number of potential statistically significant results by 
chance alone. Some researchers attempt to address this problem by adjusting for 
multiple comparisons. This approach was not adopted in this study. Rothman argues 
that adjustments for multiple comparisons should not be performed. He purports that 
each association should be considered 'on its own for the information it conveys'. In 
addition, adjustment for multiple comparisons, while attempting to reduce the chance 
of type I error, can increase the frequency of incorrect rejections of the null 
hypothesis (type II error) (Rothman, 1990). Consistent with Rothman's view, this 
thesis reports the results for all multiple comparisons, thus allowing the reader to 
quantify the number of tests and make their own adjustments for multiple testing". 
p258 Second last paragraph of discussion (Section 7.4). 
The difference in dense area between treated and untreated women might be due to 
differences in pre-treatment characteristics. Childhood growth parameters (e.g. birthweight, 
birthlength, and growth-velocity) have been associated with mammographic density and 
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differences in these factors might account for the differences observed in dense area between 
• treated and untreated women. If these parameters were independently associated with 
treatment status and mammographic density, this might explain the observed association 
(dotted line) between treatment and mammographic density. If this was indeed the 
mechanism then further adjustment for these parameters would reduce the association 
between treatment status and mammographic density. The next chapter explores a number of 
pre-treatment growth parameters and their influence on the treatment effect on 
mammographic density. 
Chapter 7: The long-term effect of high-dose estrogen exposure in adolescent girls on manimographie density 
	 255 
7.5 Conclusion 
This study found treated women to have a significantly lower mean dense area than women 
who were also assessed for tall stature but untreated. Treated women had less mean total 
breast area and percent density, and slightly greater mean adjusted non-dense area compared 
with untreated women but these differences were not statistically significant. These findings 
are reassuring for treated women, however, the difference in dense area between treated and 
untreated women might be due to differences in pre-treatment characteristics. This possibility 
is explored further in Chapter 8. 
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Box 7.1: Summary of key chapter findings 
KEY FINDINGS: CHAPTER 7 
• Treated women had a significantly lower mean mammographic dense area 
than women who were also assessed for tall stature but untreated. 
• Treated women had less mean adjusted total breast area and percent 
density, and slightly greater mean adjusted non-dense area compared with 
untreated women but these differences were not statistically significant. 
• Dense area was not associated with duration of treatment. 
• A positive association was observed between age at start of treatment and 
dense area. Since early maturity corresponds with earlier age at start of 
treatment, this suggests that dense area is higher in women who matured 
later, consistent with the observation elsewhere that mammographic density 
is positively associated with age at menarche. 
• A positive association was observed between total breast area and Tanner 
Stage of breast development at start of treatment, after adjustment for age 
and BMI. This effect remained after adjustment for age at start of treatment. 
A similar finding was observed for non-dense area. These findings suggest 
that those women who started treatment later in development had greater 
total breast area (and non-dense area) than those who started at the early 
stage of breast development. 
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8: CHILDHOOD AND ADOLESCENT GROWTH PARAMETERS, AND 
MAMMOGRAPHIC DENSITY IN TREATED AND UNTREATED WOMEN 
8.0 Introduction 
Chapter 7 has shown that women treated for tall stature in adolescence have less dense area 
than untreated women. Treated women might differ from untreated women in some pre-
treatment growth parameters associated with mammographic density (e.g. birthweight, birth-
length, growth velocity, or childhood height). From previous reports it is known that 
untreated girls generally have less growth potential at time of assessment than treated girls, 
reflected by a greater level of pubertal maturity and more advanced bone age when compared 
to their chronological age 77. If any of these variables are associated with mammographic 
density and they differ between treated and untreated women, they might explain the 
differences in mammographic density observed between treated and untreated women. 
Chapter 6 summarised studies that examined associations between a number of 
childhood anthropometric variables and mammographic density. A number of these were 
found to be positively associated with mammographic density as an adult (birthweight 431 , 
childhood height419, weight419, 426 and, height velocity 406s. ) In contrast, the studies by 
McCormack et al. (2003)496, Sellers et al. (2007)419 and Samini et al. (2008)426 each observed 
an inverse association between childhood BMI or weight and mammographic density as 
adult. As mentioned in Chapter 6, a more detailed review of these and other associations is in 
Appendix 8. 
Pre-treatment growth related variables (e.g. bone age, birthweight) could be potential 
confounders if they are associated with the exposure of interest (treatment) and independently 
associated with the outcome of interest (mammographic densi ty)482. In the scenario illustrated 
in Figure 8.1 below, treatment and mammographic density might be statistically associated 
because they have a common cause (pre-exposure variables), even if the causal pathway 
signified by a dotted arrow does not exist. Any analysis of the association between treatment 
and mammographic density should adjust for these factors if possible. 
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Figure 8.1: Directed acyclic graph illustrating confounding of the association between 
treatment and mammographic density by pre-exposure variables. 
Treatment   	Mammographic Density 
/'• 
Pre-exposure variables 
Caution is needed when interpreting the effect of these added variables on the 
association between treatment and mammographic density. If, for example, pre-exposure 
factors are only linked along the causal pathway to treatment (bold arrows; Figure 8.2) but 
not the outcome of interest (dotted arrow, Figure 8.2) then adjusting for the pre-exposure 
variable might reduce or remove the visible association between treatment and 
mammographic density. If this was to occur, it might appear that the pre-exposure variable 
was confounding the obsenied association when in fact it was not. For it to be considered a 
confounder, it is important that the pre-exposure variable has an independent association with 
mammographic density if its addition to the regression alters the association in any way. 
Figure 8.2: Directed acyclic graph illustrating a non-confounding scenario of the 
association between treatment and mammographic density. 
On the other hand, post-treatment variables such as weight and BMI change and age 
when maximum height was attained following treatment might explain the association 
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between treatment and mammographic density observed in the previous chapter. That is, 
treatment might not act directly on mammographic density; instead it might act indirectly 
through any changes on these growth parameters. If this is so, these variables would be 
mediators. 
The Tall Girls Study collected a number of growth related variables from the medical 
records of study participants. This rich data-set provided the opportunity to explore the 
independent effects of a number of childhood growth variables on mammographic density. In 
follow-up '2, additional variables were also extracted from the medical records of the 
participants who had previously provided their consent to extract information from the 
records (e.g. birthweight and birth-length). 
This chapter reports on the association between a number of childhood 
anthropometric variables and mammographic density at follow-up and the effect of some of 
these variables on the observed association between treatment and mammographic density. 
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8.1 Study Aim 
There are two main aims to this chapter: 
1. To examine the degree to which a number of pre-treatment growth parameters 
sueh as birthweight, birthlength, childhood height, BMI, and bone age might influence the 
association observed between treatment and mammographic density. 
2. To examine the association between a number of adolescent anthropometric 
measures that might have been influenced by treatment (e.g. BMI change, age at which 
maximum height was attained) on each of the mammographic measures for treated women 
only. 
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8.2 Method 
Childhood anthropometric data were collected from the medical records of participants who 
provided their written consent. Bone age and height, weight and BMI at first assessment were 
collected from the records at first follow-up, and birthweight, birth-length, and the variables 
derived from multiple height and weight data were collected from the records at second 
follow-up. Each variable is described in more detail in the following sections. 
8.2.1 Birthweight and birth -length data 
Birthweight and birth-length data were often, but not always, recorded in the medical records 
by the treating endocrinologist. Birthweight data were available for 184 participants (59.5%) 
(72 treated and 112 untreated). Birth-length data were available for 106 participants (34.3%) 
(48 treated and 68 untreated). 
The specificity of the data suggests that birthweight and birth-length were extracted 
from birth records of the child, however, it is likely that some parents did not present their 
child's birth records to the endocrinologist, and instead relied on memory to report 
birthweight and birth-length. The endocrinologist's records did not specify the source of the 
data. 
Data were recorded in stones and pounds or kilograms (kg). Stones and pounds were 
converted to kilograms. Birth-length data were recorded in feet and inches or centimetres 
(cm). Feet and inches were converted to centimeters. 
8.2.2 Bone age data 
Bone age was derived from wrist x-rays as described in detail in Chapter 2 (Section 2.3.1). If 
bone age was greater than a child's chronological age, then they were considered to have less 
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growth potential and td have greater skeletal maturity compared with a child of the same age, 
whose bone age is similar or less than their chronological age. 
Bone age was routinely recorded in the medical records by the treating 
endocrinologist. In this cohort, bone age measurements were available for 237 (76.7%) 
participants; treated n=109 (65.3%), untreated n=128 (90.1%). Age at which the wrist x-ray 
was taken (chronological age) was derived from the date of x-ray and date of birth. 
8.2.3 Height, weight and BMI at first assessment 
When the girl first presented to the endocrinologist, height and weight were recorded in the 
medical records. Height was recorded in feet and inches or centimetres. Weight was recorded 
in stone and inches or kilograms. Conversions were made as for birthweight and birth-length. 
BMI (kg/m2) at first assessment was derived from the weight and height data (height in 
centimetres was converted to metres). 
Height at first assessment was available for 239 participants (77.3%) or 111 treated 
and 128 untreated women while weight (and therefore BMI) at first assessment was available 
for 226 participants (73.1%); 104 treated, 122 untreated. Age at first assessment was derived 
from the date of visit and date of birth. 
8.2.4 Weight and BMI change one year following treatment 
Change in weight and BMI for each treated individual was calculated by subtracting the 
weight and BMI at commencement of treatment from the weight and BMI one year following 
commencement of treatment. Sufficient pre-treatment BMI data to calculate BMI velocity 
was not recorded in the medical records for treated 'and untreated women, but BMI changes 
following treatment was available for treated women. 
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8.2.5 Age at which maximum height was attained 
Maximum height was judged to be the woman's self reported current height as self reported 
in the CATI at second follow-up (see Methods section 7.2.6.1, Chapter 7). For many women, 
height measurements during adolescence stopped before maximum height was attained (61 of 
90 records available). For these women, age at, maximum height was judged to be greater 
than the age when measurements stopped, as verified by the final self-reported height. Age at 
maximum height was measured directly for the rest (n=29). 
A binary variable was prepared where '1' corresponds to maximum attained height if 
<15 years (n=12), and '2' if age at maximum attained height is >15 years (n=78). 
81.6 Growth after 15 years 
This measure was available for 82 treated individuals who had height measurements recorded 
in their medical records at or close to 15 years. Height was measured as close as possible to 
15 years (median=15.1, 5 th & 95 th percentiles: 14.8, 15.3). This medical record measure of 
height was subtracted from the participant's self-reported final height (current height). 
8.2.7 Statistical analysis 
Summary descriptive data on a number of childhood anthropometric characteristics of 
participants were undertaken beginning. with the raw means or proportions with significance 
tests for differences between treated and untreated women. This was then followed by an 
analysis of the univariable association between each of the anthropometric variables and the 
mammographic density measures: dense area, percent density, total breast area and non-dense 
area. For those variables that were available for treated and untreated participants (e.g. 
birthweight, birth-length, bone age; and height, weight and BMI at first assessment), the 
degree to which they influenced the association between treatment with high-dose estrogens 
and each of the mammographic density measures was examined. Some childhood 
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anthropometric variables were available for treated women only (height, weight and BMI 
change after treatment, height change after 15 years, age at maximum height attainment), and 
were examined within this group only. 
Significance tests of differences in characteristics between treated and untreated women were 
performed using the chi-square test for categorical data and t-test for continuous data. 
Univariable and thultivariable associations between the dependent mammographic measures 
and the independent variables were performed using linear regression. Stata 9 was used for 
all analyses. 
8.2.8 Ethics 
Ethics approval was sought from (the Tasmanian Health and Medical Human Research 
Ethics Committee, H0008334) for this study to access data previously collected at first 
follow-up and again to extract additional information from the medical records (birthweight 
and birth-length). See Appendix 19 for the ethics approvals. 
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8.3 Results 
8.3.1 Characteristics of study participants 
Summary descriptive data of childhood anthropometric characteristics for treated and 
untreated women are presented in this section, beginning with the raw means or proportions 
and significance tests for differences between treated and untreated women. 
8.3.1.1 Pre-treatment anthropometric characteristics of study participants 
A summary of childhood anthropometric characteristics of participants, by treatment status, is 
presented in Table 8.1. Treated women were similar in mean birthweight, birth-length, 
weight and BMI and age at first assessment, and age at bone measurement compared with 
untreated women. Treated women, on the other hand, were taller at first assessment after 
adjusting for age at measurement (p<0.001). Skeletal maturity also differed between the 
groups. The bone age of untreated girls tended to be more advanced than their chronological 
•age (borie age minus chronological age = 0.33 years (SD 0.85)) when measured at a mean 
chronological age of 12.1 years, whereas treated women tended to have less advanced bone 
age (bone age minus chronological age= —0.01 years (SD 0.85)), when measured at a mean 
chronological age of 12.3 years. This suggests earlier bone maturity, and hence less growth 
•. 
potential at a given age, in untreated girls. This is consistent with the decision not to provide 
treatment in these girls. 
Table 8.1: Anthropometric characteristics of treated and untreated participants. 
Characteristic Treated Treated 
Mean (range) 
Untreated Untreated 
Mean (range) 
P-value 
Birthweight (kg) 72 3.6 (2.6 to 5.4) 112 3.5 (2.2 to 5.0) 0.132 
Birth-length (cm) 48 53.2 (48.3 to 57.2) 58 52.9 (48.3 to 61) 0.525 
Bone age-chronological age (years) 109 -0.01 (-2.4 to 2.1) 128 0.33 (-1.6 to 3.1) 0.002 
_ 
Age bone age measurement (years) 109 12.3 (7.0 to 16.0) 128 12.1 (4.9 to 16.9) 0.561 
Age at first assessment (years) • 111 12.3 (7.0 to 16.0) 130 12.1 (5.0 to 16.9) 0.470 
Height at first assessment (years) 111 166.8 (125.1 to 183.2) 128 162.1 (120.2 to 184.2) <0.001 
Weight at first assessment (kg) 108 51.1 (26.5 to 79.5) 122 	' 49.3 (23.1 to 78.0) . 	0.352 
.. 
BMI at first assessment (kg/m 2) 108 18.2 (13.2 to 25.9) 122 18.5 (13.5 to 25.50) 0.168 
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8.3.1.2 Childhood anthropometric characteristics of treated women 
A number of childhood anthropometric characteristics are summarised in Table 8.2 for 
treated women only. These data were not available for untreated women. Weight changes in 
the first year following treatment were considerable for some girls (mean 7.1 kg). Most of the 
girls reached their maximum height after age 15 (87% compared with 13.3%). The average 
height change after age 15 years was 2.1 cm. This estimation includes girls who were treated 
before and after 15 years. Figure 8.3 depicts a scatter plot of the association between height 
change after 15 years and age at start of treatment. There appears to be no relationship 
between the two variables. 
Table 8.2: Childhood anthropometric characteristics of treated women. 
Characteristic 	 Treated Women 
Weight change first year of treatment (kg) 
Mean (range) 
BMI change first year of treatment (kg/m2) 
Mean (range) 
Age maximum height reached (n) (%) 
<15 years 
>15 years 
Height change after 15 years (cm) 
Mean (range) 
7.1 (-1.6 to 17.8) 
1.83 (-0.73 to 5.2) 
12 (13.3) 
78 (86.7) 
2.1(-0.4 to 5.8) 
Age at start 
of treatment 
(years) 
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Figure 8.3: Scatter plot of age at start of treatment and height change after age 15 
years. 
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8.3.2 Associations between childhood anthropometric variables and the 
mammographic density measures 
A univariable analysis of the association between each of the parameters described in Tables 
8.1 and 8.2 above and each of the mammographic density measures: dense area, percent 
density, total breast area and non-dense area was undertaken and a summary of the findings 
presented in Table 8.3. The associations for weight and BMI change following first year of 
treatment, age at maximum attained height and height change after 15 years are estimated for 
treated women only. This data were not available for untreated women. 
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Table 8.3: Univariable analysis of the association between pre-treatment anthropometric measures and the outcome variables dense area 
(cm2) (sqrt), percent density CYO, total breast area (cm2) (log), and non-dense area (cm 2) (log). 
Covariate 	 Dense area 	 Percent density 	 Non-Dense Area 	 Total Breast Area 
Regression coefficient 
(95% CI) 
P- 
value 
Regression 
coefficient 
(95% CI) 
P- 
value 
Regression 
coefficient 
(95% CI) 
P- 
value 
Regression 
coefficient 
(95% Cl) 
P- 
value 
Birthweight (kg) 0.44 (-0.10 to 0.98) 0.11 0.26 (-0.30 to 0.82) 0.36 0.02 (-0.17 to 0.21) 0.86 0.04 (-0.09 to 0.17) 0 . 52 
Birth-length 
(cm) 
-0.05 (-0.20 to 0.11) 0.56 -0.01 (-0.17 to 0.14) 0.89 -0.02 (-0.07 to 0.03) 0.56 	. -0.02 (-0.05 to 0.02) 0.42 
Bone age - 
. chronological -0.45 (-0.75 to -0.14) 0.005 -0.76 (-1.07 to -0.44) <0.001 0.27 (0.16 to 0.38) <0.001 0.16 (0.08 to 0.23) <0.001 
, age (years)* 
Height at first 
assessment 
(cm)* 
-0.05 (-0.09 to -0.01) 0.014 -0.08 (-0.12 to -0.03) <0.001 0.02 (0.01 to 0.04) 0.002 0.01 (0.002 to 0.02) 0.013 
1- Weight at first 
assessment (kg)* -0.03 (-0.06 to 0.001) 0.059 -0.08 (-0.11 to 0.05) <0.001 0.03 (0.02 to 0.04) <0.001 0.02 (0.02 to 0.03) <0.001 
- - 
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Covariate 	 Dense area 	 Percent density 	 Non-Dense Area 	 Total Breast Area 
Regression coefficient 
(95% CI) 
P- 
value 
Regression 
coefficient 
(95% CI) 
P- 
value 
Regression 
coefficient 
(95% CI) 
P- 
value 
Regression 
coefficient 
(95% Cl) 
value 
-0.07 (-0.18 to 0.03) 0.16 -0.24 (-0.34 to -0.13) <0.001 0.11 (0.07 to 0.14) <0.001 0.07 (0.05 to 0.10) <0.001 
0.04 (-0.07 to 0.14) 0.48 0.07 (-0.05 to 0.18) 0.25 70.02 (-0.06 to 0.01) 0.19 -0.01 (70.04 to 0.01) 0.38 
0.11 (-0.22.to 0.44) 0.51 0.19 (-0.17 to 0.55) 0.29 -0.07 (-0.19 to 0.05) 0.23 -0.03 (-0.11 to 0.05) 0.45 
0.49 (-0.59 to 1.57) 0.37 0.97 (-0.17 to 2.12) 0.097 -0.33 (-0.72 to 0.05) 0.091 -0.19 (-0.47 to 0.08) 0.16 
0.16 (-0.11 to 0.42) 0.25 0.20 (-0.09 to 0.49) 0.17 -0.06 (-0.16 to 0.04) 0.22 -0.03 (-0.10 to 0.04) 0.41 
BMI at first 
assessment 
(kg/m2)* 
Weight change 
first year of 
treatment (kg) t 
BMI change first 
year of 
treatment 
(kg/m2) t 
Age maximum 
height reached 
?_15 years t 
Height change 
after 15 years 
(cm) 
*At first assessment. Adjusted for age at measurement 
t Estimated for treated women only. . 
Chapter 8: Childhood and adolescent growth parameters. and mammographic density in treated and untreated women s 	271 
The anthropometric variables that were significantly associated with any one or more 
of the four mammographic outcome variables (see Table 8.3) included bone age minus 
chronological age; and height, weight and BMI at first assessment,. adjusted for age at 
measurement. Bone age minus chronological age and height at first assessment (adjusted for 
age at assessment) were negatively associated with dense and . percent density, and positively 
associated with non-dense and total breast areas. Weight and BMI at first assessment 
(adjusted for age at assessment) were negatively associated with percent density, and 
positively associated with non-dense and total breast areas. A weak negative association was 
observed between dense area and weight at first assessment (p=0.059). 
The association between height at first assessment with each of the mammographic 
measures remained after further adjustment for current height. In contrast, the associations 
between weight at first assessment (adjusted for age at measurement) and dense area, percent 
density and total breast area were no longer statistically significant after adjusting for current 
BMI (p-values 0.51, 0.10, and 0.06, respectively). The association with non-dense area 
remained (p=0.04). Similarly, the association between BMI at first clinic visit and dense area, 
percent density, total breast area and non-dense area were no longer statistically significant 
after adjusting for current BMI (p-values p=0.97, 0.35, 0.06, and 0.13 respectively). 
None of the other anthropometric variables summarised in Table 8.3 were 
significantly associated with the mammographic outcome variables, although birthweight and 
age when maximum height was attained appear to be potentially relevant covariates based on 
the size of the coefficients and the confidence intervals for some mammographic measures 
(e.g. dense area). 
8.3.3 The influence of anthropometric parameters on the association between 
treatment and mammographic density 
The childhood anthropometric variables available for treated and untreated women 
(birthweight, birth-length, bone age minus chronological age and height, weight and BMI at 
first assessment) were included in the model for treatment effect on dense area and each of 
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the other mammographic measures to assess the degree to which they might influence these 
associations. The following section describes these analyses separately for dense area, 
percent density, non-dense area, and total breast area. 
8.3.3.1 Dense area 
The following section describes the treatment coefficients for dense area (sqrt) adjusted for 
age and BMI for each of birthweight, birth-length, bone age minus chronological age and 
height, weight and BMI at first assessment. These analyses were performed in a restricted 
sample using only those for whom data for each of the anthropometric variables were 
available. The univariable analyses using restricted samples differ slightly from the larger 
sample analyses reported above in Table 8.3. The variables that remained in the final model 
in Chapter 7 were included in the regressions. 
Dense area and birthweight and birth-length 
In the restricted sample of 184 women for whom birthweight data were available, 
birthweight, when added to the regression (with age and BMI), enhanced the difference in 
dense area between treated and untreated women, from —0.50 (95%. CI: —1.07 to 0.07; 
p=0.09) to a coefficient of —0.57 (95% CI: —1.14 to —0.002; p=0.05). However, this was not 
the case for birth-length in the analysis of women for whom birth-length data were available 
(n=106). 
In the restricted sample of 106 women for whom birth-length were available, the age 
and BMI adjusted regression coefficient for treatment on dense area did not change [-0.85 
(95% CI: —1.62 to —0.09; p=0.03) to —0.84 (95% Cl: —1.61, —0.07; p=0.032)] with the 
addition of birth-length to the regression equation. 
Dense area and bone age 
The difference between bone age and chronological age is a measure of bone maturity. When 
adjusted for age at measurement (chronological age), bone age minus chronological age 
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increases the difference observed between treated and untreated in dense area as 
demonstrated by the larger negative coefficients. The age and BMI adjusted regression 
coefficient for treatment effect on dense area in the restricted sample for whom bone age data 
is available (n=237) changed from —0.40 (95% Cl: —0.88 to 0.08; p=0.10) to —0.52 (95% CI: 
—1.01 to —0.03; p=0.04) with the addition of bone age minus chronological age. 
Dense area and height at first assessment 
When adjusted for age at measurement (chronological age), height at first assessment reduced 
the difference observed between treated and untreated as demonstrated by the lower negative 
coefficients. In the restricted sample of 239 women, height at first assessment, when added to 
the regression along with age and BMI, reduced the difference in dense area between treated 
and untreated women, from —0.43 (95% CI: —0.92 to 0.05; p=0.080) to —0.33 (95% Cl: 
—0.85, 0.18; p=0.21). 
Dense area and weight at first assessment 
When adjusted for age at measurement (chronological age), weight at first assessment 
(adjusted for age at assessment) did not alter the difference in dense area between treated and 
untreated. The age and BMI adjusted regression coefficient for treatment on dense area 
changed from —0.49 (95% CI: —1.00 to 0.01; p=0.055) to —0.49 (95% CI: —1.00 to 0.02; 
p=0.059) with the addition of weight at first assessment to the regression equation (n=224). 
Dense area and BMI at first assessment 
When adjusted for age at measurement (chronological age), BMI at first assessment did not 
affect the difference observed between treated and women. The age and BMI adjusted 
regression coefficient for treatment on dense area changed from —0.49 (95% CI: —1.00 to 
0.01; p=0.055) to —0.50 (95% CI: —1.01 to 0.01; p=0.053) with the addition of BMI at first 
assessment to the regression equation (n=224). 
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Bone age, height at first assessment and birthweight 
When height at first assessment was added to the regression for treatment effect on dense 
area adjusted for age, BMI and bone age minus chronological age (n=234) (further adjusted 
for age at bone age measurement) the regression changed minimally from -0.52 (95% CI: - 
1.01 to -0.02; p=0.040) to -0.56(95% CI: -1.14 to 0.02; p=0.059). 
Adding birthweight to the equation (restricted to n=183 for whom birthweight data 
were available) containing age, BMI and bone age minus chronological age (adjusted for age 
at measurement) changed the treatment coefficient for dense area (sqrt) from —0.65 (95% CI: 
—1.22 to —0.07; p=0.028) to —0.70(95% CI: —1.27, —0.13; p=0.017). 
8.3.3.2 Percent density 
The following section describes the treatment coefficients for percent density (sqrt) adjusted 
for age, BMI and number of livebirths for each of birthweight, birth-length, bone age minus 
chronological age and height, weight and BMI at first assessment. These analyses were 
performed in a restricted sample using only those for whom data for each of the 
anthropometric variables were available. 
Percent density, birthweight and birth-length 
In the restricted sample of 184 women for whom birthweight data were available, 
birthweight, when added to the regression (along with age, BMI and number of livebirths), 
enhanced the difference in percent density between treated and untreated women, from —0.55 
(95% CI: —1.06 to —0.04) (p=0.034) to a coefficient of —0.62 (95% CI: —1.13 to —0.12; 
p=0.016). However, this was not the case foebirth-length in the analysis of women for whom 
birth-length data were available (n=106). The age, BMI and number of livebirths adjusted 
regression coefficient for treatment on percent density did not change [-0.79 (95% CI: —1.47 
to —0.11; p=0.024) to —0.79 (95% CI: —1.48, —0.11; p=0.024)] with the addition of birth-
length to the regression equation. 
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Percent density and bone age 
When adjusted for age at measurement (chronological age), bone age minus chronological 
age increased the difference observed between treated and untreated in percent density as 
demonstrated by the larger negative coefficients. The regression coefficient for treatment 
effect on percent density in the restricted sample (n=237) changes from —0.40 (95% CI: —0.84 
to 0.05; p=0.081) to —0.51(95% CI: —0.96 to —0.05; p=0.028). 
Percent density and height at first assessment 
In the restricted sample of 237 women, height at first assessment, when added to the 
regression, reduced the difference in age, BMI and number of livebirths adjusted percent 
density (sqrt) between treated and untreated women, from —0.41 (95% CI: —0.85 to 0.04; 
p=0.076) to —0.29 (-0.77, 0.19; p=.0.23). 
Percent density and weight at first assessment 
When adjusted for age at measurement (chronological age), weight at first assessment 
(adjusted for age at assessment) the difference in percent density between treated and 
untreated did not change. The age, BMI and livebirths adjusted regression coefficient for 
treatment on percent density changed from —0.45 (95% CI: —0.92 to 0.01; p=0.056) to —0.41 
(95% CI: —0.88 to 0.06; p=0.087 with the addition of weight at first assessment to the 
regression equation. 
Percent density and BM' at first assessment 
BMI at first assessment (adjusted for age at assessment) did not significantly affect the 
difference in percent density between treated' and untreated. The age, BMI and livebirths 
adjusted regression coefficient for treatment on percent density changed from —0.45 (95% CI: 
—0.92 to 0.01; p=0.056) to —0.46(95% CI: —0.93 to 0.004; p=0.052) with the addition of BMI 
at first assessment to the regression equation. 
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Bone age, height at first assessment and birthweight 
When height at first assessment was added to the regression for treatment effect on dense 
area adjusted for age, BMI and bone age minus chronological age (adjusted for age at 
measurement) (n=234), the regression coefficient did not change [-0.51 (95% CI: -0.97 to - 
0.05; p=0.028) to -0.51 (-1.05 to 0.03; p=0.062)]. 
Adding birthweight to the model for percent density (sqrt) adjusted for age, BMI, 
number of livebirths and bone age minus chronological age (adjusted for age at 
measurement) (restricted to n=183 for whom birthweight data were available) changed the 
treatment coefficient from —0.67 (95% CI: —1.18 to —0.16; p=0.011) to —0.73(95% CI: —1.23 
to —0.22; p=0.005). 
8.3.3.3 Non -dense area 
The following section describes the treatment coefficients for non-dense area (log) adjusted 
for age, BMI and number of livebirths for each of birthweight, birth-length, bone age minus 
chronological age and height, weight and BMI at first assessment. These analyses were 
performed in a restricted sample using only those for whom data for each of the 
anthropometric variables were available. 
Non-dense area and birthweight and birth-length 
In the restricted sample of 184 women for whom birthweight data were available, 
birthweight, when added to the regression, did not dramatically influence the regression 
coefficient for treatment on non-dense area; [changed from 0.12 (95% CI: —0.03 to 0.27; 
p=0.12) to 0.14 (0.08) (95% CI: —0.02 to —0.29; p=0.082)]. 
Similarly for birth-length (n=106) the age, BMI and livebirths adjusted regression 
• coefficient for treatment on non-dense area changed minimally from 0.15 (95% CI: —0.07 to 
0.37; p=0.18) to 0.16 (95% C1:-0.06 to —0.38; p=0.16) with the addition of birth-length to the 
regression equation. 
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Non-dense area and bone age 
When adjusted for age at measurement (chronological age), bone age minds chronological 
age did .not significantly influence the coefficient for treatment effect on non-dense area in 
the restricted sub-sample of participants for whom bone age data were available (n=237). The 
regression coefficient for treatment effect on non-dense area (adjusted for age, BMI and 
number of livebirths) in the restricted sample changed from 0.06 (95% CI: —0.08 to 0.19; 
p=0.42) to 0.08 (95% CI: —0.06 to 0.22; p=0.26). 
Non-dense area and height, weight and BMI at first assessment 
When adjusted for age at measurement (chronological age), height, weight and BMI at first 
assessment did not alter the regression coefficient for treatment on non-density in any 
meaningful way in the restricted samples of participants for whom data were available for 
each of these variables. 
8.3.3.4 Total breast area 
Restricted analysis within the samples for whom data were available for each of birthweight, 
birth-length, bone age; and height, weight and BMI at first assessment, did not affect the age 
and BMI adjusted regression coefficient for treatment once they were added to the regression. 
For instance, adding birthweight to the restricted sample of n=184 did not change the age and 
BMI adjusted coefficient for treatment on total breast area: from 0.05 (95% CI: —0.05 to 0.15; 
p=0.35) to 0.05 (95% CI: —0.05 to 0.16; p=0.31). This was similar for birth-length, from 0.03 
(95% CI: —0.11 to 0.17; p=0.65) to 0.03 (95% CI: —0.11 to 0.17; p=0.65); bone age from 0.02 
(95% CI: —0.08 to 0.11; p=0.75) to 0.02 (95% CI: —0.07 to 0.11; p=0.68), height at first 
assessment from 0.009 (95% CI: —0.08 to 0.10; p=0.85) to 0.0001(95% CI: —0.10 to 0.10; 
p=0.99). 
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8.4 Discussion 
This final chapter aimed to assess the degree to which a number of pre-treatment childhood 
anthropometric measures such as childhood height, BMI and bone age might influence the 
association observed between treatment and mammographic density that was reported in 
Chapter 7. The study also aimed to examine the association between a number of childhood 
anthropometric measures that might have been influenced by treatment (e.g. BMI change, age 
at which maximum height was attained) on each of the mammographic measures for treated 
women only. 
The pre-treatment variables were investigated because they were possible 
confounders in the association between mammographic dense area as an adult and treatment 
with high-dose estrogens in adolescent girls. If any of these anthropometric variables were 
independently associated with mammographic density and they were found to differ between 
treated and untreated women, they might change' the magnitude of the difference in the 
separate independent treatment effect on mammographic density in treated and untreated 
women. 
The post-treatment variables were investigated because they were possible mediators 
in the association between mammographic dense area as an adult and treatment with high-
dose estrogens in adolescent girls. These variables were investigated in treated women only. 
One of the reasons untreated girls were not treated with high-dose estrogens was that 
their bone age indicated insufficient growth potential to warrant treatment 25 . As expected, 
bone maturity at a given• chronological age was greater in untreated girls compared with 
treated girls. It is possible that this parameter confounded the association observed between 
mammographic density and treatment as they were significantly associated with both 
treatment and outcome as demonstrated by a univariable analysis. However, adjusting for 
bone age minus chronological age (further adjusted for age at measurement) increased the 
difference in square root dense area between treated and untreated women. A similar effect 
was observed with percent density, which reached significance. Bone age minus 
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chronological age (adjusted for age at measurement) acted as a negative confounder because 
adjusting for it resulted in a strengthening of the association between treatment with high-
dose estrogens and dense area, and percent density. 
No published studies have examined the association between bone age in 
adolescence and mammographic density. Bone age has been used as a surrogate marker of 
growth plate senescence483 . Girls whose bone age indicates little growth potential are also 
more advanced pubertally than those with a lower bone age at the same age or 
measurement484 . The results suggest a strong negative univariable association between bone 
age minus chronological age and dense area and percent density, and a positive association 
with non-dense area and total breast area. This translates to increasing mammographic 
density with lower skeletal maturity or a later age of puberty, consistent with the established 
finding that early age of menarche is associated with reduced mammographic density. If 
treated girls had less advanced bone maturity, as indicated by the difference in bone age 
minus chronological age between treated and untreated girls measured at a mean age of 12 
years, then it would be expected that they would have a higher mammographic density, 
independent of the effect of treatment. Adjusting for bone age minus chronological age would 
be expected to reduce this pre-treatment component to mammographic density. Since treated 
women had lower mean dense area compared with untreated women, this negative difference 
would be widened when adjusted for bone age minus chronological age; as observed. Added 
to this is the possibility that treatment accelerated puberty, resulting in less net growth of 
dense area. 
It is interesting to note that Luo et al.(2003) 485 found faster linear growth during 
infancy and childhood (up to.age 8) to be associated with earlier peak height velocity (PHV) 
during adolescence and less height gain between ages 8 and 18. This is consistent with a 
study by Biro et al. (2001)486 which could suggest that untreated children were taller at 
younger years, and therefore reached skeletal maturity and consequently pubertal maturity 
earlier (PHV occurs —12 months before menarche). 
The other anthropometric variables that were significantly associated with all of the 
mammographic measures (dense area, percent density, total breast area and non-dense area) 
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included childhood height, weight and BMI at first assessment; however the associations with 
the latter two did not remain after adjustment for current BMI. They also did not change the 
coefficient for treatment for each of the mammographic density measures when included in 
the full multivariable models. 
Height at first assessment, adjusted for age at measurement was negatively associated 
with dense area and percent density, and positively with total breast area and non-dense area. 
While statistically significant, the associations were small, and remained after adjustment for 
current height. The direction of the association is consistent with McCormack et al. (2003) 406 
who found height at 11 years in girls had a negative association with higher Wolfe grade 
density OR 0.89 (95% CI: 0.80 to 1.00; p=0.04) (n=1090). They interestingly, observed an 
opposing association for children 2 years of age when followed-up; adjusted OR 113 (95% 
Cl: 1.01 to 1.26; p=0.03) (n=1033). They found no significant association between height at 
ages 4, 7, or 15 years and Wolfe grade. In contrast, Sellers et al. (2007) 419 observed a positive 
association between height at.ages 7 (p<0.001), 12 (p<0.001),-and 18 years (p<0.001) with 
percent density (n=1893). In this PhD study, adjusting for height at first assessment (further 
adjusted for age at measurement) reduced the difference in square root dense area between 
treated and untreated women; however it had no effect when bone age minus chronological 
age remained in the model. A similar result occurred for percent density. 
While birthweight was not statistically significantly associated with any of the 
mammographic measures, the confidence intervals and p-values suggest a positive 
association with dense area and to a lesser extent, percent density. This is consistent with a 
study that also examined the association between birthweight and density measured using a 
computer assisted technique by Cerhan et al. (2005)431 . However, no association was 
observed in three studies using Wolfe grade as the measure of mammographic density360, 406, 
433 . Luo et al. (2003)485 in their longitudinal study found greater birthweight and length to be 
associated with later peak height velocity in adolescence. If later peak height velocity, and 
therefore menarche (peak height velocity occurs —1 year before menarche), was associated 
with higher mammographic density then it would be expected that greater birthweight and 
birth-length would also be positively associated with mammographic density. 
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. When birthweight was added to the regression equation along with age, BMI and 
bone age rriinus chronological age, the difference in dense area (sqrt) between treated and 
untreated women increased. A similar effect was observed with percent density (with 
additional adjustment of number of livebirths). Birth-length did not have any effect when 
added to the regression model. 
This chapter also aimed to examine the influence of anthropometric variables that 
might have been influenced by treatment e.g. (age at maximum height, and weight change 
following treatment). It is possible that changes to these' variables following treatment 
mediate the reduced mammographic density observed in treated women compared with 
untreated women in Chapter 7, age at maximum height or growth beyond 15 years, were not 
associated with any of the mammographic measures for treated women, though numbers 
were small in the sub-group analysis. However, these findings are supported by Sellers and 
co-investigators in their study with larger numbers (n=1298) 419 . They found no association • 
between age at which participants stopped getting taller and mammographic density 
measured by a similar computer assisted thresholding technique. 
Weight gain following treatment might suggest a greater degree of estrogen 
responsiveness compared to those whose weight did not change. However weight gain one 
year after commencement of treatment was not associated with any of the mammographic 
measures in the univariable analysis, and even less so in the multivariable analysis. This is in 
contrast to the findings of McCormack et al. (2003)406 . In their study, increases in BMI 
during any period up to age 43 years were associated with reduced odds of a greater Wolfe 
grade, with larger inverse associations in the preadolescent years (7-11 years). 
Strengths of the study include the use of medical record data for childhood 
anthropometric data and the inclusion of bone age data which is not normally available in 
child health records. Bone age data were collected close to the time of height, weight and 
BMI measurements at first assessment providing , more consistency in these growth related 
exposures. 
On the other hand, a limitation of the study was the lack of medical record data for 
some women in the study. This reduced the sample size for many of the sub-group analyses. 
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Not all women provided consent to access their records, and not all records were available. 
Also of those records that were available, not all data were recorded for all (e.g. birth-length). 
In addition, growth velocity, which might have differed between treated and untreated girls 
(before treatment and as a result of treatment), could not be measured. McCormack et al. 
(2003)406 found a positive yet statistically insignificant greater odds of having a higher Wolfe 
grade with increasing height velocities at ages 11-15 years (p=0.08) but to a lesser extent in 
7-11 years (p=0.96) (n=1030). 
Another limitation is the potential inaccuracy of bone age data. According to Drop et 
al. (1998)44 the techniques of bone age assessment are subjective, and that this subjectivity is . 
reflected in the inter- and intra-rater variability. The technique used in this study cohort was 
the Greulich-Pyle atlas for bone age assessment. Between 1959 and 1975, for all tall girls, the 
bone age of the hand-wrist was assessed by one observer. The mean intra-observer difference 
in assessments was calculated to be 1.1 months °. 
Self-reported height data at follow-up is a likely source of measurement error. 
However, according to Spencer et al. (2002) 487, taller women report height more reliably than 
shorter women. In addition, height is a prominent characteristic for women with a history of 
assessment or treatment for tall stature77 . Similarly, age at maximum height is crudely 
measured in this study and is likely to be a source of measurement error. 
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8.5 Conclusion 
The aims of this chapter were 1) to examine the degree to which a number of pre-
treatment childhood anthropometric measures influenced the association observed between 
treatment and mammographic density; and 2) to examine the association between a number 
of post-treatment childhood anthropometric measures that might have been influenced by 
treatment (e.g. weight and BMI change, and age at which maximum height was attained) on 
each of the mammographic measures for treated women only. 
Birthweight and bone age minus chronological age and height, weight and BMI at 
first assessment (adjusted for age at assessment) all showed univariable relationships with 
mammographic density of which only bone age minus chronological age and birthweight 
remained in the larger model for treatment effect on dense area and percent density. These 
two variables did not reduce the treatment effect on dense area and percent density, rather 
they increased it. In treated women, weight and BMI change following treatment and age 
which maximum height Was attained were not associated with any of the mammographic 
measures after adjustment, and are unlikely to have had a mediating effect on the association 
between dense area and high-dose estrogen exposure in adolescent girls. 
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Box 8.1: Summary of key chapter findings. 
KEY FINDINGS: CHAPTER 8 
• Birthweight and bone maturity at first assessment (measured as bone 
age minus chronological age) and height, weight and BMI at first 
assessment (adjusted for age at assessment) all showed univariable 
relationships with mammograp_hic density. 
• Of the above variables, only bone age minus chronological age and 
birthweight remained in the larger model for treatment effect on 
dense area and percent density. 
• Bone age minus chronological age and birthweight strengthened the 
treatment effect on dense area and percent density. 
• In treated women, weight and BMI change following treatment and 
age which maximum height was attained were not associated with 
any of the mammographic measures after adjustment, and are 
unlikely to have had a mediating effect on the association between 
dense area or percent density and high-dose estrogen exposure in 
adolescent girls. 
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9: CONCLUSION 
The aim of this research was to examine the short- and long-term effects of adolescent 
exposure to high-dose estrogens on the breast. Chapter 4 explored the short-term side effects 
on the breast in a cohort of Australian women who were treated with high-dose estrogens in 
adolescence. Self-reported breast-related side effects of treatment included breast lumps, 
galactorrhea, breast pain, dry cracked or bleeding nipples and increased pigmentation of the 
nipple and areolae. Dry cracked nipples, not reported previously in the literature on treatment 
for tall stature, might be associated with nipple hyperkeratosis which is known to be 
associated with estrogen treatment in humans 235 and animals236 . 
Side effects most frequently reported were increased pigmentation of the nipple 
(33.7%) followed by breast pain (8%). These appear to be similar in frequency to that 
observed elsewhere22 ' 23 ' 29 . Also, more diethylstilbestrol (DES) treated women seemed to 
have experienced these side effects compared with ethinyl estradiol (EE) treated women. The 
observation of breast pain may be significant to breast cancer risk as Crandall et al. (2009)237 
observed an increased risk in women who had experienced new-onset breast tenderness 
following hormone replacement therapy (HRT) use. 
Chapter 4 also explored the risk of having had a breast biopsy and breast surgery 
(including lumpectomy) in treated and untreated women. Biopsies and surgery were more 
likely to be remembered by participants compared with reporting a diagnosis of benign breast 
disease or a breast lump, and evidence of a clinical investigation was considered iniportant 
for a diagnosis. No significant difference was observed in having had these procedures 
between treated and untreated. women. While the number of breast biopsies may not 
accurately represent the prevalence of benign breast disease in this study cohort, if treated 
women had more cases of breast disease than untreated women it would be expected that they 
would have had more breast biopsies and breast surgery for lumpectomy (excluding cancer) 
for a given age. 
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Treated women were no more likely to have had a diagnosis of breast cancer than 
untreated women. While the cohort size was too small to pick up sufficient cases for a 
reliable assessment of the level of breast cancer risk associated with high-dose estrogen 
treatment in tall girls, it provided some indication of the difference in the rates between the 
two groups of women. If breast cancer risk was hugely increased in treated women it might 
have been observed with the current sample size. Future studies should consider a longer 
follow-up period to include women who are at an age when the incidence of breast cancer is 
greater, and a larger sample size. 
Chapter 5 examined the long-term effect's of treatment on lactation, in particular, 
breastfeeding commencement and duration. This study found no meaningful differences in 
breastfeeding commencement or breastfeeding duration, between women who were either 
•treated or untreated with high-dose estrogens during adolescence. 
The reasons for stopping breastfeeding were similar between treated and untreated 
women further validating the findings on breastfeeding initiation and duration. Treated 
women were no more likely to have stopped breastfeeding 'because of a lack of milk, nipple 
trauma or pain, or mastitis. More treated than untreated women reported stopping because 
their breasts did not engorge or fill with milk but the numbers were small for bath groups. 
Women with insufficient glandular tissue of the breast are known to suffer from 
lactation failure and a lack of breast enlargement during pregnancy 230 ' 258 . Complaints of flat 
chestedness by girls treated with estrogens for tall stature have been reported 23 ' 41 • It is 
possible that the reduced IGF-I levels observed with treatment" could result in reduced 
glandular tissue in the developing breast and therefore increase the risk of breast hypoplasia 
and consequently a lack of breast enlargement during pregnancy and lactation insufficiency. 
However this study found that women treated with estrogen during adolescence for tall 
stature were no more likely to report a lack of breast enlargement during pregnancy or 
lactation insufficiency than untreated women. In addition, a lack of breast engorgement or 
filling of the breasts as a reason for stopping breastfeeding did not seem to be associated with 
breast hypoplasia because most of the women reporting a lack of breast engorgement or 
filling of the breasts reported an increase in breast size during pregnancy. Chapters 7 and 8 
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• examined the effect of treatment on total breast area, and while treated women had less mean 
total breast area than untreated women, this difference was not statistically significant. 
To better investigate long-term breast effects, mammographic density, a well 
established risk factor of breast cancer, was investigated in Chapters 7 and 8. The Australian 
cohort of women who were assessed for tall stature in adolescence and either treated or not 
treated were followed up a second time. Women's mammograms were collected and 
mammographic density measured using a computer-assisted thresholding technique. This 
study found that women treated with estrogen for tall stature in adolescence had a 
significantly lower mean dense area than women who were assessed for tall stature but 
untreated. Treated women had lower percent density, and slightly greater adjusted mean non-
dense area compared with untreated women but these differences were not statistically. 
significant. 
Chapter 8 examined the degree to which a number of pre-treatment growth 
parameters influenced the association observed between treatment and mammographic 
density. It also explored the association between a number of adolescent anthropometric 
measures that might have been influenced by treatment (e.g. weight and BMI change, and age 
at which maximum height was attained) on each of the mammographic measures for treated 
women only. While birthweight and bone age minus Chronological age and height, weight 
and BMI at first assessment (adjusted for age at assessment) all showed univariable 
relationships with mammographic density, only bone age minus chronological age and 
birthweight remained in the final model for treatment effect on dense area and percent 
density. These two variables did not reduce the treatment effect on dense area, rather they 
increased it. 
There are a number of limitations of this study. Treated women (mean age 39.8 
years) were asked to recall side effects of treatment that occurred in adolescence. While recall 
might have been biased towards those side effects that were troublesome, the side effects that 
were recalled are likely to be accurate. Reassuringly, the type and frequency of side effects 
reported by the women in the study were found to be consistent with those in published case-
series reports. 
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Recall error is also relevant to breastfeeding history. Women were asked to recall 
their breastfeeding history on average 10.7 years (range 0.4-33 years) after breastfeeding 
their first infant. However, a review of 11 studies that examined the reliability and validity of 
breastfeeding recall data found maternal recall to be a valid and reliable estimate of 
breastfeeding initiation and duration, but was less satisfactory for exclusive breastfeeding 259 . 
The examination of mammographic density as a measure of breast cancer risk was a 
strength of this study. With respect to concerns about high-dose treatment during adolescence 
and future breast cancer risk, this study has shown that such treatment does not ,,increase 
mammographic density. On the contrary, treated women in this study had an overall lower 
mean mammographic dense area than untreated women. , 
There are a number of limitations of the mammographic density measure in this 
study. It is a 2-dimensional measure that does not capture 'depth' of density and there is a 
degree of variability in the quality of the mammograms and subjectivity in its measurement. 
Yet, despite these shortcomings, studies consistently show an association between 
mammographic density, using the methods used in this study, and breast cancer risk. Boyd 
and colleagues suggest that every 4.06 cm 2 increase in total mammographic dense area is 
associated with an increase of 3% in breast cancer risk 36 . If true, our study would suggest that 
treated women were at a 3% reduced risk of breast cancer if all other risk factors remained 
the same. 
This study suggests that hormone treatment in adolescence has had an effect many 
years after the discontinuation of treatment and that that hormonal exposures during the 
pubertal mammary development period have long lasting effects. The mechanism of this 
action is not clear. 
The observed effects (and lack of effects) of adolescent exposure to high-dose 
estrogens observed in this study should not be generalised to all exogenous estrogen 
exposures that might occur during adolescence. Estrogen has a biphasic effect on some 
tissues' exerting a different action at low concentrations than at high concentrations. It may 
follow, therefore, that lower exogenous estrogen exposures during adolescence may have a 
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different effect on breast tissue and function than that observed with the high estrogen 
exposures in this study. 
This is the first study to examine the long-term effects of high-dose estrogen 
exposure in adolescence on the breast. The retrospective cohort study adopted to examine 
these effects was the optimum design of choice. An RCT was not possible, and a case-control 
study design would not have been suitable, given that treatment is not common. While a 
retrospective design has its shortcomings (e.g. relies on medical records or recall for exposure 
measurement), it also has its strengths. This study design enabled an extended follow-up of 
the effects of an uncommon exposure •and the examination of potential confounders in the 
data analysis. 
While strength of study design and the exclusion of potential confounders as possibly 
explanatory factors are important in the determination of causality, other criteria need to be 
considered. Bradman Hill's widely used and cited list of causal criteria include, strength of 
association, consistency in findings across studies, temporality, biological gradient, 
plausibility, coherence, experimental evidence, specificity and analo gy488. Strength of 
association should not necessarily be considered when interpreting causality. Rothman argues 
that weak associations can be causal and strong associations non-causal. In relation to the 
second criterion above, (consistency in findings across studies) this is the first study to have 
explored the association between treatment for tall stature and mammographic density as an 
adult. Additional studies would be helpful and may or may not add further support to the 
findings. 
Temporality is important when considering causality. In relation to Hill's criteria of 
temporality, exposure is required to precede the outcome. It is possible that girls treated with 
high dose estrogens had lower mammographic density than untreated girls before treatment. 
This study cannot discount this possibility. In addition, pre-treatment factors associated with 
mammographic density later in life might have differed between the groups. The untreated 
participants were similarly tall as girls. The main reasons for not being treated were because 
the girl's estimated mature height or remaining growth potential at time of assessment did not 
warrant treatment. While it is possible that pre-treatment anthropometric differences may 
explain some of the effects on marnmographic density, potential anthropometric confounders 
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were collected from the medical records and included in the analysis. They did not reduce the 
observed effect on mammographic density. 
Biological gradient is not relevant to this study because dose of estrogen treatment 
was similar for all treated girls. Plausibility as a criterion of causality can be questioned. A 
causal association can exist without knowing the mechanism underpinning the association. 
None-the-less, the findings that girls treated with high dose estrogens had lower 
mammographic dense tissue than untreated girls could possibly be explained by the 
observations made elsewhere that IGF-I levels were reduced during treatment. IGF-I has been 
positively associated with mammographic density, and a reduction during puberty could 
possibly contribute to a reduction in mammographic density as an adult. 
Specificity is not necessarily an important criterion of causality. Many factors. do 
contribute to change in mammographic density. In terms of coherence with existing theory 
and knowledge, the association between mammographic density and exposure to high-dose 
estrogens as an adult was explored because there was a strong a priori reason for doing so. 
Hormone treatment as an adult is known to influence adult mammographic density and 
suggests that hormone treatment in adolescence might also have an effect. While Bradman 
Hill did not promote the use of his list of causal parameters to be used as a checklist, they can 
be useful when relevant to the association under investigation. On balance, the association 
between mammographic dense area and treatment with high-dose estrogens in adolescence 
appears likely to be causal, but replication of these findings in other studies, or alternative 
studies that explore the association between hormone treatment and mammographic density 
in adolescence would be needed to support the causal inferences made in this study. 
As well as helping to address the concerns of treated women, the research provided a 
rare opportunity, internationally, to examine the long-term biological effects of this treatment. 
While this study found that women treated with high-dose estrogens for tall stature in this 
cohort experienced unpleasant side effects on the breast during treatment, it also provides 
some reassurance for these women that treatment does not appear to affect their ability to 
lactate or increase their risk of having breast disease requiring a breast biopsy or surgery, and 
is unlikely to increase their risk of breast cancer through mechanisms related to 
mammographic density. The study also has broad implications for our understanding of the 
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biology of breast development and for breast cancer research. It has shown us that exposure 
to sex 'hormones during adolescence can have a sustained effect on breast tissue as 
demonstrated by a reduction in mammographic dense tissue in adulthood. 
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Sample size calculation for breast cancer risk 
Appendix I: Sample size calculation for breast cancer risk 
APPENDIX I 
In Australia, the 20 year breast cancer prevalence rate for women 35-39 years of age in 2006 was 
1.6%. This prevalence rate is based on the number of surviving persons who received a breast 
cancer diagnosis in the last 20 years'. 
The mean ages of women in the Tall Girls Study were 39.7 years (treated) and 37.7 years 
(untreated) at the time that they were asked about their breast cancer history. It would be expected, 
assuming there was no increased or decreased risk of breast cancer in these women and based on 
the population prevalence rates, that at least 1.6% of women would have had a diagnosis of breast 
cancer previously. 
The known sample size for treated and untreated women in the cohort is 371 and 409, respectively. 
Using the sampsi command in Stata, if more treated women have had a previous diagnosis of breast 
cancer than untreated women, then at least 6% of treated women would need to have had breast 
cancer for the study to have 80% power to detect a significant difference between the two groups 
(assuming the proportion of untreated women is 1.6%). 
Stata command: sampsi .06 .016, alpha (.05) power (.8) 
To observe a 20% relative increase in risk in treated women 
P=proportion 
P treated / P untreated =1.20 
P treated =1.20 x P untreated 
P treated = 1.20x 1.6/100= 1.92/100 
The difference-in the absolute scale is 1.92/100 -1.6/100 = 0.32/100 or 0.32% 
Stata command: sampsi .0192 .016, alpha (.05) power (.8) 
We would need a sample size of 27,000 for each of the treated and untreated groups. 
To observe a RR of 2.0 or relative increase of 100%: 
P treated/P untreated =2.00 
P treated= 2.00 x P untreated 
P treated = 2.00 x 1.6/100= 3.2/100 
The difference in the absolute scale is 3.2/100 — 1.6/100 = 1.6/100 or 1.6% 
. Stata command: sampsi .032 .016, alpha (.05) power (0.8) 
We would need 1558 for each treated and untreated. 
Source: http://distancejhsph.edu/statr2/heart/modules/resources/pdf/statr2-sec3c 6.pdf 
1. Australian Institute of Health and Welfare & National Breast Cancer Centre 2006. Breast cancer 
in Australia: an overview, 2006. Cancer series no. 34. Cat. no. CAN 29 Canberra: AIHW. 
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Follow-up 1 study invitation letter, information brochure and consent form 
Appendix 2: Follow-up 1 invitation letter, study information sheet and consent form. 
APPENDIX 2 
October 22, 2002 
Dear «First_nameo, 
We are writing to ask for your help in our study that aims to find out about the long-term effects of hormone 
treatment to reduce the adult height of tall girls. Treatment with oestrogens to reduce the adult height of tall girls 
has been available in Australia and in other countries since the 1950s but there have been few follow-up studies. This 
research, which includes treated and untreated tall girls, will make an important contribution to our understanding of 
the health and psychosocial issues that are important to tall women and girls. The National Health and Medical 
Research Council has funded the study which is being conducted by a team of researchers at the Centre for the 
Study of Mothers' (St Children's Health, La Trobe University and the Royal Children's Hospital. 
Your name was obtained from: a list of names provided to us by the late Dr )0C(, the mailing list of Tall Girls Inc., or 
from the details you gave us when you contacted us and expressed an interest in this study. Dr XXX gave the study his 
full support before his death in late 2000. We are seeking your help even if you never had treatment for tall stature. 
This will allow us to compare outcomes in tall girls who were treated with those who were not treated. Eligible women 
are those who consulted a doctor about their growth and had x-ray assessment to predict their expected mature 
height. 
Participation in the study will involve answering the enclosed questionnaire asking about your health and wellbeing, and 
satisfaction with treatment or the decision not to have treatment. In addition, We would like to ask you to complete a 
telephone interview about your medical and reproductive history, at a time convenient to you, in the next few months. 
We also ask you to give us permission to obtain information from your medical records. The enclosed information sheet 
and consent form give further details. 
Participation in the study is entirely voluntary. If you choose to participate, you are free to withdraw from the study 
at any time. The information you provide will be kept confidential. The results of the study will not be published in any 
way that would allow you to be identified. 
The enclosed questionnaire will take about 30 minutes to complete. We would be grateful if you could complete it and 
return it with the informed consent form in the enclosed reply paid envelope as soon as possible. If we do not hear 
from you in the next few weeks we may contact you again to check that you have received this letter. It is very 
important for us to have as many replies as possible. We would like to hear from women with good health as well as 
those with health problems, and from women with a range of views about the medical assessment and treatment of tall 
stature. If you have any questions about the study, please feel free to contact Jo Rayner or Penny Jones, the study's 
research nurses, on (03) 8341 8582. 
We look forward to hearing from you soon. 
Yours sincerely 
404;AAAisiu 	 co—y_ 
Dr Alison Venn 
	
Professor George Werther 
Centre for the Study of Mothers' 
	
Royal Children's Hospital 
& Children's Health 
«ID_number» 
Appendix 2: Follow-up 1 invitation letter, study information sheet and consent form. 
Long-term health and psychosocial effects of hormone treatment to reduce the adult height of 
tall girls 
Study information sheet 
What is the study about? 
This study aims to find out about the long-term health and psychosocial effects of hormone treatment to 
reduce the adult height of tall girls. 
Who is eligible to participate? 
You are eligible to participate if you had a medical assessment of your expected mature height before 1990. 
Assessment would have included an x-ray of your hand and wrist as well as measures of your height when 
you were in your adolescence. We want to follow-up tall girls who were not treated, as well as those who 
received hormone treatment to reduce their adult height. 
How did you get my name? 
Your name was obtained from one or more of the following: 
• A list of patient names provided by XXX prior to his death in late 2000. 
• Details you gave us when you contacted us previously to register your interest in the study. 
• The mailing list of Tall Girls Inc. 
What exactly do you want me to do? 
• Answer a postal questionnaire about yourself, your health and satisfaction with your treatment decision 
• Measure your height and weight 
• Complete a telephone interview about your medical and reproductive history 
• Give us permission to access your medical records so that we can confirm details about your height 
assessment and, if applicable, your treatment for tall stature. 
In the coming months you may also be asked to participate in an in-depth individual interview about your 
experiences of being tall and assessed or treated. However, only a small number of women will be asked to do 
this and you do not have to agree to such an interview now. 
Do I have to participate? 
Participation in the study is entirely voluntary. You are free to withdraw from the study at any time. You are 
also free to not answer any particular question. If you do not wish to participate in the study, please let us know 
and we will not contact you further. 
What's in it for me? 
This study will be the first study to examine the long-term outcomes for women who had an assessment or 
treatment for tall stature when they were girls. You may find that you experience some benefit from being able 
to give an account of your experiences and health. The study will benefit other women and the medical and 
research community by increasing our understanding of the effects of oestrogen treatments during puberty. It 
will also help us to evaluate the effectiveness of treatment for tall stature. The study will increase our. 
knowledge of how being tall, or being treated for tall stature, has affected women's lives. It is likely that the 
findings will be helpful to clinicians in addressing the concerns of tall girls and their families who present for 
clinical assessment, even though this now occurs relatively infrequently. 
Appendix 2: Follow-up 1 invitation letter, study information sheet and consent form. 
What about my privacy? 
The information you provide will be kept confidential The data collected will be used only for the purposes of 
this study. Your answers to the questionnaire and telephone interview will be coded and entered onto a 
computer without your name. The telephone interviewer will only know your first name. They will not know 
your full name or treament status. The study results will be published in a way that will not allow you to be 
identified. The study has been approved by the ethics committees of La Trobe University and the Royal 
Children's Hospital. 
Who is doing the research? 
The study is being conducted by a group of researchers led by Dr Alison Venn. Professor Judith Lumley and 
Dr Priscilla Pyett (Centre for the Study of Mothers' & Children's Health, La Trobe University) and Professor 
George Werther (Centre for Hormone Research, Royal Children's Hospital Research Institute) are the other 
researchers involved in the study. Their collective expertise is in epidemiology, health sociology and paediatric 
endocrinology. Ms Penny Jones and Ms Jo Rayner are the study's research nurses and Ms Fiona Bruinsma is 
the data manager. 
Who is funding the study? 
The study is funded by a grant from the National Health and Medical Research Council. 
Can I be told about the results? 
We expect to have results in about two years' time. If you would like to hear about the results, please indicate 
this in the postal questionnaire. You can follow the study's progress on our website at 
http://www.latrobe.edu.au/csmch/tallqirls/  
Who do I contact if I have questions or concerns? 
If you have any concerns or questions or would like more information contact Jo, Penny or Fiona 
Centre for the Study of Mothers' & Children's Health, 
251 Faraday Street, Carlton VIC 3053 
Phone (03) 8341 8583, fax (03) 8341 8555 
Email tqstudyalatrobe.edu.au   
If at any time you have any concerns about your involvement in the study that the researcher has not been 
able to answer to your satisfaction, you may contact the Ethics Liaison Officer, Human Ethics Committee, La 
Trobe University, Bundoora, VIC 3083 (ph (03) 9479 1443, email: humanethicsalatrobe.edu.au  
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Study ID number: 	  
CONSENT FORM 
The long-term health and psychosocial effects of 
oestrogen treatment to reduce the adult height of tall girls. 
Chief Investigators: 
Centre for Ilte Study of 
Mothers and Children's Health 
gt LA TROBE UNIVERSITY 
DR ALISON VENN 
Centre for the Study of Mothers' & Children's 
Health, 
La Trobe University and Menzies Centre for 
Population Health Research, University of Tasmania 
PROFESSOR JUDITH LUMLEY & DR PRISCILLA 
PYETT 
Centre for the Study of Mothers' & 
Children's Health, La Trobe University 
PROFESSOR GEORGE WERTHER 
Centre for Hormone Research, Royal Children's Hospital Research Institute 
(A) 	Consent to participate 	 • 
I have read and understood the information on the study information sheet. Any questions I have asked have 
been answered to my satisfaction. 
I agree to participate in the project by: 
• filling in the questionnaire 
• providing information on my current height and weight 
• participating in the telephone interview 
I realize I may withdraw at any time. I agree that research data provided by me or with my permission during 
the project may be included in a thesis, presented at conferences and published in journals on the condition 
that neither my name nor any other identifying information is used. 
Name of participant 	  
Signature 
 
Date 
 
(B) Consent to obtain medical information  
We would like to contact the doctor(s) who assessed and/or treated you for tall stature. We will, however, only 
do this with your permission. We are requesting access to your medical records so that we can confirm details 
about your height assessment and, if applicable, your treatment for tall stature. All the information we collect 
will be kept confidential. The information we collect will be used solelylor the purposes of this research 
study. 
Please provide us with the name and address(es) of the doctor or hospital who assessed or treated 
you for tall stature, and the year that you attended. If you are unsure of a doctor's name or address, 
please give us whatever information you do have. 
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(1) Dr or hospital 	 Year attended 
• Address 	  
State 
Postcode 	 
(2) Dr or hospital 	 Year attended 
Address 	  
	 State 	 
Postcode 	 
Your name 	Maiden/other surname(s) used 
(print name) 
Your signature 	 Date    	
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Follow-up 1 postal questionnaire 
( f" 
Please answer every question. Please complete the questionnaire by 
(ii) circling a number 0 	OR 
(iii)ticking a box 
If you hove any additional Information please add comments near that question 
or at the end of the questionnaire. 
(i) filling in the appropriate number in each bo an eg. How tall are you now? 	feet Inches OR 
Appcnui 3: F011(INV-irp I postal que:tionnaire 
CONFIDENTIAL 
The Tall Girls Study 
POSTAL QUESTIONNAIRE 
We would be grateful If you would ogres to take part in our study by answering this questionnaire. It asks questions 
about your experiences of being tall, belng assessed and/or being treated for tall stature. as wen as your health and 
medical history. It takes about 30 minutes to comPlete. 
When r.oinpleted please return It In the reply paid envelope to 
Tall Girls Study 
Fteply Paid number 64593 
Centre for the Study of Mothers & Children's Health 
251 Faraday Street 
Carlton 3053 
VICTORIA c 
If you have any questions about the study 
or would like assistance to complete this questionnaire over the telephone, 
please call Penny Jones (03) 8341 8581 or Jo Rayner (03) 8341 8582. 
The study has been funded by the National Health and Medical Research Council. 
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Please read below instructions 
secnoN A These questions ask about your general health 
These questions ask for your views about your health, how you feel and how well you are able 
to do your usual activities. 
Answer every question by marking the answer as indicated. If you are unsure about how to 
answer a question, please give the best answer you can. 
Al 	In general, would you soy your health Is 
(circle one number) 
Excellent 
Very good 	 2 
Good 	 3 
Fair . 	4 
Poor 	 5 
Al Compared to one year Pao  how would you rate Your health In general Ligs? 
khrk one number) 
Much better now than one year ago 
Somewhat better now than one year ago 	2 
About the some as one year ago 	 3 
Somewhat worse now than one year ago 	• 4 
Much worse now than one year ago 	 5 
For offki use onlY 
Date sent 4-/ 
	 ID 	  
Oats received 	 - 
Checked by F8 P3 JR bate checked 
Aoponlix .1: Follow-up I postal questiormaire 
i5ectIon..4caiitinuesi 	. 
A3 The following questions ore about activities you might do during a typical day. 
Does your health now limit you in these activities? If so, how much? 
circle me number on each line 
ACTIVITIES 
' Yes, 
limited a 
lot 
Yes, 
limited a 
little 
No, not 
limited 
at all 
(a) Vigorous octWities such as running. lif ting heavy objects. 
participating in strenuous sports 1 2 3 
(b) I Moderate actIvItise, such as moving a table. pushing a 
vacuum cleaner, bowling or playing golf 1 2 3 
(C) Lifting or carrying gro ceries 1 2 3 
(d) CIOnbinge_rell flIt ts at rain 1 2 3 
(e) Climb.lmone flight of stairs 3 ..... 	_ .I 
(1) Ilendini, knu±aor stoolii.N_ I 2 3 • 
(g) Walking more than one kilometre I 3  2 
(h) Wulki 	half a kilometre 1 2 3 
(I)  Wolid 	100 metros I 2 3 
(1) Bathing or dressing yourself 1 2 3 
A4 During the post 4 weelo, have you had any of the following problems with your 
work or other regular daily activities aS a result of your alwsical health? 
(ckale one number on each line) 
YES 
	
• NO 
Cu) Cut down on Ms amount of time you spent on work or other activities 	 2 
(12) Aeeanollshed less than you would like 
	 2 
(c)Were limited In the kind of work or other activities 
	 2 
(d)Had difficulty performing the work or other activities 
(for example it took extra effort) 
AS During the past 4 week,s, have you had any of the following problems with your 
work or other regular daily activities as a result of any emotional problems (such 
as feeling depressed or arudous)? 
(circle one number en eoch and 
YES 	NO 
(a)Cut dawn on the amount of time you spent on work or other activities 	 1 	2. 
(b)Accomplished lets than you would like 	
2 
(c)Didn't do work or other activities as carefully as usual  
A6 	During the post 4 wee 	, to what extent has your physical health or emotional 
normal social activities with family, friends, 
(circle one numbed 
problems interfered wtt your 
neighbours or groups? 
Not r oll 
Slightly 2 
Moderately 3 
Quite akin 4 
Extremely 
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A7 How much 14say pain have you had during the post 4 weeks? 
(axle one /embed 
No bodily pain 
Very mild 2 
Mild 3 
Moderate 
Severe 5 
Very severe 6 
AS During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
Not stall 
(deck ane numbed 
A little bit 2 
Moderately 3 
Quite a bit 4 
Extremely . 5 
49 These questions are about how you feel and how things have been with you 
dyrIna the post 4 week.q. For each question, please give the one answer that comes 
closest to the way you have been feeling. 
How much of the time during the 4/L5_2/EA& - 
Aro, Ms 
tire 
Mosta 
thetine 
-Agamibit 
of then= 
Smear 
tiering 
A iltdeof 
*cline 
Neneof 
Petite 
(a)l2ld you feel full of life? 1 2 3 4 5 6 
(b) Have you been a very nervous 
_..person? 
(c) Have you felt so down In the dumps 
that n_.!.._,11.__Nd 	cheer you_up? _could 
I 2 3 4 5 6 
1 2 3 4 5 6 
...(01 .14avei3ufelt c_alm and_peaceful? I 
(e)(31d tot, have a lot of energy/ . 2 3 4 5 
(f) Have .r..2 felt down) 1 2 3 4 	. 5 6 
(g) bid you feel worn out) I 2 3 4 5 6 
,(h1....Hdyeyou been o happy person? I 2 3 4 5 6 
, (i) bid you tee! tired? . 1 2 3 4 5 6 
410 During the East 4 weeks, how much of the time has your phvsical 	ofth pr 
emotional problems  interfered with your social activities (like visiting with friends, 
relatives, etc)? 	 (mirk one numbed 
All of the time 
Moot of the time 
Some of the time 	3 
A little of the time 	4 
None of the time 
fen* me /ember mead, Oct.) 
3 
Please now measure your height following the instructions below and write down the 
result in Cl. You might also pref or to have someone help you do this. 
SELP MEASUREMENT INSTRUCTIONS 
I This measurement needs to be done before 12 midday because our height decreases very 
minimally over the day. You need to be in bare feet and on a hard floor, without carpet, fade 
this measurement. 
2 Taboo firm picture frame or similar rectangular or square object. 
3 Have a pencil ready and stand with your back to the wall as straight and stretched as 
possible, keeping your chin tucked in. 
4 Place the picture frame edge against the wall above your head so that the frame is horizontal -
and projecting over your head. 	 . 
5 Slide the frame down the well until the horizontal edge is sitting on your head. While holding 
the frame in place, use your other hand to draw a horizontal mark on the wall immediately 
Inkne the frame edge. This mark will represent your height. 
6 Uses tape measure to measure f ram the floor to the mark and record this as your height. 
7 Please repeat the whole process as o check. 
Cl 
	
How tall are you without shoes on? (Give fraction of inch or aenhaletnel 
eg. 	5 	II 	3, OR 	181.5 
feet Inches. ten 
nrnll oRrnn .Lj  
feet 	inches 	 cm 
C2 How much do you currently  
	 tilD or nor:H.ri weigh without clothes or 
shoes? 	 stones 	pounds 	 kg 
C3 	be you have any of the following rare conditions that have been occasionally 
associated with tall staturencitcle the number that applies' 
YES NO 
Marten's syndrome 1 2 
HomocystInura (clotting problems) 1 2 
Pituitary gigantism (acromegaly) 1 2 
47XXX karyotype 1 2 
Sotos' syndrome 1 2 
Neurofibromatosis 1 2 
Hyperthyroidism I 2 
Precocious puberty 1 2 
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F  
All How TRUE or FALSE is egg of the following statements for you? 
(carols one number en each anal 
(a)I seem to get sick a little cosier 
than other people 
(b)/ am as healthy as anybody I know 
(o) I expect my health to get worse 
(d) My health is excellent 
Definitely 
true 
1 
1 
1 
I 
Mostly 
true 
2 
2 
2 
. 2 
Don't 
know 
3 
3 
3 
3 
Mostly 
false 
4 
4 
4 
4 
Definitely 
false 
5 
5 
5 
5 
-,-MMT itft 	 ;°. 
The following statements have been used by many people to describe how much support they 
get from other people. We would like to know whether you share any of these feelings and how 
strongly you feel about them, by circling a number according to whether you strongly agree, 
agree, disagree or strongly disagree with each one. If you are undecided, circle the column 
with this heading (3). 
• Shag!, 
Undecided Disayee  
Sire* 
81 People don't come to visit me as often as 1 
would like. 1 2 3 4 5 
82 I find it easy to make friends. 1 2 3 4 5 
83 I often need help from other people 
but can't get it. 5 
84 rm afraid of being left alone. 1 2 3 
85 I seem to have a lot of friends. 1 2 3 
86 I don't have anyone that I can confide in. 
117 The person who means most to me takes an 
Interest in my affairs. • 
118 There Is someone who needs moos much as 
I need them. 
1 2 3 4 5 
89 I don't haves veity close friend. 1 2 3 4 5 
810 The person who means most to me 
doesn't spend time with me. 1 2 3 
811 I have no-one to lean on in times of 
I 	trouble. 
1 2 
BIZ I have someone to share good news with. 1 2 
813 There Is someone who can always cheer 
me up when rm down. 
1 2 3 
814 
■._. 	.,...... 
B15 
I of ten feel very lonely. 1 2 
I I feei there is something missing from my 
life.  
1 2 3 4 ' 5 
4 
5 
Appendix 3: Follow-up 1 pustul questionnaire 
The next few questions ask you to think about the advantages and disadvantages of being 
tall when you were young and as an adult. - 
C9a Please complete the following two statements: 
When I was growing up, the gilt things about being tall were 
..... 	........ 
C7a In your opinion, what is the maximum 
	 E 
feet 	inches 
C7b Why? , 
C8a In your opinion, what is the Ideal height for your partner? 
(circle one numbed 
Taller than me 
Shorter than me 	2 
Same sire as me 3 
Don't hove an opinion 	4 
acceptable height for a woman? or 
00 
3. Folk , \ ..Lip I 1)0,411 quustithinaire 
SeatiOn  
C4 In general, are you satisfied with your current height? 
(circle one number) 
Yes 
No. 	 2 
Undecided 
	
3 
C5a Ideally, what height would you like 
	El EC] or 
feet 	inches 	 cm 
C5b Why? 
. .. 
idIneayi apightnt awhwocit.wonu?id be the C6a r  Ei[il or 1-1[71 
feet 	inches 
- 00 
Cbli Why? 	 C9b "When I was growing up, the mow things about being tall were 
00 
CIO Zr my experience being a tall woman is an 162,310,1 because 
(circle one number on each fine) 
Strongly 
oars. 
Agree Undecided Disagree Strongly 
diso_o__ 
(sIrt Is easier to reach things_ 1 2 3 4 5 
(b)I can see over_pemletn a crowd 1 2 3 4 5 
(c)It has helped my work/career options ' 	1 2 3 
(d)Tall women are considered more 1 2 3 	4 , 5 
___elecant 	 — "--1 
1 2 3 5 (e)Tall stature gives you natural 
authority_ 
4 
(f) Other women on 	my height 1 2 3 	4 5 
„_(g) It has allowed me to excel In !port 1 2 3 4 5 
, (h) It has enabled mono have more 
equal relationshiJILI men 
1 2 3 4 5 
(i) r can easily attract the attention 
of others 1 2. 3 4 5 
6 	
7 
pi:,cntlix 3: I 	lI5''.5fl I postal questionnaire 
• 
C11 In my experience being a tall woman is a disadvantage because 
ercle one number on each line 
51""ns'Y 
Wu 
Ar.. ()Wedded IRA 
(a).Standani size fuimiture is aroblem 
(b) It is difficult to find clothes that are 
suitable 
.... 	I 
I 
2 3 
3 4 
_..... 
5 2 - 
(c)Pestle hove unrealistic expectations of me 
(d)Tall stature has limited my 
opportunities to achieve 
I 2 3 4 5 
I 2 3 4 5 
(e)People make unwelcome comments 
about my_height I 2 3 	• 4 5 
(f)Men ore reluctant to ask me out I 2 3 4 5 
(9) It is difficult to find shoes that fit 
(h) I can never avoid being noticed 
I 
1 
2 3 
3 
___—___ 4 5 
4 	• 5 
(I) It has limited my work/career options I 2 3 4 5 
Cl2 Overall, being tall has increased my opportunities to 
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The next group of questions ask about assessment and treatment you received as a tall girl. 
CIS 	As far as you can recall, who flat suggested that you should have a medical 
assessment for your height? 
(circle one number) 
Doctor 	 I C 
Family friend/neighbour 	 2 
Parents together 	 3 
Father 	 4 
Mother 5 
School teacher 	 6 
CI6 	How old were you, when you were first 
assessed? 
^ 
. =El 
years 	months 
C17 	When you were 	d as a girl, what 
height did the doctor predict you would 
grow to as an adult? 
  
	 F11-1 0. I It 
hitt 	Inch. 	 Sn 
. 	1-1 
boat know/don't remember 
CI8 	Who mode the decision to have or not to have treatment? 
_________....._,..............___-___ 
(a)Father's concern about his_c_taNhter beim:too bulr 1 
(b)Mother's concern about her doughter_being 'too tall' 	_ _. 	.. 
11. 1 .Fomik was teldtlfatmentwas available _______ 	__ 	_ 	__. 
isiMedla coverage about avallabifity of treatment 
:1
1r1 
(f) Mether's_personal uperience of tall 'stature 6 
(g) Difficulties at school 7 
(h) DiffIculnetindimelothes that fitted 
(9 Dott..knoy,:. 	_ 
I  .31 
Father 
(circle only oft. number) 
Mother 2 
Parents together 3 
I did 4 
I did with my parents 5 
Don't know 6 
Other (please specify).. 7 
• 
• 
9 
C19 	Do you think you had an active say In making the decision about whether or not to 
have treatment to reduce your adult height? 
Yes 
No 	 2 
Comments... 
C13 Overall, being tall has decreased my opportunities to 
'00 
CI4 As far as you can recall, why did your family seek a medical eginhaft about your 
height? 	 (circle as many numbers as appropriate) 
Appendix 3. Follo ■,up I postal qUeSI ioimairC 
1.Section C odtlhued  
C20 Did you receive treatment to reduce your adult height? 
(circle one nunberl 
Yes 
No 
	
2 
Don't know 
	
3 
C21 On balance. are you satisfied with the decision that was mode about whether or 
not to have treatment? 
(circle one number) 
Yes 	 1 
No 2 
Comments... 	 .1• 
If you did not receive treatment for tall stature go to C28 
If you cannot remember the exact dates for the next two questions please give an estimate. 
C22 How old were you when you 
started treatment? 
months 
C23 How old were you when you 
completed treatment? 	 Li -- Lill 
years 	months 
C24 What was the name of the drug you took? id,* as maw nwobersosossficobisi 
DES (diethylstilboeStral or stilboestroi) 
EE (ethinyl estradlol) 	 2 
Other (please specify) ........ 3 
Not sure/cannot remember name 	 4 
C25 If you can remember, when you were prescribed this treatment did you 	? 
(circle one numbed 
Take most of the tablets regularly 1 
Tube most of them irregularly 2 
Take the tablets infrequently 3 
Cannot remember 4 
Comments.. 
10  
Appendix 3: Follow-up I postal questionnaire 
,:••• 
C26 Did you ever experience any of the following side effects whilst on this treatment? 
0 NO side effects experienced (rick bar if opplicabk) 
Problematic weight gain 1 Ovarian cysts 11 
Heavy periods 2 Nausea 12 
Irregular pyyy 3 Vomiting 13 
Plantation on face 4 Improved skin 14 
Increased pigmentation of nipple_s Excessive sweating 15 
Dark line from navel to pubic hair •6 Thrombosis (blood clot) 16 
(Nivea nigns) Calf cramps 17 
Pigmentation elsewhere 7 Depression 18 
Increased vaginal secretions 8 Aggression 19 
Leaking breasts (oalactorrIvoea) 9 Mood swings 20 
Breast pain 10 ' Breast lumps 21 
C27 After treatment had finished, did you ever notice a spontaneous leakage of milk or 
discharge from your breasts? 
fords ono noinberj 
Y es 
	
1 	If YES, how long did this lost? 	or ['weeks 
No 2 
Daft know 
C28 How do you think your parents felt about the height you achieved when you finished 
growing? 
. 	(Circle one choke for (0) and for Oil 
(a) MOTHER 	0 Not applicable 	(b)ltd_11. R 0 Not applicable 
Very happy I 	 Very happy 
Happy 	 2 Happy 	 2 
Satisfied 3 	 Satisfied 3 
Mixed feelings 	4 Mixed feelings 	 4 
Disappointed 5 	 Disappointed 5 
Other (Please specify) 	6 Other (please specify) 
- 	• — 
11 
F-11. 
years 
■■•■. 
Appoldixi ro;loy,...p I postal questionnaire 
5etleinC.ctintinioed-,,Yr::: .::, 
C29 Women have reported a broad range of experiences of being assessed and treated 
for tall stature. The next few questions ask about your experience and how you felt 
about the assessment and treatment procedures. 
How often, if ever, did you experience the following when you were assessed or 
treated for tall stature? 
(circle ow number on each line) 
1.2 
times 
3.5 
times 
6 or Mere 
times 
Height measured 1 2 3 4 
fleinitveighed 3 4 
1 2 3 
An explanation from the doctor about what 1 2 3 4 
02Se22inen't Involved 
Breast examination 1 2 3 4 
Genital examination 
Blood tests 1 2 3 4 
peLlithotographed 1 2 3 
An explanation from the doctor about what 
treatment involved 2 3 4 
1 2 3 4 _ 	_ 
.._..................... 	_. ...... --....................._......................................... ._. 	............. 	.................... . 	..................... 
C30 Was your Why, or other close relative present in the room with you for any of 
the following procedures? 
circle one number on each line 
. 	_ Yes No 
Cannot 
renumber 
Not 
Applicable 
Height measured 1 2 3 4 
Being_u sighed 1 3 4 
Melia X-Rays 1 2 3 4 
An explanation from the doctor about what, 
assessment involved 
1 2 3 4 
Breast examination   1 
H  _ Genital ixelnatiorj _ 	. 1 P  4 Blood tests 1 4 
Ilejapholara3hed 1 3 4 
otheLiplease spe) .. 1 2 3 4 
Comments 	 _ 
.. 	........................................................ 
I 2  
AppOndix 3: Follow-up I postal questionnaire 
C30a Was anyone present during any of these procedures who you did not Want to be 
There? 
Yes 	 1 
No go to C31 
C30b If YES, who was there and for which procedure(s) were they unwelcome? 
Person 	 Procedure 
.. 
, .... . ..... 
... 	 • 	. 	. 	 • • 
• 
C31 Were you undressed for any of these procedures? 
(circle e 'ember on each 
1  -hii-re.Th—ad this -.L.X.d.. No? undressed laillE2 
He'.ht measured  1 2 3 	4 
BeiNa_velted  1 
311,illittoin lut_d - 	1 3 4 
C32 How did you feel when you were having the tests or procedures that are listed 
below? 
• 	 (circle one number on each Thief 
Special Comfortable Indifferent Uncomfortable Embareessed 
Height measured 
Bei • Kiel •hed 
1 
1 
2 
2 
3 4 5 
3 4 5 
X.is 1 2 3 4 5 
Breast examination 1 2 3 4 5 
Genital examination 1 2 3 4 5 
Blood tests 1 2 3 4 5 
Bejaphotojrallted
Other (please specify) 
1 2 3 4 3 
1 2 
- 
3 4 5 
C33 In your opinion what were the best aspects of the assessment/treatment? 
. 0 
. 13 
Net 
opoileobie 
C37o How tall Is/was your 
mother? 
C37b How tall Is/was your 
father? I OR 
feet 	M 
C37d How tall Is/was your 
tallest brother? 
LEI 
CM 
LJ 1-17 
fret 	in 
7 F-1 08 
feet 	in 
I 	II 	I C37c How tall Is/was your tallest sister? 
F-17 oR 
feet 	in 
14 
I 	I 
cm 
Appoldi ■ 3! Vt ■ ilow.1111 I po , tal out:stionnau'e 
C34 In your opinion what were the worst aspects of. the assessment/treatment? 
• • 	• 	 • 
I felt supported 	 1 	 I was distressed 	7 
It was embarrassing 2 I felt reassured 8 
I felt special 	 3 	 I felt uncomfortable 	9 
It was intrusive 4 It was painful 	 10 
It was acceptable 	 5 	 I 1 elt.indif ferent 11 
It was scary 	 6 I was comfortable 	12 
Other (please specify). 	 13 
C36 If a friend was concerned that their doughtier was going to be very tali, 
what advice would you give? . . 
C37 Now we are going to ask about the heights of your family members: 
Family heights - please complete the table below. It you are unsure about any measurements 
give an Citi11106.  
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C38 Were any of your sisters or brothers assessed for tall stature? 
[circle one number for (Wend (b)) 
(a)  ister(s) 	 • (b)  rother(s) 
YES 	 I 	 YES 	 1 
NO 2 NO 2 
Don't have any sisters 	3 	 Don't have any brothers 	3 
Don't know 	 4 Don't know 	 4 
(a) Sister(s) (b) Brother(s) 
YES 1 YES 
NO 2 NO 2 
Don't have any sisters 3 Don't have any brothers 3 
Don't know 4 Don't know 4 
15ection D These questions ask about your general health and lifestyle 
DI Slow. 
last 
 V:0t e: il t:lir you consulted the following peon e for your own health in 
 	farm. 
_ 
None 
ant), 
1.2 
times 
one numoer 
3-4 
times 
on  
5-6 
times 
n wori 
7 or 
mot, 
times 
Ftlidoctor or another general practitioner 1 2 3 4 5 
A hospital doctor (eg in outrilents or casuolty) I 2 4 5 
A specialist doctor 1 2 3 4 5 
An allied health professional (cg optician, dentist, 
physiotherapist. podiatrist, dietician. counsellor etc) 
i 2 3 4 5 
An 'alternative" health practitioner (eg herbalist. 
chiropractor, naturopoth, acupuncturist, etc) 
I 2 3 4 5 
132 Have you tur been told by a doctor That you haven 
(0i001. 000 number on each bne) 
YES 	NO 
(a) Diabetes (high blood sugar) 
	
1 	2 
(b) Heart disease 	 2 
(c) Hypertension (high blood pressure) 
	
2 
(d) Stroke 
(c) Thrombosis (blood clot) 
	
2 
15 
C Overall, .what best describes your experience of The assessment/treatment procedures 
3 for tall stature? 	 C39 Were any of your sisters or brothers treated for tall stature? 
5 (circle. many number, fn. NJ et applicable) 	. 
leIrcle one number for (a)ancl (b)J 
Aopt- ndix 	I-nlkm.up I nal quesiionnaire 
(f)Low iron level (anaemia) 
(g)Asthma 
(h)Bronchitis/emphysema 
(I) Osteoporosis 
(j) Cancer (please specify) ..... 
(k)Other major illness (please specify) 
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2 
 
2 	I 	3 
     
2 
2 
2 
    
ISeitiahltterait1inie4 - 	 - 	 :- 
03 	In the Jost 1Z months have you had any  of the following; 
circle one number on each line 
.. r._ .._. 	_ .... 
I (0) Allergies, hoy .feyer, sinusitis 
.(.9. D.'Lli.45f.V1".2155-'1 1.?'2r.! 	- ._ 
Chest pain 
1 
__.!.__ 
Sometimes Often 
3 1 I 	
I  
, 	
I  
3 
I- 
I  
(e) Heodoches/mIgraines 4 
(f) Severe tiredness 1 2 3 4 
(I/Stiff or_ELnf ul joints I 4  2 3 
(h) Back 	 r I 2 3 4 
. (I) A broken bone (fracture) 1 4  3 
(j) Urine that burns or stills 
.1._ 
1 	2 4  3 
Sk) Leaking urine 	. ._  1 3 	. 
V
'  
VI  
tips 
! 
3 
,Sm) Haemorrhoids/p./111s _ I 3 	. 
4 
(a) Vaginal discharge or irritation 1 2 3 
1 2 3 4 
( 	ImeVar monthperiods I 2 3 4 
( 	Premenstrual tension 
(s) Severe period pain 
3 4 
1 2 3 
(t1Hot flushes .. . 	
--I-- 
, 
1 3 4 
(1.11tattsweats 3 
(.9 Skin problems I 	i2 3 4 
(w)Eyesj9ht .problems 1 
(5) Hearing problems I 	2 3 4 
ly) Difficulty slespin9 1 	2 3 4 
16 	
17 
ApieiiIi3. I otlovt -up I postal questionnitirc 
L 
These next few questions aSk about screening.f or breast and cervical cancer. - 
El 
	
A breast examination Is when the breasts are felt for lumps to detect possible breast 
cancer. 
Have you gar had a breast examination by a doctor or other health professional? 
Yes 
No 	 2 	go to E4 
E2 	Do you have reaular breast examinations by a doctor or other health professional? 
Yes 
No 
	
2 	go to E4 
E3 	How often do you have a breast examination by a doctor or other health professional? 
Monthly 
6 Monthly 	 2 
Yearly 3 
Other (please specify.— 
E4 	Do you reoularly examine your breast for lumps? 
Yes 	 1 
No 2 go to E6 
E5 	How often do you examine your breasts? 
Monthly 1 
6 Monthly 2 
Yearly 3 
Other (please specify) ............ 4 
E6 
	
A mammogram is an X-ray taken of the breast by a machine that presses against the 
breast while the picture is taken. 
Have you gar had a mammogram?, 
Yes 
No 	 2 	go to EIO 
E7 	What is the usual  time period between your mammograms? 
Specify number of years 	ED 1 
Only had one 	 2 
18  
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Es When did you have your ka_q mammogram? 
Less than one year ago 
year to less than 2 years ago 
	
2 
2 years to less than 3 years ago 3 
3 years to less than 4 years ago 
4 years to less than 5 years ago 
	
5 
5 or more years ago 
	 6 
E9 	Why did you have this mammogram? 
Symptoms present 
Family history of breast cancer 
Had breast cancer in the past 
	
3 
General check-up 
	 4 
Don't know 
	 5 
Other (specify)._ 	 6 
Have you ever been diagnosed as having breast cancer? 
Yes 
• 
No 	 2 go to El2 
How old were you when you were first diagnosed with breast cancer? 
OD YEARS 	• 
A Pap Smear Test, sometimes called a Pap Test, Is a routine test carried out by a 
doctor or nurse. It is recommended for all women for early detection of canter of the 
cervix. 
Have you 'gar had a Pap Smear Test? 
Yes 
No 	 2 go to El5 
E13 When did you have your last Pap Smear Test? 
Less than 1 year ago 	 1 
1 year to less than 2 years ago 	2 
2 years to less than 3 years ago 	3 
3 years to less than 4 years ago 	4 
4 years to less than 5 years ago 	5 
5 or more years ago 	 6 
E14 What is the wad time period between your Pap Smear Tests? 
Specify number of years 	DE 1 
Less than one year 
Only had one 	 3 
19 
EIO 
Ell 
El2 
E15 Now we would like to ask you some questions about SMOKING 021 LNow we would like to ask you some questions about DRINKING ALCOHOL 
How often do you usually  drink alcohol? 
(circle one number) 
I never drink alcohol 
	
1 	go to Fl 
I drink rarely 
	
2 
Less than once a week 
	
3 
On I or 2 days o week 
	
4 
On 3 or 4 days a week 
	
5 
On 5 or 6 days a week 
	
6 
Every day 
	
7 
A "standard drink" is a small glass of wine or middy of beer, 
a nip of spirits, or a mixed drink 
E22 On a day when you drink alcohol, how many drinks do you loyally have? 
(circle one number) 
1 or 2 drinks per day 
	
1 
3 or 4 drinks per day • 
5 -8 drinks per day 
	
3 
9 or more drinks per day 
	
4 
E23 How often do you have five or more standard drinks of alcohol on one occasion? 
(circle one number) 
Never 	 1 
Less than once a month 	 2 
About once a month 	 3 
About once a week 	 4 
More than once a week 	 5 
Appi.milix 	Fo!low-up I postal questionnaire 
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Which of the following best describes your smoking status nog 
(circle one number) 
I hove never smoked 	 I 	Go to E21 
I used to'smoke 	 2 	Go to El6 
I now smoke occasionally 	3 	Go to 018 
I now smoke regularly 4 	Go to Eta 
016 If you ysetto smoke, how long ago did you give up smoking? 
(circle one number) 
Within the last 6 months 	5 
6 - 12 months ago 	 6 
1-5 years ago 	 1 
6-10 years ago 2 
11-20 years ago 	 3 
More than 20 years ogo 	4 
017 If you used to smoke, how many cigarettes did you usually smoke in a day? 
(circle one number) 
1-19 a day 
20-39 a day 	 2 
40-59 a day 3 
60.790 day 
80 or more a day 	 5 
003 If you gggi smoke, how many cigarettes do you usually smoke in a day? 
(circle one number) 
1-19 a day 	 1 	• 
20-39 a day 2 
40-59 a day 	 3 
60-79 0 day 4. 
130 or more day 	 5 
E19 At what age did you start smoking? ED YEARS 
,E20 Hove you gm smoked dolly for six months or more? 
(circle one number) 
YeS 
Na 	 2 
Never smoked 	 3 
20 	
21 
'hilt lip I pushal quest iotlimire 
umarkmam funk. 	::;r1;7 `",, P54Z1 
Fl What Is your date of birth? 
	rn/ rn/' 9 rn 
day • 	month 	year . 
F2 	What is your present marital status? 
(circle one mother) 
Married 
	
1 
De facto (opposite sex) 
	
2 
be facto (same sex) 3 
Separated 
	
4 
Divorced 5 
Widowed 
	
6 
Single 7 
• 
F3 	What Is the highest level of education you have completed? 
(circle one numbed 
Primary school 
Intermediate Certificate/Year 10 (or equivalent) 	2 
Higher School 6/or Leaving Certificate/Year 116 12 
3 (or equivalent) 
Trade/apprenticeship leg Hairdresser, Chef) 	 4 
Cereificate/diplorna (es Child Care, Technician) 5 
University degree 	 6 
Higher University degree leg Grad Dip. Masters, PhD) 	7 
F4 	Which of the following best describes your m_cid) current employment 
status? 
_At:2mm one 
On full thneiald work 
numo_st- 
1 
In art fime or casual paid work 2 
Woltwithoutzyleii_ a faitilly_buskLeEL_________ 3_________ 
Home dutiei_o l work 4 
_51Lidy79:elpaid work 5 
Unemployed - looking for work 6 
Unpaid voluntary work 	• 7 
Retired 8 
Unable to work due to sickness or injury . 9 
22  
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F5 	What Is/was your min occupation and If you have a partner, what Is their 
mo la oecaootlon?• 
saF PARTNER 	 -1 
(circle one weber foe yourself ono' one for partner) 0 (Mk bee it no partner) 	I 
Manager or Administrator (eg personnel manager, managing 
supervisor) 
i 1 
Professional (eg teacher, social worker, doctor, artist) 2 2 
Para-prof essionof leg welfare worker, technical officer. 
registered nurse, police) 
3 3 
Trade (9_hairdresser, cook, mechanic) 4 4 
Administrative assistant (9 secretn, tel 	1.92cnist) 5 
Sales and personal service worker (cg sales assistant, bar 
attendant, child care worker, enrolled nurse) 
6 
6 
Machineoperator or driver Sate_vi9 machinist) 7 7 
Manual worker leg labourer, cleaner, kitchenhand) 8 8 
Never had a paid job 9 9 
Othelease skui.._ 	 _I_ io . 10 
F6 	What is your total annual family income before tax (Including pensions and 
dividends)? 
(circle the number that applies to you) 
$O - $25,999 
$26 000 - 51,999 
	
2 
$52,000- 77,999 3 
$70,000- 103,999 
5104.000 • 
	
5 
F7 	Do you have anything else you would like us to know? 
•••••..,••••••••••••••,,•••.,••••••••••••.,••••••••••••••••••••••,.••••••••••••'••••••••••••••••• 	 1.• ••••••y• ••+•••••••••••..-•••• ••••••••••••••••-•••••••-•••••••••••.- 
• 1 
■ 
F8 	The results of this study will be available In approximately two years. 
Would you like as to send you a copy of the results? 
Yes 	1 	(please notify us of any change of address, if known write new address below) 
Na 	2 
23 
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Tall Girls Study 
The next stage of the study involves a telephone interview. If you agree to take part, you 
will be contacted by an interviewer from Millward Brown. This professional organisation will 
be conducting the interviews on our behalf. The interviewer will know only your first name 
and telephone number. They will not know about your assessment or treatment and will not 
have access to the answers you have provided in this postal questionnaire. 
So that we can arrange the telephone interview please 
• provide your telephone number(s) 
• indicate the times you can be contacted 
• complete the top part of yellow consent form, on the back page of this questionnaire, 
regarding the telephone interview. 
Telephone numbers (I) ( 	.) 	 ..home/work 
Best time(s) to contact you 
AM ' 
	
PM 	EVENING 
Monday 
Tuesday 
Wednesday 
Thursday 
Friday 
Saturday 
Sunday 
Finally, we would like to contact the medical practitioner who assessed or treated you, 
so that we can confirm details about your assessment and, if appropriate, treatment 
for tall stature. To give us permission, please complete the lower part of consent form, 
on the back page of this questionnaire. 
Your contribution has been very valuable. 
Thank you very much for the time and trouble you have taken 
in completing this questionnaire. 
Tall Girls Study 
FINAL CHECK LEST 
1 	1 If you have left your height measurement to do until a time 
before 12 midday, have you now filled in this height 
measurement (Cl)? 
2 Have you signed the consent form for the telephone interview 
on the adjacent page? 
3 If you are willing to provide contact details of your doctor or 
hospital where you were treated, have you completed and signed 
the lower portion of consent form? 
24 
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This rusilionhalre Includes lite 5/46' Health Survey. Stun Amber* Al to All i tHatetortiehhalre. 
Repretiured with 	1,,boel the Aletreal Outcomes Trtat, Crptviyht 1997. 
Appendix 3 Fullow -up I postul quesiionmire 
Study ID number: 	  
CONSENT FORM 
The long•term health and psychosoclal effects of - 
oestrogen treatment to reduce the adult height of tall girls. 
Chief InvestlgatOret 
DR ALISON VENN 
Centre fOr the Study of Mother, 6 Ch0dren's Health, 
La Tmbe University and Menzies Centre for Population 
Health Research, University of Tasmania 
PROFESSOR GEORGE WERTHER 
Centre for Hormone Research, Royal Chddren's Hospital Research Institute 
hone read end on the study information sheet. Any questions I have asked have been answered 
to my satisfaction. 
I agree to participate in the project by: 
• filing in the questionnaire 
• DWI:ling intonation on my current height and weight 
• participating in the telephone interview 
I realize I may withdraw at any Una. I pm that research data provided by ma or with my petrel's/on during the project may be 
Included in a Wale, presented at conferences and published In journals on the condition that neither my nun nor any other 
Identifying information Is used. 
Name of participant 	  
PROFESSOR JUDITH LUMLEY & DR PRISCILLA PYETT 
Centro for the Study Of MOtheri 
Children's Health. La Troll' Univesity 
26 
Signature 
 
Date 	/ 	 
 
(s) Consent to obtain medical Information 
We would like to contact the doctor(o) who assessed and/or treated you for tall stature. We will, however. only do this with 
your permission. We are requesting access to your medical records so that we can confirm details about your hetht 
assessment and. 0 applicable, your treatment for tall' stature. All the inforrnabon we collect will be kept confidential. The 
Information we collect wOO be used solely for the purposes of this  It study. 
Please provide us with (he name and addressfiss) of the doctor Or hospital who aSSeSsed or treated you for tail stature, and 
the year that you attended. If you are unsure of a doctor's name or address, please give us whatever information you do 
have. 
(1) Dr or hospital 	 Year attended 	  
Address —. 
	 State 	Postcode 	 
(2)Dr or hospital 	 Year attended 	  
Address ..... 
	 State 	Postcode 	 
Your wane 	 Maiden/other surname(s) used .. (print name) 
Your signature 	 Sate  	/• 
27 
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CONFIDENTIAL 
	
ID no: 	  
Date 
Interviewer .... . . . 
Time 
Time finish:... 	. 	. 
Yaff irk c4tUCry 
CATI Questionnaire 
-1-1ARI) COPY 
HI I'm _ 	- form La Trobe University 
Your answers to this questionnaire are confidential and your participation is voluntary. The 
questions I am about to ask include details of your 
• Menstrual and reproductive history, 
• Psychological wellbeing 
• and Sexual experiences. 
Preliminary research with treated and untreated tall women has suggested that these areas 
of women's health should be explored. 
The questions I will be asking hove been used In a number of other studies in Australia and 
elsewhere and everyone in this study will be asked this same set of questions. 
If at anytime you wish me to skip a question or stop this telephone call please let me know. 
This call may be monitored for quality assurance purposes, if you do not wish your call to be 
monitored please let me know. 
Now the first group of questions Is about your medical history 
particular your gynaecological health 
S
ix E .C.iTUCt A ATMiggrOTOWcinKlitaggginifee.,„NORP'S:" 
The first two questions are about whether you have had any gynaecological health 
problems or procedures 
If YES, 
In what year Old you 
Al Has a doctor ever diagnosed you as having (CONOITION)- FIRST have 
Ill read my list YES NO 	
(CONDITION). 
Endometriosis? 1 2 0000 
An abnormal Pap Smear or Smear Test? 1 2 0000 
Cervical dysplasia, LIN, or CIS? 1 Z0000 
[cervical intraepithelial neoplasia or carcinoma in situ] 
A benign tumour of the reproductive organs eg fibroid? 
if YES, specify 
1 2 0000 
00001 
Cancer of the reproductive organs 2 m00 
If YES, what kind of cancer? 0000 
..- 
Any other cancer? 2 0000 
If YES, what kind of cancer? 0000 
A2 Have you ever had (PROCEDURE)? n read Ty list 
If YES, 
In what year did 
you FIRST have 
YES 
(PROCEDURE)? NO 
A hysterectomy [removal of uterus Cl. ovaries] 1 2 MEC 
Exploratory pelvic surgery, eg. a laparoscopy [incision Into the 1 2 moo 
'abdomen to look at reproductive organs'? 
An ovarian cyst removed 2 EIEM 
Laser therapy of the cervix, cryosurgery or cautery of the cervix 2 0000 
Cervical suture or stitch [inserted during pregnancy] 2 0000 
Endometrial ablation [diathermy or laser of uterine lining] 2 0000 
Other gynaecologic surgery 2 
• If YES to 'other gynaecological surgery', 
• [please specify 0000 
A breast biopsy (sample of breast tissue] 2 0000 
A mastectomy [surgery to remove breast] 2 0000 
Other breast surgery 2 
• If YES to 'other breast surgery', 
• (please specify 
A2b(i) Have you ever had a Co d C [dilatation and curettage)? 
Yes 	 1 	(If Yes), how many have you had? 0 
No 2 go to A3 
A2b(ii) If yes, how many of your Da Cs were related to 0 
a pregnancy condition? 	 • 
MOO 
1 	 2 
Cl 	Have you ever been pregnant? Including all your pregnancies: miscarriages, stillbirths, 
terminations, molar or tubal pregnancies, as well as live births or current pregnancy. 
Yes, 	 I 	C2 
(if YES) how mcmr times have you 
been pregnant U 
go to Cl 	 No 	 2 	go to C19 
If YES, year 
first hod this 
(PROCEDUR 0_ _ _ 
REER  
•• 	• • • 	• 
SECTION:130.7iRe 	 __y_A sfo r.1.8.0imileo-dsvgartztNg., SE 	ON CITime4o first pregnan •,071,41,•.;44,..0,., 	 r:•;,. • 
These next few questions are about your ability to become pregnant 	 The next couple of questions I am going to ask are about becoming pregnant 
Have you ever tried to become pregnant for 12 months 
or more without succeeding? 
Hove you ever seen o doctor because you were having trouble 
getting pregnant? 
YES 
NO 
DK 
YES 
NO 
1 
2 
3 
I 
2 
YES NO DK 
Did you have (PROCEDURE)? I'll read my list 
To chart your temperature? 1 2 3 
A test of your hormone levels? I 2 3 
A post-coital test of your cervical mucus? I 2 3 
A hysterosalpingogram, an x-ray in which dye is put into the 
fallopian tubes to look for a blockage? 
1 2 3 
An endometrial biopsy, a sample of the lining of the uterus? 1 23 
A laparoscopy (incision into the abdomen to look at 
reproductive organs]? 
 3
81 
82 
83 
85a 
B5b 
84 ,)-las a doctor ever told you (or your partner) that you 	YES 	NO 	DK 
hove (DIAGNOSIS) r11 read my not 
a 	An ovulatory problem? 	 1 	2 	3 
b 	A tubal problem? 	 1 2 -.go to B4c 3 -• go to 84c 
(bi) If YES. was the problem in one or both tubes? One 	 3 
tuba 	Both tubes 
O A uterine problem? 	 I 	2 	3 
d A cervical mucus problem? 	 1 2 
. A hormonal problem? 	'. 1 	2 	3 
f 	Semen abnormalities? 1 2 3 
9 	Sperm antibodie-s2 	 1 	2 -.go to B4h 3 -4 go to 84h 
(91)rf YES. are the antibodies to your partner's 	1 2 	 3 
sperm? 
(911) If YES, does your partner have antibodies to 	I 	2 
his own sperm? 
h Any other identified fertility problem? 	1 	2 	3. 
(hi) If YES, what was the problem(s)? 
• An unexplained fertility problem 
	
1 	2 	3 
Have you ever taken fertility drugs for the treatment of infertility? 
Yes 
No 	 2 	go to CI 
If YES to taking fertility drugs, 	 00 number of cycles 
What is the total number of cycles of fertility Prompt 0 1-2, 	3-5, 0 6-11:0 ,12 
drug treatment that you've had? 
New t would iika to ask pent.. questions about egnancy(laS) rtorting syi1/1 yen. finer pr.gnwnny.  
CL in OW MONTH 
and YEAR did yaw (X) 
prearancy end? 
C3. How did your (M)preorarey end? 
Circle OM number below 
OR.N.o ....D 44 
Thu babrmit, at 
birth? boa. 
MULTIPLE 
eIRTHS 
CS. W.Va.. 
thishlwee baby 
(owes) born early. 
late ew an time? 
at* amber balm. 
C6. How many 
ffff  (eNDY, 
lataP 
a. Hew wow weeks 
did tIlla ragnanPY 
6s1 -from y.... last 
normal toanstrual 
period? 
00E000 
0 ..,,,,,, ,,,‘ 
'en. CU 
I Dm birth 	 ...(C4) 
2 rana,Th -.(a) 
3 ..i...,4.11.110.1..... 	-.)Cl) 
1 ineweeilekethw torrettatien 	..(a) 
5 nixel/eomple preeroney 	...(cf) 
6 Rohr prerowerAwdothl wale 	...(a) 
•• •. ,. 
• • Mil 
I - early 
2 - an time -4a) 
3 - late 
NMI •i•  
00 
who • r is 
MRS telnINANd — — Weeks 
:: :I: 
. 
00/0000 
0 kw.", MIN.. 
'en. CU 
l t.. birth 	 .4C4) 
""M"` ...(a) 
3 .g....4,164h.■ ...... 	-.(a) 
1 behmedfelmilvo terminotIon 	...(C7) 
5 Mal/adapts ptsratry 	-4C7) 
6 66661warme/ARdatH eala -47) 
• gy_kil 
•MAN 
• • •r• 
1 - early 
2 - on timt ..(a) 
3 . late 
f  "   ...- — Vne.C112 •• MIO 
WIRD 
I  
00/0000 
0 ....dr Nes* 
es to Cll 
1 Roe birth 	 -4K4) 
2 ,""" -la) 
3 mIsmw4srAdlehtefil ow.a. 	-4c7) 
4 indusedIMeetlos vervehwalea 	-.(C) 
5 Mal/oetopee pmsnaney 	..(a) 
6 orb" prterancyrhydand ' ,eh 	-.(a) 
_4 1 tL7g.n 
PAI-R. 
• OM • 
NM a • 
Is IN le IN 
• • mt. 
LI 	 OX 
I -.my 
2 . an time -..hO) 
3 - late 
OD 
maths - wo ft 
NWT FRECIONCV 
ar 1:11 
Ii  
00/0000 
ID anomaly pmemat os 
ts CO 
1 Bea birth 	 -.(C 
2 ..2114rth -.(a) 
3 misearebso/b4htad moo 	-40) 
4 IndwaulPolealos landowtion 	-4C7) 
I hladleshade pnenan'a 	-.OM 
6 Nair prayeary/h"datigl web 	..(a) 
U Up 
en 
• • • 
•,...gi 
I . .0, 
2 - ea Wm. -.(a) 
a- lee 
I 	
I t 
81117 
weeks 
ewnd Now would lin t. ash sena ohms elm. all A 	len 	wl 
CB. Did ystu 
.wwwewe. 
breastfewEng 
this baby? 
C9.14ow km did yaw 
baby have breast 
WOG*? 
C10. How Iona. &Sven 
breastfeed this baby 
all nvether Oncluelln9 
when tills baby Fad 
farnsAall/ar solids) 
CIla. Why did re step 
breastfeedIng this baby? (Ask at 
en sped ended wastian and enter 
numbers Me app41 
Sea table CM 
-C12a. If you didn't comment:a 
breastEnd this baby -what 
was the reason? OW tat an 
yea ended paeslhaa anal  
amber" that apply) 
Sae table CM 
C13. bid you 
manna that 
your [rem? 
increased In 
size while 
or. nom? 
BABY 
1 
YES H -. C9 
NO 	-. al 
' 	Days 
irk Week. 
III III /Mehl 
• awrently1.4.441. 
OL. NY. 111,. Weeks 
• ern.* bYeeitwe 
111 1 •1 Months  
ENTER NUMBERO) 
DOLE -.96 ta Cis 
ENTER NUMBER. 
DODO 
yes  U 
NO U 
BABY 
2 
YES C?H-. 
NO 	-. C12 
• l• Days 
a: Weeks 
• • Menthe 
• anew*, 10,mM, 
• • Day. 
Mill Waelw 
• • Montkt 
• sweet, Moans 
ENTER NI.INAs) onou-,...0, ENTER NUMBE R(s ) onalo 
• -ftjo to C 
YES U 
NO 0 
YES 8--- 
NO 
BABY 
I 
YES 	-. C9 
NO 	st Of 
II _ Days 
fly. W.A. 
• II Month* 
• a.rowntly M.A.. 
sil , 	Bats 
1. • Weeks 
• • Months 
swoon, Maar., : 
ENTER NUMBER(s) 
00E30 -4. e. CI3 
ENTER MINDEN') 
DODO 
-wm to C 
BABY 
4 
testj-t CS 
. NO UO2 
Ilya Days 
0111 Weal* 
AM Months 
• ammo* bleedlne 
116 D"..1. • 11 W 
• 1. *Wale 
• earrently Idiwading . 	b.y. 
• • Weeks 
IBM Months 
• wwwwwb lefiweR• 
ENTER NUMBER(s) oono -n. . C" 
. 
ENTER NtaAs) 
DODD -.go to C13 
ENTER NUMBER).) 
DODO 
-Dye to C 
ENTER NUMBEks) 
00.010 
-le N C 
YES 
NO 
1:1 
• 
YES H 
NO 
BABY 
5 
YES Ust CS 
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MILLWARD BROWN to set up for B pregnancies and for a breestfeeding *enclitics please 
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Triigiag.c ...,____IsAr4VdtaMANT:4114-.7iNgg*:, i: 	. -,,,, 	,..1, 
1 Didn't want to breastfeed or didn't want to breastfeed any longer 
2 Nipple trauma 
3 Nipple pain 
4 Felt there was not enough milk 
5 Unable to get baby to attach/suck/difficulties attaching the baby to the breast 
6 Baby very premature 
7 Lack of help/support/supervision with breastfeedinq 	 '  
Mastitis 8 
9 Recurrent mastitis 
10 Baby had poor weight gain 
11 Advice from professional -who (please state eq GP, psychiatrist) 
12 Employment reasons 
13 Baby lost interest/always looking around/stopping St starting feeding 
14 Breasts didn't fill or became engorged in first few days 
TABLE Cl 2b REASONS WHY NEVER ATTEMPTED TO BREASTFEED BABY 
1 
2-1 
Old not want to breastfeed 
Wanted to bottle feed 
3 Employment/work reasons 
4 Partner preferred meta bottle feed 
Family preferred me to bottle feed 
6 To avoid the discomfort/pain associated with breastfeeding 
7 Baby very premature 
B Body Image Issues 
9 Felt uncomfortable feeding in public 
10 So others could share the work of feeding/ caring far the baby 
11 To regain strength after the birth 
C14 The following questions ask about your FIRST preonancY - 
Before your first pregnancy, when you and your partner got pregnant, had you been 
(i) trying to get pregnant 	 1 	go to C16a 
(ii) trying NOT to get pregnant . 	2 
(iii) not concerned either way 3 
C15a Now I want to ask you a few questions about your use of contraception around the time you 
conceived your first Pregnancy - this Includes anything that might prevent pregnancy - such 
as oral contraceptive pill, condoms, diaphragm, withdrawal, safe days by the calendar, 
IUD's or any other method. 
Around the time you became pregnant, with your first pregnancy, were you or your partner using 
my method of contraception, for some or all of the time? 
Yes 	 1 
No 2 	go to C160 , 
Cannot remember 	 3 
C15b Was your use of contraception regular and consistent around that time or was it somewhat 
irregular? (Tick box that applies) 
regular and consistent 	 1 	go to C15d 
somewhat irregular 2 
Mc if YES. (somewhat irregular). for how many months in a 
row had you and your partner been using contraception 
somewhat irregularly before you became pregnant? no of months 
Cl5d Were you taking the oral contraceptive pill or using an IUD at this time? 
Yes 	 I 	go to C18 
No 2 	go to C18 
C16a Was taking the pill, the last method of contraception you used before you got pregnant? 
Yes 	 1 
No 2 	go to C17 
C16b if YES, some couples wait a few months after stopping the pill before letting themselves get 
pregnant. bid you use something to prevent pregnancy or avoid sex right after stopping the pill? 
Yes 	 1 
No 2 	go to C17 
if YES- for how many months did you tryto 
prevent pregnancy right after stopping the pill? 	00 No. of months 
0 Cannot remember 
C17 Some couples get pregnant right away when they have sexual intercourse without doing anything 
to prevent pregnancy, others take a long time, or need medical treatment. 
For your first pregnancy did you become pregnant during the first menstrual cycle of 
unprotected intercourse? 
Yes 	 go to CI8 
No 2 
if NO, the second month? 
Yes 	 I 	go to C18 
No 2 
if NO, the third month? 
Yes 	 I 	go to C18 
No 
Please estimate the number of months of unprotected 
intercourse before you became pregnant 	 Ei 	no. of months  
D4 	Some women keep a record or calendar of their menstrual cycles. Do you keep any kind of 
record of the dotes of your periods? That record could help you answer these questions. May I 
hold the phone while you get that record? 
YES 	 1 	go to 04b 
NO "that's "Me" 	2 go to D5 
D4b Record used 	 1 
Record not used 2 
D5 	On what date did your most recent period start? 
day 	month 	year 
D6 How suriare you, of when you had your last period? 
Are you very sure, fairly sure, or not so sure 
Very sure 
C18 During the month before you got pregnant, how many 
on average, did you usually have sexual intercourse? 
times a 	, Fairly sure 	 2 
Not so sure 3 
00 times per week 
0 Cannot remember 
D7 On average how many days of bleeding or menstrual flow do you have 
CI9 I am going to now ask you a couple of questions that you have already answered, so that I with your period? Count from the time bleeding or spotting starts 	number of days 
can skip to the next group of questions that will apply to you until it completely stops. 
Are you (or have you) 
YES 	NO 	OK , 	D8 Approximately, how often do you have cramps or backache, with your menstrual periods? 
Currently pregnant 	 I - go to D27 	2 	3 - go to D27 Would you say: 
Currently breast-feeding 	 1 - go to D27 	2 Never 	 I 	go to DIO 
Currently taking the oral contraceptive pill or any 
other prescribed hormone (READ HORMONE BOX)? 
1 - go to D27 	2 	3 - go to 027 Sometimes 	2 
Often ' 3 
Hormones include oral contraceptive pills, progestins, 
and oestrogens. 
Always 	 4 
DK 5 
Some are pills like premarin d provera 
Also, some forms are skin patches, like ertraderm, or 
suppositories. 
D9 When you have menstrual cramps or backache. how would you describe your pain? 
Had a hysterectomy 	 1 
Gone through menopause or the change of life 
- go to D27 	2 	3 
- go to 027 	2 	3 	go to 027 
4:1VORSM,41 
Would you describe your pain as mild, moderate or severe? 
[Interviewer to read list below] 
DEFINITIONS OF 'mild, moderate, severe pain" 
Your daily activities are not usually affected and pain mea'ication is rarely needed 1 
DI 
D2 
03 
The next few questions relate to your menstrual periods 
How old were you when you got your first menstrual period? 
AGE 	Years 
2 
3 
1 
2 
go to El 
go to D4 
Moderate Your daily activities may be affected, polo medication is often needed and usually 
relieves your pain 
Severe Your &WY-activities ore definitely affected. Pain medicotion is needed but ofte:i 
does not relieve the 
Mild 	 1 
Moderate 	2 
Severe 3 
Varies 	 4 
DK 5 
DK 
Never menstruated 
Do you still have periods? 
YES 
NO 
For what reasons have your periods stopped? 
..•- • • 	-• ^-• • 	. • •- 
IF "NO PERIODS" SKIP TO D16 
9 
	
l0 
010 The next three questions are about the LENGTH of your MENSTRUAL CYCLES 
On average, how many days are there from the first day of one period to the 
first day of your next period? 
	
DO 
Prompt (if too irregular to answer] days 
D11 What is the shortest menstrual cycle you've had in the last 12 months? 
Again, count how many days there are there from the first day of one period 
	rn 
to the first day of your next? 
	
days 
012 What is the longest menstrual cycle you've had in the last 12 months? 	
CO 
days 
• 
013 	During the last 12 months did you have any times when you had heavy gushing-type bleeding that 
was too much for your pods or tampons, even when you changed frequently? 
Yes 	 1 
Na 2 so to 014 
DI3b If YES, how often did this happen? 
Every period 	 1 
Most periods 2 
During occasional periods 
Just once 	 4 
OK 
014 During the past 12 months, did you ever go for more than 6 weeks without having a menstrual 
period? Please do NOT count times when you were pregnant, breastfeeding, or taking the pill. 
Yes 1 If YES, please explain why? 
016 
Have you aver 
consulted a doctor 
about the following 
(CONDITIONS)? /17/ 
read my list) 
a 	cramps or backache 
	
YES I 
associated with your 
	NO 2 .016b 
periods 
b 	irregular menstrual 
	
YES I 
cycles 
	 NO 2-.016o 
e PMS (pre-menstrual 	YES 1 
syndrome) 
	
NO 2 .-.016d 
d heavy or prolonged 
	
YES I 
menstrual bleeding 
	NO 2 -.017e 
e absence of a period for at 	YES I 
kart 6 weeks, not due to 	NO 2 -4016f 
pregnancy, breastf ending or 
taking the pill (probe when 
given a ).es'response) 
017 
If YES, in 
what YEAR 
did you first 
seek medical 
help for this 
010 
Have you 
ever taken 
prescribed 
medication 
for this? 
YES 1 
019 
Was the prescribed 
medication o 
hormone? 
(if YES read out 
HORMONE BOX 
below). 
If YES, go to 020 
YES 1 
NO 2 -.016b 
bK 3 -.016b 
YES 1 
NO 2 ..016c 
DK 3-•016c 
YES 1 
NO 2 -.01641 
OK 3 -.016d 
YES 1 
NO 2 .016e 
OK 3 -.016a 
YES 1 
NO 2 -.016f 
bK 3 -.016f 
YES 1 
NO 2 _.016g1 
OK 3 .0 i6gi 
YES 1 
NO 2-cool 
OK 3-,021 
020 
Are you now 
taking that 
hormone for 
this problem: 
YES I 
 
NO 2 
YES 1 
NO 2 
YES I 
NO 2 
YES 1 
NO 2 
YES 1 
NO 2 
NO 2 
YES 1 
NO 2 
YES 1 
NO 2 
YES I 
NO 2 
YES 1 
NO 2 
YES 1 
NO 2 
•YES 1 
NO 2 
 
f 	menopause 
	 YES I 
NO 2 -6016g 
gi 	other menstrual problem YES I 
NO 2 -.02I 
gii 	(please specify) 
000E3 
0000 
YES 1 
NO 2 
YES 1 
NO 2 
No 	2 
015 	Again, during the last 12 months, have you noticed any changes in: 
a the amount of bleeding with your Yes 1 If M, is it lighter now 	 1 
periods? Na 2 Heavier now OR 	 2 
Does it vary: sometimes lighter, 	3 
sometimes heavier 
b the total number of days of Yes 1 If MS, are there 
bleeding with your menstrual 
periods 
No 2 Less days of bleeding now 
More days of bleeding now OR 	2 
Does it vary: sometimes fewer days, 	3 
sometimes more 
c the length of your cycle, that is Yes 1 If YES., is it shorter now 	1 
the number of days from the 
first day of one period to the 
first day of the next 
No 2 Longer now OR 	 2 
Does it vary: sometimes shorter, 	3 
sometimes longer 
d the amount of cramping with 	• Yes 1 If YES, is the amount less now 	1 
your periods No 2 More nOw OR 	• 	 2 
Does it vary, sometimes less, 	3 
sometimes more 
(lORAfONE LIM Hormones include oral controceptim pills. progertins, end oestrogens. 
some ore pills like prernorM and proven.. 
Also, some forms are skin porches, like estroderm, or suppositories. 
Have you ever taken the oral contraceptive pill for any YES 1 
reason? 
	
NO 2 
	
go to 023 
For how many years, altogether, have you taken the 	YEARS 
	
MONTHS 
pill? -not counting the times you may have stopped. DEJ 
Have you ever had night sweats not due to illness? 
YES 
NO 
	
2 
D24 Have you ever hod hot flushes? 
YES 
NO 
	
2 
I No sweats and hot flushes — GO TO El 
025 	At what age did you start to have either hot flushes or night sweats? 
AGE 	 years 	 1 
DK 2 
D2I 
022 
D23 
11 	 12 
YES I 
NO 2 -.0306 
YES I 
NO 2 -.030c 
YES 
NO 2-.030d 
YES I 
NO 2 .2130e 
YES I 
NO 2-.030f 
0000 
0000 
0000 
0000 
0000 
026 	Have you had either hot flushes or night sweats in the last 3 months? 
Yes 	 I 	go to Et 
No 2 	go to E1 
1)27 	How old were you when you got yOur first menstrual period? 
reason? 
036 For how many years. altogether, have you taken the 
pill? -not counting the times you may have stopped. 
NO 2 go to 037 
DO months 
DO years 
030 
AGE 	years 
OK 
Never menstruated 
Have you ever 
consulted a doctor 
about the following 
(CONDITIONS)? 
(iv read my list) 
cramps or backache 
associated with your 
periods 
irregular menstrual 
cycles 
PM5 (pre-menstrual 
syndrome) 
heavy or prolonged 
menstrual bleeding 
absence of o period 
for at east 6 weeks, 
not due to pregnoncy, 
breastfeeding or 
taking the pill 
(probe ows response) 
menopause 
I 	continue 
2 	continue 
3 	go to El 
031 	032 	033 
	
034 
If YES, in 	Have you 	Was the Are you now 
what YEAR over taken 	prescribed 
	
taking that 
did you 	prescribed 	medication a 
	
hormone for 
first seek 	medication 	hormone? this 
medical help for this? 	(if YES read out 	problem? 
for this 	 HORMONE BOX 
If YES, go to 034 
YES I 	YES 1 	YES 1 
NO 2 .-.0313b NO 2 030b 	NO 2 
OK 3 D3Ob 
YESI 	YES 1 	YES I 
NO 2 -.1330. NO 2 . 030o 	• NO 2 
OK 3 -. 030c 
YES I 	YES 1 	YES 1 
NO 5 -.030d NO 2 030d 	NO 2 
OK 3-. 030d 
YES I 	YES 1 	 YES 1 
NO 2 -.030e NO 2 030. 	NO 2 
OK 3 -; D30e 
YES 1 	YES 1 	YES 1 
No 2 -.030f NO 2 030f 	NO 2 
OK 3-. 030f 
YES I 	YES! 	 YES! 
NO 2 -.0309 NO 2 030g 	NO 2 - 
OK 3 030g  
037 Have you ever had night sweats not due to illness? 
YES 
NO 
038 Have you ever had hot flushes? 
YES ' 
NO 
	
2 
No sweats and hot flushes - go to El (CIDI) 
039 	At what age did you start to have either hot flushes or night sweats? 
AGE 
	
years 
OK 2 
040 	Have you had either hot flushes or night sweats in the last 3 months? 
Yes 	 1 
No 2 
ASKCIDI NOW (sections E. F. G) saying this introduction 
"The next group of questions cover some areas that may be personal or sensitive, and you are 
under no obligation to answer them. Please keep in mind that your answers are treated 
confidentially and your openness would be gratefully appreciated.' 
The questions ask about depression and eating problems and they come from standard 
questions used in psychological health and well being surveys." 
Thank you ...... Now we come to the last, group of questions. 
028 On what date did your most recent menstrual period start? (if hod hysterectomy ark when 
LAST menstrual period was, can give guesstimate) 
/1:10 /EEO: 
day 	month year 
029 How sure are you, of when you had your last period? Are you: 
Very sure 	 1 
Fairly sure 2 
Not so sure 	 3 
YES I 
NO 2 -.030g 0000 
g 	other menstrual 
problem 
gi (please specify) 
YES I 
NO 2 -.035 
YES I 
0000- NO 2 -.035 
YES 1 
NO 2 D35 
OK 3-.032 
YES 1 
NO 2 
035 Have you ever taken the oral contraceptive pill for any YES 1 
13 
	
14 
PROMPT: If- Can't remember or unsure response "As close as you can remember?'  
If still unsure PROMPT - Were you under 182, 172, 16.a, 152, 142. 
If still unsure PROMPT- 	you remember if you were at school? hod left school?" 
CriaN.  
These questions ask about your sexuality and sexual health, that is your teenage and adult sex life. They 
are all questions used in standard surveys about sexual issues. If you feel uncomfortable about any of 
these questions, you do not have to answer that question. It is important for the validity of the study 
that women provide honest answers, so we would really appreciate it if you can answer as many as 
possible. 
I-11 	Do you currently have a regular sexual partner? Someone you have an ongoing sexual 
relationship with? 
Yes 	 1 
No 2 	go to HB 
Refuse to answer 
142 	Do you live with your regular partner? 
Yes 	 1 
No 2 
Refuse to answer 	 3 
143 	How long have you been in this relationship? (including any time before you were living 
together) 
Less than I year. 	 1 
More than 1 year but less than 2 years. 	2 
More than 2 years but less than 5 years. 3 
More than 5 years but less than 10 years. 	4 
More than 10 years but less than 20 years. 	5 
More than 20 years. 	 6 
VFMNWERtIVROFF 
144 	How many times in the past 4 weeks have you had sex with your partner? Even if this 
wasn't typical for you. Not Just intercourse but including other forms of sex. 
DO times 
Can't remember. 
Refuse to answer 
145 	Thinking now about your relationship with your partner. How physically pleasurable do you 
find sex with your partner to be? (is. within the last 12 months] Is it_ 
Extremely pleasurable. 	1 
Very pleasurable. 	 2 
Moderately pleasurable. 	3 
S lightly  pleasurable. 4 
Not pleasurable at all. 	5 
Refuse to answer  
146 	How emotionally satisfying do you find your relationship with your partner to be? 
tie, within the last 12 months] Is it_ 
Extremely satisfying 
Very satisfying 
	
2 
Moderately satisfying 
	
3 
Slightly satisfying 4 
Not at all satisfying 
	
5 
Refuse to answer 6 
H7 . Is your partner? 
Male 
Female 
	
2 
Refuse to answer 
	
3 
H8 	How old were you when you first had sex ie, sexual intercourse? (if necessary, 
clarify this means vaginal intercourse) 
OD Years 
Can't remember (PROMPT HERE-see list below) A 
Refuse to answer 	 B (after 3 continuous refuses to answer H161 
Never had intercourse 	 C go to H16 
(Any other information/comments offered by respondent) 
H9a In your whole life, how many men have you had sex with (ie, sexual intercourse)? 
0 	 A ge to H120 
DO number of men 
Can't remember 	[PROMPT HERE-see list below] C 
Refuses to answer 
H9b 
	
PROMPT: 'Would that be" 
0 1 	(If .6 men ask respondent to be 
	
0 6-10 
	
(.6 men do NOT need to be 
0 2 	exact and write number 
	
0 11-20 	exact) 
0 3-5 	in box above) 
	
0 .20 
H10a In the last 5 years [that is, since month year], how many men have you had sex 
15 
	
16 
	0 6-10 	(16 men do NOT need to be 
0 11-20 	exact) 
HI0b PROMPT:Would that be, 
01 	af .6 men osk respondent to be o I 	exact and write number 
in box above) 
0 6-10 	(.6 men do IVOT need to be 
' 	11-20 	exact) 
Hllb 	PROMPT: 'Would that be 
I 	gf .6 men ark respondent to be 
U 2 	exact and wile number 
In box above) 
0 6-Jo 	(6 women do NOT need to 
0 11-20 	be exact) 
DO number 
Can't remember 	(PROMPT HERE) C 
Refuses to answer 
H14b 	PROMPT: 'Would that be'? 
01 	(If .6 women ark respondent to be 
0 2 	exact and write number 
in box above) 
Yes 
No 
1 
2 
Ifk, ett,K AVAnalfg1 ;;f:::- 
4-6) 
Heterosexual/straight (normal) I 
Lesbian (or gay) 	 2 
Bisexual 	 3 
Queer 	 4 
Not sure: undecided 	 5 
Something else 	 6 
Other (specify) _ 7 
Refuse to answer 	 8 
0 6-10 	(,6 women do NOr need to 
12 II-20 	be exact) 
HI3b 	PROMPT: "Would that be, • 
0 1 	(If women ask respondent to be 
0 2 exact and write number 
in box above) 
2 
YES (please notify us of any change of address) 
NO 
with (ie, sexual intercourse)? 
0 	 A 	go to H12a 
DO number of men 
Can't remember (PROMPT HERE) 	C 
Refuses to answer 
H11a Di the last 12 months [that is, since month year], how many men have you had 
sex (le, sexual intercourse) with? 
0 
DO number 
Can't remember (PROMPT HERE) 
Refuses to answer 
H12a 	In your whole life, how many women have you had sex with? [that is, oral sex, or 
other forms of genital contact] 
O A 	go to H15 
D O number 
Can't remember 	(PROMPT HERE) 
Refuses to answer 
HI2b 	PROMPT. 'Would that be'? 
0 1 	(rfo600menoskrespondenttobe 
02 	exact and write number 	 0 11-20 	be exact) 
is box above) 
H13a 	In the last 5 years [that is, since month year], how many women have you had 
sex with? 
O A 	go to H15 
D O number 
Can't remember 	(PROMPT HERE) 
Refuses to answer 
A 	go to H12a 
0 6-10 	(x3 women do NOT need to 
H14a 	In the last 12 months [that is, since month year], how many women have you had 
sex with? 
O A 	go to H15 
17 
H18 	The results of this study will be available in approximately two years. 
Would you like us to send you a copy of the results? 
18 
Ufgatc e-47INItiWer17 473,—FILt.e.W.NMEEPI "c7.0. -RtIVORSW, 
HIS During sex do you worry whether your body looks unattractive? 
Refuse to answer 	 3 
Comment' 
Interviewer- P/ease record any comments, eg Well, Sometimes, Don't think about it, Depends who 
with etc 
H16 	Do you think of yourself as Read out the categories 1-3- if other response then click on 
H17 Do you have anything else that you would like us to know? 
We have finished the main questionnnaire now and 
THANK YOU for answering all those questions. 
There are just a COUPLE OF GENERAL QUESTIONS to finish with — 
We may do more research in this area and would like to know if you would be happy to be 
contacted again 
YES 
NO 
Think about it 
Thank you very much for your help with this study. 
' INTERVIEWER'S COMMENTS (-from notes taken during interview) 
• 
19 
Literature review of studies that examined the influence of tamoxifen and GnHRA 
use on mammographic density 
Appendix 5: Literature review of studies that examined the influence of tamoxifen and GnHRA use on 
mammographic density. 
Tamoxifen and mammoqraphic density 
A review of the literature identified one cross-sectional and nine longitudinal studies that had 
examined the association between tamoxifen use and mammographic density. These are presented 
in Table A5.1. 
Ursin et al. (1996)' appeared to be the first to hypothesize and test an association between 
mammographic density and tamoxifen use. Their preliminary study of 19 women, compared 
mammographic density before and 12 months after breast cancer treatment with tamoxifen, across 
three treatment arms: radiation only, tamoxifen with or without radiation, and chemotherapy with 
our without radiation. Change in density was assessed by a crude subjective five point sale and 
tamoxifen had a more favourable score, demonstrating a greater reduction in density, compared 
with the other treatment groups (p=0.03). 
Of the eight longitudinal studies since published, all observed a reduction in mean 
mammographic density, Wolfe grade, or other qualitative scaling system, in tamoxifen users. Those 
that reported change in percent density included Descenci et al. (2007) 2 , Brisson et al. (2000) 3 , 
Cuzick et al. (2004) 4 (Boyd scale) and Chow et. al. (2000) 5 . Reductions of 15.4%, 5.8%, and 6.4% 
in mean density were observed in tamoxifen users compared with riOn-users over a period of 1-4.5 
years, for the first three of these studies, respectively. Chow et al. (2000) 5 reported a 4.3% mean 
density reduction with tamoxifen use per year over a period of 2.5 years. 
In contrast to the findings of the longitudinal studies above, a cross-sectional study by 
Tiersten et al. (2004)6 failed to find an association between tamoxiferi use and mammographic 
density in BI_RADS categories or % density. This study had a small sample size, and study 
participants were selected regardless of stage or age at time of breast cancer diagnosis or treatment. 
This is reflected in the large difference in ages between the tamoxifen and control groups (Table 
A5.1). The effect of tamoxifen on mammographic density might be modified by age or stage of 
disease or treatment. Cuzick et al. (2004)4 found age to modify the effect of tamoxifen on 
mammographic density. In women 45 years or younger,.tamoxifen appeared to reduce 
mammographic density by 13.4% (95% CI: 8.6 to 18.1) in contrast to a reduction of 1.1% (95% CI: 
3.0 to 5.1) in women 55 years of age or older4 . 
9 
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mammographic density. 
. As for HRT, it appears that the effect of tamoxifen on mammographic density lasts for only 
as long as treatment is continued. Slanetz et al.(2004) 7 reported a case-study of a premenopausal 
woman whose mammographic density returned to normal after she stopped taking tamoxifen. 
Konez, Goyal and Reavan 8 similarly observed a reversal of effect in 13 of 16 (48%) of women 
whose density previously reduced with tamoxifen use.. 
Gonadotropin releasing hormone agonist (GnRHA) 
Three studies associated to the same investigative team have examined the effect of GnHRA on 
mammographic densities and these are described below. 
In a US study (1994) 9, 21 premenopausal women with a high risk of breast cancer were 
randomly assigned to GnRHa (n=14) treatment or a control group (n=7) and followed up after a 
period of 12 months. The GnRHA treated women were also provided with 'add-back' estrogen and 
a cyclic progestagen. These steroids were taken in low doses to reduce exposure to the breast while 
benefiting the cardiovascular and endometrial system. Compared to baseline, GnRHa treated 
women who had adhered to treatment had a greater reduction in mammographic density (measured 
visually) compared with untreated women (p =.04). (See Figure A5.1 for three examples of breast 
density reduction). 
Gram et al. (2001) 1°, described a further follow-up of the previous study's 
cohort. This follow-up measured % density using a more robust computer thresholding technique 
described in Chapter 6. Women were followed for a period of 24 months while on treatment, and 6- 
12 months after completion of treatment. Consecutive reductions in percent density from baseline 
were observed; 9.7% (+/-3.5%; p=0.01) and 11.4% (+1-3.5%, P=0.01) after 12 months and 24 
months, respectively. No statistically significant change was observed in the control group —3.2% 
(+1-3.0%) (p=0.30), —2.5% (+1-2.5) (p=0.47), at 12 months and 24 months, respectively. The 
reduction in densities was not sustained after cessation of treatment. Six to twelve months after the 
completion of treatment, mean percent mammographic density returned to baseline levels (See 
Figure A5.2). 
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Table A5.1: Studies that have examined the association between tamoxifen use and mammographic density. 
Study Country Study type Method of 
Measurement 
Age 
(Mean) 
Meggiorini et al. Italy Longitudinal BI-RADs Controls (80) 63.9 
(2008) II (12 months) Tamoxifen (68) 58.5 
• _ 
Decensi et al. Italy Longitudinal- % density Placebo and 54 
(2007) 2 RCT 
(12 months) 
Tamoxifen -1 mg/day, 
5mg/day orlOmg per week 
T 	- Tiersten et al. US Cross-- sectional BI-RADS Controls (never used) (29) 51 
(2004) 6 % density 
categories 
Tamoxifen (ever used) (13) 64 
CuZick et al. UK Longitudinal Boyd Placebo (430) 
(2004) 4 (54 months) Category* 
Tamoxifen (388) 
Konez, Goya! 
; and Reaven 
(2001)8 
US Longitudinal - 
(2-3, 5 years 
and 1 year 
following 	• 
Wolfe grade 
densiometer 
Tamoxifen (24) 67 
discontinuation 
of treatment) 
Results 
More women reduced BI-RADs 
category in tamoxifen group 
compared with non-tamoxifen 
group (p=0.021) 
Tamoxifen, particularly in the 
larger dose of 5 mg/day, induced • a 
larger reduction in mean 
mammographic density compared 
to placebo 
Density did not 
correlate significantly with ever, 
never, current, or duration of 
tamoxifen use.(No data presented) 
• - 7.3% change from baseline 
(95% Cl: 6.1,8.4) p<0.001 
- 13.7% charige from baseline ( 
95% CI:12.3,15.1) p<0.001I 
21% experienced reduction in 
Wolfe grade 
60% experienced reduction based 
on densiometer .  
. 	 . 	 . 
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Study 	 Country Study type 	Method of 	N 
	
Age 	Results 
Measurement (Mean) 
Chow et al. (2000) . 	Longitudinal 	% density** 	Control (20) 
(up to 2.5 yrs) 
Tamoxifen (32) 
Brisson et al. 	Canada Longitudinal 	Wolfe grade Placebo (33) 
(2000)3 
	
(3.4 years) 	% density 
Tamoxifen (36) 
Atkinson et al. 	UK 	Longitudinal 	Wolfe grade Control (188) 
(1999) 12 	 (14 months) 
Tamoxifen (94) 
Son and Oh 
	
Korea 	Longitudinal 
(1999) 13 (22 months) 
- - 
Ursin et 	US 	Longitudinal 
al.(1996) 1 (12 months) 
51 	+/- 0% per yr p= 0.88 
50 	- 4.3% per yr p=0.0007  
50 	-3.6% mean percent density 
15.2% experienced reduction in 
Wolfe grade 
-9.4% mean percent density 
51 	(p=0.01 vs placebo) 
44.4% experienced reduction in 
Wolfe grade 	_ _ 
59 	+ 0.03 change in Wolfe grade 
score (mean)t (p=0.06 vs 
baseline) 
- 0.37 in Wolfe grade score 
(p=0.001 vs baseline) 
28.6% had category decrease 
59.8% had category decrease 
_ 
44 	0.10 score 
39 	0.38 score 
40 	0.13 score 
Horizontal 
axis 
multiplied 
by vertical 
axis 
Subjective 
scale 
Control (io) 
Tamoxifen (102) 
Radiotherapy 
Tamoxifen and radiotherapy 
Chemotherapy and 
radiotherapy (n=19 in total) 
* Boyd Categories: 0%, 1%-10%, 11%-25%, 26%-50%, 51%-75%, 76%-100%. 
** Also used Wolfe Grade and BI-RADS which analysed as continuous category scores 
t Mean of scores assigned to each Wolfe Grade: 1 for the most lucent (Ni) pattern, 2 for PI, 3 for P2, and 4 for the most dense (DY) pattern. 
Regression coefficients for tamoxifen treatment did not differ between univariable and multivariable models — including age and BMI. 
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Appendix 5: Literature review of studies that examined the influence of tamoxifen and GnHRA use on 
mammographic density. 
Figure A5.1: Mammograms at baseline (left) and 12 months on GnRHA (right) for 
three participants in the study by Spicer et al. 9 
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Appendix 5: Literature review of studies that examined the influence of tamoxifen and GnHRA use on 
mammographic density. 
Figure A5.2 Changes in the percent mammographic density from baseline in 13 
women treated with GnitHA. Sourced from Gram et al. 10 
The same investigative team undertook a third study on the association between GnRHA 
and mammographic density in women with a high risk of breast cancer. To be eligible in the 
previous studies, women either had to have a first degree relative with bilateral breast cancer before 
50 years of age, or have had a prior personal diagnosis of lobular carcinoma in situ. In the later 
study (2007), women had to have had a deleterious BRCA I mutation. In this study of only 6 
women, the median 12 month reduction in percent mammographic density, measured using a 
computer thresholding technique, was 8.3%; p = 0.04. The authors suggested that breast cancer risk 
could be reduced in BRCAlmut carriers by the GnHRA regimen. 
While the treatment regimen involved 'adding back' estrogen and a cyclic progestagen, the 
overall effect of treatment was to reduce the serum levels of estrogen below normal levels (Spicer et 
al. 1994)9 . From the evidence available this reduction appears to result in a corresponding reduction 
in mean riercent density during treatment with GnRHA. 
Overall, the evidence presented above suggests that the 'anti-estrogens' tamoxifen and 
GnHRA reduces mammographic density at least for the duration of treatment. 
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Literature review of studies that examined the association between endogenous 
estrogen and mammographic density 
Appendix 6: Literature review of studies that examined the association between endogenous estrogen levels 
and mammographic density. 
• 
Circulating estrogens and mammographic density in postmenopausal women 
•A search of the research literature identified eight studies that had examined the association 
between circulating estrogen levels and mammographic density in postmenopausal women. These 
are summarised in Table A6.1. The three forms of circulating estrogen examined in these studies 
included plasma estradiol (free form and bound) and estrone. One study by Warren et al. (2006)' 
also looked at estrone sulfate, a derivative of estrone. As can be seen in Table A6.1 three studies" 
found no association between each of the estrogens measured and mammographic density. One 
study4 observed a statistically significant negative association between percent mammographic 
density and each of the three estrogen types measured but only in women who had used HRT 
previously. No association was observed in women who had never used HRT (data not in table). 
Two studies observed a statistically significant positive association 8 '6 between each of the estrogens 
measured and mammographic density, while two studies observed an association with only one 
form of estrogen, but not other forms 7 ' 8 . Of these, Boyd et al. (2002) 7 observed a negative 
association between mammographic density and free estradiol, but not n with bound estradiol, while 
Bremnes et al. (2007) 8 observed no association between mammographic density and either form of 
estradiol, nor estrone but did observe a positive association with estrone, but only if IGF-I levels 
were below the median value for the cohort. 
These studies differ across a number parameters including the time period between 
mammographic density measurement and the taking of blood samples for hormone measurement 
(e.g. zero difference in the studies by Verheus et al. (2007) 3 , Bremnes et al. (2007) 8 and Greendale 
et al. (2005) 6 and a median/mean difference of eight months in studies by Tamimi et al. (2005) 2 and 
Boyd et al. (2002) 7, cohort mean estrogen levels and % mammographic density, and sample size 
(Table A6.1). There appears, however, no pattern between the observations of the studies and these 
differences. 
• All studies had assessed the effect of age and BMI/body fat/weight on the association 
between estrogen and mammographic density. Tamimi et al: (20 .05) 2 and Verheus et al. (2007) 3 
observed a negative association between each of the measured estrogens and 
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and mammographic density. 
mammographic density but the association diminished once the investigators adjusted for 
BMI/weight height ratio. In contrast; Greendale et al. (2005)6 initially observed no association 
between plasma estrogens and percent mammographic density until they adjusted for BMI, after 
which a positive association was observed. BMI and estradiol levels have been reported to be highly 
correlated9 . According to the Melbourne Collaborative Cohort study I°, total and free estradiol has 
been shown to be highly correlated with BMI but only after six years post-menopause. 
BMI is negatively associated with percent density". It is believed that this association is 
largely due to the dependence of percent density on non-dense area (fatty area of the breast). It is 
therefore important that BMI is considered in any association concerning percent density. Yet, 
adjusting for BMI might mask the influence of estradiol levels because of the correlation between 
estradiol levels and BMI. 
Dense area might be a more suitable measure because dense area is not as strongly 
. associated with 13M1 12 . While four studies examined the association between dense area and 
endogenous estrogen levels, all, except the study by Verheus et al. (2007) 3 presented BMI adjusted 
coefficients. The effect that adjusting for BMI had on any association between mammographic 
density and endogenous estrogen levels was not detailed in these reports. However, the study by 
Verheus et al. (2007)3 suggests that BMI is not masking an association between mammographic 
density and estrogen levels. This study observed no association despite the lack of BMI adjustment. 
Circulating estrogens and mammographic density in pre -menopausal women. 
Three studies examined the association between plasma levels of estrogen and mammographic 
density in pre-menopausal women (Table A6.2). None of these studies found an association 
between mammographic density and each of the estrogens measured including the study by Meyer 
et al.(1985) 13 which examined urine levels of estradiol,.estrone and estriol. 
Postmenopausal women don't encounter the cyclic fluctuations in hormone levels observed 
in premenopausal women, therefore, the timing of hormone measurement in these studies should 
not be an issue (see Figure A6.1). In the studies on pre-menopausal women, all hormone 
measurements were taken during the luteal phase of the menstrual cycle.. 
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Appendix 6: Literature review of studies that examined the association between endogenous estrogen levels 
and mammographic density. 
Figure A6.1: Levels of plasma estradiol across the stages of the menstrual cycle. 
Sourced from Rosenberg et al. (1994) 14 
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	0.63 	Adjusted: age, waist, and sex 
0.03 hormone binding globulin (SHBG) 
Adjusted: age, BMI, parity, prior use 
of HRT, time since last HRT use, 
interaction between latter two 
0.76 
0.06 
0.014 
0.009 
0.018 
Table A6.1: Cross-sectional studies of association between circulating estrogen and mammographic density in 
postmenopausal women. 
Study Country N Density 
Measure 
Hormone 
Aiello et al. US 88 % density Estrone 
(2005)4 Estradiol 
Free estradiol 
• Dense area Estrone 
Estradiol 
Free estradiol 
Tamimi et 
al. (2005)2 
US 520 % density Estrone 
Estradiol 
Free estradiol 
Dense area Esirone 
Estradiol 
Free estradiol 
Boyd etal. Canada 189 % density Estr'adiol 
(2002)7 Free estradiol 
Dense area Estradiol 
Free estradiol 
Greenda le 
et al. 
US 404 % density Estrone 
Estradiol 
(2005)6 Free estradiol 
Association 	P=value 	Conditions/Adjustments 
0.01 
	
Association in former HRT users 
0.003 only 
0.004 
NS 
	
Adjusted: age, body fat, years since 
menopause, ethnicity 
0 0.81 
• 0 0.88 
NS 
0 	0.55 Adjusted: age, BMI 
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Study Country N Density 
Measure 
Hormone Association P=value 
Verheus et 
al. (2007) 3 
Netherlands 775 % density Estrone 
Estradiol 
0.12 
0.58 
Free estradiol 0.34 
Dense area Estrone NS 
Estradiol 
Free estradiol 
Bremnes et 
al. (2007)8 
Norway 772 % density Estrone 
Estradiol 
Free estradiol 
0 
0 
p-trend 0.07 
p-trend 0.42 
p-trend 0.69 
Estrone +ve 0.02 
Johansson 
et al. 
Italy 226 % density Estradiol 0.04 
(2008) 5 
Warren et al UK 1,413 . % six Estrone 0.93 
(2006)' category Estrone sulfate 0 0.98 
Estradiol 0 0.91 
. - 	- Adjusted: age, BMI, number of 
children, age at menopause, and HT 
use 
If IGF-I levels below median 
Adjusted: age, BMI 
Adjusted: BMI, parity, cigarette 
smoking, years since menopause, 
and age at menarche 
Age was significantly associated 
with density, but not included in the 
models because it was collinear with 
years since menopause, which was 
felt to be the more biologically 
relevant measure 	• 
Conditions/Adjustments 
Adjusted: BMI (other variables 
including age were added to the 
model but had no effect on the 
association) 
21 
Association P-value 
0 0.29 
0 0.17 
0 0.45 
0 0.77 
0 0.42 
0 0.91 
0 0.36 
0 0.40 
0 0.47 
0 0.85 
NS 
0 
Adjusted 
Adjusted: age, weight, height, 
ethnicity, age at menarche, parity, 
age at first livebirth 
Adjusted: age, waist, and sex 
hormone binding globulin (SHBG) 
Table A6.2: Cross-sectional studies of association between circulating estrogen and mammographic density in 
premenopausal women. 
Study Country N Density Measure Hormone 
, Noh et al. US 204 % density Estrcine 
(2006) 15 Estradiol 
Free Estradiol 
Dense area Estrone 
Estradiol 
Free Estradiol 
Boyd etal. Canada 1931 % density Estradiol 
(2002)7 Free estradiol 
Dense area Estradiol 
Free estradiol 
Meyer et al. US 110 Wolfe grade Estrone (urine) 
(1986)u Estradiol 
(urine & 
plasma) 
Estriol (urine) 
22 
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Appendix 7: Evidence of an association between IGF-I and mammographic density 
IGF-I and Mammographic Density 
A number of epidemiological studies have examined the association between IGF-I and 
mammographic density. The findings of these studies are relevant to this PhD study because girls 
treated with high-dose estrogens for tall stature have been shown to have reduced circulating IGF-I 
levels throughout the duration of treatment. 
A search of the research literature identified one prospective and ten cross-sectional studies. 
The cross-sectional studies are summarised in Table A7.1. Nine of these examined the association 
in postmenopausal women. Of these, only one' observed a positive association between IGF-I and 
mammographic density. Of the seven that studied the association in premenopausal women, four, 
including the large study by Diorio et al. (2005) 2 observed a positive association for both percent 
density2 and dense area3 . Two of the three studies that did not observe a statistically significant 
association had sample sizes below 250 and according to Diorio and colleagues 2, were not large 
enough to provide the power to detect a significant association of the size demonstrated in their 
study for percent mammographic density (correlation coefficient r=0.08, p= 0.02). The third of 
these studies, by Maskarinec et al. (2007)4 involved a pooling of four different ethnic cohorts from 
different locations. According to the investigators of this study, variations in the timing between 
mammograms and the taking of blood samples and incomplete controlling for confounding 
variables across the four sub-studies may have affected the results. 
An important prospective study undertaken by Verheus et al. (2007) 5 examined the 
menopausal transitional change in mammographic density with premenopausal IGF-I levels. These 
investigators followed up 684 premenopausal women from the PEPI-Cancer and Nutrition cohort 
through to menopause. They found that women with higher premenopausal IGF-I levels had smaller 
increases in non-dense area and a slightly smaller decrease in dense area during menopause, 
resulting in higher breast density after menopause. This suggests that postmenopausal 
mammographic density is dependent on premenopausal levels of IGF-I. This study (not incliided in 
Table A7.1) did not find an association between premenopausal IGF-I levels and mammographic 
density. 
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• Overall the evidence for an association between mammographic density and IGF-I is still 
inconclusive, but based on the larger of the studies summarised in Table A7.1, it appears that a 
• 
positive association is likely, particularly in premenopausal women. These findings on 
mammographic density and IGF-I, at least for premenopausal women, are consistent with the effect 
of IGF-I on the proliferative activity of mammary tissue shown in animal 6-9 and primate studies. 
The findings are also consistent with the positive association between IGF-I and breast cancer risk 
described earlier in Chapter 3, Section 3.3.4.3. It is possible that levels prior to menopause, when 
levels are typically higher, particularly adolescence (see Figure A7.1), contribute more to 
mammographic density than postmenopausal levels. A prospective study by Verheus et al.(2007) 5 
suggests that postmenopausal mammographic density is dependent on premenopausal levels of 
IGF-I. Based on the evidence above, it is plausible that treatment with high-dose estrogens for the 
treatment of tall stature in adolescent girls could reduce mammographic density. Treated girls have 
been shown to have reduced levels of IGF-I as described in Chapter 2. 
Figure A7.1: Range of plasma IGF-I levels (ng/ml) by age (years) for normal males and 
females. Sourced from Le Roith (1997) 11 
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' Maskarinec et al. 	US 	525 pre, 
, 20074 	 802 post 
US 
% density IGF-I 
IGFBP-3 
IGF-I/IGFBP-3 
Aiello et al. 
2005 12 0 
>0.15 
>0.29 
0.04 
% density IGF-I 
IGFBP-3 
IGF-I/IGFBP-3 
88 post 
dos Santos Silva 	UK 	215 pre - % (tensity IGF-I 
, et al. 2006 13 241 post 	 IGF-II 
IGFBP-3 
IGF-I/IGFBP-3 
Dense 
area 
IGF-I 
IGF-II 
IGFBP-3 
IGF-I/IGFBP-3 
0.83/0.57* 
0.91/0.67 
0.67/0.67 
0 	>0.15 
0 
0 
0 
Adjusted: ethnic/location 
group, age, BMI, digital 
mammogram, parity, age at 
menarche, age at first live 
birth and HRT use, and IGF-
I or IGFBP-3 where 
appropriate. 
Association in former HRT 
users only. Adjusted: age, 
body fat, years since 
menopause, ethnicity. _ 
Adjusted: age, time since 
blood collection, age at first 
birth, BMI, waist 
circumference, smoking 
habits, past oral 
contraceptive use and serum 
levels of IGFBP-3/IGF-- 
I/IGF-II 
Table A7.1: Cross-sectional studies of the association between plasma IGF-I and mammographic density. . 
Study 	Country 	(N) 	Density 	Hormone 	Association 	P-value 	Conditions/Adjustments 
Pre/Post 	Measure Pre/Postmenopausal 
menopause 
Non- 	IGF-I 
dense 	IGF-II 
area 	IGFBP-3 
IGF -I/IGFBP-3 
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Study Country (N) Density Hormone Association P-value 
Pre/Post 
menopause 
Measure Pre/Postmenopausal 
Boyd et al. 2002 14 Canada 193 pre % density IGF-I +10 0.03/0.48* - 
189 post IGFBP-3 0/0 0.95/0.57 
Dense IGF-I +/O 0.05/0.43 
area IGFBP-3 0/0 0.95/0.28. 
Diorio et al. 2005 Canada 783 pre % density IGF-I +/0* 0.02/0.37 
2 792 post IGFBP-3 40 0.0005/0.72 
IGF-I/IGFBP-3 0/0 0.06/0.41 
Maskarinec et al. US 240 pre % density IGF-I 0.06/0.01 
2003 15 IGFBP-3 0.02/0.09 
IGF-I/IGFBP-3 0.03/0.007 
Dense IGF-I 0 0.09/0.06 
area IGFBP-3 0 0.44/0.73 
IGF-1/1GFBP-3 0 0.15/0.09 
Non- 1GF-1 0 0.13/0.07 
dense 
area 
IGFBP-3 
IGF-I/IGFBP-3 
+/— 0.004/0.03 
0.02/0.02 
Bremnes et al. Norway 997 post % density IGF-I - 0.03/0.03 (P for trend)I 
2007 1 IGFBP-3 0 0.88/0.55 (P for trend) 
IGF-I/IGFBP-3 0.03/0.06 (P for trend) 
Dense IGF-I 0.03/0.04 (P for trend) 
area IGFBP-3 0 0.75/0.46 (P for trend) 
IGF-I/IGFBP-3 0.05/0/07 (P for trend) 
Adjusted: age, BMI,IGF-I, 
or IGFBP-3 if applicable 
Adjusted: age, BMI, 
ethnicity, year of lab 
analysis, family history of 
breast cancer, reproductive 
variables and IGF-I or 
IGFBP-3 (if applicable 
-Adjusted: age, BMI, number 
of children, age at 
menopause, and HT use. 
No association among 
current HRT users. 
Conditions/Adjustments 
Adjusted: age, waist, and 
IGF-I or IGFBP-3 whichever 
applicable. 
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Study Country (N) Density Hormone Association P-value 
Pre/Post 
menopause 
Measure Pre/Postmenopausal 
Johansson et al. Italy 226 post % density IGF-I 0 0.43 	• 
2008 16 IGFBP-3 0 0.10 
IGF-1/1GFBP-3 0 0.25 
, Byrne et al. US 65 pre % density.  IGF-I +10* 0.007/0.92* 
2000 17 Canada 192 post IGFBP-3 —10 	. 0.07/0.52 
IGF-I/IGFBP-3 +10 0.004/0.83 
,. 	. 
Lai et al. 2004 18 Canada 206 pre % density 1GF-I 0 0.9/0.5* 
206 post IGFBP-3 0 0.4/0.8 
IGF-I/IGFBP-3 0 0.8/0.5 
*Premenopausal /postmenopausal results 
f non HRT us'ers tformer HRT users/never HRT users 
Conditions/Adjustments 
Adjusted: age, BM1. 
Adjusted: Age, alcohol - 
intake, batch, BMI, and age 
at first birth (for 
postmenopausal) and IGF-I 
or,IGFBP-3 (if applicable) 
Multivariable adjusted. 
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mammographic density. 
IGFBP-3 and mammoqraphic density 
Many of the studies that examined the association between IGF-I and mammographic density, also 
examined insulin-like growth factor binding protein-3 (IGFBP-3), and the ratio between the two. 
IGFBP-3 is the most abundant of the six growth factor binding proteins (See Table A7.1 above). It 
is responsible for binding >95% of circulating IGF-I". IGFBP-3 reduces the availability of IGF-I by 
preventing the factor from interacting with the receptors. It is believed that dissociation allows' IGF 
to leave the circulation and reach target tissues. Because this dissociation is highly regulated, and 
binding prolongs the half-life of IGF-I its biological response. IGFBP-3 might also have direct 
actions, independent of IGF-I. For example, IGFBP-3 has been reported to inhibit breast epithelial 
cell growth°. This action has led to the suggestion that IGFBP-3 might act as a tumour 
suppressor° . 
Maskarinec et al.(2003) 15 , Byrne et al. (2000) u and Diorio et al. (2005)2 observed an inverse 
association between IGFBP-3 and percent mammographic density (see Table A7.1). The other four 
studies in the table that examined the association with IGFBP-3 did not observe an association. The 
study by Diorio et al., found that women with a combination of high IGF-I and low IGFBP-3 had 
higher levels of percent breast density. Many of the studies examined the IGF-I/IGFBP-3 ratio. It is 
suggested that a high ratio, indicating high IGF-I to low IGFBP-3, would also demonstrate a 
positive association with mammographic density. Among the studies that examined the association 
between the IGF-I/IGFBP-3 ratio with perCent mammographic density, five observed no association 
while four observed a positive association (one of which was only for premenopausal women only). 
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mammographic density. 
• This appendix reviews the evidence relating to the association of birthweight, birth,length, and 
other childhood anthropometric parameters on mammographic density. 
Birthweight and birth - length 
It is possible that girls treated with high-dose estrogens had a different birthweight and/or birth-
length than girls who were not treated. Some studies have indicated associations between these 
anthropometric variables and mammographic density and breast cancer. A review of these studies is 
presented below. 
Birth weight and mammo graphic density 
Six studies have examined the effect of birthweight on adult mammographic density (see Table 
A8.1). Ekbom and colleagues (1995) 1 found no association between Wolfe grade mammographic 
density and increasing birthweight (P for trend=0.53) in their cross-sectional study of 370 Swedish 
women. Similarly, McCormack and colleagues (2003) 2 found no meaningful association between 
birthweight and Wolfe grade, OR 1.03 (95% CI: 0.93 to 1.14), in their large cross-sectional study 
(n=1298). These findings are supported by Jeffreys et al. (2004) 3 when they examined the 
association between birthweight and percent mammographic density in 628 Scottish women (>25% 
versus <25%) (n=628) (adjusted P trend=0.82). 
In contrast to the findings of the three studies above, Cerhan et al. (2005) 4 (Table A8.1) 
reported a positive association between birthweight and percent mammographic density, measured 
by a computer assisted thresholding technique. However, a strong association was only observed in 
postmenopausal women (P trend. <0.01) with an adjusted mean percent density of 17.1% for 
birthweight <2.95 kg and 21.0% for birthweight >3.75 kg. A similar association was observed for 
dense area. This association was not apparent in premenopausal women (P for trend=0.16). 
Similarly, Tamimi et al. (2009) 5 using the computer assisted thresholding technique and birth 
records, found a positive association between birthweight and percent density in postmenopausal 
women. A later study by Jeffreys et al. (2008) 6 using the volumetric method of measurement 
identified a quadratic relationship. 
Jeffreys et al. 
(2004)3 
Cerhan et al. 
(2005)4 
628 	59 	% 
density 
940 	60.4 % 
density 
and 
dense 
area 
Jeffreys et al. 490 	54.1 	Volum- 
(2008) 	 etric % 
density. 
Tamimi et al. 893 	61.2 	% 
. (2009)5 
	
density 
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mammographic density. 	• 
Table A8.1: Summary of studies that have examined the association between mammographic 
density and birthweight. 
Study 	N 	Age 	Measure 	Outcome Scale 	Results 
(years) 
Ekbom et al. 370 	40-74 Wolfe 
(1995) 1 	 grade* 
McCormack 1294 	53 	Wolfe 
et al. (2003)2 	 grade 
Binary 
P2 & DY (high 
risk) vs. Ni &P1 
(low risk) 
Three binary 
outcomes: 
DY vs. P2, P1 NI, 
DY, P2 vs. P1 Ni, 
DY, P2 P1 vs. N1. 
Binary variable: 
>25% vs. 
<25% dense _ 	_ 
Continuous 
N.B. Not 
transformed — 
assumption that 
data is normally 
distributed. 
Categorical. 
Continuous 
Binary variable: 
(50% cutoff) 
No association • 
P for trend 0.53 
No association 
Common OR 1.03 
(95% CI: 0.93 to 
1.14) for each SD 
increase in 
birthweight for each 
binary outcomes 
No association 
P for trend 0.82 
Positive association 
for postmenopausal 
only 
P for trend <0.01 
Quadratic pattern: 
lowest risks in 
women born under 
2.5 and_over 4 kg. 
Linear trend p=0.02 
Binary: birthweights 
3001-3500g had • 
higher odds of having 
high mammographic 
density OR: 2.9 
(95% CI: 1.1 to 7.9) 
compared with 
birthweights >4000g. 
* Wolfe Grade: N = fatty radiolucent breast, P1 and P2 greater levels of prominence of 
fibroglandular tissue (hence density), DY = dense sheets of fibroglandular tissue. 
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Birth weight and breast cancer 
A recent review and meta-analysis (Xue and Michels, 20O7) updated from a previous analysis 8 
including 11 cohort and 17 case-control studies observed an overall increased risk of breast cancer 
in women who had a higher birthweight regardless of menopausal status. They calculated a 
summary estimate of RR 1.15 (95% CI:1.09 to 1.21). These findings are supported by two earlier 
reviews (Okasha et al., 2003 9 and Forman et al., 2005 1°). The first of these did not differentiate 
between menopausal status while the latter observed an increased risk with increasing birthweight 
only in premenopausal women. 
Birth-length and mammo graphic density 
Fewer studies have examined the association between birth-length and mammographic density or 
breast cancer. As well as birthweight as reported above, Ekbom et al. (1995) 1 , found no association 
between birth-length and Wolfe grade mammographic patterns (P for trend 0.52). Nor did Tamimi 
et al. (2009) 5 with the continuous measure of percent density measured using a computer 
thresholding technique. No other reported study has examined the association between birth-length 
and mammographic density. Since many of the risk factors for breast cancer are shared with 
mammographic density, reports of associations between birth-length and breast cancer are of 
relevance. 
Birth-length and breast cancer 
Two reviews of birthweight and breast cancer mentioned earlier also examined the association 
between birth-length and breast cancer risk. The meta-analysis reported by Xue, and Michels 
(2007) 7, involved four case-control and four cohort studies and found an increased risk of breast 
cancer with increasing birth-length. They calculated a summary estimate of RR 1.28 (95% CI: 1.11 
to 1.48). 
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Childhood height 
It is likely that girls treated with high-dose estrogens were taller at different stages of childhood 
than the girls who were not treated. Some studies have indicated associations between height at 
different ages in childhood and mammographic density or breast cancer. A review of these studies 
is presented below. 
Childhood height and mammographic density 
• Two studies examined the association between childhood height and mammographic density with 
both finding positive associations between the two variables. McCormack et al. (2003) 2 found 
height at ages two and 11 had significant but opposing associations with higher Wolfe grade 
density; adjusted OR 1.13 (95% CI: 1.01 to 1.26) (p=0.03) (n=1033), and OR 0.89 (95% CI: 0.80 to 
1.00) (p=0.04) (n=1090), respectively, however, no significant association was observed for ages 4, 
7, or 15 years. In contrast, Sellers et al. (2007) m observed a positive association between height at 
ages seven (p<0.001), 12 (p<0.001), and 18 years (p<0.001) with percent density (n=1893). The 
minimum adjusted mean difference in percent density between the tallest and shortest girls was 3%, 
while the maximum difference was 7%. 
Childhood height and breast cancer 
A number of studies have examined the association between childhood height and breast cancer risk 
and report conflicting results (Table A8:2). 
Le Marchand et al. (1988) 12 undertook an age matched nested case-control study of 38,084 
women born between 1918 and 1943 (607 cases of breast cancer), on whom information about 
weight and height had been recorded in Hawaii in 1942-1943. They found no association between 
height at age 10-14 years and risk of premenopausal or postmenopausal breast cancer. 
Herrinton and Husson (2001) 13 undertook a case-control study of 214 breast cancer cases 
(predominantly premenopausal) and 214 matched controls and observed a positive association 
between height at 15-18 years (tall for age vs. short for age) and breast cancer risk, OR 2.2 (95% 
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mammographic density. 
CI: 1.1 to 4.3) but did not find an association with height at earlier years (9-11 years), OR 1:0 (95% 
CI: 0.5 to 1.8), which is consistent with the larger case-control study by Le Marchand and 
colleagues described above. 
Whitely et al. (2009) 14 undertook a study of a sub-population of the Boyd-Orr cohort 
(2009) 14 that involved 2960 women followed-up for 59 years (69 cases of breast cancer). They 
similarly found no increased risk of breast cancer with increasing childhobd height (1 sd increase) 
OR 1.07 (95% Cl: 0.81 to 1.42) adjusted for age at measurement. 
In contrast to the studies above, one case-control and two cohort studies support a positive 
association between childhood height and breast cancer risk. Hilakivi-Clarke et al. (2001) 15 studied 
the childhood height records of 3447 women born in Finland during 1924-1933 and found that at 
each age between 7-15 years, the girls who later developed breast cancer as an adult were on 
average taller. Unadjusted hazard ratios rose across the range of height at age seven years (p=0.01). 
Swerdlow et al. (2002) 16 undertook a case-control study of twins pooled from four studies 
across Europe. This study involved 400 cases and 400 co-twins who had not yet developed breast 
cancer. They found that risk of premenopausal breast cancer was increased for the co-twin who was 
taller at age 10 years; OR 1.27 (95% CI: 0.95 to 1.70). They did not examine the risk of 
postmenopausal cancer in this cohort of women. 
Ahlgren et al. (2006) 17 undertook a retrospective cohort study of 117,415 Danish women 
(3,333,359 person-years of follow-up, 3,340 cases of breast cancer) and found height at eight years 
to be positively associated with breast cancer risk: adjusted RR 1.11(95% CI: 1.07 to 1.15). This 
relative risk is not unlike that observed by Whitley et al. (2009) 14 in the Boyd-Orr study reported 
above, which had too few breast cancer cases. 
Table A8.2: Height at certain childhood ages and breast cancer risk. 
Study Country Design N Age Results Adjustments 
(year) 
' Le Merchand et al.(1988) 12 US Case-control 38,084 10-14 p>0.01 Age matched 
Herrinton & Husson (200l) Case-control 428 3-5 OR 0.8 (95% CI: 0.3 to 1.9)* Age matched 
6-8 OR 0.9 (95% CI: 0.5 to 1.8)* 
9-11 OR 1.0(95% CI: 0.5 to 1.8)* 
12-14 OR 1.7 (95% CI: 1.1 to 2.8)* 
15-18 OR 2.2 "(95% CI: 1.1 to 4.3)* 
Hilakivi-Clarke et al. (2001) 15 Finland Cohort 3,447 7 HR 1.9 (95% CI: 1.1 to 3.1)t 
15 HR 1.9 (95% CI: 1.2 to 3.2)§ 
Swerdlow et al. (2002) 16 Europe Aggregate of 800 7 OR 1.21(95% CI: 0.91 to 1.61)1 Twin matched 
4 case- 10 OR 1.27 (95% CI: 0.95 to 1.70)11 Parity 
controls 20 OR 1.22 (95% CI: 0.94 to 1.58)11 Weight 
De Stavola et al. (2004) 18 UK Cohort 1,782 2 OR i.16(95% CI: 0.88 to 1.54)** 
1,944 4 OR 1.12 (95% CI: 0.86 to 1.46) 
1,925 7 OR 1.30 (95% CI: 0.99 to 1.71) 
1,862 .11 OR 1.16 (95% CI: 0.88 to 1.53) 
1,689 15 OR 1.33 (95% CI: 0.97 to 1.80) 
Study Country Design N Age Results Adjustments 
(year) 
Ahlgren et al. (2006) 17 Denmark Cohort 117,415 8 RR 1.11(95% CI: 1.07 to 1.15) Birthweight 
Age at 
menarche 
Whitley et al. (2009) 14 UK Cohort 
(59 year 
follow-up) 
2,960 2-14 OR 1.07 (95% CI: 0.81 to 1.42) Age at height 
measurement 	- 
* Tall for age vs. small for age 
f >123 cm vs. <114.5 cm 
§ >163 cm vs. <153 cm 
Premenopausal women. Postmenopausal women not examined. 
** Estimated univariable odds ratios for breast cancer according to a one-standard-deviation increase in childhood height at 
different ages. 
Childhood BMI 
It is possible that untreated girls had a higher BMI during adolescence compared with 
treated girls. BMI in childhood is highly correlated with BMI in adulthood 19-21 and untreated 
women had a higher BMI, on average, than treated women. If childhood BMI and mammographic 
density are associated, this might explain or influence the difference in mammographic density 
observed between treated and untreated women. The following section reviews the studies that have 
reported on the association between childhood BMI and mammographic density and breast cancer. 
Childhood BMI and mammo graphic density 
McCormack et al. (2003) 2 and Sellers et al. (2007)" in their studies reported above, also 
examined the association between childhood BMI or weight and mammographic density. 
McCormack and colleagues2 found a lower odds ratio for a standard deviation increase in BMI at 
any age during childhood (or adult life) after controlling for breast size and BMI at mammography 
(See Table A8.3). 
Table A8.3: Odds ratios for standard deviation increase in BMI by age controlled for breast 
size and BMI at mammography. 
Age 	N 	Odds Ratio (95%CI) 	P-value 
, 	2 994 0.88 (0.79 to 0.98) 0.02 
1093 0.8-9 (0.80 to 0.99) 0.03 
1074 0.72 (0.64 to 0.80) 0.01 
11 1079 0.56 (0.49 to 0.64) . 	<0.001 
; 	15 989 0.56 (0.49 to 0.64) <0.001 _ 
26 1129 0.62 (0.53 to 0.75) <0.001 
, 43 1209 0.54 (0.43 to 0.68) <0.001 
Sellers et al." likewise found weight (p=0.005) and adiposity (p=0.005) at age 12 years to 
be inversely associated with adult percent density. This effect remained following adjustment for 
current BMI. And similarly, Samini et al. (2008) 22 , in their cross sectional analysis of 1398 women 
in the Nurses Health Study, observed childhood body fatness to be inversely associated with percent 
mammographic density (p=0.0004) (adjusted r= — 0.19 for premenopausal and —0.15 
postmenopausal). Confidence intervals were not reported. 
Childhood BMI and breast cancer 
A number of studies have examined the association between childhood weight/BMI with breast 
cancer risk later in life. 
Okasha et al. (2003) 9 undertook a review of 35 case-control and seven cohort studies on the 
association between childhood weight and breast cancer risk. There was no consistent pattern of 
association between weight in childhood or adolescence and risk of breast cancer. Case-control 
studies suggested a reduced risk of breast cancer among women who were overweight in early life, 
while cohort studies were inconsistent with early life BMI appearing to have a protective significant 
effect (n=3 studies), or no effect (n=4). Two of the latter studies had too few breast cancer cases 
ranging from eight to 69. 
Three studies that have been published since the review by Okasha et al.(2003) 9 all support 
an inverse association between childhood BMI or weight and later breast cancer risk. In the multi-
centred pooled case-control study of twins by Swerdlow et al. (2002) 16 reported above and 
summarised in Table A8.2, risk of premenopausal breast cancer was increased for the co-twin who 
was less obese at age 10 years; OR 1.44 (95% CI: 1.08 to 1.91). This association was not 
statistically significant for weight at seven years OR 1.29 (95% Cl: 0.97 to 1.69). 
Cerhan et al. (2004)23 showed family history of breast cancer to modify the effect of obesity 
in early adolescence (e.g. 12 years) on breast cancer risk later in life. Of those who had a family 
history of the disease, the risk of breast cancer was increased in those with below average weight at 
age 12 (RR 1.55, 95% CI: 0.67 to 3.64) and strongly increased in those with above average weight 
(RR 4.25; 95% CI: 1.71 to 10.5) compared to those with average weight. In contrast, among those 
without a family history of breast cancer there was only a weak positive association for those with 
below average weight (RR=0.75, 95% CI: 0.26 to 2.16), compared to those with average weight. 
This study, similar to that by Swerdlow et al. (2002) 16 above, relied on self-reported recall of 
weights at childhood. 
A large cohort study that used direct measures of childhood weight was undertaken by 
Ahlgren et al. (2004) 24 (separately reported in 2006"). Their cohort study of 117,415 Danish 
women (3340 breast cancer cases) found BMI measured at age 8, 10, 12 and 14 years of age to be 
inversely associated with the risk of breast cancer, however, only the association with BMI at 14 
years remained after adjustment for age at menarche. The adjusted attributable risk of BMI at 14 
years of age was 15% and the relative risk of breast cancer for each unit increase in BMI = 0.97 
(95% CI: 0.96 to 0.98). Age at menarche is inversely associated with BMI at childhood 25 . Adjusting 
for age at menarche might have removed any 'true' association between BMI at ages 8, 10 and 12 
and mammographic density if age at menarche and BMI were collinear. 
Childhood weight/BMI velocity 
Girls treated with high-dose estrogens commonly experienced rapid increases in weight gain 
following treatment26 . Evidence suggests that change in weight gain is associated with 
mammographic density as described below. 
Childhood weight/BMI velocity and mamrnographic density 
• McCormack et al. (2003)2 examined the effect of BMI velocity at different age intervals with Wolfe 
grade breast parenchymal patterns. They found that an increase in BMI during any period up to age 
43 years was associated with reduced odds of a greater Wolfe grade with larger inverse associations 
in the preadolescent years (7-11 years) (See Table A8.4). 
Table A8.4: Odds ratios for standard deviation increase in BMI by age controlled for breas.t 
size and BMI at mammography. 
Age N Odds Ratio (95°/oCI) P-value 
2-4 911 0.56 (95% CI: 0.49 to 0.64) <0.001 
4-7 950 0.62 (95% CI: 0.54 to 0.71) <0.601 
7-11 975 0.50 (95% CI: 0.43 to 0.59) <0.001 
11-15 929 0.72(95% CI: 0.63 to 0.83) <0.001 
15-26 904 0.72 (95% CI: 0.63 to 0.83) <0.001 
26-36 1054 0.86 (95% CI: 0.75 to 0.99) 0.03 
, 36-43 119 0.85 (95% CI: 0.75 to 0.98) 0.02 
43-53 1188 0.94(95% CI: 0.82 to 1.07) 0.33 
Childhood BMI/weight velocity and breast cancer 
The findings reported above by McCormack and colleagues on weight velocity/gain and 
mammographic density are consistent with the association observed between BMI velocity at ages 
2-4 years and breast cancer risk in the retrospective cohort study by De Stavola et al. (2004) 18 . They 
observed an odds ratio of 0.68 (95% CI: 0.48 to 0.83) for BMI velocity (kg/height (m) 2 /year) 
measured at 2-4 years. However no association was observed in the 4-7 or 11-15 age categories. 
Childhood height velocity 
Linear growth velocity is another parameter of interest to this study. Treated and untreated women 
might have had different rates of pre-treatment or post-treatment linear growth velocity. 
Differences in pre-treatment rates of growth velocity would be expected if treated and 
untreated girls differed in height at particular ages. Untreated girls might have reached maturity 
earlier and therefore reached their peak velocity earlier. Peak height velocity typically occurs one 
year prior to menarche. Less growth potential was one of the main reasons untreated girls were not 
treated. It is possible, therefore, that they have reached mean peak height velocity earlier than 
treated women. On the other hand, treated women may have been taller at particular childhood ages 
than untreated women. If so, it is likely that height velocity was greater in treated girls compared 
with untreated girls. 
Post-treatment differences in height velocity are also likely. It has been reported that 
treatment with high-dose estrogens for the curtailment of growth in adolescent girls reduces height 
velocity22 . 
If any childhood height velocity or the age at which it reaches its peak is associated with 
mammographic density, then differences in these variables between treated and untreated women 
might explain the association observed between treatment and mammographic density reported in 
Chapter 5. Studies that have examined the association between childhood height velocity and 
mammographic density and breast cancer risk are summarized below. 
Childhood height velocity and mammo graphic density 
A positive association between height velocity (cm/yr) from 15 years to adulthood, and Wolfe grade 
mammographic patterns was found by McCormack et al. (2003) 2. The odds of having had a higher 
grade of mammographic pattern was increased with every standard deviation increase in height 
velocity OR 1.16 (95% CI: 1.03 to 1.29) (p=0.01). Increased odds were also observed for other 
ages, but these were not statistically significant [11-15 years, OR 1.11 (95% CI: 0.99 to 1.24) 
(p=0.08) (n=950) and 7-11 years OR 1.00 (95% CI: 0.86 to 1.15) (p=0.96) (n=1,030)]. In contrast, 
a reduced odds of higher Wolfe grade was observed for a standard deviation increase in height 
velocity between ages 2-5 years (0R=0.85, 95% CI: 0.76 to 0.96). 
Childhood height velocity and breast cancer 
While only one study has examined the association between height velocity and mammographic 
density, a number of studies have examined the association with breast cancer risk. Of these was by 
Berkey et al. (1999.28. ) They modelled peak growth velocity from the three variables: age at 
menarche, body fatness at age 10 years and final height. Women who participated in the Nurses 
Health Study (n= 65,140) were followed up for 16 years. Of these, 806 developed premenopausal 
breast cancer and 1485 were diagnosed with postmenopausal breast cancer. They found that the 
women who were in the two highest quintiles of linear peak height velocity in adolescence had a 
30% (adjusted RR 1.31; p=0.00I) and 40% (adjusted RR 1.40, p=0.001) higher risk of pre and 
postmenopausal breast cancer, respectively, compared to those in the lowest quintile. A limitation 
of this study is that peak height velocity was modeled using age at menarche, adult height and body 
fatness at age 10, that latter was self-reported as an adult using diagrams of body shapes. 
De Stavola et al. (2004)' s analysed prospective growth data from a British cohort of 2,547 
girls (59 breast cancer cases) and found that height velocity at ages 4-7 years was associated with 
an increased risk of breast cancer (for a one-standard-deviation increase, OR 1.54, 95% CI: 1.13 to 
2.09). An increased risk waS also observed for increasing height velocity between the ages of 11-15 
years but this was not statistically significant (OR 1.29, 95% CI: 0.97 to 1.71). 
Ahlgren et al. (2006)" in their study of 117,415 Danish women observed an increased 
breast cancer risk with large increases in height during puberty (8-14 years of age). The adjusted 
relative risk for breast cancer was 1.17 (95% CI: 1.09 to 1.25) for each 5cm increase in height , 
during this age period. These investigators also examined the age at peak height velocity in relation 
to breast cancer risk. They calculated an adjusted relative risk of 0.94 (95% CI: 0.91 to 0.97) per 
one-year increase in age at peak growth and an adjusted attributable risk of 9% for earlier age at 
peak growth. 
Age at maximum height 
A few studies have examined the association between the age at which maximum height was 
achieved and mammographic density or breast cancer risk. The age at which maximum height is 
achieved is not a pre-treatment parameter since treatment might have influenced this, however, if 
this variable influences the association observed between treatment and mammographic dense area, 
it might tell us something about the mechanism of action of treatment on dense area. 
Age at maximum height and mammographic density 
Sellers et al. (2007)" examined the association between age at which participants (n=1298) stopped 
getting taller and mammographic density measured by a computer assisted thresholding technique. 
They found no association (P for trend 0.10) between the two variables. 
Age at maximum height and breast cancer 
Li et al. (1997)29, in a study of 747 women from the United States, diagnosed with invasive breast 
cancer before 48 years and 961 controls, observed a trend of decreasing risk of breast cancer with 
increasing age of maximum height attainment. A 30% reduction in the risk of breast cancer was 
calculated for women who reached their maximum height 218 years of age compared with women 
who reached their maximum height <13 years of age (OR 0.7, 95% CI: 0.5 to 1.0) (P for 
trend=0.02). 
Baer et al. (2006) 3° examined the association between age at maximum attained height with 
premenopausal breast cancer in 37,572 premenopausal women participating in the Nurses Health 
Study II. They found no overall increased risk of breast cancer in women who attained their 
maximum height 218 years of age compared to those whose age at maximum height was attained 
before 14 years RR 0.96 (95% CI: 0.66 to 1.39) (P for trend = 0.65). A limitation of both this and 
the study above by Li and colleagues is that age at which maximum height was attained was self-
reported many years after the event. 
3 Li et al. (2007) ' , again assessed the relationships between age at which maximum height 
was attained and risk of different types of breast cancer in a prospective cohort of 27,536 women 
who had previously participated in the VITamins and Lifestyle study. Women who reached their 
maximum height <12 years of age had a 1.4 fold (95% CI: 1.0 to 1.8) increased risk of breast cancer 
compared to those who reached it 217 years of age (P for trend 0.04). This association, however, 
was limited to estrogen receptor-negative tumours HR 1.9 (95% CI: 1.0 to 3.9). Age at maximum 
height was again self-reported. 
Bone age 
Age at menarche is positively associated with breast density 32 suggesting that treated women who 
matured later are likely to have higher density than untreated women. Bone age is a predictor of age 
at nienarche33 '34  and was measured in both treated and untreated girls at first assessment. Girls with 
a bone age greater than their chronological age have a greater level of skeletal maturity at age at 
measurement and less growth potential compared to girls with a bone age lower than their 
. 	. 
chronological age. It is known that a large number of girls were not treated because they had little 
growth potential at time of height assessment, indicating that they had greater bone maturity or bone 
age for a given chronological age 35 . It is' possible then that this difference in bone age at time of 
measurement may explain differences in dense area between treated and untreated women, 
independent of treatment. A review of the literature failed to find any studies reporting the 
association between bone age and mammographic density or breast cancer risk. 
Overview of research literature and relevance to the study 
The review above suggests an association between a number of childhood growth parameters and 
mammographic density and/or breast cancer risk. Only one study' had examined the association 
between birth-length and mammographic density. This study found no association between the two 
variables, however breast cancer risk is different. A meta-analysis 7 of studies demonstrated greater 
consistency in the findings across studies and calculated a significant positive association between 
both birthweight and birth-length with breast cancer risk. Childhood height and growth velocity has 
been shown to be associated with both mammographic density 2 ' I I and breast cancer risk I5-7 , though 
the ages at which these associations exist differed across the studies. Some studies, in contrast, 
found no association with breast cancer risk I2-14 . 
Evidence is more consistent for an association between childhood BMI and mammographic 
density and breast cancer risk, particularly in later studies. Studies suggest that earlier age at peak 
height velocity" and age at which maximum height is attained29.3I (but not that by Baer et al. 
(2006)3°  is associated with breast cancer risk, but the studies that examined the latter association 
relied on self-reported measures of age at which maximum height was attained. No association was 
observed in the one study that examined age at maximum height and mammographic density". 
Box A8.1: Key Points from the literature: Appendix 8 
KEY POINTS FROM THE LITERATURE: APPENDIX 7 
• Evidence suggests an association between a number of childhood growth 
parameters and mammographic density and or breast cancer risk. 
• The only study that examined the association between percent density and 
birthweight and had used a continuous measure of percent density found a 
positive association in postmenopausal women only. 
• The one reported study that has examined the association between birth-
length and mammographic density found no association. 
• Evidence suggests a positive association between both birthweight and birth-
length with breast cancer risk. 
• Childhood height and growth velocity has been shown to be associated with 
mammographic density. Studies that examined the association between 
growth velocity and breast cancer risk are less consistent in their findings. 
• Earlier age at peak height velocity and age at which maximum height is 
attained have cautiously been associated with breast cancer risk. 
• Childhood BMI has been consistently shown to be inversely associated with 
mammographic density and breast cancer risk. 
• Only one study examined the association between age at maximum height 
and mammographic density. It relied on self reported age at maximum height 
as an adult. 
• Pre-exposure and variables directly associated with both the exposure and 
outcome variables could be potential confounders for the association between 
treatment with high-dose estrogens in adolescence and mammographic 
density. 
• Treatment induced changes (e.g. BMI) that are directly associated with 
mammographic density might mediate any association between treatment 
with high-dose estrogens in adolescence and mammographic density. 
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Appendix 9: Follow-up 2 consent form, study invitation letter, information brochure and mammogram release form. 
Menzies 
Research 
Institute 
CONSENT FORM 
1. I have read and understood the 'Information Sheet' for this study. 
2. The nature and possible effects of the study have been explained to me. 
3. I understand that the study involves the following procedures: 
• A telephone interview about myself, my health and medical history; 
• Providing permission to access the x-ray film of a mammogram if I have had one in 
the past two years, 
• If I have not had a mammogram in the past two years, to have one at a convenient 
BreastScreen centre as part of a breast cancer screening check and give the 
investigators permission to access the film. 
• Allowing BreastScreen to provide the study investigators with information about my 
BreastScreen attendances including HRT use at the time of my mammogram. 
4. 	I understand that the following risks are involved: 
• Screening mammography for breast cancer is not 100% accurate. This means that 
sometimes women may be brought back for further tests, which would otherwise not 
have been necessary. It also means that for a very small number of women the 
screening mammogram may not find all cancers. 
• Screening mammograms involve exposing women to a small amount of radiation. 
The level of radiation women receive is low, similar to that from other x-rays people 
commonly have. 
• Compressing the breast during the mammogram may cause discomfort. 
• There is a small possibility that the original mammogram may be lost in transit for 
analysis. 
• Some BreastScreen services or private radiology clinics at their discretion, choose to 
copy the original film prior to sending it to us, however the copy may not be as good a 
quality as the original. 
5.. 	I understand that all research data will be securely stored on the University of Tasmania 
premises until no longer required, at which time it will be destroyed). 
6. Any questions that I have asked have been answered to my satisfaction. 
7. I agree that research data gathered for the study may be published (provided that I 
cannot be identified as a participant). 
8. I understand that my identity will be kept confidential and that any information I supply to 
the researcher(s) will be used only for the purposes of the research. 
9. I agree to participate in this investigation and understand that I may withdraw at any time 
• without any effect, and if I so wish, may request that any personal data gathered be 
withdrawn from the research. 
Name of participant: 
Signature of participant: 	  Date: 
TALL GIRLS 
BREAST DENSITY STUDY 
Appendix 9: Follow-up 2 consent form, study invitation letter, information brochure and mamMogram release form. 
22 September 2010 
«ID_number» 
«First_name» «Surname» 
«MailAddress1» 
«MailAddress2» 
«MAILSUBURB» «MAILSTATE» «MailPostcode» 
Dear «First_name» 
You may remember that in 2002 you participated in the Tall Girls Study by completing 
a postal questionnaire and telephone interview. A total of 836 women contributed to 
this research which resulted in some important findings on the long-term effects of 
treatment for tall stature. We remain very grateful for your contribution to this research. 
A summary of the findings can be found at 
http://www.latrobe.edu.au/mchr/tallgirls.html.  
When you completed the telephone interview, you indicated that you would be willing to 
be contacted again for further research. We are now inviting women who were treated 
or assessed and not treated for tall stature during adolescence, and who are aged 40 
years and over, to participate in a new study - the Tall Girls Breast Density Study. It is 
important that untreated as well as treated women participate in this study. 
This study is being conducted by Associate Professor Alison Venn (now of the Menzies 
Research Institute, University of Tasmania) and PhD student Helen Jordan, in 
collaboration with Associate Professor Anne Kavanagh and Associate Professor 
Dorota Gertig (University of Melbourne). 
The Tall Girls Breast Density Study aims to find out whether oestrogen treatment to 
reduce the adult height of tall girls has had any long-term effects on breast tissue. One 
of the features of breast tissue is the proportion of dense tissue that appears on a 
breast x-ray (mammogram). This feature, referred to as mammographic density, has 
become recognised as a risk factor for breast cancer. Mammographic density is 
affected by hormones such as oestrogen, however, it is not known whether hormone 
levels in "adolescence have any long-term effects on the breast. 
If you agree to participate in this study, we will need to have access to your 
mammogram. If you have had a mammogram in the last two years, we would like your 
permission to borrow your mammogram from the service where you had the procedure 
or where it is currently being held. 
If you have not had a mammogram in the past two years, we would like you to make an 
appointment to have a mammogram at a convenient BreastScreen centre. 
BreastScreen 
will send us the mammogram after they have performed their usual breast cancer 
screening tests and have informed you of the result. The attached brochure explains 
the procedure involved in having a breast cancer screening mammogram. 
We will arrange to get your mammogram from the BreastScreen centre or 
medical practice holding it: you will not need to organise this. We will need to 
retain the mammogram for approximately one month while we take 
measurements of breast density. 
To help us retrieve your mammogram, we would also like your permission for 
BreastScreen to provide us with information about your BreastScreen attendances 
including HRT use at the time of mammogram. This will assist us to retrieve the most 
relevant mammogram. 
We would also like to interview you by telephone, at a time convenient to you to ask 
questions about a range of factors that may be associated with your breast density. 
This interview will take approximately 20 minutes. 
You are under no obligation to be part of the study and should you decide to 
participate, you are free to withdraw from the study at any time. Your confidentiality will 
be maintained and personal information will not be released without your consent. 
Enclosed is an information sheet describing the study, as well as consent and 
mammogram release forms. We ask that you read the information sheet carefully and 
ask us any questions you may have about the study prior to making a decision about 
participating. 
If you are willing to participate in this study, please fill in the yellow consent and 
mammogram release forms and mail them back in the enclosed reply-paid envelope as 
soon as possible. The white consent form is for your records. If we do not hear from 
you, you may receive a call from us to check that you.have received this letter. Please 
note that you do not need to have had a mammogram, or to have made an 
appointment for a mammogram, before returning the consent form 
If you are willing to participate, one of our research staff will telephone you to answer 
any questions you have about the study and to arrange a convenient time for you to be 
interviewed. 
If you have any questions, please contact Emma Stubbs on (03) 6226 4709. 
Yours sincerely 
Associate Professor Alison Venn 
CHIEF INVESTIGATOR 
ENCL. 
'. What about my priVacy? 
The information you provide for the study will be kept 
confidential and held at the Menzies Research Institute 
at the University of Tasmania. The data collected will 
be used only for the purposes of this study. Data will 
be coded and entered onto a computer without your 
name. The results of the research will be published in a 
form that will not allow individuals to be identified_ 
if you attend BreastScreen for a mammogram. you will 
be treated ri the same way as all other women in the 
community attending the service and will be required 
to provide them with information about yoursetf. The 
BreastScreen service will allow us to access your 
mammogram but the staff at each service might not be 
aware of this study and they WI not know whether or 
not you were created as a tall girl. 
'L Who is doing the research? 
The study is being conducted by a group of 
researchers led by Associate Professor Alison Venn 
(Menzies Research Institute. University of Tasmania). 
Ms Helen Jordan (PhD candidate at the Menzies 
Research Institute). Associate Professor Anne 
Kavanagh and Associate Professor Dorota Gerfig 
(University of Melbourne). 
C4n I be told about the results? 
The overall study results on the effects of hormone 
treatment for tall stature will be provided to you if you 
would like this information. We expect to have 
results of the study in about two years. If you would 
like to hear about the results, please indicate this when 
asked in the telephone interview. They will also be 
made available on our website: 
www.menzies.utas_edu.au. 
The BreastScreen service you attend will provide you 
with the results of your screening test for breast 
cancer. Your individual breast density result will not be 
available to you. While breast density measurement 
has proven research value, it has not been shown to 
have clinical benefit for individuals. 
What do I do now if I agree to 
pearticipate? 
Complete the two yellow consent forms and mail them 
back in the enclosed reply-paid envelope. The white 
consent form is for your records. 
We will contact you in the near future to answer any 
questions you may have about the study and arrange an 
appropriate interview time with you. 
Who do I contact if I have questions or 
concerns? 
If you have any concerns or questions or would like 
more information. contact Emma Swbbs on (03) 6226 
4709 or freecall 1800 638 124. 
If at any time you have any concerns about your 
involvement in the study that the researcher has not 
been able to answer to your satisfaction, you may 
contact the Executive Officer of the Htima.n Research 
Ethics Committee (Tasmania) Network on (03) 6116 
2763. 
Menzies Research institute 
University of Tasmania 
Private Bag 23 
HOBART TAS 7001 
Phone: (03) 6226 4709 
Fax: (03) 6226 7704 
meitrics 
Research . 
Instiane 
* THETALL CIS  
BREAST...DENO" 
STUDY 
STUDY INFORMATIOW 
, What is . the study about? 
Th'e Tall Girls Breast Density Study aims to find out 
whether oestrogen treatment to reduce the adult 
height of tall girls has had any long-term effects on 
breast tissue. One of the features of breast tissue is the 
proportion of dense tissue that appears on a breast 
x-ray (mammogram). This feature, referred to as 
-rnammographic density-, has become recognised as a 
risk factor for breast cancer. Fatty tissue appears dark 
on a mammogram. while denser tissue appears as light 
areas. Mammographic density is known to be affected 
by hormones such as oestrogen. However, it is not . 
known whether hormone levels in adolescence have any 
long-term effects on the breast 
Some women who were treated with oestrogens to 
reduce their adult height have been concerned about 
the possibility of an increased risk of breast cancer. The 
number of tall girls who have been treated in Australia 
is too small for us to be confident about detecting any 
increase in breast cancer risk. However, by looking at 
mammographic density, we will be able to see if 
treatment for tall stature is associated with any long-
term changes to breast tissue and breast cancer risk 
Currently little is known about the effect of hormones 
in adolescence on breast cancer risk This research will 
tell us whether hormonal exposures during adolescence 
have any long-term effects on mammographic density 
and hence breast cancer risk. 
Who is eligible to participate? 
Yu are eligible to participate in the study if you are 
aged 40 years or over, and you participated in the 
prepous Tal Girls Study_ It is very important that our 
stutly irrcludes tall girls who were assIssed but not 
treated 	 those who were treated. 
HoW did you get my name? 
Your name was obtained from the names of eligible 
women who consented to participate in the previous 
Tall Girls Study, and who expressed an interest in 
being involved in further research. 
■ What exactly do you Want me to do? , 
If you agree to participate in this study. we will ask you 
to: 
• Complete a telephone interview about yourseff. 
your health and medical history. 
• If you have had a mammogram in the past two 
years. we would like you to give us permission to 
access the x-ray film. 
• If you have not had a mammogram in the past two 
years. we would like you to have one at a 
convenient BreastScreen .centre and give us 
• permission to access the mammogram after all 
follow-up at BreastScreen is complete. The attached 
brochure explains the BreastScreen mammogram 
and foCow-up procedure. It is free of charge_ The 
results of the screening mammogram and any 
appropriate follow up wKI be made available to you 
by the BreastScreen service, completely 
independently of our study. Once you have had 
your mammogram we would like you to contact us 
on (03) 6226 4709 or freecall 1800 638124 to tell 
us when and where you had your mammogram 
performed. (Please note that if you have had 
implants in both breasts we will not ask you 10 have 
a mammogram). 
• To give BreastScreen permission to provide us with 
information about your Breast-Screen attendances 
including HRT use at the time of your mammogram. 
This win assist us to retrieve the MOSE relevant 
Mammogram. 
Once we have retrieved and scanned your 
mammograms, we will send them back, usually within 
I month. Mammograms borrowed from BreastScreen. 
your doctor or a clinic will be returned directly to the 
service. Mammograms borrowed directly from you 
wil/ beriF-urned to you by registered mait Iliou.need 
• 
your mammograms at short notice after we have \ 
1. 	• 
received them, please call us so that we can return 
them to you quickly.- 
Do I have to participate? 
Participation in the study is entirely voluntary_ You are 
free to withdraw from the study at any time. You are 
also free to not answer any particular question during 
the interview_ If you do not wish to participate in the 
study. please let us know by filling out the appropriate 
box on the consent form (yellow form) and sending it 
back to us in the enclosed self- addressed envelope_ 
• What's in it for me? „ 
As well as improving understanding of the long-term 
effects of oestrogen treatment for tall stature, this 
study will help to increase scientific understanding of 
how hormones in adolescence influence breast 
development and longer-term breast cancer risk_ 
If you have not had a mammogram in the past 2 years. 
and you agree to participate in this study. you Can 2150 
expect to receive the benefits of marnmographic 
breast cancer screening_ 
What are the benefits of , 
Mammographic screening? 
Having regular screening mammograms is the best way 
to fad breast cancer at an early stage, before it can be 
felt or noticed. Finding breast cancer early often 
means that the breast cancer is small, has less likely 
spread to other parts of the body and is more 
effectively treated. 
Whilst all women are at risk of developing breast 
canter, if is far more common as we grow older: It is 
clear that mamrrictgraphy screening of women over 50 
reduces the number of deaths from breast cancer. 
However, screening has been shown to be less 
effective for women aged between 40 and 49 years. as 
breast tissue in younger women tends to be denser_ 
This makes it more difficult to detect small changes in 
the breast_ While the national breast screening 
program is active in recruiting women in the 50-69 
year age group, women aged 40 years and over are 
eligible to be screened. 
What are the risks of participating in 
'this study? 
If you have not already had a breast screening 
mammogram, and you agree to have one as part of 
this study. you will need to consider the risks 
associated with screening mammography. While 
screening mammography can find most breast cancers 
present at the time of screening, like many other 
medical tests, it is not 100% accurate_ This means that 
sometimes women are brought back for further tests, 
which would otherwise not have been necessary. It 
also means that for a very small number of women the 
screening mammogram may not find all cancers. 
Screening mammograms involve exposing women to a 
small amount of radiation. The level of radiation 
received is low, similar to other common x-rays (e.g. 
chest). 
Compressing the breast during the tfiarnmogram may 
cause discomfort. Some women may experience more 
discomfort than others. 
In the course of this study there is a very small risk 
that an original mammogram could be mislaid or 
damaged in transit We can reassure you that all effort 
will be made to avoid this. The process we are using 
has been used for another Australian study and to date 
this study has borrowed and scanned more than 2000 
mammograms without incident As an additional safe-
guard. some BreastScreen Services or other 
radiological services holding your mammogram may. at 
their discretion, choose to make a copy of the 
mammogram prior to it being released. The quality of 
a copy may not be as good as the original and cannot 
be guaranteed. 
Please refer to the information provided by 
BreastScreen for further details about what you can 
expect with breast cancer screening. 
Appendix 9: Follow-up 2 consent form, study invitation letter, information brochure and mammogram 
release form 
   
Menzies 
Research 
Institute TALL GIRLS 
BREAST DENSITY STUDY 
    
    
    
     
AUTHORISATION TO RELEASE MAMMOGRAM AND 
HISTORY OF MAMMOGRAM SCREENING 
Firstname 
	
Middlename 
	
Surname 
Date of Birth 	/ 	/ 19 	, hereby authorise: 
BreastScreen 
or 
(name of your doctor, or the clinic at which you mammogram is held 
(address of doctor, or the clinic at which your mammogram is held 
to release my ORIGINAL mammogram on a temporary basis to Associate 
Professor Alison Venn, Menzies Research Institute, University of Tasmania, to be 
scanned for use in the Tall Girls Breast Density Study; and 
for BreastScreen to provide Associate Professor Alison Venn, Menzies Research 
Institute, University of Tasmania, with a history of my BreastScreen attendances 
and information about my HRT use at time of each mammogram. 
I understand and agree that: 
• The mammogram will be used in a research study of Mammographic Density 
• My left and/or right cranio-caudal mammography X-Ray will be released to the 
researchers, for.the purpose of this study, but only after all follow-up at 
BreastScreen is complete, and at . no cost to me 
• The mammogram will be returned to BreastScreen, the Doctor/Clinic or me as 
soon as it has been scanned, after about one month 
• While all efforts will be made to avoid the loss of the mammogram during 
handling, there is a very small risk that the mammograms could be damaged or 
lost in transit 
• At their discretion, the BreastScreen service or private service holding the 
mammogram may choose to make a copy of the mammogram, at•no cost to 
me, before releasing the original to the researchers 
• The BreastScreen registry can inform the study co-ordinator that I have 
attended their service and had a mammogram. 
Signature of participant: 	  Date: 	  
Appendix 9: Follow-up 2 consent form, study invitation letter, information brochure and mammogram 
release form 
Telephone Contact:  
Please provide your phone number(s) so we can contact you to arrange a suitable 
interview time: 
Phone: 	  (h) 	 (w) 	(m) 
TALL GIRLS 
BREAST DENSITY STUDY 
• 	 MAMMOGRAM DETAILS 
Please fill Out if you have had a mammogram in the past two years. 
If you are to have a mammogram, once it is performed, please ring Emma 
Stubbs on 
(03) 6226 4709 or free call 1800 638 124 to tell us when and where you had 
your mammogram. 
The year I had my most recent mammogram was: 
Year: 	 
I had my most recent mammogram at: 
BreastScreen 	 Location: 
Private Radiology Clinic 	Location: 
My most recent mammogram is held by: 
LI Me 
LI 	BreastScreen 
01 	Doctor/Clinic 
Name of Doctor/Clinic::- 
Address of Doctor/Clinic: 
Phone of doctor/clinic: 
El I am not sure 
Appendix 9: Follow-up 2 consent form, study invitation letter, information brochure and mammogram 
release form 
APPENDIX 10 
Plot of optical density vs pixel grey level 
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Appendix 10: Plot of optical density 
Plot of optical density vs pixel grey level 
A plot of the calibration measures (optical density and average pixel grey level) of the first 
mammographic images scanned (date 13/10/06) against the last batch of images scanned (date 
14/09/07) is below in Figure A10.1. 
Figure A10.1: Pixel grey level vs optical density (OD) for first and last set of mammogram 
film scans. 
Ave Pixel Grey Level vs Optical Density 
APPENDIX 11 
Plot of right breast with benign breast disease vs left non-diseased breast 
Appendix 11: Plot of right breast with benign breast disease vs left non-diseased breast 
Percent mammographic density of the right breast with benign breast disease was plotted 
against the corresponding left non-diseased breast of the same woman (See Figure A11.1). A 
Spearman coefficient of 0.99 was calculated. 
Figure A11.1: Percent mammographic density in the right benign breast diseased breast 
and the corresponding left non-diseased breast. 
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Independent variables collected in follow-up 2 
Appendix 12: Independent variables collected in follow-up 2 
Independent variables collected and analysed in Chapter 7 
Age (years) 	At interview 
At mammogram 
Postmenopausal * 
Postmenopausal t 
Age at menarche (years) 
Number of livebirths 
Age at first livebirth (years) 
Ever breastfeed (°/0) 
'Breastfeeding total mean (wks) 
Height (cm) 
Weight (kg) 
BMI (kg/m2) 
EMH—final height (cm) 
Weight Change (kg) 18 to 30 yrs 
18 yrs to current 
30 yrs to current 
Fertility drugs taken (yin) 
Fertility cycles 
HRT 	 Ever used 
Current use 
Total use (years) 
Type 
Hormonal Contraceptive Ever used 
Current use 
Total use (years) 
Age first used 
Ever used hormones for endometriosis 
Duration of hormone use to treat endometriosis (weeks) 
Ever used hormones for menstrual problems 
Ever used aspirin 
Ever used over the counter anti-inflammatories 
Ever used prescription anti-inflammatories ) 
Smoking 	Ever smoked 
Currently smoke 
Alcohol use 	Never or rarely drink 
Occasionally (<once a week) 
Once or twice a week 
Three or more days a week 
Marital status . 	Married 
De facto 
Separated 
Divorced 
Widowed 
Single 
Educational Level Primary School 
Intermediate/Year 11 
High School/Year 11&12 
Certificate/ Diploma 
University Degree 
• 	 Higher University Degree 
Country of Birth 	Australia 
UK 
Other 
Benign Breast Disease 
Polycystic Ovary Syndrome 
Ovarian Cysts 
Uterine Fibroid 
Endometriosis4 
Appendix 12: Independent variables collected in follow-up 2 
Breast Cancer5 
Vaginal/Uterine cancer 
Breast cancer: 1st degree relative 
Ovarian cancer: 1st degree relative 
* Definition of postmenopausal: last period > 52wks, and if HRT started before last period and current 
age was 255 years. 
t Definition of postmenopausal: Same as above but women who had not had a period for 252 Weeks 
because of hysterectomy (while retaining one or both ovaries), endometrial ablation, IUD, or hormone 
implants, they were considered to be premenopausal unless they were 255 years of age 
Independent variables collected and analysed in Chapter 8 
Birthweight (kg) 
Birth-length (cm) 
Bone age-chronological age (years). 
Age bone age measurement (years) 
Age at first assessment (years) 
Height at first assessment (years) 
Weight at first assessment (kg) 
BMI at first assessment (kg/m 2) 
Birthweight (kg) 
Birth-length (cm) 
Bone age-chronological age (years) 
Age bone age measurement (years) 
Weight change first year of treatment (kg) 
BMI change first year of treatment (kg/m 2 ) 
Age maximum height reached ?15 years 
Height change after 15 years (cm) 
Follow-up 2 CATI questionnaire 
ars.. 
runs. ID Number: 	  
Interview Date: (dd/mMfyyyy) 	 A, Medical and Suralcal History  
Interviewer Initials: 	  
Timis Start 	 I'm going to ask questions about a number of Illnesses and surgical 
lime Finish: procedures you may have had. 	_ 
Tall Girls Breast Density Study 
QUESTIONNAIRE 
(TO BE TRANSLATED TO CAT! FORMAT) 
My name is 	and I'm from the Menzies Research Institute, The University of 
Tasmania. X , the study administrator, contacted you earlier and arranged this tints for you 
to be interviewed. Is this time still fine with you? It should take approximately X minutes. 
Before we begin, I want to you to know that your answers to this interview are confidential 
and that your participation is voluntary. The questions I am about to ask relate to 
I) Your current and past health, including an update of your reproductive history 
2) Usage of some medications that may have an effect on the breast 
3) Your lifestyle, and family history of breast and ovarian cancer; and 
4) Your Mammogram history 
When you participated in the earlier Tall Girls study you were Interviewed on (date of 
Interview). A few of the questions that will be asked during this interview will repeat those 
asked in the earlier interview. This is so that we can update our Information. 
Please feel free to ask mete clarify or repeat • question anytime during the interview, and if 
you wish me to skip • question or stop this telephone call, please let me know. 
If you would like to discuss any aspect of this interview with the study coordinator (Helen 
Jordan) or Chief Investigator (Alison Venn) please contact them during working hours on 
the numbers peovided in your information brochure. If you do not have this available please 
feel free to ask me for these numbers following the interview. 
Are you happy to continue? Do you have any questions before we stare? 
Al. Has a doctor ever told you that you had benign breast disease, such 
as a non-cancerous cyst or benign breast lump? 
Yes 	 0 
No (go to A4) 
Don't know (go to A4) 0 
A2. How old were you when this was brildiagnosed? 
Age Of first diagnosis 	 (years) 
Don't Know - 	0 
A3 Which breast or breasts were affected? 
Both 0 
Left only 0 
Right only 0 
A4 Have you ever been diagnosed as having had an In-situ cancer of the 
breast ? (this Is also known as a NON-malignant or NON-Invasive breast 
cancer) 
Yes 	 0 
No (go to A8) 	0 
AS Was It ductal carcinoma In-situ or lobular carcinoma In situ? 
Ductal 
Lobular 	0 
Don't Know 
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• 
AG How old were you when this was first diagnosed? 
Age 	 (years) 
Don't Know 	0 
AT Which breast or breasts were affected? 
BOth 	 0 
Left only 	0 
Right only 	0 
Alf Have you ever been diagnosed as having had malignant or Invasive 
breast cancer? 
Al2 In which breast did you have surgery? 
Both 	0 
Left only 	0 
Right only 0 
Al 3 What was your age when you first had this procedure? 
Age 	years 
A14 Have you ever had any other form of breast surgery Or al no to AO 
AND A8) Have you over had breast surgery of any kind? 
Yes 
No Go to Al6 0 
Yes 0 
	 A15 What was the purpose of the surgery? 
No 0 (Go to All if said Yes to A4) 	 a) Removal of a breast lump 	0 
(Go to A14 If said No to A4) A15_1 Age of procedure? 	years 
A15_2 Which breast? 
Ail'How old were you when this was first diagnosed? 	 Both 	 0 
Age 	 (years) 	 Left only 	0 
Don't Know 	0 	 Right only 	0 
A10 Which breast or breasts were affected? 
Both 	 0 
Lett only 	0 
Right only 	0 
All (If said yes to A4 or A8) Have you ever had surgery for the treatment 
of breast cancer? 
Yes 	0 
No 	0 (go to A14) 
b) Breast Reduction 	0 
A15_1 Age of procedure? 	years 
A15_2 Which breast? 
Both 	 0 
Lett only 	0 
Right only 	0 
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c) Breast Enlargement 
A15_1 Age of procedure? 	years 
A15_2 Which breast? 
Both 	 0 
Left only 
Right only 	0 
A17. What was the type of cancer and your age when it was FIRST 
diagnosed? 
First Cancer A17_1Type 
Ovarian 0 
Vaginal/Uterine/Cervical 0 
Colon 0 
d) Other 	 0 	 Other 	 0 	specify 	  (if 'other' is 
Specify reason 	 skin cancer, ask if melanoma - only include if it is, 
A15_1 Age of procedure? 	years 	 or they don't know) 
A15_2 Which breast? 
Both 	 0 	
A17_2 Age when first diagnosed 	(years) 
:AM only 	0 
Alla: Has a doctor ever told you that you had any other form of cancer? 
Right only 
15a) Have you had any other type of breast surgery? 
Yes (repeat Question 15) 	 No 	0 (GO to A18) 
No (go to A16) 
. Al 61 have asked about breast cancer, has a doctor ever told you that 	 A17_1 Second Cancer Type 
you had any other type of cancer? 
Yes 	 0 
	 Ovarian 	 0 
No — (go to A18) 	0 
Vaginal/Uterine/Cervical 0 
Colon 	 0 
Other 0 	specify 	  (If 'other' Is 
skin cancer, ask if melanoma - only include If It Is, 
or they don? know) 
Al7a: Have you had any other form of cancer? 
Yes 	0 (Ask 11 it Is a primary or secondary cancer - only say 
yes' if It is a primary cancer.) 
No 	0 (Go to A18) 
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Yes 	0 (Ask if It is a primary or secondary cancer - only say 
'yes' if it is a primary cancer.) 
A17_1 Third Cancer Type 	 A22 Have you ever had an ovarian cyst removed? 
Ovarian 	 0 
Vaginal/Uterine/Cervical 0 
Colon 	 0 
Other 	 0 	specify 	  (II What' Is 
skin cancer, ask If melanoma • only Include If it Is, 
or they don) know) 
A 18 Has a doctor ever told you that you had polycystic ovary 
syndrome? 
Yes 	 0 
No 	 0 (go to A20) 
Don't Know 	0 (go to A20) 
A 19 How old were you when polycystic ovary syndrome was first 
diagnosed? 
Age 	 • 	 (years) 
Don't Know 	0 
A 20 Has a doctor ever told you that you had cysts In one or both 
ovaries that was not diagnosed as Polyeystie Ovary Syndrome? 
Yes 
No 	0 (go to A23) 
Don't know 0 	(go to A23) 
A21 How old were you when ovarian cysts were first diagnosed? 
Yes 	 0 
No 	 0 
Don't Know 	0 
A23 Have you ever had one or both ovaries removed? 
Yes 
No 	 0 (go to A29) 
A24 How many ovaries have you had removed? 
One 	0 
Two 	0 
A25 How old wars you when you had your first ovary removed? 
Years 	 
Don't know 
A25 Why was It removed? 
To treat ovarian cancer 	 0 
To prevent getting cancer in that ovary 0 
As part of treatment for breast cancer 0 
As part of prevention of breast cancer 0 
To help treat or stop endometriosis 	0 
As part of a hysterectomy 	 0 
Other. specify reason 	 0 
Don't know 	 0 
Age" 	(years) 	 (if participant had only one ovary removed when responding to 
A24, go to A29 
If participant had two ovaries removed answer next question) 
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A27 How old were you when You had your second ovary 
Age 	Years 
removed? A32 How old were you when it was first diagnosed? 
Age 	 (years) 	• 
the result of a laparoscopy? Don't know 	 0 
A28 Why was it removed? 
A33 Was the endometrlosis diagnosed as 
Yes 	0 (go to Fri 
To treat ovarian cancer 0 No 	0 (go to A34) 
To prevent getting cancer in that ovary 0 Don't Know 0 (go to A34) 
As part of treatment for breast cancer 0 A34 What diagnostic procedure was used to diagnose the 
endometriosis? 
As part of prevention of breast cancer 0 
To help treat or stop andometrlosis 0 Laparotomy 0 
As part of a hysterectomy 0 Hysteroscopy 0 
Other - specify reason 0 Hysterectomy 0 
Don't know 0 Ultrasound (and/or MRI) 0 
Other surgical procedure, specify 0 
A29 Has a doctor ever diagnosed you as having had a uterine fibroid? 
Don't Know 0 
Yes 	 0 	 EL Height and Weight 
No 	 0 (go to A31) 	 Now I'm going Co ask about your height and weight 
OK 	 0 (go to A31) 	 81. How tall are you without shoes on? Please be as accurate as you 
can. (Give fraction of an inch or centimetre) 
A30 How old were you when It was first diagnosed? 	 e.g. 6 	11 	 114 	OR 	181.5 cm 
feet inches 	 cm 
Age 	(years) 
Feet _ Inches _ 	7 OR Centimetres_ 
A31 Has a doctor ever diagnosed you as having had endometriosls? 	 Don't know 
Yes 	 0 	 82. What Is your current weight without clothes? 
No 	 • 0 	(go to 131) 	 stone 	pounds 	OR kilograms 
Don't know 
DK 	 0 (go to 81) 
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C3 For the first next of these pregnancies since (data of last 
Interview/D01) what month and year did this pregnancy end? 
l et pregnancy: 
0 0 0 0 0 0 Month/Year (Go to C4) 
Currently pregnant 0 How many months pregnant? 	(Go to 69) 
2' pregnancy: 
0 0 / 0 0 0 0 MonthNear (Go to C4) 
Currently pregnant 0 How many months pregnant? 	(Go to C9) 
3rd pregnancy: 
0 / 0 0 0 Month/Year (Go to C4) 
Currently pregnant 0 How many months pregnant? 	(Go to C9) 
4th pregnancy: 
0 / 0 0 0 Month/Year (Go to C4) 
Currently pregnant 0 How many months pregnant? 	(Go to 69) 
C4 A full term pregnancy Is 40 weeks. How many weeks pregnant were 
you when this pregnancy ended? - 
First pregnancy since DOI 
Second pregnancy sines DOI 
Third pregnancy since DOI 
Fourth pregnancy since DOI 
Fifth pregnancy since DOI 
Weeks (go to CS) 
Weeks (go to 09) 
Weeks (go to CS) 
Weeks (go to CS) 
Weeks (go to CS) 
B3. What was your weight when you were between 18 and 21 years old? 
stone 	pounds 	OR kilograms 
Don't know 
84 What was your weight at 30 years? 
stone 	pounds 	OR kilograms 
Don't know 
C, ReproductIve Illstorv 
Now I'd like to ask about your pregnancies and use of fertility drugs. 
preanancv History 
Cl Since your last interview on [date of interview), have you been 
pregnant? (Including all your pregnancies: miscarriages, stillbirths, 
terminations, molar or tubal pregnancies, as well as Ilve births or current 
pregnancy) 
Y83 
No (go to C9) 	0 
C2 How many times have you been pregnant since (date of last 
Interview)? 
_Number of times pregnant 
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C5 How did this pregnancy end? 
First Pregnancy: 
Live birth 	0 	C5a Specify single birth 	0 Go to C6 
twin 	 0 Go to C6 
other multiple birth 0 Go to C6 
Stillbirth 	0 Return to C3 if more pregnancies Or to C9 If not 
Miscarriage 0 	Return to C3 If more pregnancies or to C9 if not 
Termination 0 	Return to C3 If more pregnanc ies or to C9 If not 
Ectoplc 	0 	Return to C3 if more pregnancies or to C9 if not 
Molar Pregnancy0 Return to C3 if more pregnancies or to C9 If not 
Don't Know 0 	Return to C3 If more pregnancies or to C9 if not 
Second Pregnancy: 
Live birth 	0 
	
C5a Specify single birth 	0 Go to C6 
twin 	 Go to C6 
other multiple birth 0 Go to CS 
Stillbirth 	0 Return to C3 if more pregnancies or to C9 If not 
Miscarriage 0 	Return to C3 if more pregnancies or to C9 If not 
Termination 0 	Return to C3 If more pregnancies or to C9 if not 
Ectopic 	0 	Return to C3 If more pregnancies or to C9 if not 
Molar Pregnancy0 Return to C3 If more pregnancies or to C9 if not 
Don't Know 0 	Return to C3 if more pregnancies or to C9 If not 
'Miscarriage 0 
	
Return to C3 if more pregnancies or to C9 if not 
Termination 0 
	
Return to C3 if more pregnancies or to C9 if not 
Ectopic 0 Return to C3 if more pregnancies or to C9 if not 
Molar Pregnancy0 Return to C3 If more pregnancies or to C9 If not 
Don't Know 0 Return to C3 If more pregnancies or to C9 If not 
Fourth Pregnancy: 
Live birth 	0 	C5a Specify single birth 	0 Go to C6 
twin 	 0 Go to C6 
other multiple birth 0 Go to C6 
Stillbirth' 	0 Return to C3 If more pregnancies or to C9 if not 
Miscarriage 0 	Return to C3 If more pregnancies or to C9 if not 
Termination 0 	Return to C3 If more pregnancies or to C9 If not 
Ectopic 	0 	Return to C3 If more pregnancies or to C9 If not 
Molar Pregnancy0 Return to C3 If more pregnancies or to C9 if not 
Don't Know 0 	Return to C3 if more pregnancies or to C9 If not 
Fifth Pregnancy: 
Live birth 	0 	C5a Specify single birth 	0 Go to CS 
twin 	 0 Go to C6 
other multiple birth 0 Go to CO 
Stillbirth 	0 Return to C3 If more pregnancies or to C9 if not 
Miscarriage 0 	Return to C3 if more pregnancies or to C9 If not 
Termination 0 	Return to C3 if more pregnancies or to C9 If not 
Ectopic 	0 	Return to C3 if More pregnancies or to C9 If not 
Third Pregnancy: 
Live birth 
Stillbirth 
0 	CSa Specify single birth 	0 Go to.CrIt 
twin 
	
0 Go to C6 	 Molar Pregnancy0 Return to C3 if more pregnancies or to CS If not 
other multiple birth 0 Go to CS Don't Know 0 	Return to C3 If more pregnancies or to C9 if not 
0 Return to C3 If more pregnancies or to CS If not 
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C6. (if said livebirth to C5) Did you commence breastfeeding after this 
birth? 
First pregnancy resulting In live birth since DOI 
Yes 0 (if there were no more pregnancies go to Cl, if more go 
to C8a) 
No 0 (Return to CS if more pregnancies or go to C9 If not) 
Second pregnancy resulting In live birth since 001 
Yes 0 (If there were no more pregnancies go to C7, If more go 
to C8a) 
No 0 (Return to CS if more pregnancies or go to C9 if not) 
Third pregnancy resulting In live birth since DOI 
Yes 0 (If there were no more pregnancies go to C7, If more go 
to C8a) 
No 0 (Return to C3 If more pregnancies or go to C9 if not) 
Fourth pregnancy resulting in live birth since 001 
Yes 0 (if there were no more pregnancies go to Cl, if more go 
to CBs) 
No 0 (Return to C3 if more pregnancies or go to C9 if not) 
Cl Are you currently breastfeedIng? 
No 0 Go to C8a 
Yes 0 Go to C8b 
C8a How long did you breastfeed? 
Days 	(go to CS) 
Weeks 	(go to C3) 
Months 	(go to C3) 
C8b How long have you breastfed following this pregnancy so far? 
Days 
Weeks 
Months 
infertIlitv Drum; 
C9 Have you ever seen a doctor because you were having trouble 
getting pregnant? 
Yes 	 0 
No (go to Section D) 	0 
C10 Have you ever taken fertility drugs for the treatment of Infertility? 
Yea 	 0 
No (go to Section D) 	0 
C11 In total, what is the number of cycles of fertility drug treatment that 
you've had (Include IVF cycles and ovulation induction)? 
cycles of fertility treatment 
C12 How old were you when you first started fertility drug treatment? 
Aga 	(Years) 
C13 How old were you when you last had fertility drug treatment? 
Age 	 (Years) (give current age if still using treatment) 
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0 
08. How long after your last period did you take HRT? 
Months 
Weeks 
Years 
Don't know 	0 
07 How old were you when you first used/resumed/changed the HRT 
medication? 
1 	Age (years) (go to 08) 
2 	Age (years) (go to 08) 
3 	Age (years) (go to 08) 
4 	Age (years) (go to 05) 
5 	Age (years) (go to 08) 
Natural menopause (that is, periods stopped by themselves) 0 
Hysterectomy (uterus or womb removed) 
Both ovaries removed 	 0 
Radiation or chemotherapy 	 0 
Pregnant/breast feeding 	 0 
Serious Illness (e.g. Anorexia) 	 0 
Strenuous exercise 	• 	 0 
Other (specify) 
Don't know 
D4. Have you ever taken prescription oestrogens, progesterone or other 
female hormones for menopause, (that Is, prescription hormone 
replacement therapy or HRT)? 
The preparation may be pills, Injections, skin patches. This question does not 
Include birth control pills or hormonal contraceptives. 
Yes 	 0 
No 	 0 (go to 017) 
Don't know 	 0 (go to D17) 
If less than one year go to D4 	 05. Were you still having periods when you first took HRT? 
If one year or more continue to D2. 
02 What age were you when you had your last period? 	 Yes 	 0(90 to 07) 
Age 	 (years) 	 No 
03. Why did your menstrual periods stop? 	 Don't know 	0(go to 07) 
(Read options 8 record only one answer) 
Section D. Menopause and Hormone Replacement Therapy 
Now I'm going to ask questions about menopause and hormone replacement 
therapy or HRT 
Dl. How long ago was your last period? 
	Days 
Weeks 
	Months 
Year(s) 
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08 What was the name of the hormone medication you took (when you 
first started HRT / at this time)? 
4. Progesterone Only 0 
1.Name of Medication 	 (go to 010) Progesterone and oestrogen 0 
Don't Know (continue to 09) 	0 
Oestrogen only 0 
2 Name of Medication 	 (go to 010) DK 0 
Don't Know (continue to 09) 	0 
Go to 010  
3 Name of Medication 	 (go tO 010) 
010 How was It taken? 
Don't Know (continue to 09) 	0 
1, 	Orally 0 
4. Name of Medication 	 (go to 010) implants 0 
. 	Don't Know (Continue to 09) 	0 	. Injections 0 
09 Were the hormones In the meAlcatIon : Vaginally 0 
1. Progesterone Only 	 0 Other 0 
Progesterone and oestrogen 	0 Go to D11  
Oestrogen only 	 0 
OK 	 0 2. 	Orally 0 
• implants 0 
Go to 010 
Injections 0 
2. Progesterone Only 	0 Vaginally 0 
Progesterone and oestrogen 	0 Other 0 
Oestrogen only 	 0 Go to 011 
OK 	 0 
3. Orally 0 
Go to D10 
Implants 0 
3. 	Progesterone Only 	 0 Injections 0 
Progesterone and oestrogen 	0 Vaginally 0 
Oestrogen only 	 0 Other 0 
OK 	 0 
Go to 011 
Go to 010 
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4. 	Orally 	 ' 0 
Implants 	 0 
Injections 	 0 
Vaginally 	 0 
Other 
Go to 1311 
011 At any time after this, did you stop taking HRT for more than 12 
months, or change the medication you were using? 
1. Yes 	0 Go to 012 
No 	0 Go to 1316 
2. Yes 	0 Go to 012 
No 	0 Go to 016 
3. Yes 	0 Go to 012 
No 	0 Go to D16 
4. Yes 	0 Go to D12 
No 	0 Go to D16  
012 For how many months did you use It before you stopped or 
changed It at this time? 
1. 
months 
Go to 13 
2. 
	months 
Go to 13 
3. 
	months 
Go to 13 
months 
Go to 13 
013 Did you stop or change it? 
1. Stopped (go to 014) 	0 
Changed (go back to 07 and repeat cycle) 	0 
2. Stopped (go to 014) 	0 
Changed (go back to 07 and repeat cycle) 
3. Stopped (go to 014) 	0 
Changed (go back to 07 and repeat cycle) 
4. Stopped (go to 014) 
.Changed (go back to 07 and repeat cycle) 	0 
014 How old were you when you stopped it? 
1 	Age (years) (go to 015) 
2 	Age (years) (go to 015) 
3 	Age (years) (go to 015) 
4 	Age (years) (go to D15) 
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5 	Age (years) (go to 015) 	 018 Which anti-oestrogen did you take? 
016 Did you over take HRT again after that? 
1. Y03 (go back to D7) 0 
No (go to 017) 	0 
2. Yes (go back to 07) 0 
No (go to 017) 	0 
3. Yes (go back to 07) 0 
No (go to 017) 
4. Yes (go back to 07) 	0 
No (go to 017) 	0 
0113 Are you currently using HRT7 
Yes (go to 017) 
No (go to D16_1) 
016_1 How old were you when you last took HRT7 
Age_years 
017 Have you over taken tamoxifen, raloxifene or other and-oestrogen 
medication? (such as EvIsta, Tamoxen. Genoa, Nolvadex, Noxiton, Tamosin) 
Yes 	 0 
No (go to Section E ) 	0 
Don't know (go to Section E) 0  
Tamoxifen 0 
Raloxifene 0 
Other, specify 	  
Don't Know 0 
019 How old were you when you first took the medication? 
	Age (years) 
020 Are you currently taking Tamoxiten. Raloxlfene or other anti-
oestrogen medication? 
	
Yes (Go to 022) 	0 
No 
21. How old were you when you last took Tamoxlfen, Raioxifene or 
other anti-oestrogen medication? 
Age 	Years 
22. In total for how many weeks, months or years have you taken 
them? 
Weeks 
Months 
Years 
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Section E. Contraceptive Use 
E4 How was it taken? 
orally 0 
Now I am going to ask you about your use of hormonal contraception, 
El. Have you ever used birth control pills or other hormonal 
contraceptives such as Implants or Injections? Please Include 
contraceptives used for other reasons than contraception. 
implants 
injections 
other 
0 
0 Specify 
Yes 	0 2. orally 
implants 0 
No 	0 (go to E11) 
injections 0 
Don't know 	o (go to E11) other 0 Specify 
E2 Were these contraceptive hormones used for anything other than 
contraception? 
3. orally 0 
implants 0 
Yes • 	0 	Specify reason/condition Injections 
No 	0 other 0 Specify 
4. orally 0 
E3 How old were you when you first/next used the pill or hormonal 
contraceptive? Implants 0 
1. Age (years) injections 0 
• 
2. Age (years) other 0 Specify 
3. (years) _Age 
5. orally 
4. Age (years) 
implants 0 
5. Age (years) injections 0 
6. __Age (years) other 0 Specify 
6. orally 
implants 0 
injections 0 
other 0 Specify 	  
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E5 At any time after this, did you ever stop using it for 12 months or 
more? 
1. Yes 	 0 
No (go to E9) 	0 
2. Yes 	 0 
No (go to E9) 	0 
3. Yes 	 0 
1. 
(go to E8) 
No (go to E9) 	0 
2. 	 Weeks 
E6 How old were you then? 
1. Age (years) 
2. Age (years) 
3. Age (years) 
4. _Age (years) 
5. Age (years) 
6. Age (years) 
E7 For how many weeks, months or years did you take it before you first 
stoppedIstopped It this time? 
	Weeks 
Months 
Years 
7. 	orally 	 0 
Implants 	0 
injections 	0 
other 	 0 Specify 
	
4. 	Yea 	 0 	Months 
No (go to E9) 	0 	Years 
5. 	Yes 	 0 	
(go to E8) 
No (go to E9) 	0 3. 	 Weeks 
6. 	Yes 	 0 	Months 
No (go to E9) 	Years 
7. 	Yes 	 0 
No (go to E9) 
• 
(go to E8) 
4. 	Weeks 
	Months 
Years 
  
(go to E8) 
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5. 	Weeks 
	
E9 Are you currently taking the pill or a hormonal contraceptive? 
Months 
Yes 
	
0(go to Ell) 
No 
	0 
(go to E8) 	
El0 How old were you when you last took the pill or a hormonal 
contraceptive? 
6. 	Weeks 
Months 
Years 
(go to E8) 
L8 Did you ever take the pill or hormonal Contraceptive again after that? 
1. Yes (Go back to ES and repeat cycle) 	0 
No (go to Ell) 
2. Yes(Go back to ES and repeat cycle) 
No (go to Ell) 
Yes (Go back to E3 and repeat) 
No (go to Ell) 
Yes (Go back to E3) 
No (go to Ell) 	 0  
	Age (years) 
Ell Apart from the oral contraceptive pill or hormonal contraceptives for 
which we have covered, have you taken any other hormonal medication 
for ? 
El 1_1 (if said yes to A33) Endometriosis 
Yes 0 	No 0 Go to El i_2 
a) If yes, What Is the name of the hormone medication 
you were taking for this condition? 
Name of medicine 	 
b) In total for how many weeks, months or years have 
you taken hormonal medication for this condition? (if 
you took this medication over different time periods, 
add up together all the times you took medications). 
C) How old were you when you first took this 
medication? 
0 	 Weeks 
Months 
Years 
Age 	_(years) 
5. 	Yes (Go back to ES) 
	
0 
No (go to Ell) 
	
0 	 d) How old were you when you last took this 
medication? 
Yes (Go back to 63) 	 0 
	
Age 	(years) 
Na (go to Ell) 	 0 
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E11_2 said yes to A20) Polycystic Ovary Syndrome 
Yes ID 
No 0 Go to 211_3 
Weeks 
Months 
Years 
C) How old were you when you first took this 
medication? 
a) If yes, What Is the name of the hormone medication 
you were taking for this condition? 
Name of medicine 
b) In total for how many weeks, months or years have 
you taken hormonal medication for this condition? (if 
you took this medication over different time periods, 
add up together all the time you took medications). 
Weeks 
Months 
Years 
C) How Old Were you when you first took this 
medication? 
Age____(years) 
d) How old were you when you last took this 
medication? 
Age__(years) 
- 
E11_3 (If said yes to A22) Ovarian Cysts (other than PCO) 
Yes 0 	No 	Go to El 1_4 
a) if yes, What Is the name of the hormone medication 
you were taking for this condition? 
Name of medicine 
b)In total for how many weeks, months or years have 
you taken hormonal medication for this condition? (If 
you took this medication over different time periods, 
add up together all the time you took medications). 
Ace_(years) 
d) How old were you when you last took this 
medication? 
Age. 	(years) 
E11_4 (If said yes to A29) Uterine Fibroid 
Yes 0 	No CI Go to Ely 
a) If yes, What is the name of the hormone medication 
you were taking for this condition? 
Name of Medicine 	 
b)In total for how many weeks, months or years have 
you taken hormonal medication for this condition? (if 
you took this medication over different time periods, 
add up together all the time you took medications). 
Weeks 
Months 
Years 
e) How old were you when you first took this 
Medication? 
Age(years) 
d) How old were you when you last took this 
medication? 
Age_(years) 
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E11_5 Menstrual Problems not due to endometriosis, ovarian 
cysts, PCO or uterine fibroids. 
Yes 0 	No 0 Go to El2 
If yes, What is the name of the hormone medication 
you were taking for this condition? 
Name of medicine 	 
In total for how many weeks, months or years have 
you taken hormonal medication for this condition? (if 
you took this medication over different time periods, 
add up together all the time you took medications). 
Weeks 
Months 
Years 
c) How old were.you when you first took this 
medication? 
Age 	(years) 
d) How old were you when you last took this 
medication? 
Age 	(years) 
E12 Have you been given hormone medication for anything else as an 
adult? 
'Yes 
No (go to F1) 0 
E13 For which conditions? 
1.Condlton 
2. Condition 
3. Conditon  
E14 (For each of the conditions in E13) What hormonal medication was 
used for the condition? 
1. Medication for Condition 1 	  
2. Medication for Condition 2  
3. Medication for Condition 3 
E15 (For each of the conditions in E13) in total for how many weeks, 
months or years have you taken hormonal medication for this 
condition? (If you took this medication over different time periods, add up 
together all the time you took medications) 
Condition 1 
	 Weeks 
Months 
	 Years 
	 Weeks 
Months 
	 Years 
Condition 3 
	 Weeks 
Months 
	 Years 
Eta What age were you when you last used this medication? 
Age 	 (Years) 
Anti4nffammatories 
I am now going to ask about your use of antkinflammatories 
In table format 
F1 Have you ever taken Aspirin (such as Aspro, Disprin, Cardiprin, 
Cartia , Solprin) at least twice a week for a month or longer? 
Yes 	 ' 
	
No 	 p(go 	to F5) 
Don't Know 	0(go 	to FS) 
Condition 2 
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F2 How many times per day or week did you take this medication, when 
you were taking it at least twice a week for a month or longer? 
Per Day 
Per Week 
F3 For how many months or years. In total, have you taken this 
medication for at Mast twice a week for a month or longer? 
	Months 
Years 
F4 Was it standard dose or low dose Aspirin that you took when taking it 
at least twice a week for a month or longer? ( e.g. Carta, Cardiprin) 
Standard Dose 
Low Dose 
Both 
OK  
F8 What was the name of the medication or medications? 
	 medication 
	 medication 
medication 
F9 Have you ever taken anti-Inflammatorles that requires prescription 
by a doctor at least twice a week for a month or longer? 
Yes 	 0 
No 	 0(go to Section G) 
Don't Know (go to Section G) 0 
F10 What was the name of the medication or medications? (Give some 
examples In box if needed - prompt for Vioxx, Celebrex or Mobic) 
medication 
	 medication 
Ft Have you ever taken over the counter anti-inflammatorles at least 
twice a week for a month or longer? 
Yea 
	
0 
No 
	
0(go to F9) 
Don't Know 
	
0(go to F9) 
FS How many times per day or week did you take over the counter anti-
Inflammatories, when you were taking it at least twice a week fore 
month or longer? 
	Per Day 
Per Week 
F7 For how many years or months, in total, have you taken this over the 
counter anti-inflammatories for at least twice a week for a month or 
longer? 
Months 
Years 
Don't Know 0 
F11 How many times per day or week did you take anti-Inflammatories 
that require a prescription by a doctor, when you were taking it at least 
twice a week for a month or longer? 
	Per Day 
Per Week 
F12 For how many years or months, in total, have you taken anti-
Inflammatories that require s prescription by a doctor at least twice a 
week fore month or longer? 
	Months 
Years 
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G. Smoking 
of cigarette smoking. 
your smoking status now? 
(go to Section H) 	0 
H. Alcohol 
patterns. 
often you usually 
responses) 
The next questions are about your history 
01 Which of the following best describes 
I have never smoked 
The next questions are about your alcohol consumption 
Ht Which of these statements best describes how 
drink alcohol ( such as beer, wine or spirits)? (read 
I never drink alcohol (go to Section J) 
I used to smoke occasionally (go to 02) 	0 
I drink rarely 0 
I used to smoke regularly (go to 02) 
Occasionally, but less than once a week 0 
I now smoke occasionally (go to 04) 	0 
On. 1 or 2 days a week 0 
I now smoke regularly (go to 04). 
On 3 or 4 days a week 0 
02 if you used to Smoke, what age were you when you last smoked? On 5 or 6 days a week 0 
Age 	(years) Every day 0 
03 If you used to smoke, how many cigarettes did you usually smoke In 
a day? 
cigarettes per day 	 
Go to GS 
04 How many cigarettes do you usually smoke in a day? 
cigarettes per day 	 
05 Have you ever smoked daily for six months or more? 
Yes 	0 
No 	0 
06 At what age did you start smoking? 
Age_(years) 
A "standard drink" Is a small glass of wine or middy of beer, a nip of 
spirits, or a mixed drink. 
H2 On a day when you drink alcohol, how many drinks do you usually 
have? 
drinks 
H3 Have you ever consumed alcohol daily for six months or more? 
Yes 	0 
No 	0 
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	). FAMILY HISTORY 	 .14. Are there any aunts on your fathers side who have had breast 
cancer? 
These questions are about breast and ovarian cancer In your family; I'm going 
to ask about your biological relatives, not including step or adoptive 	 NO 	. 0 relatives. 
Yes 0 	J4a If yes, how many aunts?. 	 
.11. Has your mother ever had breast cancer? 
.14b if yes, age first diagnosed 
1 ST Aunt 	yrs 
No 	0 	 2"° Aunt yrs 
3"" Aunt 	yrs 
Yes,. 	0 	Jla.Age 1st diagnosed? 	years old 	 4m aunt Yrs 
Don't know 0 Don't Know 0 
J2. DO you have any sisters who have had breast cancer? 
No 	0 
Yes. 	0 	.I2a If yes, how many sisters? 
Don't know 
.15 Are there any aunts on your mothers side who have had breast 
cancer? 
J2b If yes. age first diagnosed 
1" Sister 	yrs No 0 
2"° Sister _yrs 
30" Sister yr. Yes 0 J5a if yes, how many aunts? 
4" Sister 	yrs .15b If yes, age first diagnosed 
1" Aunt 	yr. 
Don't Know 	0 250 Aunt yrs 
3" Aunt 	Yr. 
4"." aunt Yns Don't know 	0 Don't Know 
.13 Do you have any daughters who have had breast cancer? Don't know 0 
No 0 
Yes 0 	j3a If yes, how many daughters? 
J3b If yes, age first diagnosed: 
1" daughter 	yrs 
2" daughter 	yrs 
3° daughter yrs 
4° daughter 	yrs 
Don't Know 0 
Don't know 0 
 
./6. Has either of your grandmothers had breast cancer? 
No 	0 Go to 19 
Maternal 	0 Go to .17 
Paternal 	0 Go to J8 
Both 	0 Go to J7 and .18 
Don't Know 0 Go to n 
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J7 What age did the maternal grandmother have breast cancer? 
Age 
Don't know 	0 
.18 What age did the paternal grandmother have breast cancer? 
Age 
Don't know 	0 
J9. Have any of your sisters, or mother, or daughters had ovarian 
cancer? 
No 
	
0 OotoIII 
Yes 
	
0 Go to J10 
Don't Know 0 Go toll I 
J10 How many of your sisters, or aunts, or daughters have had ovarian 
cancer? 
	 Number of sisters, mother or daughters 
.111 Are there any aunts on your mother's side who have had ovarian 
cancer? 
No 	0 Go to J13 
Yes 	0 Go to J12 - 
Don't Know 0 Go to Ji2 
.112 What is the number of aunts on mother's side who have had ovarian 
cancer? 
Number of Aunts on mother's side  
.113 Are there any aunts on your father's side who have had ovarian 
cancer? 
No 
	
0 Go to J15 
Yes 
	
0 ,Go tone 
.114 What Is the number of aunts on your father's side who have had 
ovarian cancer ? 
Number of Aunts on mother's side 	 
.115 Has any of your grandmothers had ovarian cancer? 
Fathers side 0 
Mothers Side 0 
Both 	0 
No 	0 
Don't Know 0 
K. Background Information 
I'm going to finish off by asking some questions about your background 
Can you give me your date of birth so we can confirm It with earlier records? 
K1. Date of birth? 	/ 	/ 	(dcl/maVyyyy) 
K2. What is the highest level of education you have completed? (one 
response) 
Primary school (some or all) 	 0 
Intermediate certificate/year 10 (or equivalent) 	0 
Higher School Slor Leaving Certificate/Year 11 & 12 0 
Trade/apprenticeship (e.g. Chef, Hairdresser) 	0 
Certificate/Diploma (e.g. Child Care, Technician) 	0 
University degree 	 0 
Higher University degree (e.g. Grad Dip, Masters. PhD) 	0 
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K3. What is your preient marital status? (one response only) 
Married 0 
De facto 0 
Separated 0 
Divorced 0 
Widowed 0 
Single 0 
KS. In which country were you born? 
. 	K4a You 
What about K4b Your Mother 
K4c Your Father 
K4d Your mother mother 
K4e Your mothers father 
K4f Your fathers mother 
K4g Your fathers father 
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Ethical approvals, obtained for follow-up 2 
Tasmania 
• DEPARTMENT of 
HEALTH and 
HUMAN SER VICES 
UNIVERSITY 
OF TASMANIA 
HUMAN RESEARCH ETHICS COMMITTEE (TASMANIA) NETWORK 
11 August 2005 . 
A/Prof Alison Venn 
Menzies Centre' 
Private Bag 23 
Dear A/Prof Venn 
REF NO: 	1)0008334 
17111: 	Moiesaent expos= b honnone treatment for tall stature In girls: long terms effects on 
breast tissue 
The Southern Tasmania Health and Merkel Human Research Ethics Committee considered and 
approved the above documentation at its meeting on 21 July 2005. 
M committees operating under the Human Research Ethics Committee (Tasmania) Netwolk are 
registered and required to campy with the National Statement on the Ethical Conduct in Research 
Involving Humans 1999 (NHMRC guidelines). 
Therefore, the Chief Investigatoes resporrehthly is to ensure that 
(1) The incividual 'researcher's protocol complies with the HREC approved protocol. 
(2) Modifications to the protocol do not proceed until approval is obtained in writing from the HREC. 
(3) The confidentiality and anonymity of all research subjects is maintained at all times, except as 
raffalrea by  law,• 
(4) Clause2e3IfititaittEldiE22RMO: 
An MEC shalt as a coneftion of approval of eadi protocol, require that researchers immeclately 
report anything vilgch might warrant review of ethical approval of the protocol, ladtkrink 
a. Serious or unexpected adverse effects on partiopants; 
,b .proposed changes In the protocol; and 	• 
C. Unforeseen events that might affect continued ethical acceptsliffly of the project 
The appropriate forms for reporting such events in relation to drug trials can be located at the 
website below. All adverse events must be reported mgangess of whether or not the event, in your 
opinion, is a cfirect effect of the drug being tested. 
hlto://www.researchutas.edu.ati/rdotethiestuman.htm  
(5) All subjects must be provided with the current Patient Information Sheet arid Consent Form as 
approved by the Ethics committee. 
(6) The Committee is notified if any investigators are added to, or cease involvement with, the project. 
Research and Development Me, UnlversIty of Tasmania, Prfrata Bagel HOBART TAS 7001 
Tel (03) 62tez 	/03 Fax: (03) 62252765 Email: AmandaMcaully @etas. eelu-au 
(7) This study has approval for 4 years contingent upon annual review. An Progress Report is to be 
provided on the anniversary date of your approval. Your first report is due 21 July 2006. You wit be 
sent a courtesy reminder closer to this due date. 
Clause 235 of the National Statement states: 
Asa minimum an MEC must require at regular periods, at least annually, reports from principal researchers 
on matters inclurfing: 
a progress t o date or outcome in the case olcompleted researd); 
b. maintenance and secunly o records; 
c. compliance with the approved protocol,. and 
d. compfiance with any conditions of approval 
(8) A Feral Report and a copy of the published material, either in full or abstract, must be provided at 
the end of the project 	
_ 
Should you have any queries please do not hesitate to contact Rachael Cowen leanovic on 62261751 in the 
first instance. 
Zrs sincazrvoly 
ve. 
Alunanda McAugy 
1 Executive Officer 
Human Research Ethics Committee (Tasmania) Network 
ACT HEALTH HUMAN RESEARCH ETHICS COMMITTEE  
Outcome of Consideration of Protocol 
Submission No: ETH.5/06.313 	Date of Approval: 14 August 2006 
Project Title: 
Exposure to High Dose Estrogens in Adolescence: Long Tern) Effects on 
Mammographic Breast Density 
Submitted by: 
Associate Professor Alison Venn 
Your project was considered by the ACT Health Human Research Ethics Committee 
and approved for a period of one year 
Further Action required: 
Review due: August 2007 
The Ethics Committee require as part of the review process that: 
• At regular periods, and not less frequently than annually, Principal Investigators 
are to provide reports on matters including: 
- security of records 
- compliance with approved consent procedures and documentation 
- compliance with other approved procedures. 
- as a condition of approval of the protocol, that Investigators report 
immediately: 
- adverse affects on subjects 
- proposed changes in the protocol 
- unforeseen events that might affect continued ethical acceptability of the 
project. 
• All published reports to carry an acknowledgement stating: 
- approved on 14 August 2006 by the ACT Health and Community Care 
Human Research Ethics Committee. 
MS ELIZABETH GRANT AM, CHAIR 
	
Date: 14 August 2006 
.0. 	Departing)! II 
of Health 
Government 
of South Australia 
Human Research Ethics Committee. 
Ms Helen Jordan 
6 Casley Street 
BEN DIGO VIC 3550 
ABM 97 643 356590 
Cdi Centre Building 
11 Hindrnarsh Square 
Adelaide SA 5000 
PO Box 287 
Rundle Mall 
Adelaide SA 5000 
Dear Ms. Jordan, 
RE: Exposure to high dose estrogens in adolescence: long term effects on 
mammographic breast density. 
Thank you submitting the above project to the Department of Health Human Research 
Ethics Committee for consideration. The Committee met on the 14 th December 2005 to 
review your proposal. 
I am pleased to inform you that ethics approval has been given to the above proposal. 
Approval is given subject to: 
.D The plain language statement containing further specific information relating to the risks 
(both medical and psycho-social) associated with participation in this project, to ensure 
that the participants can make an informed decision about their involvement. 
.D The research being conducted in accordance with the 'National Statement on Ethical 
Conduct in-Research Involving Hurrian .s.:. ,., 
ID Provision of a final report when the project is comp leted .  
D Immediate notification to HREC of any adverse events involving participants. 
D Immediate notification of any unforeseen events that might affect continued ethical 
acceptability of the project. 
D Submission of any significant changes to the original proposal. Such changes should be 
approved by the HREC before they are implemented. 
D Immediate advice, giving reasons, if the project is discontinued before its completion: . 
Approval is given for a period of three (3) years only, and if the research is more prointiwr 
than this, a new submission will be required. 
Should you have any questions or concerns, please contact Sarah Lawson, Executive 
Officer of the HREC. Tel 8226 6367 or sarah.lawson@health.sa.aov.au .  
We wish you all the best with the "Exposure to high dose estrogens in adolescence: long 
term effects on mammographic breast density." project. 
Yours sincerely, 
LL- 
Ian Olver 
A/CHAIRPERSON 
HUMAN RESEARCH ETHICS COMMITTEE 
/12/2005 
tr, 
Date: tie' August 2006 
Associate Professor Alison Venn 
Deputy Director 
Menzies Research Institute 
University of Tasmania, 
Private Bag 23 
Hobart TAS 7001 
Dear Associate Professor Venn, 
cancer institute 
/ 1 
Cancer Indttule NSW 
Level 1, Biomedical Su1drig 
Aushofian Teclnology Pork 
Eveleigh NSW 2015 
PO Box 41. A/exondtio NSW 1435 
102 8374 5000 
02 8374 5700 
wwwzoncerins18vIchorOu 
ASH 48 538 442 394 
Re: Cancer Institute NSW Reference N 20061061003 
Exposure to high dose estrogen in I • 
denzoly 
Thank-you for your correspondence dated 1 
Institute NSW Ethics Committee's labs of 20. 
I anfpleased to inform you that following a 
your study has been 'given. The Committee 
Cancer Institute NSW Ethics Committee is 
ongoing monitOring of these approvals and 
• That tire study continues to. be 
application and all subsequent 
• Compliance with the NHMRC 
Involving Humans 1999, NSW 
Health Records & Information • . 
• An Annual Report is submlited. 
completion. 
• The Institute is to be provided with 
Mk*. • The Cancer Institute NSW Ethics 
amendments unforseen and/or 
• Compliance with policies and guide 
Committee. 
Should you require any further assistance hi 
. me on (02) 8374-5759 or kirsten. • e• 	• 
Yaws sincerely. 
Project Officer—Ethics  
long term effects on mammogrephic breast 
uly 2006. were you reSponded to the Cancer 
2006. 
of your letter, formal ethical approval for 
to reconfrm, that as of June 5" 2004, 9ie 
primary ethics committee responsible for all 
ongoing aOproval is conditional on the 
ucted in accordance with the aPproved 
Statement on Ethical Conduct in Research 
Privacy Manual (Version 1, 2004) and the 
(NSW) 2002 
later than August 2007, and at the study 
I publicab3ns or reports generated by the 
Is to be advised of any Intended protocol 
events occurrirg in relation to the study. 
Issued by the Cancer Institute NSW Ethics 
lion to this study, please feel free to contact 
stitute. 
• 
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 7 November 2005 
Associate Professor Alison Venn 
C/- Ms Helen Jordan 
Program Evaluation Unit 
School of Population Health 
The University of Melbourne 
4'" Floor. 207 Bouverie Street 
Carlton Vic 3010 
BreastScreen 
VICTORIA 
Coordination Unit 
31 Pelham Street 
Carlton South 
Victoria 3053 
Phone 03 9660 6888 
Facsimile 03 9662 3881 
Email infoebreastscreen.org.au  
Website vnyw.breastscreen.org.au  
Email: hjordan@unimelb.edu.au  
Dear Alison 
Re: Exposure to high dose estrogens in adolescence: long term effects on 
mammographic breast density • 
The above project was considered by the BreastScreen Victoria Research and 
Evaluation Committee CREC*) on 25 October 2005. 
I refer to your intention to ask women who have not had a mammogram in the last 
two years to have one at a convenient Bn3astScreen service. The REC believed 
many of the women in your study would be in the 40 to 50 age group. It was 
recommended that a statement about the smaller benefit of mamMography for this 
age group should be provided to these women. 
Subject to the above, the REC agreed that your project be endorsed. 
We look forward to receiving a summary of the project findings at completion. 
Yourincerely 
Anna Maloney 
Project Officer 
Quality and Research in Practice 
BreastScreen Victoria 
p: (03) 9660 6857 
e: arnaloney©breastscreen.org.au  
BreastScreen Victoria inc. 
Regd. no. A0025878W 
ABN 54 505 206 361 
Her 
tor, Cancer Screening Services Unit 
12 / 2005 
e Queensland Government 
Queensland Health 
CANCER SCREENING SERVICES UNIT 
PUBLIC HEALTH SERVICES BRANCH 
Associate Professor Alison Venn 
Menzies Research Institute 
Private Bag 23 
HOBART TAS 7001 
Enquiries to: 	Kirsten Mayne 
Telephone: 	(07) 3234 1260 
Facsimile: 	(07) 3225 2629 
Our Ref 	0243-0271-003 
( 34 0 E+ 0 
Dear Assoc Prof Venn 
Your research proposal entitled "Exposure to high dose estrogens in adolescence: long term effects 
on mammogaphic breast density" was considered at the BreastScreen Queensland Monitoring, 
Research and Evaluation Sub-committee meeting held on Monday 5 December 2005. 
The Sub-committee considered your request and support your application in principle. However 
BreastScreen Queensland will not allow original mammograms to be transported outside of the 
State to be digitised. Therefore, if you wish to use BreastScreen Queensland clients in your research 
you will need to make arrangements for original mammograms to be digitised in Brisbane. Any 
cost associated with the digitising of the mammograms must be met by the researchers. 
In addition, valid, informed, written consent must be obtained from each BreastScreen Queensland 
client before access to identifying client information is permitted. 
If you wish to discuss options for digitising original mammograms in Brisbane or you have any 
other questions, do not hesitate to contact Ms Kirsten Mayne, Senior Project Officer (Quality) on 
(07) 3234 1260. 
Yours sincerely 
Office 	 Postal 	 Phone 	 Fax 
86 Floor Cancer Screening Services Unit • 	(07)3234 1596 	(07) 3225 2629 
Queensland Health Building 	GPO Box 48 
147-163 Charlotte Street BRISBANE QID 4001 
BRISBANE QLD 4000 
Health 
Human Research Ethics Committee 
PO Box 499 
Too‘vong Q 4066 	. 
Phone: 37327500 	Facsimile: 32327109 
Email: ethics:Vie:health:contain 
Ms Helen Jordan 
Menzies Research Institute 
University of tasmnia 
Privte Bag 23 
HOBART TAS 7001 
Document Submission and Approval Form 
Correspondence: 	from Helen Jordan, University of Tasmania, dated 18 th June 2007 
Study Title: 	Tall Girls Breast Density Study 
Investigator: - 	Helen Jordan 
Details of documents reviewed: 
• Application for approval to access recent mammogram at The Wesley 
Breast Clinic 
This application is approved. 
Douglas Killer MBBS FRACP 
Executive Officer 
20/06/2007 
The Uniting HealthCare Human Research Ethics Committee is constituted and operates in accordance with the National 
Health and Medical Research Council's Statement on Human Experimentation and Supplementary Notes 
toiewlone •• 	a u-t-tv 
Facsimile • 61 3 6226 7146 
EriaiI Humari.Elhics@juias.odu.au 
vew.researc Ii. .1 t s 	aultium an ..ethic0 
(TASMANIA) 
NETWORK UTAS 
3 September 2007 
AssocProf A Venn 
Menzies Research Institute 
University of Tasmania 
Private Bag 23 
Hobart Tas 7001 
Dear AssocProf Venn 
REF NO: H0008334 
TITLE: 	Adoletcent exposure to hormone treatment for tall 
stature in girls: long terms effects on breast tissue 
Extension of data collection to include birth weight and length for both 
treated and untreated women 
The Tasmanian Health and Medical Human Research Ethics Committee considered 
and approved the above documentation at its meeting on 3 September 2007. 
All committees operating under the Human Research Ethics Committee (Tasmania) 
Network are registered and required to comply with the National Statement on Ethical 
Conduct in Human Research (NHMRC 2007). . 
Should you have any queries please do not hesitate to contact.me on (03) 6226 2763. 
Yours sincerely 
Katherine Shaw 
Ethics Officer, Health and Medical 
On behalf of the Executive Officer 
HREC (TAS) Network '7.111 
Tasmania 
Extievethe tossiViTtuo 
Consent forms to obtain medical records 
Appendix 15: Consent forms to obtain medical records 
    
Menzies 
Research 
Institute 
... 	. 
 
    
    
STUDY ID NUMBER: 	  
CONSENT FORM 
Consent to obtain medical information for the: 
Study of long-term health and psychosocial effects of hormone treatment to reduce the 
adult height of tall girls. 
We would like to contact the doctor(s) who assessed and/or treated you for tall stature. 
We will, however, only do this with your permission. We are requesting access to your 
medical records so that we can confirm details about your height assessment and, if 
applicable, your treatment for tall stature. All the information we collect will be kept 
confidential. The information we collect will be used solely for the purposes of this 
research study. 
Please provide us with the name and address(es) of the doctor or hospital who assessed 
or treated you for tall stature, and the year that you attended. If you are unsure of a 
doctor's name or address, please give us whatever information you do have. 
(1) Dr or hospital 	 Year attended 	 
Address 	  
	 • State 	Postcode 	 
(2) Dr or hospital 	 Year attended 	 
Address 	  
	 State 	Postcode 
(3) Dr or hospital 	 Year attended 	 
Address 	  
	 State 	 Postcode 
Please sign here to give your consent 
	 give permission for Dr Alison Venn 
from the Centre for the Study of Mothers' and Children's Health, La Trobe 
University, to contact my above named doctor(s), to verify information from my 
medical records regarding my assessment and/or treatment for tall stature. 
Signed 	 Date 	  
Maiden name if different from above 	  
Thank you for this information 
Appendix 15: Consent forms to obtain medical records 
APPENDIX 16 
Box-plots of dense area, percent density, non-dense area and total breast area by 
menopausal status (alternative definition*) and age category (<50 years, ? 50 years 
of age) 
• Menopause — definition 2 
$ 
• 
Appendix 16: Box-plots 
Figure A16.1: Box-plot of dense area (cm 2) by menopausal status and age category (<50 
years, >50years). 
Dense Area 
(cm 2) 
Premenopausal Postmenopausal Premenopausal Postmenopausal 
<50 years 	 >50 years 
* Postmenopausal if last period > 52wks, and if HRT started before last period and current age was >55 
years but women who had not had a period for 252 weeks because of hysterectomy (while retaining one 
or both ovaries), endometrial ablation, IUD, or hormone implants, were considered to be premenopausal 
unless they were 255 years of age. 
Premenopausal Postmenopausal Premenopausal Postmenopausal 
<59 years 	 >50 years 
Menopause — definition -2 
a 
Appendix 16: Box-plots 
Figure A16.2: Box-plot of percent mammographic density by menopausal status and age 
category (<50 years, ?..50years). • 
Percent 
Density (%) 
400 _ 
Menopause — definition2 
• 
• 
300 - 
• • • • 
200 
100_ 
Premenopausal Postmenopausal Premenopausal Postmenopausal 
<50 years 	 >50 years 
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Appendix 16: Box-plots 
Fig A16.3 : Box-plot of total breast area (cm 2) by menopausal status and age category (<50 
years, >50years). 
Total Breast 
Area (cm 2) 
Appendix 16: Box-plots 
•Figure A16.4: Box—plot of non-dense area (cm2) by menopausal status and age category 
(<50 years, >50years). 
Non-dense 
area (cm 2) 
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Post-estimation diagnostics for treatment effect on dense area. 
Appendix 17: Post-estimation diagnostics for treatment effect on dense area 
A number of diagnostic tests were performed on the regression model to verify that it fulfilled 
the assumptions of linearity and normality, and to identify and examine highly influential data 
points. 
Collinearity 
Collinearity between independent variables in regression analysis can cause imprecise and • 
inflated differences in regression coefficients, and increase the standard error with the added 
consequence of reducing the test of significance'. 
A useful way to detect collinearity between independent variables in a regression is to 
examine the variance inflation factors (VIF) for each variable in the regression or the inverse 
(Tolerance factors)'. Individual VIF values greater than 10 or an overall mean VIF of >6 should 
be examined. As well, tolerance values (1NIF) if small (e.g. <0.10) should be examined'. 
Variance inflation. and tolerance factors for the independent variables in the regression 
of treatment effect on dense area, adjusted for age and BMI are presented in Table A17.1. 
Table A17.1: Variance Inflation Factors and Tolerance factors (1NIF) for the regression 
of treatment effect on dense area adjusted for age and BMI. 
Independent Variable VIF 1/VIF 
Treatment 1.08 0.93 
Age 	 • 1.07 0.94 
BMI 
. 
1.02 0.98 
. 
Mean 1.06 0.95 
The VIF and TIFs in Table A17.1 suggest no issue with collinearity in the regression of 
treatment effect on dense area. To confirm these findings, the individual correlations between 
each of the independent variables is presented in Table A17.2. 
Appendix 17: Post -estimation diagnostics for treatment effect on dense area 
Table A17.2: Correlation coefficients of each of the independent variables in the 
regression of treatment on dense area adjusted for age and BMI. 
Treatment Age BMI 
Treatment 1.00 
Age 0.24 1.00 
BMI -0.12 0.05 1.00 
Functional Form of the Model 
Each of the variables needs to demonstrate linearity so that the regression line through 
the coordinates has a slope equal to the estimated coefficient in the regression equation 2 . A plot 
that is useful for examining the functional form of the regression equation is the component-
plus-residual plot2 . Component-plus-residual plots for each of the continuous variables in the 
regression equation are presented in Figures A17.1. 
b) BMI 
• 
• 
• 
• 
20 	30 	40 	50 
BM I kg/m` 
10 
Appendix 17: Post-estimation diagnostics for treatment effect on dense area 
Figures A17.1 Component plus Residual Plots of continuous variables a) age, and b) BMI 
in the regression of treatment effect on dense area (cm 2) (sqrt). 
a) Age 
The plots suggests no major issue of non-linearity in the regression line for either age or 
BMI, though BMI may require further investigation using a fractional polynomial model 
comparison test. 
'Appendix 17: Post-estimation diagnostics for treatment effect on dense area 
Fractional Polynomial Model Comparison 
A Fractional Polynomial Model Comparison was undertaken of BMI and age and linear models 
were found to be suited for both (See Tables A17.3 and A17.4 below) 
Table A17.2 Fractional polynomial model comparisons test for age in the regression of 
treatment effect on dense area adjusted for age and BMI. 
Age df Deviance Res. SD Gain P (term) Powers 
Not in model 0 1226.699 1.76984 
Linear 1 1219.190 1.75133 0.000 0.007 1 
m = 1 2 1217.952 1.74783 1.237 0.270 3 
m = 2 4 1214.105 1.73983 5.085 0.153 -2-2 
Table A17.3 Fractional polynomial model comparisons test for BMI in the regression of 
treatment effect on dense area adjusted for age and BMI. 
BMI df Deviance Res. SD Gain P(term) Powers 
Not in model 0 1244.628 1.82194 , -- 
Linear 1 1219.190 1.75133 0.000 0.000 1 
m = 1 2 1219.190 1.75133 0.000 1.000 1 
m = 2 4 1219.174 1.75416 0.016 0.992 .53 
The "not in model" refers to the scenario where age or BMI is not affecting the outcome 
variable. The p-value indicates that the linear model is significantly different to 'not in model' 
for both age and BMI. 
Residual vs Predictor Plots 
Another assumption of linear regression is that variance in the residuals is random. Residual vs 
predictor or residual vs fitted plots provide a way to examine the distribution of the variance. If 
Appendix 17: Post-estimation diagnostics for treatment effect on dense area 
the assumption of random variance is fulfilled, there should be no pattern in the plots 2 . For 
instance, the variation in the residuals should not change as the variable of interest changes 2 . 
Residual vs predictor plots for each of the continuous variables age and BMI are presented in 
Fig. A17.2 
Figure A17.2. Residual vs predictor plots for age and BMI (kg/m2) 
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The assumption appears to be fulfilled for age and BMI. A few data points of high BMI . 
present a potential issue, but these are too few to be conclusive. More data points in the higher 
BMI range might show a more consistent pattern in the variation about zero. 
A residual vs fitted plot of the regression should also show no pattern to the residuals. A 
residual vs fitted plot is presented in Figure A17.3. 
Figure A17.3: Residual vs fitted plot of the regression model. 
The first seven points in the plot suggest a potential issue but again, there are too few 
data points here to suggest nonconstant variance or heteroskedasicity—an increasing or 
decreasing variation in the residuals plotted against the fitted values'. 
The observations with high BMI (>30) illustrated above in the residual vs predictor 
plots might be responsible for these patterns. Removing these values produces a more evenly 
distributed pattern of residuals against the fitted values (see Figure A17.4). 
Appendix 17: Post -estimation diagnostics for treatment effect on dense area 
Figure A17.4: Residual vs Fitted plot (N=266) without the observations with BMI >30. 
The regression coefficients for treatment effect on dense area did not significantly 
change when the observations of BM1 >30 (n=43) were removed from the dataset (see Table 
A17.4). 
Table A17.4: Regression results with and without BMI >30 
Coefficient (SE) 95%.CI p value 
Regression (n=309) -0.45 (0.21) -0.86 to -0.04 0.032 	- 
Regression w/o values 
with BMI>30 (n=266) . -0.46 (0.21) -0.88 to -0.04 0.035 
• 
0 
Inverse Normal 
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Heteroskedasticity 
A Breusch-Pagan/Cook-Weisberg test for heteroskedasticity was performed and some degree of 
heteroskedasticity was suggested (p=0.035). To accommodate this, a robust regression was 
performed. The robust regression did not have any significant effect on the age and BMI 
adjusted regression coefficient, standard error or p-value for treatment effect on dense area [- 
0.45 . (SE 0.20) (95% Cl: -0.84 to -0.05; p=0.026)] compared with the non-robust regression [- 
0.45 (SE 0.21) (95% CI: -0.86 to -0.04; p=0.032)]. 
Test for Normality 
Another assumption that needs to be fulfilled in linear regression is that the residuals are 
normally distributed. A plot of actual vs expected residuals is presented in Figure A17.5. 
Figure A17.5: Actual residuals vs expected residuals. 
This plot suggests that the actual residuals meet the assumption of normality. 
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Appendix 17: Post-estimation diagnostics for treatment effect on dense area 
Test for outliers 
Added variable plots (see Figure A17.6) allow for outliers, with extreme y-values, to be 
observed. 
Figure A17.6: Added variable plot for treatment, age and BMI. 
-10 	0 	10 	20 	30 
e(BMII X) 
According to Figure A17.6, there appear to be a few potential outliers. Tests of influence were 
undertaken to assess the potential of these and other observations for influencing the results. 
Tests of influence 
A leverage vs squared residual plot (see Figure A17.7) can highlight potential 
influential observations. Points above the horizontal have higher than average leverage, while 
points to the right of the vertical line have higher.than average residuals2. 
• 
.01 	.02 	.03 
Normalized residual squared 
:04 
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Figure A17.7. Leverage and squared residual plot for the regression of treatment effect on 
dense area adjusted for age and BMI. 
If an observation has both a large residual and high leverage, that observation is 
potentially influentia13 . According to the leverage vs residual squared plot above (Figure 
A17.7), a few observations could be considered to be influential. A more specific measure of 
the degree of influence is the Cooks D test, or Cook's distance 2 . 
Cooks Distance 
Cook's D is one measure of influence of an observation. A Cooks distance test was 
performed. Seven points were found to have a Cooks d of >4/n (range 0.013-0.087). These were 
removed from the regression and the effect was observed to be minimal with the regression 
coefficient for treatment effect on dense area (sqrt) (See Table A17.5). 
Table A17.5: Regression results with and without the points with Cooksd >=41n. for 
treatment effect on dense area (cm 2) (sqrt). 
Coefficient (SE) 95% CI p value 
Regression (n=309) -0.45 (0.21) -0.86 to -0.04 . 	0.032 
Regression w/o values 
with Cooks d > 0.04 
(n=302) 
-0.42 (0.20) -0.81 to -0.03 0.036 
Component plus residual plot for BMI in the regression for treatment effect on 
non-dense area 
Appendix 18: Component plus residual plot for BMI in the regression for treatment effect on non-dense 
area. 
Post-estimation diagnostics and sensitivity analysis was performed as for dense area and percent 
density. No influential points were found to significantly change the results. Removing digital 
images from the analysis did not affect the results. While the assumptions of linearity and 
normality were found to be fulfilled for the independent variables age and livebirths, this was 
not the case for BMI. While BMI and non-dense area are positively correlated, the relationship 
is curvilinear (the gradient is reduced at the larger end of the BMI scale) (See Figure A18.1). 
Figure A18.1 Component plus residual plot of BMI in the regression equation for non-
dense area adjusted for age, BMI and livebirths. 
 
4 - 
 
   
 
3 - 
 
2 
 
 
 
 
0 - 
  
10 	20 
	
30 	40 	50 
BMI kg/m2 
For BMI adjusted analyses, where the response variable is non-dense area, an inverse 
square root transformation of BMI was carried out to meet the assumptions of linearity (See 
Figure A18.2 below for the component plus residual plot of BMI after transformation. While 
the coefficient of the transformed BMI will now, be negative this does not matter in the results 
as it is the coefficient for treatment that is of interest here. 
Appendix 18: Component plus residual plot for BMI in the regression for treatment effect on non-dense 
area. 
Figure A18.2 Component plus residual plot of BMI (inverse square root transformed) in 
the regression for non-dense area adjusted for age, BMI and livebirths. 
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Ethics approvals to access data previously collected at first follow-up and again 
to extract additional information from the medical records (birthweight and birth- • 
length) 
iewptione • 	J 	w 
Facsimilt: • 61 3 6226 71415 
Email 1-fuomn.E1 hic sOwas.vdu.au  
veNvi.roseard ,Aitas..7.d..iwitkuman othicq 
(TASMANIA) 
NETWORK UTAS . 
3 September 2007 
AssocProf A Venn 
Menzies Research Institute 
University of Tasmania 
Private Bag 23 
Hobart Tas 7001 
Dear AssocProf Venn • 
REF NO: H0008334 
TITLE: 	Adole§cent exposure to hormone treatment for tall 
stature in girls: long terms effects on breast tissue 
Extension of data collection to include birth weight and length for both 
treated and untreated women 
The Tasmanian Health and Medical Human Research Ethics Committee considered 
and approved the above documentation at its meeting on 3 September 2007. 
All committees operating under the Human Research Ethics Committee (Tasmania) 
Network are registered and required to comply with the National Statement on Ethical 
Conduct in Human Research (NHMRC 2007). 
Should you have any queries please do not hesitate to contact me on (03) 6226 2763. 
Yours sincerely 
Katherine Shaw 
Ethics Officer, Health and Medical 
On behalf of the Executive Officer 
HREC (TAS) Network 
• N.6.44. i *is  lriff
Tasmania 
644ewe Ow r40101144. 
